assay_id,assay_subcellular_fraction,assay_cell_type,assay_type,confidence_score,curated_by,assay_test_type,doc_id,assay_organism,bao_format,cell_id,assay_tissue,assay_category,variant_id,tid,src_id,description,assay_tax_id,assay_strain
1,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12052,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,
2,,,F,0,Autocuration,,684,,BAO_0000219,,,,,22226,1,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,
3,,,B,0,Autocuration,,15453,,BAO_0000019,,,,,22226,1,,,
4,,,B,4,Autocuration,,17841,Bos taurus,BAO_0000249,,,,,104729,1,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,9913.0,
5,,143B,F,1,Intermediate,,17430,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),9606.0,
6,,143B,F,1,Intermediate,,17430,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),9606.0,
7,,143B,F,1,Intermediate,,13799,Mus musculus,BAO_0000219,163.0,,,,80001,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,10090.0,
8,,143B,F,1,Expert,,17774,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity was determined against 143B cell line,9606.0,
9,,143B,F,1,Intermediate,,3801,Homo sapiens,BAO_0000219,163.0,,,,80001,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,9606.0,
10,,143B,F,1,Intermediate,,17430,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,9606.0,
11,,143B,F,1,Intermediate,,17430,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,9606.0,
12,,143B,F,1,Expert,,17774,Homo sapiens,BAO_0000219,163.0,,,,80001,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,9606.0,
13,,,F,1,Intermediate,,11324,Staphylococcus aureus,BAO_0000218,,,,,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,
14,,,F,1,Intermediate,,11324,Staphylococcus aureus,BAO_0000218,,,,,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,
15,,,F,1,Intermediate,,11324,Staphylococcus aureus,BAO_0000218,,,,,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,
16,,,F,1,Intermediate,,11324,Staphylococcus aureus,BAO_0000218,,,,,50185,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1280.0,
17,,,A,9,Expert,,11347,Rattus norvegicus,BAO_0000357,,,,,100122,1,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,10116.0,
18,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,
19,,,B,8,Autocuration,,10091,,BAO_0000019,,,,,12054,1,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,
20,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
21,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,
22,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,
23,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
24,,,B,8,Autocuration,,16474,,BAO_0000357,,,,,12054,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,
25,,,B,0,Autocuration,,14352,,BAO_0000219,,,,,22226,1,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,
26,,,B,8,Autocuration,,5646,Oryctolagus cuniculus,BAO_0000357,,,,,12054,1,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,9986.0,
27,,,B,8,Autocuration,,5646,Oryctolagus cuniculus,BAO_0000357,,,,,12054,1,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),9986.0,
28,,,B,8,Autocuration,,10997,,BAO_0000219,,,,,12426,1,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,
29,,,B,8,Autocuration,,6309,soya bean,BAO_0000357,,,,,12054,1,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,3847.0,
30,,,B,8,Autocuration,,167,Glycine max,BAO_0000357,,,,,12054,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated,3847.0,
31,,,B,8,Autocuration,,167,Glycine max,BAO_0000357,,,,,12054,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,3847.0,
32,,,B,8,Autocuration,,11087,Glycine max,BAO_0000357,,,,,12054,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,3847.0,
33,,,B,8,Autocuration,,11087,Glycine max,BAO_0000357,,,,,12054,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,3847.0,
34,,,B,8,Autocuration,,13622,Glycine max,BAO_0000357,,,,,12054,1,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,3847.0,
35,,,B,8,Autocuration,,13622,Glycine max,BAO_0000357,,,,,12054,1,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,3847.0,
36,,,A,0,Autocuration,,11347,Rattus norvegicus,BAO_0000019,,,,,22226,1,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,10116.0,
37,,,B,0,Autocuration,,5926,Escherichia coli,BAO_0000019,,,,,22226,1,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,562.0,
38,,,B,0,Autocuration,,4567,,BAO_0000019,,,,,22226,1,Dissociation constant with dimeric 16S rRNA RNA construct B,,
39,,,B,3,Intermediate,,3782,,BAO_0000225,,,,,22222,1,Dissociation constant towards 16S rRNA construct A,,
40,,,B,3,Intermediate,,3782,,BAO_0000225,,,,,22222,1,Dissociation constant towards 16S rRNA construct B,,
41,,,B,3,Expert,,4466,Escherichia coli,BAO_0000225,,,,,100263,1,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,562.0,
42,,,B,3,Expert,,6592,Escherichia coli,BAO_0000225,,,,,100263,1,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,562.0,
43,,,B,8,Autocuration,,898,,BAO_0000019,,,,,13053,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
44,,,B,8,Autocuration,,898,,BAO_0000019,,,,,13053,1,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
45,,,B,8,Autocuration,,13163,Homo sapiens,BAO_0000019,,,,,20001,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,9606.0,
46,,,B,8,Autocuration,,13163,Homo sapiens,BAO_0000019,,,,,20001,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,9606.0,
47,,,B,9,Expert,,10691,Rattus norvegicus,BAO_0000019,,,,,12971,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10116.0,
48,,,B,9,Expert,,10691,Rattus norvegicus,BAO_0000019,,,,,12971,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",10116.0,
49,,,B,9,Expert,,10691,Rattus norvegicus,BAO_0000019,,,,,12971,1,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10116.0,
50,,,B,9,Expert,,10691,Rattus norvegicus,BAO_0000019,,,,,12971,1,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",10116.0,
51,,,B,8,Autocuration,,898,,BAO_0000019,,,,,13053,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,
52,,,B,8,Autocuration,,912,,BAO_0000357,,,,,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,
53,,,B,8,Autocuration,,912,,BAO_0000357,,,,,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,
54,,,B,8,Autocuration,,912,,BAO_0000357,,,,,11512,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,
55,Membranes,,B,5,Autocuration,,15103,Rattus norvegicus,BAO_0000249,,,,,104740,1,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,10116.0,
56,,1A9,F,1,Intermediate,,5116,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,9606.0,
57,,Oocytes,F,7,Autocuration,,14578,Rattus norvegicus,BAO_0000219,,,,,104835,1,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,10116.0,
58,,Oocytes,F,7,Autocuration,,14578,Rattus norvegicus,BAO_0000219,,,,,104821,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,10116.0,
59,,Oocytes,F,7,Autocuration,,14578,Rattus norvegicus,BAO_0000219,,,,,104848,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,10116.0,
60,,1A9,F,1,Expert,,4787,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,9606.0,
61,,1A9,F,1,Intermediate,,4787,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,9606.0,
62,,1A9,F,1,Intermediate,,3547,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,9606.0,
63,,1A9,F,1,Intermediate,,3547,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,9606.0,
64,,1A9,F,1,Intermediate,,6726,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Effective dose of compound against replication of 1A9 cell line was evaluated,9606.0,
65,,1A9,F,1,Expert,,3455,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,9606.0,
66,,1A9,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),9606.0,
67,,1A9,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,9606.0,
68,,1A9,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,506.0,,,,80002,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,9606.0,
69,,1A9,F,1,Intermediate,,3395,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Inhibitory activity against Taxol resistant 1A9 cell lines,9606.0,
70,,1A9,F,1,Expert,,3415,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,9606.0,
71,,1A9,F,1,Expert,,3415,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,9606.0,
72,,1A9,F,1,Expert,,17099,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,9606.0,
73,,1A9,F,1,Intermediate,,17099,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,9606.0,
74,,1A9,F,1,Intermediate,,17099,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,9606.0,
75,,1A9,F,1,Intermediate,,17099,Homo sapiens,BAO_0000219,506.0,,,,80002,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,9606.0,
76,,Jurkat,F,1,Intermediate,,17721,Homo sapiens,BAO_0000219,503.0,,,,81072,1,Inhibitory concentration against Jurkat cells,9606.0,
77,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,
78,,,A,9,Expert,,11347,Rattus norvegicus,BAO_0000357,,,,,100121,1,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,10116.0,
79,,,B,8,Expert,,17117,,BAO_0000357,,,,,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
80,,,B,8,Expert,,17117,,BAO_0000357,,,,,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,
81,,,B,8,Expert,,17117,,BAO_0000357,,,,,11231,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,
82,Microsomes,,B,8,Autocuration,,11375,Candida albicans,BAO_0000251,,,,,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",5476.0,
83,Microsomes,,B,8,Autocuration,,11375,Candida albicans,BAO_0000251,,,,,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",5476.0,
84,Microsomes,,B,8,Autocuration,,11375,Saccharomyces cerevisiae,BAO_0000251,,,,,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",4932.0,
85,Microsomes,,B,8,Autocuration,,11375,Saccharomyces cerevisiae,BAO_0000251,,,,,11231,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",4932.0,
86,Microsomes,,B,8,Autocuration,,11375,Sus scrofa,BAO_0000251,,Liver,,,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",9823.0,
87,,,B,8,Autocuration,,791,Rattus norvegicus,BAO_0000019,,,,,11231,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",10116.0,
88,,,B,8,Autocuration,,791,Rattus norvegicus,BAO_0000019,,,,,11231,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",10116.0,
89,,,B,8,Autocuration,,791,Rattus norvegicus,BAO_0000019,,,,,11231,1,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",10116.0,
90,Microsomes,,B,9,Autocuration,,11375,Rattus norvegicus,BAO_0000251,,Liver,,,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",10116.0,
91,Microsomes,,B,9,Autocuration,,11375,Rattus norvegicus,BAO_0000251,,Liver,,,12083,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",10116.0,
92,Microsomes,,B,9,Autocuration,,153,Rattus norvegicus,BAO_0000251,,Liver,,,12083,1,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",10116.0,
93,,,B,8,Expert,,8269,,BAO_0000357,,,,,11377,1,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,
94,,,B,8,Expert,,8269,,BAO_0000357,,,,,11377,1,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,
95,,HepG2,F,1,Expert,,17653,Homo sapiens,BAO_0000219,726.0,,,,81020,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,9606.0,
96,,HepG2,F,1,Intermediate,,14277,Homo sapiens,BAO_0000219,726.0,,,,81020,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,9606.0,
97,,HepG2,F,1,Intermediate,,1717,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,9606.0,
98,,HepG2,F,1,Intermediate,,14091,Homo sapiens,BAO_0000219,726.0,,,,81020,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,9606.0,
99,,HepG2,F,1,Intermediate,,14091,Homo sapiens,BAO_0000219,726.0,,,,81020,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,9606.0,
100,,,F,1,Expert,,17653,Hepatitis B virus,BAO_0000218,,,,,50606,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,10407.0,
101,,HepG2,F,1,Intermediate,,13105,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,9606.0,
102,,HepG2,F,1,Intermediate,,1717,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Concentration required to inhibit 50% of 2.2.15 cell line,9606.0,
103,,HepG2,A,1,Intermediate,,13105,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,9606.0,
104,,2.2.15,F,1,Intermediate,,13600,Homo sapiens,BAO_0000218,,,,,50587,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,9606.0,
105,,2.2.15,F,1,Intermediate,,13467,Homo sapiens,BAO_0000218,,,,,50587,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,9606.0,
106,,2.2.15,F,1,Expert,,17477,Hepatitis B virus,BAO_0000218,,,,,50606,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",10407.0,
107,,2.2.15,F,1,Intermediate,,1593,Homo sapiens,BAO_0000218,,,,,50587,1,In vitro anti-HBV activity in 2.2.15 cells,9606.0,
108,,2.2.15,F,1,Intermediate,,1593,Homo sapiens,BAO_0000218,,,,,50587,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,9606.0,
109,,2.2.15,F,1,Intermediate,,15089,Homo sapiens,BAO_0000218,,,,,50587,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,9606.0,
110,,2.2.15,F,1,Intermediate,,15089,Homo sapiens,BAO_0000218,,,,,50587,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,9606.0,
111,,2.2.15,F,1,Intermediate,,1593,Homo sapiens,BAO_0000218,,,,,50587,1,Cytotoxicity in 2.2.15 cells,9606.0,
112,,2.2.15,F,1,Intermediate,,1593,Homo sapiens,BAO_0000218,,,,,50587,1,Cytotoxicity in 2.2.15 cells; Not determined,9606.0,
113,,2.2.15,F,1,Intermediate,,13600,Homo sapiens,BAO_0000218,,,,,50587,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,9606.0,
114,,2.2.15,F,1,Intermediate,,13467,Homo sapiens,BAO_0000218,,,,,50587,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,9606.0,
115,,2.2.15,F,1,Intermediate,,13467,Homo sapiens,BAO_0000218,,,,,50587,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,9606.0,
116,,HepG2,F,1,Intermediate,,14764,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Antiviral activity against HBV was determined in 2.215 cell line,9606.0,
117,Microsomes,,B,0,Autocuration,,6531,Homo sapiens,BAO_0000251,,,,,22226,1,Inhibition of 20-HETE synthesis in human renal microsomes,9606.0,
118,,,B,0,Autocuration,,17322,,BAO_0000019,,,,,22226,1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,
119,,2008,F,1,Intermediate,,17072,Homo sapiens,BAO_0000219,388.0,,,,80612,1,Inhibitory concentration against 2008 (ovarian) cells,9606.0,
120,,2008,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,388.0,,,,80612,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,9606.0,
121,,2008,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,388.0,,,,80612,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),9606.0,
122,,2008,F,1,Intermediate,,17146,Homo sapiens,BAO_0000219,388.0,,,,80612,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,9606.0,
123,,2008,F,1,Intermediate,,17146,Homo sapiens,BAO_0000219,388.0,,,,80612,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,9606.0,
124,,2008/R,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,561.0,,,,80613,1,In vitro inhibition of 2008/R ovarian cancer cell line,9606.0,
125,,2008/R,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,561.0,,,,80613,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,9606.0,
126,,2008/S,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,389.0,,,,80614,1,In vitro inhibition of 2008/S ovarian cancer cell line,9606.0,
127,,2008/S,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,389.0,,,,80614,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,9606.0,
128,,,B,2,Expert,,4823,Homo sapiens,BAO_0000220,,,,,100256,1,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,9606.0,
129,,,B,2,Intermediate,,12912,Homo sapiens,BAO_0000220,,,,,100256,1,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,9606.0,
130,,,B,2,Expert,,2957,,BAO_0000220,,,,,100256,1,Inhibition of chymotrypsin-like activity of 20S proteasome,,
131,,,B,2,Expert,,2957,,BAO_0000220,,,,,100256,1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,
132,,,B,2,Intermediate,,3260,,BAO_0000220,,,,,100256,1,Inhibitory activity against 20S proteosome,,
133,,,B,0,Autocuration,,3451,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was tested for inhibitory activity against tryptase,9606.0,
134,,HepG2,F,1,Intermediate,,13885,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,9606.0,
135,,HepG2,F,1,Intermediate,,13885,Homo sapiens,BAO_0000219,726.0,,,,81020,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,9606.0,
136,,,B,0,Autocuration,,3676,,BAO_0000019,,,,,22226,1,Compound was tested for the inhibition of Alpha-glucosidase,,
137,,,B,8,Autocuration,,6043,,BAO_0000357,,,,,235,1,Inhibitory concentration against human neutrophil elastase (HNE),,
138,,,F,0,Autocuration,,11140,Rattus norvegicus,BAO_0000218,,Heart,,,22226,1,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,10116.0,
139,,,F,8,Autocuration,,10543,,BAO_0000019,,,,,19640,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
140,,,F,8,Expert,,10543,,BAO_0000019,,,,,19640,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
141,,,B,8,Autocuration,,10543,,BAO_0000357,,,,,19640,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,
142,,,F,8,Expert,,10543,,BAO_0000019,,,,,19640,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,
143,,P338,F,1,Intermediate,,11365,Mus musculus,BAO_0000219,524.0,,,,80360,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,10090.0,
144,,P338,F,1,Intermediate,,11365,Mus musculus,BAO_0000219,524.0,,,,80360,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,10090.0,
145,,PBL,F,1,Intermediate,,11803,Homo sapiens,BAO_0000219,554.0,,,,80384,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,9606.0,
146,,,F,0,Autocuration,,11803,Ovis aries,BAO_0000019,,,,,22226,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,9940.0,
147,,,F,0,Autocuration,,11803,Ovis aries,BAO_0000019,,,,,22226,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,9940.0,
148,,,B,8,Autocuration,,12278,,BAO_0000357,,,,,191,1,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,
149,,,F,0,Autocuration,,8249,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,9606.0,
150,,,F,0,Autocuration,,8249,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,9606.0,
151,,CCRF-CEM,F,0,Autocuration,,8249,Homo sapiens,BAO_0000219,635.0,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,9606.0,
152,,CCRF-CEM,F,0,Autocuration,,8249,Homo sapiens,BAO_0000219,635.0,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,9606.0,
153,,CCRF-CEM,F,0,Autocuration,,8249,Homo sapiens,BAO_0000219,635.0,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,9606.0,
154,,CCRF-CEM,F,0,Autocuration,,8249,Homo sapiens,BAO_0000219,635.0,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,9606.0,
155,,,F,0,Autocuration,,8249,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,9606.0,
156,,,F,0,Autocuration,,8249,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,9606.0,
157,,,B,6,Autocuration,,16992,,BAO_0000249,,,,,104290,1,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,
158,,,F,1,Intermediate,,10543,Streptococcus pyogenes,BAO_0000218,,,,,50264,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1314.0,
159,,,F,1,Intermediate,,17833,Human herpesvirus 3,BAO_0000218,,,,,50527,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),10335.0,
160,,HEL,F,1,Expert,,17290,vericilla zoster virus,BAO_0000218,468.0,,,,50527,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,10335.0,
161,,,F,1,Intermediate,,17290,vericilla zoster virus,BAO_0000218,,,,,50527,1,Antiviral activity against 07/1 strain of VZV; ND: No data,10335.0,
162,,,F,1,Intermediate,,17290,vericilla zoster virus,BAO_0000218,,,,,50527,1,Antiviral activity against 07/1 strain of VZV; ND=No data,10335.0,
163,,,F,1,Intermediate,,10932,escherichia cloac,BAO_0000218,,,,,50145,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",561.0,
164,,,B,0,Autocuration,,9707,,BAO_0000019,,,,,22226,1,Ratio of Ki at A2 to Ki at A1 receptors,,
165,,,B,8,Expert,,2346,Candida albicans,BAO_0000249,,,,,11143,1,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",5476.0,
166,,,B,8,Expert,,2205,Candida glabrata CBS 138,BAO_0000357,,,,,18077,1,"Inhibition of 1,3-beta-glucan synthase",284593.0,
167,,1-87 tumor cell line,F,1,Intermediate,,11900,Homo sapiens,BAO_0000219,832.0,,,,80609,1,Inhibition of growth of 1-87 human tumor cell line,9606.0,
168,,,B,9,Expert,,14864,Rattus norvegicus,BAO_0000219,,,,,12166,1,Inhibition of 1-lipoxygenase (LOX)in RBL cells,10116.0,
169,,,B,9,Autocuration,,16474,Glycine max,BAO_0000357,,,,,100171,1,Inhibitory activity against soybean 1-lipoxygenase (SLO),3847.0,
170,,,B,9,Autocuration,,16474,Glycine max,BAO_0000357,,,,,100171,1,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,3847.0,
171,,,B,9,Autocuration,,16474,Glycine max,BAO_0000357,,,,,100171,1,% inhibition against soybean 1-lipoxygenase (SLO),3847.0,
172,,,B,9,Autocuration,,16474,Glycine max,BAO_0000357,,,,,100171,1,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,3847.0,
173,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,3847.0,
174,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,3847.0,
175,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,3847.0,
176,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,3847.0,
177,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,3847.0,
178,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,3847.0,
179,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,3847.0,
180,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,3847.0,
181,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,3847.0,
182,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,3847.0,
183,,,B,9,Autocuration,,3094,Glycine max,BAO_0000357,,,,,100171,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,3847.0,
184,,,B,0,Autocuration,,10413,Mus musculus,BAO_0000019,,,,,22226,1,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,10090.0,
185,,C3H 10T1/2,F,1,Intermediate,,16929,Mus musculus,BAO_0000219,294.0,,,,80049,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),10090.0,
186,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,
187,,,B,8,Autocuration,,16587,,BAO_0000357,,,,,11489,1,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
188,,,B,8,Autocuration,,16587,,BAO_0000357,,,,,11862,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,
189,,,B,8,Autocuration,,16587,,BAO_0000357,,,,,11862,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,
190,,,B,8,Autocuration,,16587,,BAO_0000357,,,,,11489,1,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,
191,,,B,8,Autocuration,,16587,,BAO_0000357,,,,,11862,1,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,
192,,,F,9,Expert,,8058,Bos taurus,BAO_0000019,,,,,12347,1,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,9913.0,
193,,,B,9,Expert,,9065,Rattus norvegicus,BAO_0000357,,,,,100120,1,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,10116.0,
194,,,B,9,Expert,,8865,Rattus norvegicus,BAO_0000357,,Adrenal gland,,,100120,1,Inhibition of 11 beta-hydroxylase from rat adrenal gland,10116.0,
195,,,B,9,Expert,,9066,Rattus norvegicus,BAO_0000357,,,,,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase,10116.0,
196,,,B,9,Expert,,8394,Rattus norvegicus,BAO_0000357,,,,,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase,10116.0,
197,,,B,9,Expert,,8394,Rattus norvegicus,BAO_0000357,,,,,100120,1,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,10116.0,
198,,,B,8,Autocuration,,6431,,BAO_0000019,,,,,10328,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,
199,,,B,8,Autocuration,,6431,,BAO_0000357,,,,,11490,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
200,,,B,8,Autocuration,,6431,,BAO_0000357,,,,,11490,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,
201,,,F,8,Autocuration,,9295,,BAO_0000019,,,,,11134,1,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,
202,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
203,,,B,8,Autocuration,,13622,,BAO_0000019,,,,,11134,1,Compound was tested in vitro for inhibition of 12-LO human platelet,,
204,,,F,8,Autocuration,,12079,,BAO_0000019,,,,,11134,1,Inhibitory concentration against human platelet 12-lipoxygenase,,
205,,,B,8,Autocuration,,13622,,BAO_0000019,,,,,11134,1,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,
206,,,F,9,Autocuration,,12079,Homo sapiens,BAO_0000019,,,,,11134,1,Inhibitory concentration against human platelet 12-lipoxygenase,9606.0,
207,,,B,8,Expert,,13500,,BAO_0000019,,,,,11835,1,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,
208,,,B,8,Expert,,13723,,BAO_0000357,,,,,11601,1,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,
209,,,B,8,Autocuration,,16474,,BAO_0000019,,,,,11134,1,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,
210,,,B,8,Autocuration,,1630,,BAO_0000019,,,,,11134,1,Inhibitory activity against human platelet 12-lipoxygenase,,
211,,,B,8,Autocuration,,167,,BAO_0000019,,,,,11134,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,
212,,,B,8,Autocuration,,16474,,BAO_0000019,,,,,11134,1,% inhibition against human platelet 12-lipoxygenase (12-HLO),,
213,,,B,8,Autocuration,,167,,BAO_0000019,,,,,11134,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,
214,,,B,8,Autocuration,,16474,,BAO_0000019,,,,,11134,1,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,
215,,,B,8,Autocuration,,10091,,BAO_0000357,,,,,11601,1,Inhibitory activity towards porcine 12-lipoxygenase,,
216,,,B,8,Autocuration,,11966,,BAO_0000357,,,,,11601,1,Tested for inhibition against porcine 12-LO,,
217,,,B,8,Autocuration,,951,,BAO_0000019,,,,,12052,1,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,
218,,,B,8,Autocuration,,10997,,BAO_0000019,,,,,12052,1,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,
219,,,B,8,Expert,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibition of rat platelet 12-lipoxygenase,,
220,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
221,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,
222,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,
223,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,
224,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12052,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,
225,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12052,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,
226,,41M,F,1,Intermediate,,15569,Homo sapiens,BAO_0000219,621.0,,,,80007,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,9606.0,
227,,41M,F,1,Expert,,12989,Homo sapiens,BAO_0000219,621.0,,,,80007,1,In vitro antitumor activity against 41M cell line.,9606.0,
228,,41M,F,1,Intermediate,,16745,Homo sapiens,BAO_0000219,621.0,,,,80007,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,9606.0,
229,,41M,F,1,Intermediate,,15569,Homo sapiens,BAO_0000219,621.0,,,,80007,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,9606.0,
230,,41M,F,1,Expert,,12989,Homo sapiens,BAO_0000219,621.0,,,,80007,1,In vitro antitumor activity against 41McisR cell line.,9606.0,
231,,41M,F,1,Expert,,12989,Homo sapiens,BAO_0000219,621.0,,,,80007,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,9606.0,
232,,41M,F,1,Intermediate,,16745,Homo sapiens,BAO_0000219,621.0,,,,80007,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,9606.0,
233,,,B,9,Expert,,6210,Homo sapiens,BAO_0000357,,,,,84,1,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),9606.0,
234,,,B,9,Expert,,6210,Homo sapiens,BAO_0000357,,,,,68,1,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),9606.0,
235,,,B,8,Expert,,6226,,BAO_0000357,,,,,68,1,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,
236,,,B,8,Expert,,17855,,BAO_0000357,,,,,10201,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
237,,,B,8,Expert,,17855,,BAO_0000357,,,,,10201,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,
238,,,B,8,Expert,,17855,,BAO_0000357,,,,,10201,1,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,
239,,,B,8,Autocuration,,10413,,BAO_0000357,,,,,12220,1,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
240,,,B,8,Autocuration,,10413,Escherichia coli,BAO_0000357,,,,,11303,1,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",562.0,
241,,,B,8,Autocuration,,10413,Escherichia coli,BAO_0000357,,,,,11303,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",562.0,
242,,,B,8,Autocuration,,10413,Escherichia coli,BAO_0000357,,,,,11303,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",562.0,
243,,,B,8,Autocuration,,10413,,BAO_0000357,,,,,12220,1,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,
244,,,B,8,Autocuration,,10413,,BAO_0000357,,,,,12220,1,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,
245,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000357,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,
246,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",9823.0,
247,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000357,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",9823.0,
248,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000357,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",9823.0,
249,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000357,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,
250,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",9823.0,
251,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",9823.0,
252,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",9823.0,
253,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",9823.0,
254,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",9823.0,
255,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000357,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",9823.0,
256,,,B,8,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,11303,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",9823.0,
257,,,B,8,Autocuration,,7323,,BAO_0000357,,,,,11303,1,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,
258,,,B,0,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,22226,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",9823.0,
259,,,B,0,Autocuration,,7587,Sus scrofa,BAO_0000019,,,,,22226,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",9823.0,
260,,,B,8,Expert,,13750,Saccharomyces cerevisiae,BAO_0000357,,,,,100249,1,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,4932.0,
261,,,B,0,Autocuration,,7662,Rattus norvegicus,BAO_0000019,,,,,22226,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,10116.0,
262,,,B,0,Autocuration,,7662,Rattus norvegicus,BAO_0000019,,,,,22226,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,10116.0,
263,,,B,0,Autocuration,,7662,Rattus norvegicus,BAO_0000019,,,,,22226,1,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",10116.0,
264,,,F,6,Autocuration,,12211,,BAO_0000019,,,,,104698,1,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
265,,,F,6,Autocuration,,12211,,BAO_0000019,,,,,104698,1,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,
266,,,F,9,Intermediate,,12211,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,10141.0,
267,,,F,8,Expert,,12211,,BAO_0000019,,,,,10623,1,Stimulatory activity of intragastric pressure was tested in the rat,,
268,,,B,8,Autocuration,,15453,,BAO_0000357,,,,,121,1,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,
269,,,F,0,Autocuration,,11884,Rattus norvegicus,BAO_0000218,,,,,22226,1,Dose to reduce neuronal firing against 5-HT cells in rats (iv),10116.0,
270,,,F,8,Autocuration,,7185,,BAO_0000019,,,,,12688,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
271,,,B,9,Expert,,6876,Homo sapiens,BAO_0000357,,,,,121,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,9606.0,
272,,,B,9,Expert,,6876,Homo sapiens,BAO_0000357,,,,,121,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,9606.0,
273,,,F,8,Autocuration,,11863,,BAO_0000019,,,,,12198,1,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,
274,,,B,8,Autocuration,,11863,,BAO_0000357,,,,,12198,1,Inhibition constant of high-affinity 5-HT uptake,,
275,,,F,8,Autocuration,,11863,,BAO_0000019,,,,,12198,1,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,
276,,,F,8,Autocuration,,11863,,BAO_0000019,,,,,12198,1,Maximum rate was determined for high affinity transport of 5-HT,,
277,,,F,4,Autocuration,,4639,,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-HT uptake,,
278,,,B,8,Expert,,15796,,BAO_0000019,,,,,10577,1,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,
279,,,B,8,Expert,,15796,Bos taurus,BAO_0000357,,,,,105,1,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,9913.0,
280,,,B,5,Autocuration,,12801,Rattus norvegicus,BAO_0000224,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10116.0,
281,,,B,4,Autocuration,,12801,,BAO_0000224,,,,,104744,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,
282,Membranes,,B,4,Autocuration,,12120,,BAO_0000249,,,,,104744,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,
283,Membranes,,B,4,Autocuration,,12120,,BAO_0000249,,,,,104744,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,
284,,,B,4,Autocuration,,11963,,BAO_0000019,,,,,104744,1,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
285,,,F,8,Autocuration,,11701,,BAO_0000019,,,,,51,1,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,
286,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
287,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
288,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
289,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,
290,,,F,9,Intermediate,,11574,Cavia porcellus,BAO_0000019,,,,,105570,1,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,10141.0,
291,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,279,1,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
292,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,107,1,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,
293,,,F,9,Expert,,15363,Rattus norvegicus,BAO_0000019,,,,,12687,1,Efficacy against 5-hydroxytryptamine 2A receptor,10116.0,
294,,,F,8,Expert,,15329,,BAO_0000019,,,,,12687,1,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,
295,,,F,8,Expert,,15329,,BAO_0000019,,,,,12687,1,Relative potency towards 5-HT2A receptor of rat tail artery,,
296,,,F,8,Expert,,15329,,BAO_0000019,,,,,12687,1,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
297,,,F,8,Expert,,15329,,BAO_0000019,,,,,12687,1,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,
298,,,F,8,Autocuration,,15329,,BAO_0000019,,,,,12687,1,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,
299,,,F,8,Expert,,15329,,BAO_0000019,,,,,12687,1,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,
300,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,
301,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),10141.0,
302,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,
303,,,B,8,Autocuration,,12092,,BAO_0000357,,,,,10623,1,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,
304,,,F,9,Expert,,1317,Rattus norvegicus,BAO_0000019,,,,,10623,1,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10116.0,
305,,,B,8,Expert,,12409,,BAO_0000357,,,,,168,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,
306,,,B,0,Autocuration,,11126,Gallus gallus,BAO_0000019,,,,,22226,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,9031.0,
307,,,F,0,Autocuration,,11126,Homo sapiens,BAO_0000019,,,,,22226,1,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,9606.0,
308,,,F,0,Autocuration,,11126,Homo sapiens,BAO_0000019,,,,,22226,1,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,9606.0,
309,,HL-60,B,1,Autocuration,,11126,Homo sapiens,BAO_0000219,649.0,,,,80156,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,9606.0,
310,,,B,0,Autocuration,,11126,Homo sapiens,BAO_0000019,,,,,22226,1,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,9606.0,
311,,,B,0,Autocuration,,11126,Homo sapiens,BAO_0000019,,,,,22226,1,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,9606.0,
312,,Oocytes,B,7,Autocuration,,17807,Homo sapiens,BAO_0000219,,,,,104703,1,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,9606.0,
313,,,F,2,Intermediate,,16575,,BAO_0000220,,,,,100256,1,Chymotryptic inhibitory activity against 26S proteasome,,
314,,,B,2,Intermediate,,15407,,BAO_0000220,,,,,100256,1,Inhibitory activity against 26S proteasome degradation of IkB,,
315,,A2780,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,9606.0,
316,,A2780,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro inhibition of 2780/S ovarian cancer cell line,9606.0,
317,,,F,0,Autocuration,,3469,Homo sapiens,BAO_0000019,,,,,22226,1,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,9606.0,
318,,,B,3,Intermediate,,16037,,BAO_0000225,,,,,22222,1,Association constant for binding to AATT 28-mer AATT hairpin,,
319,,,B,3,Intermediate,,16037,,BAO_0000225,,,,,22222,1,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,
320,,,B,3,Intermediate,,16037,,BAO_0000225,,,,,22222,1,Reaction Rate Parameter for 28-mer AATT hairpin,,
321,,,B,3,Intermediate,,16037,,BAO_0000225,,,,,22222,1,Reaction Rate Parameter for 28-mer AATT hairpin,,
322,,,F,0,Autocuration,,16524,Homo sapiens,BAO_0000019,,,,,22226,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),9606.0,
323,,,F,0,Autocuration,,16524,Homo sapiens,BAO_0000019,,,,,22226,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),9606.0,
324,,,F,0,Autocuration,,16524,Homo sapiens,BAO_0000019,,,,,22226,1,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,9606.0,
325,,,F,0,Autocuration,,16758,Cricetulus griseus,BAO_0000019,,,,,22226,1,Cytotoxicity against cell line 2SC/20 determined by MTT test,10029.0,
326,,,F,0,Autocuration,,16758,Cricetulus griseus,BAO_0000019,,,,,22226,1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,10029.0,
327,,,F,0,Autocuration,,16758,Cricetulus griseus,BAO_0000019,,,,,22226,1,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,10029.0,
328,,,B,8,Autocuration,,14360,,BAO_0000357,,,,,241,1,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,
329,,,B,9,Expert,,14360,Homo sapiens,BAO_0000357,,,,,241,1,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,9606.0,
330,,,B,0,Autocuration,,9964,Rattus norvegicus,BAO_0000019,,,,,22226,1,Selectivity ratio of ID50 in liver and heart,10116.0,
331,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,"Selectivity, ratio of relative ID50 in liver and heart",,
332,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,
333,,,B,8,Autocuration,,9964,,BAO_0000218,,,,,12132,1,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
334,,,B,8,Autocuration,,9964,,BAO_0000218,,,,,12132,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
335,,,B,8,Autocuration,In vivo,9964,,BAO_0000218,,,,,12132,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
336,,,F,8,Autocuration,In vivo,9964,,BAO_0000218,,,,,12132,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
337,,,B,0,Autocuration,,9964,,BAO_0000019,,,,,22226,1,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,
338,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,
339,,,B,0,Autocuration,,9964,Homo sapiens,BAO_0000019,,,,,22226,1,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",9606.0,
340,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
341,,,F,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,
342,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,
343,,,B,0,Autocuration,,9964,Rattus norvegicus,BAO_0000218,,,,,22226,1,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",10116.0,
344,,,B,8,Autocuration,In vivo,9964,,BAO_0000218,,,,,12132,1,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,
345,,,B,8,Autocuration,,9964,,BAO_0000218,,,,,12132,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,
346,,,B,0,Autocuration,,9964,Rattus norvegicus,BAO_0000218,,,,,22226,1,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",10116.0,
347,,,B,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
348,,,F,8,Autocuration,,9964,,BAO_0000019,,,,,12132,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,
349,,,B,0,Autocuration,,3796,Rattus norvegicus,BAO_0000019,,,,,22226,1,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",10116.0,
350,,,B,8,Autocuration,,4251,Escherichia coli,BAO_0000357,,,,,19690,1,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,562.0,
351,,,B,8,Autocuration,,4251,Escherichia coli,BAO_0000357,,,,,19690,1,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,562.0,
352,,,B,8,Autocuration,,4251,Escherichia coli,BAO_0000357,,,,,19690,1,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,562.0,
353,,,B,8,Autocuration,,4251,Escherichia coli,BAO_0000357,,,,,19690,1,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,562.0,
354,,,B,8,Autocuration,,166,,BAO_0000357,,,,,19690,1,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,
355,,,B,8,Autocuration,,17861,,BAO_0000357,,,,,19690,1,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,
356,,,B,8,Autocuration,,166,,BAO_0000357,,,,,19690,1,Inhibition constant against 3-dehydroquinate synthase,,
357,,,B,8,Autocuration,,166,,BAO_0000357,,,,,19690,1,Association rate constant against 3-dehydroquinate synthase,,
358,,,B,8,Autocuration,,166,,BAO_0000357,,,,,19690,1,Rate constant against 3-dehydroquinate synthase,,
359,,,B,0,Autocuration,,3548,,BAO_0000019,,,,,22226,1,Inhibitory activity against fuc-TVII,,
360,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,
361,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,
362,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,
363,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,
364,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,10116.0,
365,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,10116.0,
366,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,10116.0,
367,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,10116.0,
368,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,10116.0,
369,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,10116.0,
370,Microsomes,,B,9,Autocuration,,9877,Rattus norvegicus,BAO_0000251,,Liver,,,12236,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,10116.0,
371,,,B,4,Autocuration,,3003,,BAO_0000224,,,,,104832,1,Inhibitory activity against 3-phosphoglycerate kinase.,,
372,,,B,4,Autocuration,,3003,,BAO_0000224,,,,,104832,1,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,
373,,,B,4,Autocuration,,3003,,BAO_0000224,,,,,104832,1,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,
374,,,B,9,Expert,,17185,Homo sapiens,BAO_0000357,,,,,10612,1,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,9606.0,
375,,3677 melanoma cell line,F,1,Intermediate,,6072,Homo sapiens,BAO_0000219,844.0,,,,80616,1,Cytotoxicity on 3677 melanoma cells,9606.0,
376,,3677 melanoma cell line,F,1,Intermediate,,6072,Homo sapiens,BAO_0000219,844.0,,,,80616,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,9606.0,
377,,MC-38,F,1,Intermediate,,5018,Mus musculus,BAO_0000219,700.0,,,,80617,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,10090.0,
378,,,F,0,Intermediate,,2852,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,9606.0,
379,,B16,F,0,Autocuration,,8663,,BAO_0000218,798.0,,,,22226,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,
380,,B16,F,0,Autocuration,,8663,,BAO_0000218,798.0,,,,22226,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,
381,,,F,9,Expert,,3245,Human rhinovirus 14,BAO_0000019,,,,,12464,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12131.0,
382,,,F,1,Intermediate,,3245,Human rhinovirus sp.,BAO_0000218,,,,,50085,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,169066.0,
383,,,F,1,Intermediate,,3877,human rhinovirus type 14,BAO_0000218,,,,,50679,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,169066.0,
384,,,F,1,Intermediate,,3877,human rhinovirus type 14,BAO_0000218,,,,,50679,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,169066.0,
385,,,F,9,Expert,,5861,Human rhinovirus 14,BAO_0000019,,,,,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,
386,,,F,9,Expert,,5861,Human rhinovirus 14,BAO_0000019,,,,,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,
387,,,F,9,Expert,,5861,Human rhinovirus 14,BAO_0000019,,,,,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12131.0,
388,,,F,9,Expert,,5861,Human rhinovirus 14,BAO_0000019,,,,,12464,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12131.0,
389,,,F,1,Intermediate,,13748,Enterovirus,BAO_0000218,,,,,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,12059.0,
390,,,F,1,Intermediate,,13748,Enterovirus,BAO_0000218,,,,,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,12059.0,
391,,,F,1,Intermediate,,13748,Enterovirus,BAO_0000218,,,,,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,12059.0,
392,,,F,1,Intermediate,,13748,Enterovirus,BAO_0000218,,,,,50665,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,12059.0,
393,,,B,8,Expert,,13748,Human rhinovirus B,BAO_0000357,,,,,12464,1,Inhibition of human rhinovirus 3C protease,147712.0,
394,,,B,0,Autocuration,,17699,Homo sapiens,BAO_0000019,,,,,22226,1,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,9606.0,
395,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),10090.0,
396,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),10090.0,
397,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),10090.0,
398,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),10090.0,
399,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,10090.0,
400,,3EM 37,F,1,Intermediate,,7145,Mus musculus,BAO_0000218,833.0,,,,80619,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,10090.0,
401,,3LL cell line,F,1,Intermediate,,5325,Mus musculus,BAO_0000218,847.0,,,,80620,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,10090.0,
402,,3LL cell line,F,1,Intermediate,,5325,Mus musculus,BAO_0000218,847.0,,,,80620,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,10090.0,
403,,3LL cell line,F,1,Expert,,5325,Mus musculus,BAO_0000218,847.0,,,,80620,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,10090.0,
404,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,10090.0,
405,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,10090.0,
406,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,10090.0,
407,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,10090.0,
408,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,10090.0,
409,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,10090.0,
410,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,10090.0,
411,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,10090.0,
412,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,10090.0,
413,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,10090.0,
414,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,10090.0,
415,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,10090.0,
416,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,10090.0,
417,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,10090.0,
418,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,
419,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,
420,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,
421,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,
422,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,
423,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,
424,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,
425,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,
426,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,10090.0,
427,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,10090.0,
428,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,10090.0,
429,,3LL cell line,F,1,Intermediate,,16169,Mus musculus,BAO_0000219,847.0,,,,80620,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,10090.0,
430,,3LLD122,F,1,Intermediate,,15547,Homo sapiens,BAO_0000219,971.0,,,,80621,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,9606.0,
431,,,F,0,Autocuration,,8663,,BAO_0000218,,,,,22226,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,
432,,,F,0,Autocuration,,8663,,BAO_0000218,,,,,22226,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,
433,,,F,0,Autocuration,,8663,,BAO_0000218,,,,,22226,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,
434,,,F,0,Autocuration,,8663,,BAO_0000218,,,,,22226,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,
435,,NIH3T3,F,1,Intermediate,,4504,Mus musculus,BAO_0000219,723.0,,,,80951,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,10090.0,
436,,NIH3T3,F,1,Intermediate,,4504,Mus musculus,BAO_0000219,723.0,,,,80951,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,10090.0,
437,,NIH3T3,F,8,Expert,,12695,,BAO_0000219,723.0,,,,11169,1,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,
438,,NIH3T3,F,1,Intermediate,,12695,Mus musculus,BAO_0000219,723.0,,,,80951,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,10090.0,
439,,NIH3T3,F,1,Intermediate,,12695,Mus musculus,BAO_0000219,723.0,,,,80951,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,10090.0,
440,,NIH3T3,F,1,Expert,,17642,Mus musculus,BAO_0000219,723.0,,,,80951,1,Effective dose against murine 3T3 fibroblasts cells,10090.0,
441,,NIH3T3,F,1,Expert,,17642,Mus musculus,BAO_0000219,723.0,,,,80951,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,10090.0,
442,,NIH3T3,F,1,Expert,,12340,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxic effect on 3T3 cells,10090.0,
443,,NIH3T3,F,1,Expert,,12340,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxic effect on 3T3 cells,10090.0,
444,,NIH3T3,F,1,Intermediate,,12716,Mus musculus,BAO_0000219,723.0,,,,80951,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,10090.0,
445,,NIH3T3,F,1,Intermediate,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,10090.0,
446,,NIH3T3,F,1,Intermediate,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,10090.0,
447,,NIH3T3,F,1,Expert,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,10090.0,
448,,NIH3T3,F,1,Expert,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,10090.0,
449,,NIH3T3,F,1,Intermediate,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,10090.0,
450,,NIH3T3,F,1,Expert,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,10090.0,
451,,NIH3T3,F,1,Expert,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,10090.0,
452,,NIH3T3,F,1,Intermediate,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,10090.0,
453,,NIH3T3,F,1,Expert,,17780,Mus musculus,BAO_0000218,723.0,,,,80951,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,10090.0,
454,,,F,7,Autocuration,,12751,Mus musculus,BAO_0000219,,,,,104860,1,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,10090.0,
455,,NIH3T3,F,1,Expert,,12380,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,10090.0,
456,,NIH3T3,F,1,Intermediate,,14892,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibitory activity against 3T3 cell line,10090.0,
457,,NIH3T3,F,1,Intermediate,,12695,Mus musculus,BAO_0000219,723.0,,,,80951,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,10090.0,
458,,,F,8,Expert,,12695,,BAO_0000019,,,,,11169,1,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,
459,,NIH3T3,F,1,Intermediate,,12695,Mus musculus,BAO_0000219,723.0,,,,80951,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,10090.0,
460,,NIH3T3,F,1,Intermediate,,12695,Mus musculus,BAO_0000219,723.0,,,,80951,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,10090.0,
461,,,F,8,Expert,,12695,,BAO_0000019,,,,,11169,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,
462,,,F,8,Expert,,12695,,BAO_0000019,,,,,11169,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,
463,,NIH3T3,F,1,Intermediate,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,10090.0,
464,,NIH3T3,F,1,Expert,,6277,Mus musculus,BAO_0000219,723.0,,,,80951,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,10090.0,
465,,NIH3T3,F,9,Expert,,4959,Homo sapiens,BAO_0000219,723.0,,,,9,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9606.0,
466,,NIH3T3,F,9,Expert,,4959,Homo sapiens,BAO_0000219,723.0,,,,9,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9606.0,
467,,NIH3T3,F,9,Expert,,4959,Homo sapiens,BAO_0000219,723.0,,,,188,1,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,9606.0,
468,,NIH3T3,F,9,Expert,,4959,Homo sapiens,BAO_0000219,723.0,,,,188,1,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),9606.0,
469,,NIH3T3,F,1,Intermediate,,12082,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,10090.0,
470,,NIH3T3,F,1,Intermediate,,12082,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,10090.0,
471,,NIH3T3,F,1,Intermediate,,12082,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,10090.0,
472,,NIH3T3,F,1,Intermediate,,12082,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,10090.0,
473,,NIH3T3,F,1,Intermediate,,2643,Mus musculus,BAO_0000219,723.0,,,,80951,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,10090.0,
474,,NIH3T3,F,1,Expert,,11926,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,10090.0,
475,,NIH3T3,A,1,Intermediate,,15204,Mus musculus,BAO_0000219,723.0,,,,80951,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,10090.0,
476,,NIH3T3,F,1,Expert,,15992,Mus musculus,BAO_0000219,723.0,,,,80951,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,10090.0,
477,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,10090.0,
478,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,
479,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,
480,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,
481,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,
482,,NIH3T3,F,1,Intermediate,,16279,Mus musculus,BAO_0000219,723.0,,,,80951,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),10090.0,
483,,NIH3T3,F,1,Expert,,12831,Mus musculus,BAO_0000219,723.0,,,,80951,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,10090.0,
484,,NIH3T3,F,1,Intermediate,,13497,Mus musculus,BAO_0000219,723.0,,,,80951,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,10090.0,
485,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
486,,3T3-L1,F,1,Intermediate,,13618,Mus musculus,BAO_0000219,620.0,,,,80006,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,10090.0,
487,,3T3-L1,F,1,Intermediate,,11902,Mus musculus,BAO_0000219,620.0,,,,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,10090.0,
488,,3T3-L1,F,1,Intermediate,,11902,Mus musculus,BAO_0000219,620.0,,,,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,10090.0,
489,,3T3-L1,F,1,Intermediate,,11902,Mus musculus,BAO_0000219,620.0,,,,80006,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,10090.0,
490,,3T3-L1,F,1,Intermediate,,14840,Mus musculus,BAO_0000218,620.0,,,,80006,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",10090.0,
491,,3T3-L1,F,1,Intermediate,,14840,Mus musculus,BAO_0000218,620.0,,,,80006,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",10090.0,
492,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,
493,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
494,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
495,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
496,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
497,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,
498,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,
499,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
500,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
501,,3T3-L1,F,1,Expert,,13715,,BAO_0000218,620.0,,,,80006,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
502,,3T3-L1,F,1,Expert,,13715,,BAO_0000218,620.0,,,,80006,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
503,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,
504,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
505,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,
506,,3T3-L1,F,1,Expert,,13715,,BAO_0000218,620.0,,,,80006,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
507,,3T3-L1,F,1,Expert,,13715,,BAO_0000218,620.0,,,,80006,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
508,,3T3-L1,F,1,Expert,,13715,,BAO_0000218,620.0,,,,80006,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
509,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,
510,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,
511,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000219,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,
512,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,
513,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,
514,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,
515,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,
516,,3T3-L1,F,1,Intermediate,,13715,,BAO_0000218,620.0,,,,80006,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,
517,,3T3-L1,F,8,Expert,,6411,,BAO_0000219,620.0,,,,11214,1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,
518,,3T3-L1,F,1,Intermediate,,6411,Mus musculus,BAO_0000219,620.0,,,,80006,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,10090.0,
519,,3T3-L1,F,8,Expert,,6411,,BAO_0000219,620.0,,,,11214,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,
520,,3T3-L1,F,1,Expert,,3966,Mus musculus,BAO_0000219,620.0,,,,80006,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,10090.0,
521,,3T3-L1,F,1,Intermediate,,3966,Mus musculus,BAO_0000219,620.0,,,,80006,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,10090.0,
522,,3T3-L1,F,1,Expert,,15556,Mus musculus,BAO_0000219,620.0,,,,80006,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,10090.0,
523,,3T3-L1,F,1,Expert,,5845,Mus musculus,BAO_0000219,620.0,,,,80006,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,10090.0,
524,,3T3-L1,F,1,Expert,,14422,Mus musculus,BAO_0000219,620.0,,,,80006,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,10090.0,
525,,3T3-L1,F,1,Expert,,5845,Mus musculus,BAO_0000219,620.0,,,,80006,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,10090.0,
526,,3T3-L1,F,1,Expert,,14508,Mus musculus,BAO_0000219,620.0,,,,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,10090.0,
527,,3T3-L1,F,1,Expert,,14508,Mus musculus,BAO_0000219,620.0,,,,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,10090.0,
528,,3T3-L1,F,1,Expert,,14508,Mus musculus,BAO_0000219,620.0,,,,80006,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,10090.0,
529,,3Y1 cell line,F,1,Intermediate,,6349,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,Inhibitory activity against rat fibroblast (3Y1) cell line,10116.0,
530,,3Y1 cell line,F,1,Expert,,15899,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,10116.0,
531,,3Y1 cell line,F,1,Expert,,15899,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,Cytotoxicity in 3Y1 cells.,10116.0,
532,,3Y1 cell line,F,1,Expert,,15899,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,Cytostatic effect in 3Y1 cells.,10116.0,
533,,3Y1 cell line,F,1,Intermediate,,15899,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",10116.0,
534,,3Y1 cell line,F,1,Expert,,17038,Rattus norvegicus,BAO_0000219,1118.0,,,,80622,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,10116.0,
535,,,B,0,Autocuration,,12421,,BAO_0000019,,,,,22226,1,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,
536,,,B,0,Autocuration,,12947,,BAO_0000019,,,,,22226,1,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
537,,,B,0,Autocuration,,12947,,BAO_0000019,,,,,22226,1,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,
538,,,B,9,Expert,,4896,Sus scrofa,BAO_0000019,,,,,11607,1,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,9823.0,
539,,,B,8,Autocuration,,6148,,BAO_0000019,,,,,11607,1,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,
540,,,B,8,Autocuration,,16432,,BAO_0000019,,,,,11607,1,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,
541,,,B,8,Expert,,4978,,BAO_0000019,,,,,11607,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,
542,,,B,8,Expert,,4978,,BAO_0000019,,,,,11607,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,
543,,,B,8,Autocuration,,3723,,BAO_0000019,,,,,11607,1,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,
544,,,B,8,Autocuration,,3518,,BAO_0000357,,,,,11607,1,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,
545,,,B,8,Autocuration,,4164,,BAO_0000019,,,,,11607,1,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,
546,,,B,8,Autocuration,,3518,,BAO_0000019,,,,,11607,1,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,
547,,,B,9,Expert,,4164,Sus scrofa,BAO_0000019,,,,,11607,1,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,9823.0,
548,,,B,8,Autocuration,,3518,,BAO_0000019,,,,,11607,1,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,
549,,,B,8,Autocuration,,3518,,BAO_0000357,,,,,11607,1,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,
550,,,B,8,Autocuration,,4978,,BAO_0000019,,,,,11607,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,
551,,,B,8,Autocuration,,4978,,BAO_0000019,,,,,11607,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,
552,,,B,4,Autocuration,,6455,,BAO_0000224,,,,,104733,1,Binding affinity against melatonin (MT1) receptor (pC1),,
553,,,B,0,Autocuration,,2222,,BAO_0000019,,,,,22226,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,
554,,,B,0,Autocuration,,13020,,BAO_0000019,,,,,22226,1,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,
555,,,B,0,Autocuration,,13021,,BAO_0000019,,,,,22226,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,
556,,,B,8,Autocuration,,14532,,BAO_0000357,,,,,10619,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,
557,,,B,8,Autocuration,,14118,,BAO_0000357,,,,,10619,1,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,
558,,,B,8,Autocuration,,11884,,BAO_0000221,,Hippocampus,,,51,1,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,,
559,,,B,8,Expert,,13969,,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,
560,,,B,8,Expert,,13392,,BAO_0000357,,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor,,
561,,,B,8,Expert,,14430,,BAO_0000019,,,,,51,1,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,
562,,,B,8,Autocuration,,12248,,BAO_0000221,,Hippocampus,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
563,,,B,8,Autocuration,,12249,,BAO_0000221,,Hippocampus,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
564,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
565,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
566,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
567,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,,
568,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
569,,,B,8,Autocuration,,12249,,BAO_0000221,,Hippocampus,,,51,1,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
570,,,B,8,Autocuration,,11799,,BAO_0000221,,Hippocampus,,,51,1,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
571,Membranes,,B,9,Expert,,14331,Rattus norvegicus,BAO_0000249,,,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10116.0,
572,,,B,8,Expert,,11884,Bos taurus,BAO_0000221,,Hippocampus,,,51,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,9913.0,
573,,,B,8,Autocuration,,14331,,BAO_0000221,,Hippocampus,,,51,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,,
574,,,B,8,Autocuration,,11701,,BAO_0000221,,Hippocampus,,,51,1,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,,
575,,,B,8,Expert,,11701,,BAO_0000221,,Hippocampus,,,51,1,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,,
576,,,B,8,Autocuration,,12248,,BAO_0000221,,Hippocampus,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,,
577,,CHO,B,8,Autocuration,,12248,,BAO_0000219,449.0,,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,
578,,,B,8,Expert,,12248,,BAO_0000221,,Hippocampus,,,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
579,,,B,8,Expert,,12249,,BAO_0000221,,Hippocampus,,,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,,
580,,CHO,B,8,Autocuration,,12248,,BAO_0000219,449.0,,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
581,,,B,8,Expert,,11799,,BAO_0000221,,Hippocampus,,,51,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",,
582,,,B,8,Autocuration,,634,,BAO_0000357,,,,,51,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
583,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,,
584,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
585,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
586,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
587,,,B,8,Autocuration,,9995,,BAO_0000221,,Hippocampus,,,51,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,,
588,,,B,8,Expert,,12210,,BAO_0000218,,Hippocampus,,,51,1,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,,
589,,,B,8,Expert,,13311,,BAO_0000221,,Hippocampus,,,51,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
590,,CHO,B,9,Expert,,2331,Homo sapiens,BAO_0000219,449.0,,,,51,1,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",9606.0,
591,,,F,8,Autocuration,,1375,Cavia porcellus,BAO_0000019,,,,,51,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,10141.0,
592,,,F,8,Autocuration,,1375,Cavia porcellus,BAO_0000019,,,,,51,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,10141.0,
593,,,F,8,Autocuration,,11574,Cavia porcellus,BAO_0000221,,Hippocampus,,,51,1,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,10141.0,
594,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,10141.0,
595,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,
596,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,10141.0,
597,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,
598,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,10141.0,
599,,,B,8,Autocuration,,12867,Cavia porcellus,BAO_0000221,,Ileum,,,51,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,10141.0,
600,,,B,8,Autocuration,,11574,Cavia porcellus,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,10141.0,
601,,,B,8,Autocuration,,13114,Cavia porcellus,BAO_0000357,,,,,51,1,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,10141.0,
602,,,B,8,Autocuration,,13181,Cavia porcellus,BAO_0000357,,,,,51,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,10141.0,
603,,,B,8,Autocuration,,10639,Cavia porcellus,BAO_0000221,,Hippocampus,,,106,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10141.0,
604,,,F,8,Autocuration,,10639,Cavia porcellus,BAO_0000221,,Hippocampus,,,106,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,10141.0,
605,,CHO,B,8,Autocuration,,11883,Cricetulus griseus,BAO_0000218,449.0,,,,11863,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10029.0,
606,,,B,8,Autocuration,,17785,,BAO_0000357,,,,,51,1,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,
607,,HeLa,F,8,Autocuration,,1558,,BAO_0000219,308.0,,,,51,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,
608,,HeLa,F,8,Autocuration,,1558,,BAO_0000219,308.0,,,,51,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,
609,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
610,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
611,,CHO,F,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,
612,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,
613,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,
614,,CHO,B,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
615,,CHO,B,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
616,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,
617,,,F,8,Autocuration,,14256,,BAO_0000219,,,,,51,1,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,
618,,HeLa,B,9,Expert,,3445,Homo sapiens,BAO_0000219,308.0,,,,51,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9606.0,
619,,HeLa,B,9,Expert,,3445,Homo sapiens,BAO_0000219,308.0,,,,51,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,9606.0,
620,,CHO,B,9,Expert,,17200,Homo sapiens,BAO_0000219,449.0,,,,51,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,9606.0,
621,,CHO,B,9,Expert,,17200,Homo sapiens,BAO_0000219,449.0,,,,51,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,9606.0,
622,,,F,8,Autocuration,,15180,,BAO_0000019,,,,,51,1,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
623,,,F,8,Autocuration,,15180,,BAO_0000019,,,,,51,1,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,
624,,,F,8,Autocuration,,16026,,BAO_0000019,,,,,51,1,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
625,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
626,,CHO,F,9,Expert,,2759,Homo sapiens,BAO_0000219,449.0,,,,51,1,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9606.0,
627,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
628,,CHO,F,9,Expert,,2759,Homo sapiens,BAO_0000219,449.0,,,,51,1,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9606.0,
629,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
630,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,
631,,CHO,F,9,Expert,,2759,Homo sapiens,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),9606.0,
632,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,
633,,CHO,F,9,Expert,,2759,Homo sapiens,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),9606.0,
634,,,F,9,Expert,,3445,Homo sapiens,BAO_0000019,,,,,51,1,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,9606.0,
635,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,
636,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",9606.0,
637,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",9606.0,
638,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
639,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
640,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
641,,CHO,F,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,
642,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,
643,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,
644,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
645,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
646,,CHO,F,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
647,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,
648,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,
649,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,
650,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
651,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
652,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
653,,HEK293,F,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
654,,,F,9,Expert,,6876,Homo sapiens,BAO_0000019,,,,,51,1,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",9606.0,
655,,,F,8,Expert,,6876,,BAO_0000019,,,,,51,1,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,
656,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,9606.0,
657,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,9606.0,
658,,,F,8,Autocuration,,5548,,BAO_0000019,,,,,51,1,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
659,,,F,8,Expert,,5548,,BAO_0000019,,,,,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,
660,,,F,8,Autocuration,,5548,,BAO_0000019,,,,,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
661,,,F,8,Autocuration,,5548,,BAO_0000019,,,,,51,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,
662,,,F,8,Expert,,5929,,BAO_0000019,,,,,51,1,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,
663,,,F,9,Expert,,5929,Homo sapiens,BAO_0000019,,,,,51,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",9606.0,
664,,,F,9,Expert,,5929,Homo sapiens,BAO_0000019,,,,,51,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",9606.0,
665,,,F,8,Autocuration,,16245,,BAO_0000019,,,,,51,1,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,
666,,,F,8,Expert,,5640,,BAO_0000019,,,,,51,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
667,,,F,8,Autocuration,,5640,,BAO_0000019,,,,,51,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,
668,,CHO,F,8,Autocuration,,14509,,BAO_0000219,449.0,,,,51,1,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,
669,,CHO,F,8,Expert,,14509,,BAO_0000219,449.0,,,,51,1,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,
670,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,51,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
671,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,51,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
672,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
673,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,
674,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,
675,,,F,9,Expert,,6563,Homo sapiens,BAO_0000019,,,,,51,1,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,9606.0,
676,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
677,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,9606.0,
678,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,
679,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9606.0,
680,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,9606.0,
681,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,9606.0,
682,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",9606.0,
683,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",9606.0,
684,,,F,9,Expert,,5272,Homo sapiens,BAO_0000019,,,,,51,1,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,9606.0,
685,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,51,1,Inhibition of human 5-hydroxytryptamine 1A receptor,9606.0,
686,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
687,,HEK293,B,9,Expert,,13706,,BAO_0000219,722.0,,,,105,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,
688,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,51,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,
689,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
690,,,B,8,Expert,,6861,,BAO_0000357,,,,,51,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,
691,,,B,9,Expert,,17200,Homo sapiens,BAO_0000357,,,,,51,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,9606.0,
692,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,
693,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
694,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,10116.0,
695,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,10116.0,
696,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,10116.0,
697,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,10116.0,
698,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,10116.0,
699,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,10116.0,
700,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,10116.0,
701,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,10116.0,
702,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,10116.0,
703,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,10116.0,
704,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,10116.0,
705,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,10116.0,
706,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,10116.0,
707,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,10116.0,
708,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,10116.0,
709,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,10116.0,
710,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,10116.0,
711,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,10116.0,
712,,,F,0,Autocuration,In vivo,12058,Rattus norvegicus,BAO_0000218,,,,,22226,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,10116.0,
713,,,B,4,Autocuration,,11440,,BAO_0000019,,,,,105093,1,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,
714,,,B,8,Autocuration,,6238,,BAO_0000249,,Hypothalamus,,,11923,1,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,,
715,,,B,8,Autocuration,,10046,,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,
716,,,B,8,Autocuration,,10046,,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,
717,,,B,8,Expert,,10046,,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
718,,,B,8,Autocuration,,167,,BAO_0000357,,,,,55,1,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,
719,,,B,8,Autocuration,,167,,BAO_0000357,,,,,55,1,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,
720,,,F,8,Autocuration,,11520,,BAO_0000019,,,,,12166,1,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,
721,,,F,8,Autocuration,,11520,,BAO_0000019,,,,,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
722,,,F,8,Autocuration,,11520,,BAO_0000019,,,,,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
723,,,F,8,Autocuration,,11520,,BAO_0000019,,,,,12166,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,
724,,,F,8,Autocuration,,135,Cavia porcellus,BAO_0000019,,,,,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,10141.0,
725,,,F,8,Autocuration,,135,Cavia porcellus,BAO_0000019,,,,,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,10141.0,
726,,,B,8,Autocuration,,11311,Cavia porcellus,BAO_0000019,,,,,55,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,10141.0,
727,,,B,8,Autocuration,,10193,Cavia porcellus,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10141.0,
728,,,B,9,Expert,,12281,Homo sapiens,BAO_0000357,,,,,55,1,Inhibitory concentration against 5-lipoxygenase from human whole blood,9606.0,
729,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,55,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
730,,,F,8,Autocuration,,12576,,BAO_0000218,,,,,17087,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
731,,,B,8,Autocuration,,12281,,BAO_0000357,,,,,17087,1,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,
732,,,F,8,Autocuration,,12576,,BAO_0000218,,,,,17087,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,
733,,,B,8,Expert,,11089,Sus scrofa,BAO_0000019,,,,,55,1,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,9823.0,
734,,,B,8,Expert,,11006,,BAO_0000357,,,,,12166,1,In vitro inhibition of rat 5-Lipoxygenase,,
735,,,B,9,Expert,,11481,Rattus norvegicus,BAO_0000357,,,,,12166,1,Inhibitory activity against 5-Lipoxygenase,10116.0,
736,,RBL-1,B,8,Expert,,10864,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,
737,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
738,,RBL-1,B,8,Autocuration,,11311,,BAO_0000219,702.0,,,,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,
739,,,B,8,Autocuration,,11311,,BAO_0000019,,,,,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,
740,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,
741,,,B,8,Autocuration,,11006,,BAO_0000357,,,,,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
742,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
743,,,B,8,Autocuration,,11311,,BAO_0000357,,,,,12166,1,The compound was tested for inhibition of isolated 5-Lipoxygenase,,
744,,,B,0,Autocuration,,11481,Rattus norvegicus,BAO_0000019,,,,,22226,1,Ratio of IC50 against 5-LO and COX,10116.0,
745,,,B,8,Autocuration,,11006,,BAO_0000357,,,,,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,
746,,,B,8,Autocuration,,11006,,BAO_0000357,,,,,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,
747,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,
748,,,F,8,Autocuration,,11006,,BAO_0000019,,,,,12166,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,
749,,,B,8,Autocuration,,4288,,BAO_0000357,,Prostate gland,,,120,1,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,,
750,,,B,0,Autocuration,,7587,Columba livia,BAO_0000019,,,,,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,8932.0,
751,,,B,0,Autocuration,,7587,Columba livia,BAO_0000019,,,,,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,8932.0,
752,,,B,0,Autocuration,,7587,Columba livia,BAO_0000019,,,,,22226,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,8932.0,
753,,,B,8,Autocuration,,11249,,BAO_0000357,,,,,10732,1,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,
754,,,F,9,Expert,,8003,Rattus norvegicus,BAO_0000019,,,,,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,10116.0,
755,,,F,9,Expert,,8003,Rattus norvegicus,BAO_0000019,,,,,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),10116.0,
756,,,F,9,Expert,,8003,Rattus norvegicus,BAO_0000019,,,,,12198,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),10116.0,
757,,,B,8,Expert,,12416,,BAO_0000221,,Hippocampus,,,10576,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
758,,,B,8,Autocuration,,16293,,BAO_0000357,,,,,51,1,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,
759,,,B,0,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,22226,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,
760,,,B,0,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,22226,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,
761,,,B,0,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,22226,1,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,9986.0,
762,,,B,0,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,22226,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,9986.0,
763,,,B,4,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,104744,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
764,,,B,4,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,104744,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
765,,,B,4,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,104744,1,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,,
766,Membranes,,B,4,Autocuration,,9841,,BAO_0000249,,,,,104744,1,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,
767,,,B,5,Autocuration,,8822,Rattus norvegicus,BAO_0000249,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,10116.0,
768,,,B,5,Autocuration,,9806,Rattus norvegicus,BAO_0000019,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,10116.0,
769,,,B,5,Autocuration,,9806,Rattus norvegicus,BAO_0000019,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,10116.0,
770,,,B,4,Autocuration,,8868,,BAO_0000224,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,
771,,,B,4,Autocuration,,9036,,BAO_0000221,,Hippocampus,,,104744,1,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,,
772,,,B,4,Autocuration,,11374,,BAO_0000221,,Hippocampus,,,104744,1,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,,
773,,,B,4,Autocuration,,10881,,BAO_0000224,,,,,104744,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,
774,,,B,4,Autocuration,,8822,,BAO_0000019,,,,,104744,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,
775,,,B,5,Autocuration,,9806,Rattus norvegicus,BAO_0000249,,,,,104744,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,10116.0,
776,,,B,4,Autocuration,,15463,,BAO_0000019,,,,,104744,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
777,,,B,4,Autocuration,,15463,,BAO_0000019,,,,,104744,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
778,,,B,4,Autocuration,,14542,,BAO_0000221,,Brain,,,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
779,,,B,4,Autocuration,,14542,,BAO_0000221,,Brain,,,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
780,,,B,4,Autocuration,,8569,,BAO_0000019,,,,,104744,1,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,
781,,,B,5,Autocuration,,10062,Rattus norvegicus,BAO_0000224,,,,,104744,1,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,10116.0,
782,,,B,4,Autocuration,,4771,,BAO_0000224,,,,,104744,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,
783,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104744,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
784,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104744,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
785,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104744,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,
786,,,B,4,Autocuration,,15463,,BAO_0000019,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
787,,,B,4,Autocuration,,15463,,BAO_0000019,,,,,104744,1,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,
788,,,B,4,Autocuration,,9098,,BAO_0000224,,,,,104744,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,
789,,,B,0,Autocuration,,3070,Rattus norvegicus,BAO_0000019,,,,,22226,1,Affinity for 5-hydroxytryptamine 1 receptor,10116.0,
790,,,B,4,Autocuration,,14542,,BAO_0000221,,Brain,,,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,,
791,,,B,4,Autocuration,,14542,,BAO_0000221,,Brain,,,104744,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,,
792,,,B,4,Autocuration,,6398,,BAO_0000224,,,,,104744,1,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,
793,,,B,4,Autocuration,,1344,,BAO_0000221,,Brain,,,104744,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,,
794,,,B,4,Autocuration,,11963,,BAO_0000019,,,,,104744,1,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,
795,,,B,0,Autocuration,,8908,Rattus norvegicus,BAO_0000019,,,,,22226,1,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,10116.0,
796,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104744,1,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,
797,,,B,5,Autocuration,,8841,Rattus norvegicus,BAO_0000019,,,,,104744,1,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,10116.0,
798,,,B,0,Autocuration,,8814,Rattus norvegicus,BAO_0000019,,,,,22226,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,10116.0,
799,,,B,4,Autocuration,,11752,,BAO_0000019,,,,,104744,1,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,
800,,,B,4,Autocuration,,11642,,BAO_0000221,,Brain,,,104744,1,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,,
801,,,B,4,Autocuration,,11642,,BAO_0000019,,,,,104744,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,
802,,,B,4,Autocuration,,9231,,BAO_0000220,,Brain,,,104744,1,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,,
803,,,B,4,Autocuration,,11351,,BAO_0000221,,Brain,,,104744,1,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,,
804,,,B,0,Autocuration,,4639,,BAO_0000019,,,,,22226,1,Compound was tested for binding affinity against 5-HT1 receptor,,
805,,,B,0,Autocuration,,1205,,BAO_0000019,,,,,22226,1,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,
806,,,B,8,Expert,,10025,,BAO_0000357,,,,,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
807,,,F,8,Autocuration,,13241,,BAO_0000249,,,,,10576,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
808,,,F,8,Autocuration,In vivo,16245,,BAO_0000218,,,,,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,
809,,,F,8,Autocuration,In vivo,16245,,BAO_0000218,,,,,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,
810,,,F,8,Autocuration,,12438,,BAO_0000019,,,,,10576,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,
811,,,F,8,Autocuration,In vivo,16245,,BAO_0000218,,,,,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,
812,,,F,8,Autocuration,In vivo,16245,,BAO_0000218,,,,,10576,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,
813,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,
814,,,F,8,Autocuration,,15535,,BAO_0000219,,,,,10576,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,
815,,,F,8,Expert,,15535,,BAO_0000219,,,,,51,1,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,
816,,,F,8,Autocuration,,15535,,BAO_0000219,,,,,10576,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,
817,,,B,8,Expert,,9888,,BAO_0000249,,,,,10576,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,
818,,,B,8,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,10576,1,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,,
819,,,B,8,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,10576,1,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,,
820,Membranes,,B,8,Expert,,17331,,BAO_0000249,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,
821,,,B,9,Expert,,10845,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10116.0,
822,,,B,9,Expert,,10845,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10116.0,
823,,,B,8,Expert,,10845,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,,
824,,,B,9,Expert,,10845,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10116.0,
825,,,B,9,Expert,,10845,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10116.0,
826,,,B,8,Expert,,13730,,BAO_0000357,,,,,10576,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,
827,,,B,8,Expert,,13508,,BAO_0000249,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,
828,,,B,8,Expert,,13508,,BAO_0000249,,Hippocampus,,,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,,
829,,,B,8,Expert,,12073,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
830,,,B,8,Autocuration,,4671,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,,
831,,,B,8,Expert,,13631,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,,
832,,,B,8,Autocuration,,12438,,BAO_0000357,,,,,10576,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,
833,,,B,8,Autocuration,,10483,,BAO_0000019,,,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,
834,,,B,8,Autocuration,,10483,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,,
835,,,B,8,Intermediate,,12352,,BAO_0000249,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,
836,,,B,8,Autocuration,,14732,,BAO_0000249,,Hippocampus,,,10576,1,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,,
837,,,B,9,Expert,,11049,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10116.0,
838,,,B,9,Expert,,11049,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10116.0,
839,,,B,8,Expert,,13657,,BAO_0000249,,,,,10576,1,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,
840,,,B,8,Autocuration,,11473,,BAO_0000019,,,,,10576,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,
841,,,B,8,Autocuration,,2014,,BAO_0000249,,,,,10576,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
842,,,B,8,Expert,,3086,,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
843,,,B,8,Expert,,15854,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
844,,,B,8,Expert,,10922,,BAO_0000221,,Hippocampus,,,10576,1,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
845,,,B,8,Expert,,13346,,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,,
846,,,B,8,Expert,,15311,,BAO_0000357,,,,,10576,1,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,
847,,,B,8,Autocuration,,10922,,BAO_0000221,,Hippocampus,,,10576,1,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,,
848,,,B,8,Autocuration,,10025,,BAO_0000357,,,,,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,
849,,,B,8,Expert,,10025,,BAO_0000357,,,,,10576,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,
850,,,B,8,Autocuration,,9742,,BAO_0000019,,,,,10576,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
851,,,F,8,Autocuration,,9742,,BAO_0000019,,,,,10576,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,
852,,,B,8,Expert,,12304,,BAO_0000019,,,,,10576,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
853,,,B,8,Autocuration,,15789,,BAO_0000221,,Hippocampus,,,10576,1,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,,
854,,,B,8,Autocuration,,9912,,BAO_0000019,,,,,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,
855,,,B,8,Autocuration,,9912,,BAO_0000019,,,,,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,
856,,,B,8,Autocuration,,9912,,BAO_0000019,,,,,10576,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,
857,,,B,8,Expert,,16693,,BAO_0000019,,,,,10576,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
858,,,B,8,Expert,,13276,,BAO_0000357,,,,,10576,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
859,,,B,8,Autocuration,,12678,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
860,,,B,8,Autocuration,,11825,,BAO_0000357,,,,,10576,1,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,
861,,,B,8,Expert,,12443,,BAO_0000357,,,,,10576,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,
862,,,B,8,Expert,,13830,,BAO_0000357,,,,,10576,1,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
863,,,B,8,Expert,,14286,,BAO_0000249,,Hippocampus,,,10576,1,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,,
864,,,B,9,Expert,,14356,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10116.0,
865,,,B,8,Autocuration,,15306,,BAO_0000357,,,,,10576,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,
866,,,B,8,Expert,,15306,,BAO_0000357,,,,,10576,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,
867,,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,,,,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10116.0,
868,,,B,8,Autocuration,,3651,,BAO_0000221,,Hippocampus,,,10576,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",,
869,,,F,8,Autocuration,,14331,,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
870,,,F,8,Autocuration,,14331,,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,,
871,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,10576,1,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10116.0,
872,,,B,9,Expert,,10639,Rattus norvegicus,BAO_0000019,,,,,10576,1,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10116.0,
873,,,B,8,Autocuration,,12306,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
874,,,B,9,Expert,,1348,Rattus norvegicus,BAO_0000357,,,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10116.0,
875,,,B,8,Autocuration,,13605,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,,
876,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,
877,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
878,,CHO,F,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,
879,,,B,8,Autocuration,,15267,,BAO_0000357,,,,,51,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
880,,,B,8,Autocuration,,16532,,BAO_0000357,,,,,51,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,
881,,,F,8,Autocuration,,6563,,BAO_0000019,,,,,51,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,
882,,CHO,B,8,Autocuration,,4751,,BAO_0000219,449.0,,,,51,1,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,
883,,,B,8,Autocuration,,15463,,BAO_0000357,,,,,51,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,
884,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,51,1,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,
885,,,B,8,Autocuration,,5640,,BAO_0000357,,,,,51,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
886,,,B,8,Autocuration,,6563,,BAO_0000357,,,,,51,1,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,
887,,,B,8,Autocuration,,5548,,BAO_0000357,,,,,51,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,
888,,,B,8,Autocuration,,6347,,BAO_0000357,,,,,51,1,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,
889,,HEK293,F,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
890,,,B,8,Autocuration,,13047,,BAO_0000019,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,
891,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,51,1,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,
892,,,F,8,Expert,,5640,,BAO_0000019,,,,,51,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,
893,,,F,8,Autocuration,,5640,,BAO_0000019,,,,,51,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,
894,,HeLa,B,8,Expert,,17211,,BAO_0000219,308.0,,,,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,
895,,CHO,B,8,Autocuration,,4751,,BAO_0000219,449.0,,,,51,1,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,
896,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,51,1,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,9606.0,
897,,,B,8,Autocuration,,4707,,BAO_0000357,,,,,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,
898,,,B,9,Expert,,13910,Homo sapiens,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,9606.0,
899,,HeLa,B,8,Autocuration,,16190,,BAO_0000219,308.0,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,
900,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
901,,CHO,B,8,Autocuration,,11898,,BAO_0000219,449.0,,,,51,1,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,
902,,CHO,B,8,Autocuration,,11898,,BAO_0000219,449.0,,,,51,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
903,,,B,8,Autocuration,,14331,,BAO_0000357,,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor,,
904,,CHO,B,8,Expert,,17624,,BAO_0000219,449.0,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,
905,,CHO,B,8,Autocuration,,17624,,BAO_0000219,449.0,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,
906,,,B,8,Autocuration,,3307,,BAO_0000357,,,,,51,1,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,
907,,CHO,B,9,Expert,,6563,Homo sapiens,BAO_0000219,449.0,,,,51,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9606.0,
908,,,B,8,Autocuration,,14165,,BAO_0000019,,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,
909,,,B,8,Autocuration,,5732,,BAO_0000357,,,,,51,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
910,,,B,8,Expert,,13366,,BAO_0000357,,,,,51,1,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
911,,,B,8,Autocuration,,17626,,BAO_0000357,,,,,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,
912,,HeLa,B,8,Expert,,6588,,BAO_0000219,308.0,,,,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,
913,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,51,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,
914,,,B,8,Autocuration,,15463,,BAO_0000357,,,,,51,1,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
915,,,B,8,Autocuration,,15463,,BAO_0000357,,,,,51,1,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
916,,,B,8,Autocuration,,14770,,BAO_0000357,,,,,51,1,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,
917,,Cell line,B,8,Autocuration,,16245,,BAO_0000219,1167.0,,,,51,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,
918,,,B,8,Autocuration,,16245,,BAO_0000019,,,,,51,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,
919,,,B,8,Autocuration,,5548,,BAO_0000357,,,,,51,1,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,
920,,,B,8,Expert,,5548,,BAO_0000357,,,,,51,1,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
921,,,B,8,Autocuration,,5548,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
922,,,B,8,Expert,,6876,,BAO_0000357,,,,,51,1,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,
923,,,B,8,Autocuration,,2598,,BAO_0000357,,,,,51,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
924,,,B,8,Expert,,17785,,BAO_0000357,,,,,51,1,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,
925,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
926,,,B,8,Expert,,5929,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
927,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
928,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,51,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,
929,,,B,8,Expert,,16026,,BAO_0000357,,,,,51,1,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
930,,,B,8,Autocuration,,12469,,BAO_0000219,,,,,51,1,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,
931,,,B,9,Expert,,15874,Homo sapiens,BAO_0000357,,,,,51,1,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,9606.0,
932,,,B,8,Autocuration,,15874,,BAO_0000357,,,,,51,1,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
933,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,51,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,
934,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,51,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,
935,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,51,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,
936,,CHO-K1,F,8,Expert,,13729,,BAO_0000219,485.0,,,,51,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,
937,,,B,8,Autocuration,,15413,,BAO_0000019,,,,,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,
938,,,B,8,Autocuration,,15413,,BAO_0000019,,,,,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,
939,,,B,8,Autocuration,,15413,,BAO_0000019,,,,,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,
940,,,B,8,Autocuration,,15413,,BAO_0000019,,,,,51,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,
941,,HeLa,B,9,Expert,,3445,Homo sapiens,BAO_0000219,308.0,,,,51,1,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,9606.0,
942,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
943,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,
944,,,B,8,Autocuration,,17626,,BAO_0000357,,,,,51,1,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,
945,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,51,1,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,9606.0,
946,,,B,8,Expert,,5640,,BAO_0000357,,,,,51,1,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,
947,,,B,8,Expert,,5272,Rattus norvegicus,BAO_0000357,,,,,51,1,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,10116.0,
948,,CHO,B,8,Autocuration,,4622,,BAO_0000219,449.0,,,,51,1,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,
949,,,B,8,Expert,,17085,,BAO_0000019,,,,,51,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,
950,,,B,8,Autocuration,,3025,,BAO_0000357,,,,,51,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,
951,,,B,8,Expert,,15315,,BAO_0000357,,,,,51,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,
952,,,B,8,Autocuration,,15267,,BAO_0000357,,,,,51,1,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,
953,,HeLa,B,8,Autocuration,,17158,,BAO_0000219,308.0,,,,51,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,
954,,HeLa,B,9,Expert,,14214,Homo sapiens,BAO_0000219,308.0,,,,51,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,9606.0,
955,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
956,,,B,8,Autocuration,,16532,,BAO_0000357,,,,,51,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,
957,,,B,9,Expert,,2391,Homo sapiens,BAO_0000357,,,,,51,1,Affinity for 5-hydroxytryptamine 1A receptor subtype,9606.0,
958,,,B,8,Autocuration,,14447,,BAO_0000019,,,,,51,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,
959,,,B,8,Autocuration,,14447,,BAO_0000019,,,,,51,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,
960,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,51,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,
961,,,B,9,Expert,,13051,Homo sapiens,BAO_0000357,,,,,51,1,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,9606.0,
962,,,F,8,Autocuration,,16026,,BAO_0000019,,,,,51,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,
963,,,B,8,Expert,,17085,,BAO_0000019,,,,,51,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,
964,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
965,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,51,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,
966,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
967,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,
968,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
969,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,51,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,
970,,,F,8,Autocuration,,16394,,BAO_0000019,,,,,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
971,,,F,8,Autocuration,,16394,,BAO_0000019,,,,,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
972,,,F,8,Autocuration,,16394,,BAO_0000019,,,,,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,
973,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,51,1,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,
974,,,B,8,Autocuration,,16394,,BAO_0000019,,,,,51,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,
975,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,
976,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,51,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,
977,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,51,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,
978,,HEK293,F,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
979,,,F,8,Expert,,5640,,BAO_0000019,,,,,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,
980,,,F,8,Autocuration,,5640,,BAO_0000019,,,,,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,
981,,,F,8,Autocuration,,5640,,BAO_0000019,,,,,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,
982,,,F,8,Autocuration,,5640,,BAO_0000019,,,,,51,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,
983,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,
984,,,F,8,Autocuration,,16394,,BAO_0000019,,,,,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,
985,,,F,9,Expert,,16394,Homo sapiens,BAO_0000019,,,,,51,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",9606.0,
986,,,F,9,Expert,,3445,Homo sapiens,BAO_0000019,,,,,51,1,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,9606.0,
987,,CHO,B,8,Expert,,4316,,BAO_0000219,449.0,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,
988,,,B,8,Expert,,4316,,BAO_0000019,,,,,51,1,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,
989,,,F,9,Expert,,15180,Homo sapiens,BAO_0000019,,,,,51,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9606.0,
990,,,F,9,Expert,,15180,Homo sapiens,BAO_0000019,,,,,51,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,9606.0,
991,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
992,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
993,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
994,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
995,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
996,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,
997,,,F,8,Autocuration,,15042,,BAO_0000019,,,,,51,1,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,
998,,HeLa,F,9,Expert,,15180,Homo sapiens,BAO_0000219,308.0,,,,51,1,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,
999,,HeLa,F,9,Expert,,15180,Homo sapiens,BAO_0000219,308.0,,,,51,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,
1000,,HeLa,F,9,Expert,,15180,Homo sapiens,BAO_0000219,308.0,,,,51,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,9606.0,
1001,,,F,8,Autocuration,,16245,,BAO_0000019,,,,,51,1,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,
1002,,,F,8,Autocuration,,16026,,BAO_0000019,,,,,51,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1003,,HEK293,F,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,
1004,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1005,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,
1006,,CHO,F,9,Expert,,2759,Homo sapiens,BAO_0000219,449.0,,,,51,1,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),9606.0,
1007,,CHO,F,8,Autocuration,,2759,,BAO_0000219,449.0,,,,51,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,
1008,,,F,8,Expert,,15419,,BAO_0000219,,,,,51,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,
1009,,,F,8,Autocuration,,15419,,BAO_0000219,,,,,51,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,
1010,,,F,8,Autocuration,,16026,,BAO_0000019,,,,,51,1,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,
1011,,,B,8,Expert,In vitro,1414,,BAO_0000219,,,,,51,1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,
1012,,,B,8,Expert,In vitro,1414,,BAO_0000219,,,,,51,1,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,
1013,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,51,1,Binding activity radioligand.,,
1014,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,51,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1015,,,B,8,Autocuration,,5104,,BAO_0000357,,,,,51,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1016,,,B,8,Autocuration,,5105,,BAO_0000357,,,,,51,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,
1017,,,B,8,Autocuration,,16312,,BAO_0000357,,,,,51,1,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,
1018,,,B,9,Expert,,15180,Homo sapiens,BAO_0000357,,,,,51,1,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,9606.0,
1019,,,B,8,Autocuration,,5033,,BAO_0000357,,,,,51,1,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,
1020,,CHO,B,9,Expert,,16909,Homo sapiens,BAO_0000219,449.0,,,,51,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9606.0,
1021,,,F,8,Autocuration,,2590,,BAO_0000019,,,,,51,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,
1022,,,F,8,Autocuration,,2590,,BAO_0000019,,,,,51,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,
1023,,,B,8,Expert,,16394,,BAO_0000019,,,,,51,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,
1024,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,51,1,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,9606.0,
1025,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,
1026,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,
1027,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1028,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,
1029,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,
1030,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,
1031,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,
1032,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,51,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,
1033,,,B,8,Autocuration,,15316,,BAO_0000219,,,,,51,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,
1034,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,51,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,
1035,,HeLa,B,8,Expert,,14727,,BAO_0000219,308.0,,,,51,1,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1036,,,B,8,Expert,,14727,,BAO_0000019,,,,,51,1,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,
1037,,HEK293,B,8,Autocuration,,15146,,BAO_0000219,722.0,,,,51,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,
1038,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,51,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,
1039,,,B,8,Autocuration,,16429,,BAO_0000219,,,,,51,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,
1040,,HeLa,B,9,Expert,,15042,Homo sapiens,BAO_0000219,308.0,,,,51,1,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,9606.0,
1041,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,51,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,
1042,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,51,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,
1043,,,B,9,Expert,,17200,,BAO_0000357,,,,,51,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,
1044,,,B,9,Autocuration,,13051,Homo sapiens,BAO_0000357,,,,,51,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,9606.0,
1045,,,B,8,Autocuration,,5486,,BAO_0000357,,,,,106,1,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
1046,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,105,1,Binding affinity against 5-HT1D receptor,,
1047,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,105,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1048,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,107,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,
1049,,,B,8,Autocuration,,13506,Homo sapiens,BAO_0000357,,,,,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,9606.0,
1050,,,B,8,Autocuration,,15267,,BAO_0000357,,,,,51,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,
1051,,,F,8,Autocuration,In vivo,16616,,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,
1052,,,F,8,Autocuration,In vivo,16616,,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,
1053,,,F,8,Autocuration,In vivo,16616,,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,
1054,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,10090.0,
1055,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,10090.0,
1056,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,10090.0,
1057,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,10090.0,
1058,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,10090.0,
1059,,,F,9,Expert,,16616,Mus musculus,BAO_0000218,,,,,11863,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,10090.0,
1060,,,B,8,Autocuration,,10297,,BAO_0000221,,Hippocampus,,,11863,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,,
1061,,,B,8,Expert,,13704,,BAO_0000357,,,,,11863,1,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,
1062,,,B,9,Expert,,10297,Mus musculus,BAO_0000221,,Hippocampus,,,11863,1,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10090.0,
1063,,,B,8,Autocuration,,10297,,BAO_0000221,,Hippocampus,,,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1064,,,B,9,Expert,,10297,Mus musculus,BAO_0000221,,Hippocampus,,,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,10090.0,
1065,,,B,8,Autocuration,,10297,,BAO_0000221,,Hippocampus,,,11863,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,,
1066,,,B,8,Autocuration,,217,,BAO_0000357,,,,,11863,1,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,
1067,,,B,9,Expert,,10297,Mus musculus,BAO_0000221,,Hippocampus,,,11863,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,10090.0,
1068,,,B,8,Autocuration,,4921,Sus scrofa,BAO_0000357,,,,,51,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,9823.0,
1069,,,B,8,Autocuration,,4921,Sus scrofa,BAO_0000357,,,,,51,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,9823.0,
1070,,,B,8,Autocuration,,4996,Sus scrofa,BAO_0000019,,,,,51,1,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,9823.0,
1071,,,B,8,Autocuration,,12918,Sus scrofa,BAO_0000357,,,,,51,1,Compound was evaluated for the binding affinity at 5- HT1A receptor,9823.0,
1072,,,B,8,Autocuration,,5333,Sus scrofa,BAO_0000019,,,,,51,1,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,9823.0,
1073,,,B,8,Autocuration,,4437,Sus scrofa,BAO_0000019,,,,,51,1,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,9823.0,
1074,,,B,8,Autocuration,,1742,Sus scrofa,BAO_0000019,,,,,51,1,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,9823.0,
1075,,,B,8,Expert,,16688,Sus scrofa,BAO_0000357,,,,,51,1,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,9823.0,
1076,,,B,8,Autocuration,,12861,Sus scrofa,BAO_0000357,,,,,51,1,Binding activity radioligand.,9823.0,
1077,,,B,8,Expert,,12861,Sus scrofa,BAO_0000019,,,,,51,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,9823.0,
1078,,,B,8,Autocuration,,12861,Sus scrofa,BAO_0000019,,,,,51,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,9823.0,
1079,,,B,8,Expert,,12490,,BAO_0000019,,,,,10624,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,
1080,,,B,8,Expert,,11828,Sus scrofa,BAO_0000019,,,,,51,1,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,9823.0,
1081,,,B,8,Autocuration,,11866,Sus scrofa,BAO_0000221,,Hippocampus,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,9823.0,
1082,,,B,8,Autocuration,,12827,Sus scrofa,BAO_0000249,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,9823.0,
1083,,,B,8,Autocuration,,12918,Sus scrofa,BAO_0000019,,,,,51,1,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,9823.0,
1084,,,F,8,Expert,,12919,Sus scrofa,BAO_0000019,,,,,51,1,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,9823.0,
1085,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,9986.0,
1086,,,B,9,Expert,,15796,Rattus norvegicus,BAO_0000249,,,,,10576,1,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10116.0,
1087,,,B,9,Expert,,3651,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10116.0,
1088,,,B,8,Autocuration,,188,,BAO_0000357,,,,,10576,1,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,
1089,Membranes,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,,,,10576,1,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10116.0,
1090,Membranes,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,Hippocampus,,,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10116.0,
1091,,,B,8,Autocuration,,12306,,BAO_0000221,,Hippocampus,,,10576,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1092,,,B,9,Expert,,17167,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10116.0,
1093,,,B,8,Autocuration,,14776,,BAO_0000019,,,,,10576,1,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,
1094,,,B,8,Expert,,12158,,BAO_0000357,,,,,10576,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,
1095,,,B,8,Autocuration,,13481,,BAO_0000357,,,,,10576,1,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1096,,,B,8,Autocuration,In vitro,13427,,BAO_0000219,,,,,10576,1,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
1097,,,B,8,Autocuration,,10210,,BAO_0000357,,,,,10576,1,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,
1098,Membranes,,B,8,Autocuration,,10205,,BAO_0000249,,,,,10576,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1099,Membranes,,B,8,Autocuration,,10205,,BAO_0000249,,,,,10576,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,
1100,Membranes,,B,8,Expert,,10205,,BAO_0000249,,,,,10576,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,
1101,,,B,9,Expert,,12280,Rattus norvegicus,BAO_0000357,,,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10116.0,
1102,,,B,8,Expert,,17386,,BAO_0000357,,,,,10576,1,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,
1103,,,B,8,Expert,,13654,,BAO_0000357,,,,,10576,1,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,
1104,,,B,8,Autocuration,,14423,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,,
1105,,,B,8,Autocuration,,15412,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,,
1106,,,B,8,Autocuration,,12073,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1107,,,B,9,Expert,,4101,Rattus norvegicus,BAO_0000357,,,,,10576,1,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10116.0,
1108,,,B,8,Autocuration,,10062,,BAO_0000357,,,,,10576,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,
1109,,,B,8,Autocuration,,6238,,BAO_0000249,,,,,10576,1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,
1110,,,B,8,Autocuration,,16273,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1111,,,B,8,Autocuration,,11139,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,
1112,,,B,8,Expert,,16796,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1113,,,B,9,Expert,,9548,Rattus norvegicus,BAO_0000221,,Brain,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10116.0,
1114,,,B,8,Autocuration,,10381,,BAO_0000221,,Brain,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1115,,,B,8,Autocuration,,13408,,BAO_0000249,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,
1116,,,B,9,Expert,,13825,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10116.0,
1117,,,B,8,Expert,,11147,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,,
1118,,,B,8,Autocuration,,10552,,BAO_0000249,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,
1119,,,B,8,Autocuration,,10552,,BAO_0000249,,Striatum,,,10576,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1120,Membranes,,B,9,Expert,,17136,Rattus norvegicus,BAO_0000249,,,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10116.0,
1121,Membranes,,B,9,Expert,,5778,Rattus norvegicus,BAO_0000249,,,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10116.0,
1122,,,B,8,Autocuration,,13481,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1123,,,B,8,Autocuration,,13481,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,,
1124,,,B,8,Intermediate,,13630,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,,
1125,,,B,8,Expert,,16245,,BAO_0000249,,,,,10576,1,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1126,,,B,8,Autocuration,,14509,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1127,,,B,8,Expert,,14509,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1128,,,B,8,Autocuration,,14509,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,,
1129,,,B,8,Autocuration,,14509,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,,
1130,,,B,8,Expert,,14256,,BAO_0000019,,,,,10576,1,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,
1131,,,B,8,Autocuration,,11139,,BAO_0000357,,,,,10576,1,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,
1132,,,B,9,Expert,,11047,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10116.0,
1133,,,B,9,Expert,,11047,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10116.0,
1134,,,B,9,Expert,,11047,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10116.0,
1135,,CHO-K1,B,9,Expert,,2395,Rattus norvegicus,BAO_0000219,485.0,,,,10576,1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10116.0,
1136,,,B,8,Autocuration,,9699,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1137,,,B,9,Expert,,12028,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10116.0,
1138,,,B,8,Autocuration,,12028,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,,
1139,,,B,8,Autocuration,,5815,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1140,,,B,8,Expert,,16616,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,
1141,,,B,8,Autocuration,,5815,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,
1142,,,B,8,Autocuration,,2761,,BAO_0000221,,Hippocampus,,,10576,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",,
1143,,,B,8,Expert,,13133,,BAO_0000357,,,,,10576,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,
1144,,,B,8,Autocuration,,10444,,BAO_0000019,,,,,10576,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,
1145,,,B,9,Expert,,13278,Rattus norvegicus,BAO_0000357,,,,,10576,1,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10116.0,
1146,,,B,8,Autocuration,,15874,,BAO_0000357,,,,,10576,1,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,
1147,Membranes,,B,8,Autocuration,,10552,,BAO_0000249,,Striatum,,,10576,1,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",,
1148,,,B,8,Autocuration,,11130,,BAO_0000357,,,,,10576,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,
1149,,,B,8,Autocuration,In vivo,11130,,BAO_0000218,,,,,10576,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,
1150,,,B,8,Autocuration,,14542,,BAO_0000221,,Brain,,,10576,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,,
1151,,,B,9,Expert,,13670,Rattus norvegicus,BAO_0000357,,,,,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10116.0,
1152,,,B,8,Expert,,9888,,BAO_0000249,,,,,10576,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,
1153,Membranes,,B,9,Expert,,3678,Rattus norvegicus,BAO_0000249,,,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10116.0,
1154,,,B,8,Autocuration,,11332,,BAO_0000221,,Hippocampus,,,10576,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1155,,,B,8,Autocuration,,11332,,BAO_0000221,,Hippocampus,,,10576,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1156,,,B,8,Expert,,1185,,BAO_0000357,,,,,10576,1,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1157,,,B,8,Expert,,2014,,BAO_0000249,,,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,
1158,,,B,8,Autocuration,,1185,,BAO_0000357,,,,,10576,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,
1159,,,B,8,Expert,,14429,,BAO_0000019,,,,,10576,1,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,
1160,,,B,8,Expert,,16288,,BAO_0000019,,,,,10576,1,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,
1161,,,B,9,Expert,,5432,Rattus norvegicus,BAO_0000019,,,,,10576,1,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10116.0,
1162,,,B,8,Autocuration,,14429,,BAO_0000019,,,,,10576,1,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,
1163,,,B,8,Expert,,13672,,BAO_0000357,,,,,10576,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,
1164,,,B,8,Expert,,11296,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1165,,,B,8,Autocuration,,11296,,BAO_0000357,,,,,10576,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,
1166,,CHO,B,8,Expert,,14749,,BAO_0000219,449.0,,,,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,
1167,,,B,8,Expert,,15086,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,
1168,,,B,8,Autocuration,,13462,,BAO_0000221,,Hippocampus,,,10576,1,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,,
1169,,,B,8,Autocuration,,15363,,BAO_0000019,,,,,10576,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1170,,,B,8,Autocuration,,15363,,BAO_0000019,,,,,10576,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,
1171,,,B,8,Autocuration,,10796,,BAO_0000357,,,,,10576,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,
1172,,,B,8,Expert,,12816,,BAO_0000221,,Brain,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,,
1173,,,B,8,Expert,,13542,,BAO_0000221,,Hippocampus,,,10576,1,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1174,,,B,8,Expert,,13308,,BAO_0000019,,,,,10576,1,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,
1175,,,B,8,Expert,,13541,,BAO_0000221,,Hippocampus,,,10576,1,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,,
1176,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,,
1177,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,,
1178,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,,
1179,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,,
1180,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,,
1181,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,,
1182,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,,
1183,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,,
1184,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,,
1185,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,,
1186,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,,
1187,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,,
1188,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,,
1189,,,B,9,Expert,,10058,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10116.0,
1190,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,,
1191,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,,
1192,,,B,8,Expert,,12879,,BAO_0000019,,,,,10576,1,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,
1193,,,B,8,Expert,,11964,,BAO_0000019,,,,,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,
1194,,,B,8,Autocuration,,11964,,BAO_0000019,,,,,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,
1195,,,B,8,Autocuration,,11964,,BAO_0000019,,,,,10576,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,
1196,,,B,8,Expert,,9548,,BAO_0000221,,Brain,,,10576,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,,
1197,,,B,8,Expert,,9098,,BAO_0000019,,,,,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,
1198,,,B,8,Autocuration,,9098,,BAO_0000019,,,,,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,
1199,,,B,8,Autocuration,,9098,,BAO_0000019,,,,,10576,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,
1200,,CHO,B,8,Expert,,13248,,BAO_0000219,449.0,,,,10576,1,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,
1201,,,B,8,Expert,,3147,,BAO_0000249,,,,,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,
1202,,,B,8,Expert,,13949,,BAO_0000019,,,,,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1203,,CHO,B,8,Autocuration,,11883,,BAO_0000218,449.0,,,,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,
1204,,,B,8,Autocuration,,11883,,BAO_0000218,,,,,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,
1205,,,B,9,Expert,,11883,Rattus norvegicus,BAO_0000357,,,,,10576,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10116.0,
1206,Membranes,,B,8,Expert,,15535,,BAO_0000249,,,,,10576,1,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1207,,,B,8,Autocuration,,15535,,BAO_0000249,,,,,10576,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,
1208,,,B,8,Autocuration,,15535,,BAO_0000249,,,,,10576,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,
1209,,CHO,B,9,Expert,,16372,Homo sapiens,BAO_0000219,449.0,,,,51,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,9606.0,
1210,,,B,8,Expert,,14608,,BAO_0000249,,,,,10576,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,
1211,,,B,9,Expert,,4795,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10116.0,
1212,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1213,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,
1214,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,
1215,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,
1216,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,
1217,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,
1218,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,
1219,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,
1220,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,
1221,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,
1222,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,
1223,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,
1224,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,
1225,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,
1226,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,
1227,,,B,8,Autocuration,,9742,,BAO_0000019,,,,,10576,1,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,
1228,,,B,8,Autocuration,,12073,,BAO_0000357,,,,,10576,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,
1229,,,B,8,Autocuration,,4101,,BAO_0000357,,,,,10576,1,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,
1230,,,B,8,Autocuration,,15360,,BAO_0000019,,,,,10576,1,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,
1231,,,B,8,Autocuration,,11576,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1232,,,B,8,Expert,,5834,,BAO_0000019,,,,,10576,1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,
1233,,CHO-K1,B,9,Expert,,2395,Rattus norvegicus,BAO_0000219,485.0,,,,10576,1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10116.0,
1234,,,B,8,Autocuration,,1375,,BAO_0000019,,,,,10576,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,
1235,,,B,8,Autocuration,,1375,,BAO_0000019,,,,,10576,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,
1236,,,B,8,Autocuration,,3967,,BAO_0000357,,,,,10576,1,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,
1237,,,B,8,Expert,,12884,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,
1238,,,B,8,Expert,,2343,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,
1239,,,B,8,Autocuration,,11511,,BAO_0000019,,,,,10576,1,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,
1240,,,B,9,Expert,,11511,Rattus norvegicus,BAO_0000019,,,,,10576,1,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10116.0,
1241,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,
1242,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,
1243,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,
1244,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,
1245,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,
1246,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,
1247,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,
1248,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,
1249,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,
1250,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,
1251,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,
1252,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,
1253,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,
1254,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,
1255,,,F,8,Autocuration,In vivo,16394,,BAO_0000218,,,,,10576,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,
1256,Membranes,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,,,,10576,1,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10116.0,
1257,,,B,8,Autocuration,,16796,,BAO_0000019,,,,,10576,1,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,
1258,,,B,8,Autocuration,,16796,,BAO_0000019,,,,,10576,1,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,
1259,,,B,8,Autocuration,,15629,,BAO_0000357,,,,,10576,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,
1260,,,F,8,Autocuration,,13241,,BAO_0000249,,,,,10576,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,
1261,,,B,8,Expert,,12073,,BAO_0000221,,Hippocampus,,,10576,1,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1262,,,B,8,Autocuration,,14286,,BAO_0000249,,Hippocampus,,,10576,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,,
1263,,,B,8,Autocuration,,14542,,BAO_0000221,,Brain,,,10576,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,,
1264,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1265,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,
1266,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,
1267,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1268,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,
1269,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,
1270,,,F,9,Expert,,13630,Rattus norvegicus,BAO_0000019,,,,,10576,1,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10116.0,
1271,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,
1272,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,
1273,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,
1274,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,
1275,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,
1276,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1277,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,
1278,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1279,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,
1280,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,
1281,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1282,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,
1283,,,F,8,Expert,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,
1284,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,
1285,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,
1286,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,
1287,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,
1288,,,B,8,Autocuration,,9783,,BAO_0000221,,Hippocampus,,,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,,
1289,,,B,8,Expert,,9783,,BAO_0000221,,Hippocampus,,,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,,
1290,Membranes,,B,9,Expert,,14331,Rattus norvegicus,BAO_0000249,,,,,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10116.0,
1291,,,B,8,Expert,,15260,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,,
1292,,,B,8,Autocuration,,15260,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,,
1293,,,B,8,Autocuration,,15260,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,,
1294,,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,,,,10576,1,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10116.0,
1295,,,B,8,Autocuration,,15629,,BAO_0000357,,,,,10576,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,
1296,,,B,8,Autocuration,,15086,,BAO_0000019,,,,,10576,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1297,,,F,8,Expert,,5717,,BAO_0000019,,,,,10576,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,
1298,,,B,8,Autocuration,,12652,,BAO_0000357,,,,,10576,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1299,,,B,8,Autocuration,,14608,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,,
1300,,,B,8,Autocuration,,12306,,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1301,,,B,8,Autocuration,,12306,,BAO_0000221,,Hippocampus,,,10576,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1302,,,B,9,Expert,,15247,Rattus norvegicus,BAO_0000357,,,,,10576,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10116.0,
1303,,,B,8,Expert,,17529,,BAO_0000221,,Hippocampus,,,10576,1,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,,
1304,,,B,8,Autocuration,,14826,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1305,,,B,8,Autocuration,,14826,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1306,,,B,8,Autocuration,,13241,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,,
1307,,,B,8,Autocuration,,14093,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,,
1308,,,B,8,Autocuration,,14093,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,,
1309,,,B,8,Autocuration,,14442,,BAO_0000221,,Brain,,,10576,1,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,,
1310,,,B,8,Autocuration,,9919,,BAO_0000357,,,,,10576,1,Affinity for 5-hydroxytryptamine 1A receptor site,,
1311,,,B,8,Autocuration,,9919,,BAO_0000357,,,,,10576,1,Affinity for 5-hydroxytryptamine 1A receptor site,,
1312,,,B,8,Autocuration,,11440,,BAO_0000221,,Hippocampus,,,10576,1,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,,
1313,,,B,8,Autocuration,,11257,,BAO_0000357,,,,,10576,1,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,
1314,,,B,8,Expert,,10330,,BAO_0000357,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,
1315,,,B,9,Expert,,17331,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10116.0,
1316,,,B,8,Expert,,16567,,BAO_0000249,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,
1317,,,B,9,Expert,,12058,Rattus norvegicus,BAO_0000019,,,,,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10116.0,
1318,,,B,8,Autocuration,,9699,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,,
1319,,,B,8,Autocuration,,9547,,BAO_0000357,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,
1320,,,B,8,Autocuration,,10330,,BAO_0000357,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,
1321,,,B,8,Autocuration,,14331,,BAO_0000357,,,,,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,
1322,,,B,9,Expert,,14060,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10116.0,
1323,,,B,8,Autocuration,,14744,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,,
1324,,,B,8,Autocuration,,13506,,BAO_0000357,,,,,10576,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,
1325,,,B,8,Expert,,10862,,BAO_0000221,,Brain,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1326,,,B,8,Expert,,10862,,BAO_0000221,,Brain,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1327,,,B,8,Expert,,10062,,BAO_0000357,,,,,10576,1,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,
1328,,,B,8,Autocuration,,12073,,BAO_0000357,,,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,
1329,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,106,1,GTPgammaS radioligand binding assay,,
1330,,,B,8,Autocuration,,2391,,BAO_0000357,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1331,,,F,8,Autocuration,,2391,,BAO_0000019,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,
1332,,,F,8,Autocuration,,2391,,BAO_0000019,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,
1333,,,B,8,Autocuration,,2391,,BAO_0000357,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1334,,,B,8,Autocuration,,2391,,BAO_0000357,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,
1335,,,F,8,Autocuration,,2391,,BAO_0000019,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,
1336,,HeLa,B,8,Expert,,17211,,BAO_0000219,308.0,,,,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,
1337,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,
1338,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,106,1,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,9606.0,
1339,,CHO,B,8,Autocuration,,16190,,BAO_0000219,449.0,,,,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,
1340,,,B,8,Autocuration,,14165,,BAO_0000019,,,,,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,
1341,,,B,8,Autocuration,,14165,,BAO_0000019,,,,,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,
1342,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,106,1,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,9606.0,
1343,,,B,8,Expert,,6328,,BAO_0000219,,,,,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1344,,,B,8,Autocuration,,14770,,BAO_0000357,,,,,106,1,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1345,,,B,8,Autocuration,,2598,,BAO_0000357,,,,,106,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,
1346,,,B,8,Expert,,6897,,BAO_0000357,,,,,106,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1347,,,B,8,Autocuration,,6897,,BAO_0000357,,,,,106,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,
1348,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,,
1349,,,B,8,Expert,,5843,,BAO_0000357,,,,,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,
1350,,,B,8,Expert,,14454,,BAO_0000357,,,,,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,
1351,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,106,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,
1352,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,106,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,
1353,,CHO-K1,F,8,Expert,,13729,,BAO_0000219,485.0,,,,106,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,
1354,,,F,8,Expert,,14251,,BAO_0000019,,,,,106,1,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,
1355,,,B,8,Expert,,17085,,BAO_0000019,,,,,106,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,
1356,,,B,8,Autocuration,,3025,,BAO_0000357,,,,,106,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1357,,,B,8,Expert,,15315,,BAO_0000357,,,,,106,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,
1358,,,B,9,Expert,,14214,Homo sapiens,BAO_0000219,,,,,106,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,9606.0,
1359,,,B,9,Expert,,3804,Homo sapiens,BAO_0000357,,,,,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,9606.0,
1360,,,B,9,Expert,,2391,Homo sapiens,BAO_0000357,,,,,106,1,Affinity for 5-hydroxytryptamine 1B receptor subtype,9606.0,
1361,,,B,9,Expert,,4175,Homo sapiens,BAO_0000357,,,,,106,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,9606.0,
1362,,CHO,B,8,Autocuration,,17296,,BAO_0000219,449.0,,,,106,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,
1363,,,B,8,Expert,,17085,,BAO_0000019,,,,,106,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,
1364,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1365,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,106,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,
1366,,HeLa,B,8,Autocuration,,17211,,BAO_0000219,308.0,,,,106,1,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,
1367,,,B,9,Expert,,15926,Homo sapiens,BAO_0000357,,,,,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,9606.0,
1368,,CHO-K1,B,8,Autocuration,,16312,,BAO_0000219,485.0,,,,106,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,
1369,,,B,8,Expert,,5843,,BAO_0000357,,,,,106,1,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,
1370,,,B,8,Autocuration,,5843,,BAO_0000357,,,,,106,1,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,
1371,,CHO-K1,B,8,Expert,,16312,,BAO_0000219,485.0,,,,106,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,
1372,,,B,9,Expert,,15926,Homo sapiens,BAO_0000357,,,,,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor,9606.0,
1373,,,B,9,Expert,,15926,Homo sapiens,BAO_0000357,,,,,106,1,Binding activity against human 5-hydroxytryptamine 1B receptor,9606.0,
1374,,CHO,B,9,Expert,,4540,Homo sapiens,BAO_0000219,449.0,,,,106,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,9606.0,
1375,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,
1376,,CHO,B,8,Autocuration,,17296,,BAO_0000219,449.0,,,,106,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,
1377,,CHO,B,8,Autocuration,,17296,,BAO_0000219,449.0,,,,106,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,
1378,,CHO,B,8,Autocuration,,17296,,BAO_0000219,449.0,,,,106,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,
1379,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1380,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
1381,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
1382,,CHO,B,8,Autocuration,,4199,,BAO_0000219,449.0,,,,106,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,
1383,,,B,9,Expert,,14875,Homo sapiens,BAO_0000357,,,,,106,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,9606.0,
1384,,CHO,B,8,Autocuration,,15146,,BAO_0000219,449.0,,,,106,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1385,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,106,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,
1386,,CHO,B,8,Autocuration,,14818,,BAO_0000219,449.0,,,,106,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,
1387,,CHO,B,8,Autocuration,,4829,,BAO_0000219,449.0,,,,106,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,
1388,,,F,8,Expert,,14454,,BAO_0000019,,,,,106,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,
1389,,,F,8,Expert,,14454,,BAO_0000019,,,,,106,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,
1390,,CHO,F,8,Autocuration,,14875,,BAO_0000219,449.0,,,,106,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1391,,CHO,F,8,Autocuration,,14875,,BAO_0000219,449.0,,,,106,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,
1392,,,F,8,Autocuration,,15250,,BAO_0000019,,,,,105,1,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,
1393,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,105,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,
1394,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,17105,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1395,,,F,8,Autocuration,,3025,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,9986.0,
1396,,,B,8,Autocuration,,14998,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,9986.0,
1397,,,B,8,Intermediate,,14998,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",9986.0,
1398,,,B,8,Autocuration,,14998,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,9986.0,
1399,,,B,8,Expert,,13969,,BAO_0000357,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,
1400,,,B,9,Intermediate,,13392,,BAO_0000357,,,,,10577,1,Binding affinity for 5-hydroxytryptamine 1B receptor,,
1401,,,B,9,Expert,,3651,Rattus norvegicus,BAO_0000019,,Striatum,,,10577,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10116.0,
1402,,,B,8,Expert,,10025,,BAO_0000357,,,,,10577,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1403,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,
1404,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,
1405,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,
1406,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,
1407,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,
1408,,,B,8,Autocuration,,13863,,BAO_0000357,,,,,10576,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,
1409,,,B,8,Autocuration,,4622,,BAO_0000249,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,,
1410,,,B,8,Intermediate,,14911,,BAO_0000019,,,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,
1411,,,B,8,Autocuration,,12678,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,,
1412,,,B,8,Expert,,12678,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,,
1413,,,B,8,Expert,,14235,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,
1414,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1415,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,,
1416,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,,
1417,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,,
1418,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,,
1419,,,B,8,Expert,,16118,,BAO_0000249,,,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,
1420,,,B,8,Autocuration,,3268,,BAO_0000249,,,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,
1421,,,B,8,Autocuration,,3268,,BAO_0000249,,,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,
1422,,,B,8,Expert,,16117,,BAO_0000357,,,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,
1423,,,B,8,Expert,,9783,,BAO_0000221,,Hippocampus,,,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,,
1424,,,B,8,Autocuration,,9783,,BAO_0000221,,Hippocampus,,,10576,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,,
1425,,,B,9,Expert,,14356,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10116.0,
1426,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,10576,1,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,
1427,,,B,8,Autocuration,,12306,,BAO_0000221,,Hippocampus,,,10576,1,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,,
1428,,,B,9,Expert,,13348,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10116.0,
1429,,,B,8,Autocuration,,10394,,BAO_0000249,,,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,
1430,,,B,8,Autocuration,,15260,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,,
1431,,,B,8,Expert,,10046,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
1432,,,F,8,Intermediate,,15260,,BAO_0000221,,Hippocampus,,,10576,1,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,,
1433,,,B,8,Autocuration,,12851,,BAO_0000357,,,,,10576,1,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,
1434,,,B,9,Expert,,2148,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10116.0,
1435,,,B,8,Expert,,13134,,BAO_0000357,,,,,10576,1,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,
1436,,,B,8,Autocuration,,12462,,BAO_0000019,,,,,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,
1437,,,B,8,Expert,,12462,,BAO_0000019,,,,,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,
1438,,CHO,B,8,Autocuration,,12462,,BAO_0000219,449.0,,,,10576,1,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,
1439,,,B,8,Expert,,11933,,BAO_0000357,,,,,10576,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,
1440,,,B,8,Autocuration,,11933,,BAO_0000357,,,,,10576,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,
1441,,,B,9,Expert,,403,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10116.0,
1442,,,B,8,Autocuration,,15538,,BAO_0000221,,Hippocampus,,,10576,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1443,,,B,8,Autocuration,,15538,,BAO_0000221,,Hippocampus,,,10576,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,,
1444,,,B,8,Autocuration,,15538,,BAO_0000221,,Hippocampus,,,10576,1,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,,
1445,,,B,8,Intermediate,,12464,,BAO_0000019,,,,,10576,1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,
1446,,,B,8,Expert,,1455,,BAO_0000357,,,,,10576,1,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,
1447,,,B,8,Autocuration,,12652,,BAO_0000357,,,,,10576,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,
1448,,,B,8,Autocuration,,12639,,BAO_0000221,,Hippocampus,,,10576,1,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,,
1449,,,B,8,Expert,,13949,,BAO_0000249,,,,,10576,1,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,
1450,,,B,9,Expert,,12463,Rattus norvegicus,BAO_0000357,,,,,10576,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10116.0,
1451,,,B,8,Expert,,14829,,BAO_0000221,,Hippocampus,,,10576,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,,
1452,,,B,8,Autocuration,,14829,,BAO_0000221,,Hippocampus,,,10576,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,,
1453,,,B,8,Autocuration,,12092,,BAO_0000357,,,,,10576,1,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,
1454,,,B,8,Autocuration,,403,,BAO_0000249,,,,,10576,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,
1455,,,B,8,Autocuration,,403,,BAO_0000249,,,,,10576,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,
1456,,,B,8,Expert,,3967,,BAO_0000357,,,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,
1457,,,B,9,Expert,,12771,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10116.0,
1458,,,B,8,Autocuration,,15086,,BAO_0000019,,,,,10576,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,
1459,,,B,8,Autocuration,,14909,,BAO_0000221,,Hippocampus,,,10576,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1460,,,B,8,Expert,,14949,,BAO_0000221,,Hippocampus,,,10576,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,,
1461,,,B,9,Expert,,2309,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10116.0,
1462,,,B,8,Expert,,4170,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1463,,,B,9,Expert,,11642,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10116.0,
1464,,,B,8,Autocuration,,11642,,BAO_0000221,,Hippocampus,,,10576,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,,
1465,,,B,8,Autocuration,,12953,,BAO_0000221,,Hippocampus,,,10576,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,,
1466,,,B,8,Autocuration,,12953,,BAO_0000221,,Hippocampus,,,10576,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,,
1467,,,B,8,Expert,,12953,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,,
1468,,CHO,B,8,Expert,,12903,,BAO_0000219,449.0,,,,10576,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,
1469,,,B,8,Expert,,12536,,BAO_0000357,,,,,10576,1,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1470,,,B,8,Autocuration,,10058,,BAO_0000357,,,,,10576,1,The inhibition activity of 5-HT1A at 1 uM,,
1471,,CHO-K1,B,8,Expert,,12902,,BAO_0000219,485.0,,,,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,
1472,,,B,8,Expert,,14057,,BAO_0000249,,,,,10576,1,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,
1473,,,B,8,Autocuration,,11296,,BAO_0000357,,,,,10576,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,
1474,,,B,8,Autocuration,,11296,,BAO_0000221,,Hippocampus,,,10576,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1475,,,B,8,Expert,,11296,,BAO_0000221,,Hippocampus,,,10576,1,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,,
1476,Membranes,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,,,,10576,1,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10116.0,
1477,Membranes,,F,9,Expert,,16616,Rattus norvegicus,BAO_0000249,,Hippocampus,,,10576,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10116.0,
1478,,,B,8,Autocuration,,16567,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,
1479,,,B,8,Autocuration,,16567,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,
1480,,,B,8,Autocuration,,16567,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,
1481,,,B,8,Autocuration,,16567,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,
1482,,,B,8,Autocuration,,17136,,BAO_0000249,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,
1483,,,B,8,Autocuration,,17136,,BAO_0000249,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,
1484,,,B,9,Expert,,16616,Rattus norvegicus,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10116.0,
1485,,,B,8,Autocuration,,17331,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,,
1486,,,B,8,Autocuration,,17331,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,,
1487,,,B,9,Expert,,17167,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10116.0,
1488,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1489,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,
1490,,,B,8,Autocuration,,4671,,BAO_0000357,,,,,10576,1,Ratio of binding affinity to 5-HT 1A and D2 receptor,,
1491,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1492,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,,
1493,,,B,8,Autocuration,,10058,,BAO_0000221,,Hippocampus,,,10576,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,,
1494,,,B,8,Autocuration,,12073,,BAO_0000357,,,,,10576,1,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,
1495,,,B,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1496,,,F,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,
1497,,,B,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1498,,,F,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,
1499,,,F,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1500,,,B,8,Autocuration,,9737,,BAO_0000249,,Brain,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1501,,,B,8,Autocuration,,9737,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,
1502,,,F,8,Expert,,5717,,BAO_0000019,,,,,10576,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,
1503,,,B,8,Autocuration,,12253,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1504,,,B,8,Autocuration,,14025,,BAO_0000019,,,,,10576,1,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,
1505,,,B,8,Expert,,10425,,BAO_0000249,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,
1506,,,B,8,Autocuration,,14998,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,
1507,,,B,8,Autocuration,,13694,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,,
1508,,,B,8,Autocuration,,13694,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,,
1509,,,B,8,Autocuration,,4342,,BAO_0000357,,,,,10576,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,
1510,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,,,,10576,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10116.0,
1511,,,B,9,Expert,,13144,Rattus norvegicus,BAO_0000019,,,,,10576,1,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10116.0,
1512,,,B,8,Expert,,13343,,BAO_0000019,,,,,10576,1,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,
1513,,,B,8,Expert,,12132,,BAO_0000357,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1514,,,B,8,Expert,,15419,,BAO_0000019,,,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,
1515,,,B,8,Autocuration,,1479,,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,,
1516,,,B,8,Expert,,14287,,BAO_0000019,,,,,10576,1,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,
1517,,,B,8,Expert,,13116,,BAO_0000357,,,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1518,Membranes,,B,9,Expert,,2759,Rattus norvegicus,BAO_0000249,,,,,10576,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10116.0,
1519,,,B,8,Autocuration,,2759,,BAO_0000249,,,,,10576,1,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,
1520,,,B,8,Expert,,14748,,BAO_0000019,,,,,10576,1,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,
1521,,,B,8,Autocuration,,12304,,BAO_0000019,,,,,10576,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,
1522,,,B,9,Expert,,12409,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10116.0,
1523,,,B,9,Expert,,12409,Rattus norvegicus,BAO_0000221,,Hippocampus,,,10576,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10116.0,
1524,,,B,8,Autocuration,,13267,,BAO_0000221,,Hippocampus,,,10576,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,,
1525,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,10576,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,
1526,,,B,8,Expert,,14256,,BAO_0000357,,,,,10576,1,pKi value against rat 5-hydroxytryptamine 1A receptor.,,
1527,,,B,8,Autocuration,,16567,,BAO_0000019,,,,,10576,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,
1528,,,F,8,Autocuration,,15740,,BAO_0000019,,,,,10576,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,
1529,,,B,9,Expert,,13278,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,10116.0,
1530,Membranes,,B,8,Expert,,1970,,BAO_0000249,,,,,10626,1,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,
1531,,,B,8,Autocuration,,10034,,BAO_0000221,,Brain,,,10576,1,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,,
1532,,,B,8,Autocuration,,13348,Rattus norvegicus,BAO_0000019,,,,,51,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,10116.0,
1533,,,F,8,Autocuration,,13630,,BAO_0000019,,,,,10576,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,
1534,,,B,8,Autocuration,,10862,,BAO_0000221,,Brain,,,10576,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,,
1535,,,B,8,Autocuration,,12058,,BAO_0000019,,,,,10576,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,
1536,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,51,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,
1537,,,B,8,Expert,,15453,,BAO_0000357,,,,,51,1,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,
1538,,,B,8,Expert,,4820,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1539,,,B,8,Autocuration,,1089,,BAO_0000357,,,,,51,1,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,
1540,Brain membranes,,B,8,Autocuration,,386,,BAO_0000249,,,,,51,1,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,
1541,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,51,1,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,
1542,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,51,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,
1543,,,B,8,Expert,,4402,,BAO_0000357,,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,
1544,,,B,8,Expert,,17066,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,
1545,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,51,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,
1546,,,B,8,Autocuration,,2474,,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1547,,,B,8,Autocuration,,4775,,BAO_0000357,,,,,51,1,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,
1548,,,B,9,Expert,,14294,Homo sapiens,BAO_0000357,,,,,51,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,9606.0,
1549,,,B,9,Expert,,14294,Homo sapiens,BAO_0000357,,,,,51,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,9606.0,
1550,,CHO,B,8,Autocuration,,12249,,BAO_0000219,449.0,,,,51,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1551,,,B,8,Expert,,11376,,BAO_0000219,,,,,51,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,
1552,,,B,8,Autocuration,In vivo,2474,,BAO_0000218,,,,,51,1,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,
1553,,,B,8,Autocuration,,13311,,BAO_0000221,,Hippocampus,,,51,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,,
1554,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,51,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,
1555,,,B,8,Expert,,1633,,BAO_0000357,,,,,51,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,
1556,,,B,8,Autocuration,,11866,,BAO_0000357,,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1557,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,51,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,
1558,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,51,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,
1559,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,11863,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,
1560,,,B,8,Autocuration,,13291,,BAO_0000357,,,,,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,
1561,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,11863,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,
1562,,,B,8,Autocuration,,10812,,BAO_0000357,,,,,11863,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,
1563,,CHO,B,9,Expert,,3032,Mus musculus,BAO_0000219,449.0,,,,11863,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,10090.0,
1564,,,B,8,Autocuration,,16655,,BAO_0000357,,,,,11863,1,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,
1565,,,B,8,Autocuration,,14532,,BAO_0000357,,,,,11863,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,
1566,,,B,8,Autocuration,,13944,,BAO_0000357,,,,,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,
1567,,,B,8,Autocuration,,13033,,BAO_0000357,,,,,11863,1,Binding affinity against serotonergic 5-HT1a receptor,,
1568,,,B,8,Autocuration,,10321,,BAO_0000357,,,,,11863,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,
1569,,,B,9,Expert,,2968,Mus musculus,BAO_0000357,,,,,11863,1,Binding affinity for 5-hydroxytryptamine 1A receptor,10090.0,
1570,,,B,8,Autocuration,,13964,,BAO_0000357,,,,,11863,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,
1571,,,B,8,Autocuration,,15527,,BAO_0000357,,,,,11863,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,
1572,,CHO,B,8,Autocuration,,12248,,BAO_0000219,449.0,,,,11863,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1573,,CHO,B,8,Autocuration,,12249,,BAO_0000219,449.0,,,,11863,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,
1574,,,B,8,Autocuration,,15120,,BAO_0000357,,,,,11863,1,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,
1575,,,B,8,Autocuration,,13313,,BAO_0000357,,,,,11863,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,
1576,,,B,8,Autocuration,,2613,,BAO_0000218,,,,,11863,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,
1577,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,11863,1,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,
1578,,,B,8,Autocuration,,2201,,BAO_0000357,,,,,11863,1,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,
1579,,,B,9,Expert,,1274,Mus musculus,BAO_0000357,,,,,11863,1,Binding affinity against 5-hydroxytryptamine 1A receptor,10090.0,
1580,,,B,8,Autocuration,,1317,,BAO_0000357,,,,,11863,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,
1581,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,11863,1,Tested against 5-hydroxytryptamine 1A receptor,,
1582,,,B,8,Autocuration,,14059,,BAO_0000357,,,,,11863,1,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,
1583,,,B,8,Expert,,14025,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,9986.0,
1584,,,B,8,Autocuration,,14025,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,9986.0,
1585,,HEK293,B,9,Intermediate,,14447,Gorilla gorilla,BAO_0000219,722.0,,,,105571,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9593.0,
1586,,,F,8,Autocuration,In vivo,3025,Cavia porcellus,BAO_0000218,,,,,106,1,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,10141.0,
1587,,,F,8,Autocuration,In vivo,3025,Cavia porcellus,BAO_0000218,,,,,106,1,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,10141.0,
1588,,,F,8,Autocuration,,15329,Cavia porcellus,BAO_0000019,,,,,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,10141.0,
1589,,,F,8,Autocuration,,15329,Cavia porcellus,BAO_0000019,,,,,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,10141.0,
1590,,,F,8,Autocuration,,15847,Cavia porcellus,BAO_0000019,,,,,106,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,10141.0,
1591,,,F,8,Autocuration,,15847,Cavia porcellus,BAO_0000019,,,,,106,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,10141.0,
1592,,,F,8,Autocuration,,14165,,BAO_0000019,,,,,106,1,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,
1593,,,F,8,Autocuration,,14214,,BAO_0000019,,,,,106,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,
1594,,,F,8,Autocuration,,14214,,BAO_0000019,,,,,106,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,
1595,,,F,9,Expert,,14214,Homo sapiens,BAO_0000019,,,,,106,1,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,9606.0,
1596,,CHO-K1,F,9,Expert,,13729,Homo sapiens,BAO_0000219,485.0,,,,106,1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,9606.0,
1597,,CHO,F,8,Autocuration,,3025,,BAO_0000219,449.0,,,,106,1,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,
1598,,,B,8,Autocuration,,2391,,BAO_0000357,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,
1599,,,F,8,Autocuration,,2391,,BAO_0000019,,,,,106,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,
1600,,CHO,F,8,Expert,,14956,,BAO_0000219,449.0,,,,106,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,
1601,,CHO,F,8,Autocuration,,2598,,BAO_0000219,449.0,,,,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,
1602,,CHO,F,8,Autocuration,,2598,,BAO_0000219,449.0,,,,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,
1603,,CHO,F,8,Autocuration,,2598,,BAO_0000219,449.0,,,,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,
1604,,CHO,F,8,Autocuration,,2598,,BAO_0000219,449.0,,,,106,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,
1605,,,F,8,Expert,,14956,,BAO_0000019,,,,,106,1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,
1606,,,F,8,Autocuration,,14956,,BAO_0000019,,,,,106,1,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,
1607,,,B,9,Expert,,14214,Homo sapiens,BAO_0000357,,,,,106,1,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,9606.0,
1608,,CHO,B,8,Expert,,3463,,BAO_0000219,449.0,,,,106,1,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,
1609,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,106,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,
1610,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor,9606.0,
1611,,CHO,B,9,Expert,,14159,Homo sapiens,BAO_0000219,449.0,,,,106,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,9606.0,
1612,,CHO,B,8,Expert,,14158,,BAO_0000219,449.0,,,,106,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,
1613,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,106,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,
1614,,CHO,B,8,Expert,,15250,,BAO_0000219,449.0,,,,106,1,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1615,,CHO,B,8,Expert,,15250,,BAO_0000219,449.0,,,,106,1,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1616,,CHO,B,8,Expert,,15331,,BAO_0000219,449.0,,,,106,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,
1617,,CHO,B,8,Expert,,15332,,BAO_0000219,449.0,,,,106,1,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,
1618,,CHO,B,8,Expert,,14956,,BAO_0000219,449.0,,,,106,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,
1619,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,106,1,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,
1620,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,106,1,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,
1621,,,F,8,Autocuration,,14454,Oryctolagus cuniculus,BAO_0000019,,,,,105,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,
1622,,,F,8,Expert,,14454,Oryctolagus cuniculus,BAO_0000019,,,,,105,1,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,
1623,,,B,8,Autocuration,,16288,,BAO_0000357,,,,,105,1,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,
1624,,,B,8,Autocuration,,16288,,BAO_0000357,,,,,105,1,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,
1625,,,B,8,Autocuration,,16312,,BAO_0000357,,,,,105,1,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,
1626,,,B,8,Expert,,1348,Bos taurus,BAO_0000357,,,,,105,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,9913.0,
1627,,,B,8,Autocuration,,5834,Bos taurus,BAO_0000357,,,,,105,1,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,9913.0,
1628,,,B,8,Autocuration,,13366,Bos taurus,BAO_0000019,,Striatum,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,9913.0,
1629,,,B,8,Expert,,1414,Bos taurus,BAO_0000357,,,,,105,1,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,9913.0,
1630,,,B,8,Autocuration,,14998,Bos taurus,BAO_0000019,,,,,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,9913.0,
1631,,,B,8,Autocuration,,11473,Bos taurus,BAO_0000357,,,,,105,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,9913.0,
1632,,,B,8,Autocuration,,11473,Bos taurus,BAO_0000357,,,,,105,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,9913.0,
1633,,,B,8,Autocuration,,10639,Bos taurus,BAO_0000357,,,,,105,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,9913.0,
1634,,,B,8,Autocuration,,10639,Bos taurus,BAO_0000357,,,,,105,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,9913.0,
1635,,,B,8,Autocuration,,1375,Bos taurus,BAO_0000357,,,,,105,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,9913.0,
1636,,,B,8,Autocuration,,1375,Bos taurus,BAO_0000357,,,,,105,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,9913.0,
1637,,,B,8,Autocuration,,16532,Bos taurus,BAO_0000357,,,,,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,9913.0,
1638,,,B,8,Autocuration,,11147,Bos taurus,BAO_0000357,,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,9913.0,
1639,,,B,8,Autocuration,,13366,Bos taurus,BAO_0000019,,Striatum,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,9913.0,
1640,,,B,8,Autocuration,,10444,Bos taurus,BAO_0000019,,,,,105,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,9913.0,
1641,,,B,8,Autocuration,,16532,Bos taurus,BAO_0000357,,,,,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,9913.0,
1642,,,B,8,Autocuration,,16532,Bos taurus,BAO_0000357,,,,,105,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,9913.0,
1643,,,B,8,Autocuration,,12827,Bos taurus,BAO_0000249,,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,9913.0,
1644,,,B,8,Autocuration,,12827,Bos taurus,BAO_0000249,,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,9913.0,
1645,,,F,8,Expert,,12919,Bos taurus,BAO_0000019,,,,,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,
1646,,,B,8,Autocuration,,14025,Bos taurus,BAO_0000019,,,,,105,1,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,9913.0,
1647,,,F,8,Expert,,12919,Bos taurus,BAO_0000019,,,,,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,
1648,,,F,8,Expert,,12919,Bos taurus,BAO_0000019,,,,,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,
1649,,,F,8,Expert,,12919,Bos taurus,BAO_0000019,,,,,105,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,9913.0,
1650,,HEK293,B,8,Autocuration,,14447,Gorilla gorilla,BAO_0000219,722.0,,,,105,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,9593.0,
1651,,,B,9,Intermediate,,1375,Cavia porcellus,BAO_0000019,,,,,105570,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,10141.0,
1652,,,B,9,Intermediate,,1375,Cavia porcellus,BAO_0000019,,,,,105570,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,10141.0,
1653,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000019,,,,,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,10141.0,
1654,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000019,,,,,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,
1655,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000019,,,,,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,10141.0,
1656,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000019,,,,,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,10141.0,
1657,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000019,,,,,105570,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,10141.0,
1658,,,B,9,Intermediate,,11574,Cavia porcellus,BAO_0000357,,,,,105570,1,Binding affinity against 5-hydroxytryptamine 1D receptor,10141.0,
1659,,,B,9,Intermediate,,1558,Cavia porcellus,BAO_0000357,,,,,105570,1,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,10141.0,
1660,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000218,,,,,105570,1,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,
1661,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000218,,,,,105570,1,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,
1662,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000218,,,,,105570,1,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,10141.0,
1663,,,F,9,Intermediate,,12409,Cavia porcellus,BAO_0000218,,,,,105570,1,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,10141.0,
1664,,,B,9,Intermediate,,12253,Cavia porcellus,BAO_0000019,,,,,105570,1,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,10141.0,
1665,,,B,9,Intermediate,,12936,Cavia porcellus,BAO_0000357,,,,,105570,1,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,10141.0,
1666,,,B,8,Autocuration,,13181,Cavia porcellus,BAO_0000019,,,,,105,1,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,10141.0,
1667,,,B,9,Intermediate,,12409,Cavia porcellus,BAO_0000357,,Striatum,,,105570,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,10141.0,
1668,,,B,9,Intermediate,,10639,Cavia porcellus,BAO_0000357,,,,,105570,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,10141.0,
1669,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,51,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1670,,,B,8,Autocuration,,13051,,BAO_0000357,,,,,106,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,
1671,,,F,8,Expert,,3463,,BAO_0000019,,,,,105,1,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,
1672,,,F,8,Autocuration,,15315,,BAO_0000019,,,,,105,1,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,
1673,,,F,8,Autocuration,,6011,,BAO_0000019,,,,,105,1,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,
1674,,CHO,F,9,Expert,,14159,Homo sapiens,BAO_0000219,449.0,,,,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",9606.0,
1675,,CHO,F,8,Autocuration,,14159,,BAO_0000219,449.0,,,,105,1,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,
1676,,CHO,B,8,Expert,,15250,,BAO_0000219,449.0,,,,105,1,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1677,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,105,1,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,
1678,,CHO,F,8,Expert,,15331,,BAO_0000219,449.0,,,,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,
1679,,CHO,F,9,Expert,,15332,Homo sapiens,BAO_0000219,449.0,,,,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",9606.0,
1680,,CHO,F,8,Expert,,15332,,BAO_0000219,449.0,,,,105,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,
1681,,CHO,F,8,Autocuration,,3294,,BAO_0000219,449.0,,,,105,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,
1682,,CHO,F,8,Expert,,14158,,BAO_0000219,449.0,,,,105,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,
1683,,CHO,F,8,Expert,,14956,,BAO_0000219,449.0,,,,105,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,
1684,,,F,8,Autocuration,,12469,,BAO_0000019,,,,,105,1,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,
1685,,CHO,F,8,Expert,,3463,,BAO_0000219,449.0,,,,105,1,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,
1686,,CHO,F,9,Expert,,15250,Homo sapiens,BAO_0000219,449.0,,,,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9606.0,
1687,,CHO,F,9,Expert,,15250,Homo sapiens,BAO_0000219,449.0,,,,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",9606.0,
1688,,,F,8,Expert,,14956,,BAO_0000019,,,,,105,1,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,
1689,,,F,8,Autocuration,,14159,,BAO_0000019,,,,,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,
1690,,,F,9,Expert,,14159,Homo sapiens,BAO_0000019,,,,,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",9606.0,
1691,,CHO,F,9,Expert,,14499,Homo sapiens,BAO_0000219,449.0,,,,105,1,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,9606.0,
1692,,,F,8,Autocuration,,15315,,BAO_0000019,,,,,105,1,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,
1693,,,B,8,Autocuration,In vitro,3294,,BAO_0000219,,,,,105,1,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,
1694,,CHO,B,8,Expert,,3463,,BAO_0000219,449.0,,,,105,1,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,
1695,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,105,1,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,
1696,,CHO,B,9,Expert,,14159,Homo sapiens,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,
1697,,CHO,B,8,Expert,,14158,,BAO_0000219,449.0,,,,105,1,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,
1698,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,105,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,
1699,,CHO,B,8,Expert,,15250,,BAO_0000219,449.0,,,,105,1,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,
1700,,CHO,B,8,Expert,,15250,,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1701,,CHO,B,8,Expert,,15331,,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1702,,CHO,B,9,Expert,,15332,Homo sapiens,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,
1703,,CHO,B,9,Expert,,14499,Homo sapiens,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,9606.0,
1704,,CHO,B,8,Expert,,15332,,BAO_0000219,449.0,,,,105,1,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,
1705,,CHO,B,8,Expert,,14956,,BAO_0000219,449.0,,,,105,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,
1706,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,105,1,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,
1707,,CHO,B,9,Expert,,6011,Homo sapiens,BAO_0000219,449.0,,,,105,1,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,9606.0,
1708,,CHO,B,8,Autocuration,,16190,,BAO_0000219,449.0,,,,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,
1709,,,B,8,Autocuration,,14165,,BAO_0000019,,,,,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,
1710,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,105,1,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,9606.0,
1711,,,B,8,Autocuration,,15527,,BAO_0000357,,,,,105,1,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,
1712,,,B,8,Expert,,6328,,BAO_0000219,,,,,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,
1713,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,
1714,,,B,8,Autocuration,,14770,,BAO_0000357,,,,,105,1,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,
1715,,,B,8,Autocuration,,2598,,BAO_0000357,,,,,105,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,
1716,,,B,8,Expert,,6897,,BAO_0000357,,,,,105,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,
1717,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor,,
1718,,,B,8,Expert,,5843,,BAO_0000357,,,,,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1719,,,B,8,Expert,,14454,,BAO_0000357,,,,,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,
1720,,,B,8,Autocuration,,14454,,BAO_0000357,,,,,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,
1721,,,B,8,Autocuration,,14454,,BAO_0000357,,,,,105,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,
1722,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,105,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,
1723,,CHO-K1,F,8,Expert,,13729,,BAO_0000219,485.0,,,,105,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,
1724,,,B,9,Expert,In vitro,6011,Homo sapiens,BAO_0000219,,,,,105,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),9606.0,
1725,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,105,1,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,9606.0,
1726,,,B,8,Expert,,17085,,BAO_0000019,,,,,105,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1727,,,B,8,Autocuration,,3025,,BAO_0000357,,,,,105,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1728,,,B,8,Expert,,15315,,BAO_0000357,,,,,105,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,
1729,,,B,9,Expert,,14214,Homo sapiens,BAO_0000219,,,,,105,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,9606.0,
1730,,,B,9,Expert,,3804,Homo sapiens,BAO_0000357,,,,,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,
1731,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,105,1,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,
1732,,,B,9,Expert,,2391,Homo sapiens,BAO_0000357,,,,,105,1,Affinity for 5-hydroxytryptamine 1D receptor subtype,9606.0,
1733,,,B,9,Expert,,4175,Homo sapiens,BAO_0000357,,,,,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,
1734,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,105,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,
1735,,,B,8,Expert,,17085,,BAO_0000019,,,,,105,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,
1736,,,B,9,Expert,,15926,Homo sapiens,BAO_0000357,,,,,105,1,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,9606.0,
1737,,CHO-K1,B,8,Autocuration,,16312,,BAO_0000219,485.0,,,,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,
1738,,CHO-K1,B,8,Autocuration,,16312,,BAO_0000219,485.0,,,,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,
1739,,CHO,B,4,Autocuration,,14956,,BAO_0000219,449.0,,,,104802,1,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,
1740,,,F,8,Autocuration,,3294,,BAO_0000019,,,,,105,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,
1741,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,105,1,Binding activity radioligand.,,
1742,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,105,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1743,,CHO-K1,B,8,Expert,,16312,,BAO_0000219,485.0,,,,105,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,
1744,,,B,8,Autocuration,,5104,,BAO_0000357,,,,,105,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1745,,,B,8,Autocuration,,5105,,BAO_0000357,,,,,105,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,
1746,,,B,8,Autocuration,,14499,,BAO_0000357,,,,,105,1,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,
1747,,,B,9,Expert,,15926,Homo sapiens,BAO_0000357,,,,,105,1,Binding activity against human 5-hydroxytryptamine 1D receptor,9606.0,
1748,,CHO,B,9,Expert,,4540,Homo sapiens,BAO_0000219,449.0,,,,105,1,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,9606.0,
1749,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,
1750,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
1751,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,
1752,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,105,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,
1753,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,105,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,
1754,,HEK293,B,8,Autocuration,,17451,,BAO_0000219,722.0,,,,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1755,,HEK293,B,8,Autocuration,,17451,,BAO_0000219,722.0,,,,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,
1756,,HEK293,B,8,Autocuration,,17451,,BAO_0000219,722.0,,,,105,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,
1757,,CHO,B,8,Autocuration,,4199,,BAO_0000219,449.0,,,,105,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,
1758,,,B,9,Expert,,14875,Homo sapiens,BAO_0000357,,,,,105,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,9606.0,
1759,,CHO,B,8,Autocuration,,15146,,BAO_0000219,449.0,,,,105,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,
1760,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,105,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,
1761,,CHO,B,8,Autocuration,,14818,,BAO_0000219,449.0,,,,105,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,
1762,,CHO,B,8,Autocuration,,4829,,BAO_0000219,449.0,,,,105,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,
1763,,,F,8,Expert,,14454,,BAO_0000019,,,,,105,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,
1764,,,F,8,Expert,,14454,,BAO_0000019,,,,,105,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,
1765,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,108,1,Binding affinity against 5-HT2C receptor,,
1766,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,108,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,
1767,,,B,8,Autocuration,,10639,,BAO_0000357,,,,,10577,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1768,,,F,8,Autocuration,,10639,,BAO_0000019,,,,,10577,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,
1769,,,B,8,Expert,,12352,,BAO_0000019,,,,,10577,1,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,
1770,,,B,8,Autocuration,,9098,,BAO_0000357,,,,,10577,1,Binding affinity towards 5-HT1B was determined,,
1771,,,B,8,Expert,,14430,,BAO_0000019,,,,,10577,1,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,
1772,,,B,8,Expert,,13657,,BAO_0000019,,,,,10577,1,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,
1773,,,B,8,Autocuration,,13657,,BAO_0000019,,,,,10577,1,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,
1774,,,B,8,Expert,,15854,,BAO_0000019,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1775,,,B,9,Expert,,10639,Rattus norvegicus,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10116.0,
1776,,,B,8,Autocuration,,10025,,BAO_0000357,,,,,10577,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,
1777,,,B,8,Autocuration,,10025,,BAO_0000357,,,,,10577,1,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,
1778,,,B,8,Autocuration,,14286,,BAO_0000249,,,,,10577,1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1779,,,B,8,Autocuration,,3651,,BAO_0000019,,Striatum,,,10577,1,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,,
1780,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,10577,1,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10116.0,
1781,,,B,8,Autocuration,,10639,,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,
1782,,,B,8,Autocuration,,13605,,BAO_0000019,,Striatum,,,10577,1,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,,
1783,,,B,8,Autocuration,,5834,,BAO_0000019,,Striatum,,,10577,1,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,,
1784,,,B,8,Autocuration,,10922,,BAO_0000357,,Striatum,,,10577,1,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,,
1785,,,B,8,Autocuration,,14286,,BAO_0000249,,,,,10577,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,
1786,,,B,8,Autocuration,,11825,,BAO_0000357,,,,,10577,1,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,
1787,,,B,8,Autocuration,,14826,,BAO_0000019,,Striatum,,,10577,1,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,,
1788,,,B,8,Autocuration,,9699,,BAO_0000019,,Striatum,,,10577,1,Binding affinity against 5-HT1B serotonin receptor in rat striatum,,
1789,,,B,8,Autocuration,,14423,,BAO_0000019,,,,,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,
1790,,,B,8,Expert,,10062,,BAO_0000357,,,,,10577,1,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,
1791,,,B,8,Autocuration,,10062,,BAO_0000357,,,,,10577,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1792,,,B,9,Expert,,12280,Rattus norvegicus,BAO_0000357,,,,,10577,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10116.0,
1793,,,B,8,Autocuration,,15412,,BAO_0000357,,Striatum,,,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,,
1794,,,B,8,Autocuration,,15412,,BAO_0000357,,Striatum,,,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,,
1795,,,B,8,Autocuration,,10062,,BAO_0000357,,,,,10577,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,
1796,,,B,8,Autocuration,,11147,,BAO_0000357,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1797,,,B,8,Autocuration,,9547,,BAO_0000019,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,
1798,,,B,8,Autocuration,,10444,,BAO_0000019,,,,,10577,1,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,
1799,,,B,8,Autocuration,,12469,,BAO_0000019,,Striatum,,,10577,1,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,,
1800,,,B,8,Expert,,9098,,BAO_0000019,,,,,10577,1,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,
1801,,,B,8,Autocuration,,9098,,BAO_0000019,,,,,10577,1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,
1802,,,B,8,Autocuration,,9699,,BAO_0000357,,,,,10577,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,
1803,,,B,8,Autocuration,,10394,,BAO_0000249,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1804,,,B,8,Autocuration,,12092,,BAO_0000357,,,,,10577,1,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,
1805,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,10577,1,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,
1806,,,B,9,Expert,,403,Rattus norvegicus,BAO_0000249,,,,,10577,1,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10116.0,
1807,,,B,9,Expert,,12771,Rattus norvegicus,BAO_0000357,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,10116.0,
1808,,,B,8,Autocuration,,11642,,BAO_0000019,,,,,10577,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,
1809,,,B,8,Autocuration,,12953,,BAO_0000357,,,,,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,
1810,,,B,8,Autocuration,,12953,,BAO_0000357,,,,,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,
1811,,,B,8,Expert,,12953,,BAO_0000019,,Striatum,,,10577,1,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,,
1812,,,B,8,Autocuration,,12953,,BAO_0000357,,,,,10577,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,
1813,,,B,8,Autocuration,,9737,,BAO_0000249,,Brain,,,10577,1,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1814,,,B,8,Autocuration,,9737,,BAO_0000019,,,,,10577,1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,
1815,,,B,8,Autocuration,,9737,,BAO_0000249,,Brain,,,10577,1,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
1816,,,B,8,Autocuration,,12827,,BAO_0000357,,,,,10577,1,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,
1817,,,B,8,Autocuration,,5033,,BAO_0000357,,,,,10577,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,
1818,,,B,9,Expert,,9786,Rattus norvegicus,BAO_0000019,,,,,10577,1,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10116.0,
1819,,,B,8,Expert,,13116,,BAO_0000357,,,,,10577,1,Binding affinity at 5-hydroxytryptamine 1B receptor,,
1820,,,B,8,Autocuration,,16429,,BAO_0000019,,,,,10577,1,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,
1821,,,B,9,Expert,,12409,Rattus norvegicus,BAO_0000249,,,,,10577,1,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10116.0,
1822,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,10577,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,
1823,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,10577,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1824,,,B,4,Autocuration,,5486,,BAO_0000019,,,,,104686,1,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,
1825,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,106,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,
1826,Brain membranes,,B,8,Autocuration,,386,,BAO_0000249,,,,,106,1,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,
1827,,,B,8,Autocuration,,2474,,BAO_0000357,,,,,106,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,
1828,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,106,1,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,
1829,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,106,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,
1830,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,106,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,
1831,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,106,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,
1832,,,B,8,Expert,,1633,,BAO_0000357,,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,
1833,,,B,8,Autocuration,,1633,,BAO_0000357,,,,,106,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,
1834,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,
1835,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,106,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,
1836,,,B,8,Autocuration,,11574,,BAO_0000357,,,,,106,1,Binding affinity against 5-hydroxytryptamine 1B receptor,,
1837,,,B,8,Autocuration,,10321,,BAO_0000357,,,,,106,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,
1838,,,B,8,Autocuration,,15527,,BAO_0000357,,,,,106,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,
1839,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,106,1,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,
1840,,,B,4,Autocuration,,14423,,BAO_0000224,,,,,104802,1,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,
1841,,,B,8,Autocuration,,5834,Bos taurus,BAO_0000357,,,,,108,1,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,9913.0,
1842,,,B,8,Autocuration,,11473,Sus scrofa,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,9823.0,
1843,,,B,8,Autocuration,,11473,Sus scrofa,BAO_0000357,,,,,108,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,9823.0,
1844,,,B,8,Autocuration,,10639,Sus scrofa,BAO_0000357,,,,,108,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,9823.0,
1845,,,B,8,Autocuration,,10639,Sus scrofa,BAO_0000357,,,,,108,1,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,9823.0,
1846,,,B,8,Autocuration,,14331,Sus scrofa,BAO_0000357,,,,,108,1,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,9823.0,
1847,,,B,8,Autocuration,,10796,Sus scrofa,BAO_0000357,,,,,108,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,9823.0,
1848,,,B,8,Expert,,9098,Sus scrofa,BAO_0000357,,,,,108,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,9823.0,
1849,,,B,8,Expert,,14331,Sus scrofa,BAO_0000357,,,,,108,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,9823.0,
1850,,,B,8,Expert,,11828,Sus scrofa,BAO_0000019,,,,,108,1,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,9823.0,
1851,,,B,8,Autocuration,,11866,Sus scrofa,BAO_0000357,,,,,108,1,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,9823.0,
1852,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,108,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,9986.0,
1853,,,B,9,Autocuration,,188,Rattus norvegicus,BAO_0000357,,,,,12689,1,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,10116.0,
1854,,,B,9,Autocuration,,11825,Rattus norvegicus,BAO_0000357,,,,,12689,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,10116.0,
1855,,,B,9,Autocuration,,11825,Rattus norvegicus,BAO_0000357,,,,,12689,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,10116.0,
1856,,,B,9,Expert,,11624,Rattus norvegicus,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,10116.0,
1857,,,B,9,Autocuration,,11139,Rattus norvegicus,BAO_0000357,,,,,12689,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,10116.0,
1858,,,B,9,Autocuration,,11147,Rattus norvegicus,BAO_0000357,,,,,12689,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,10116.0,
1859,,,B,9,Autocuration,,10444,Rattus norvegicus,BAO_0000019,,,,,12689,1,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,10116.0,
1860,,,B,9,Expert,,11624,Rattus norvegicus,BAO_0000357,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,10116.0,
1861,,,B,9,Autocuration,,11662,Rattus norvegicus,BAO_0000019,,,,,12689,1,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,
1862,,,B,9,Autocuration,,11662,Rattus norvegicus,BAO_0000019,,,,,12689,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,
1863,,,B,9,Expert,,11662,Rattus norvegicus,BAO_0000019,,,,,12689,1,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,
1864,,,B,9,Autocuration,,11662,Rattus norvegicus,BAO_0000019,,,,,12689,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",10116.0,
1865,,,B,9,Autocuration,,9098,Rattus norvegicus,BAO_0000357,,,,,12689,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,10116.0,
1866,,,B,9,Autocuration,,10394,Rattus norvegicus,BAO_0000249,,,,,12689,1,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,10116.0,
1867,,,B,8,Expert,,11933,,BAO_0000357,,,,,12689,1,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,
1868,,,B,9,Autocuration,,12092,Rattus norvegicus,BAO_0000357,,,,,12689,1,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,10116.0,
1869,,,B,9,Autocuration,,12253,Rattus norvegicus,BAO_0000019,,,,,12689,1,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,10116.0,
1870,,HEK293,B,9,Autocuration,,12253,Rattus norvegicus,BAO_0000219,722.0,,,,12689,1,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,10116.0,
1871,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,108,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1872,,,B,8,Autocuration,,2474,,BAO_0000357,,,,,108,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1873,,,B,8,Autocuration,,2474,,BAO_0000357,,,,,108,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,
1874,,,B,8,Autocuration,,11574,,BAO_0000357,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1875,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,12689,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,
1876,,,B,8,Autocuration,,13944,,BAO_0000357,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,
1877,,,B,8,Autocuration,,13033,,BAO_0000357,,,,,12689,1,Binding affinity against serotonergic 5-HT1c receptor,,
1878,,,B,8,Autocuration,,10321,,BAO_0000357,,,,,12689,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,
1879,,,B,8,Autocuration,,11866,,BAO_0000357,,,,,12689,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,
1880,,,B,8,Autocuration,,14454,Oryctolagus cuniculus,BAO_0000019,,,,,105,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),9986.0,
1881,,,B,4,Autocuration,,11574,,BAO_0000224,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,
1882,,,B,4,Autocuration,,11574,,BAO_0000224,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,
1883,,,B,4,Autocuration,,13631,,BAO_0000019,,,,,104686,1,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,
1884,,,B,5,Autocuration,,9630,Rattus norvegicus,BAO_0000019,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,10116.0,
1885,,,B,5,Autocuration,,8822,Rattus norvegicus,BAO_0000249,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,10116.0,
1886,,,B,5,Autocuration,,9064,Rattus norvegicus,BAO_0000221,,Brain,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,10116.0,
1887,,,B,4,Autocuration,,8868,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,
1888,,,B,4,Autocuration,,9064,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,
1889,,,B,4,Autocuration,,9806,,BAO_0000019,,,,,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,
1890,,,B,4,Autocuration,,9098,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
1891,,,B,4,Autocuration,,8868,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,
1892,,,B,4,Autocuration,,12765,,BAO_0000224,,,,,104686,1,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
1893,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1894,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1895,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,
1896,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,
1897,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1898,,,B,4,Autocuration,,11473,,BAO_0000019,,,,,104686,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,
1899,,,B,4,Autocuration,,11473,,BAO_0000019,,,,,104686,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,
1900,,,B,4,Autocuration,,3086,,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,
1901,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1902,,,B,4,Autocuration,,11049,,BAO_0000019,,,,,104686,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,
1903,,,B,4,Autocuration,,10639,,BAO_0000019,,,,,104686,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,
1904,,,B,4,Autocuration,,10922,,BAO_0000019,,,,,104686,1,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,
1905,,,B,5,Autocuration,,9064,Rattus norvegicus,BAO_0000221,,Brain,,,104686,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,10116.0,
1906,,,B,4,Autocuration,,10748,,BAO_0000221,,Brain,,,104686,1,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,,
1907,Membranes,,B,4,Autocuration,,11614,,BAO_0000249,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1908,Membranes,,B,4,Autocuration,,11615,,BAO_0000249,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1909,,,B,4,Autocuration,,11615,,BAO_0000224,,,,,104686,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,
1910,Membranes,,B,4,Autocuration,,11614,,BAO_0000249,,,,,104686,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,
1911,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,
1912,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1913,,,B,5,Autocuration,,11702,Rattus norvegicus,BAO_0000224,,,,,104686,1,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,10116.0,
1914,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,
1915,,,B,4,Autocuration,,13346,,BAO_0000019,,,,,104686,1,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,
1916,,,B,4,Autocuration,,10025,,BAO_0000224,,,,,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1917,,,B,4,Autocuration,,10025,,BAO_0000224,,,,,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
1918,,,B,4,Autocuration,,10025,,BAO_0000224,,,,,104686,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
1919,,,B,4,Autocuration,,9036,,BAO_0000224,,,,,104686,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,
1920,,,B,4,Autocuration,,9036,,BAO_0000224,,,,,104686,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,
1921,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,
1922,,,B,4,Autocuration,,12304,,BAO_0000019,,,,,104686,1,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,
1923,,,B,4,Autocuration,,13276,,BAO_0000224,,,,,104686,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,
1924,,,B,4,Autocuration,,11825,,BAO_0000224,,,,,104686,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1925,,,B,4,Autocuration,,12443,,BAO_0000224,,,,,104686,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,
1926,,,B,4,Autocuration,,13830,,BAO_0000224,,,,,104686,1,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,
1927,Membranes,,B,4,Autocuration,,9592,,BAO_0000249,,,,,104686,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,
1928,Membranes,,B,4,Autocuration,,9592,,BAO_0000249,,,,,104686,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,
1929,,,B,4,Autocuration,,10881,,BAO_0000224,,,,,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,
1930,,,B,4,Autocuration,,13605,,BAO_0000019,,,,,104686,1,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,
1931,,,B,5,Autocuration,,11624,Rattus norvegicus,BAO_0000224,,,,,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor,10116.0,
1932,,,B,4,Autocuration,,4101,,BAO_0000224,,,,,104686,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1933,,,B,4,Autocuration,,4101,,BAO_0000224,,,,,104686,1,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,
1934,,,B,4,Autocuration,,15360,,BAO_0000019,,,,,104686,1,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,
1935,,,B,4,Autocuration,,11576,,BAO_0000019,,,,,104686,1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,
1936,,,B,4,Autocuration,,5834,,BAO_0000019,,,,,104686,1,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,
1937,,CHO-K1,B,5,Autocuration,,2395,Rattus norvegicus,BAO_0000219,485.0,,,,104686,1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,
1938,Membranes,,B,4,Autocuration,,11965,,BAO_0000249,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,
1939,,,B,4,Autocuration,,3967,,BAO_0000224,,,,,104686,1,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,
1940,Brain membranes,,B,4,Autocuration,,11130,,BAO_0000249,,,,,104686,1,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,
1941,,,B,4,Autocuration,In vitro,13427,,BAO_0000219,,,,,104686,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
1942,,,B,4,Autocuration,,9443,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
1943,,,B,4,Autocuration,,9443,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
1944,,,B,4,Autocuration,,11825,,BAO_0000224,,,,,104686,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,
1945,Membranes,,B,4,Autocuration,,12120,,BAO_0000249,,,,,104686,1,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,
1946,Membranes,,B,4,Autocuration,,12120,,BAO_0000249,,,,,104686,1,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,
1947,,,F,4,Autocuration,,11963,,BAO_0000019,,Thoracic aorta,,,104686,1,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,,
1948,,,B,4,Autocuration,,9069,,BAO_0000019,,,,,104686,1,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,
1949,,,B,4,Autocuration,,8868,,BAO_0000224,,,,,104686,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
1950,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,10624,1,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,
1951,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,10624,1,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,
1952,,,B,8,Expert,,13969,,BAO_0000357,,,,,17106,1,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,
1953,,,B,9,Expert,,13392,,BAO_0000357,,,,,17106,1,Binding affinity for 5-hydroxytryptamine 1D receptor,,
1954,,,B,8,Autocuration,,1742,,BAO_0000249,,,,,17106,1,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1955,,,B,8,Autocuration,,1742,,BAO_0000249,,,,,17106,1,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1956,,,B,8,Autocuration,,14331,,BAO_0000357,,Striatum,,,17106,1,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,,
1957,,,F,8,Autocuration,,12861,,BAO_0000019,,,,,17106,1,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,
1958,,,B,8,Expert,,12861,,BAO_0000019,,,,,17106,1,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,
1959,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,17106,1,Binding activity radioligand.,,
1960,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,17106,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
1961,,,B,8,Expert,,12861,,BAO_0000019,,,,,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
1962,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
1963,,,B,8,Autocuration,,675,,BAO_0000249,,,,,17106,1,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,
1964,,,B,8,Expert,,12490,,BAO_0000019,,,,,17106,1,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,
1965,,,B,8,Expert,,11828,,BAO_0000249,,,,,17106,1,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,
1966,,,B,8,Autocuration,,11866,,BAO_0000357,,,,,17106,1,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,
1967,,,B,8,Autocuration,,773,Sus scrofa,BAO_0000357,,,,,105,1,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,9823.0,
1968,,,B,8,Expert,,13047,Oryctolagus cuniculus,BAO_0000357,,,,,105,1,The compound was tested for intrinsic activity against 5-HT1D receptor,9986.0,
1969,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,105,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,9986.0,
1970,,,B,8,Expert,,13047,Oryctolagus cuniculus,BAO_0000357,,,,,105,1,The compound was tested for binding affinity against 5-HT1D receptor,9986.0,
1971,,,B,8,Autocuration,,188,,BAO_0000357,,,,,10578,1,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,
1972,,,F,8,Autocuration,,10639,,BAO_0000019,,,,,10578,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,
1973,,,F,8,Autocuration,,12438,,BAO_0000019,,,,,10578,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,
1974,,,B,8,Autocuration,,12438,,BAO_0000357,,,,,10578,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,
1975,,,B,8,Expert,,15854,,BAO_0000019,,,,,10578,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,
1976,,,B,8,Autocuration,,10394,,BAO_0000249,,,,,10578,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,
1977,,,B,8,Autocuration,,12092,,BAO_0000357,,,,,10578,1,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,
1978,,,B,8,Expert,,3389,,BAO_0000019,,,,,10578,1,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,
1979,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,105,1,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,
1980,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,105,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,
1981,,,B,8,Autocuration,,2474,,BAO_0000357,,,,,105,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,
1982,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,105,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,
1983,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,105,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,
1984,,,B,8,Autocuration,,11866,,BAO_0000357,,,,,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,
1985,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,105,1,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,
1986,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,105,1,Tested against 5-hydroxytryptamine 1D receptor,,
1987,,,B,8,Autocuration,,10321,,BAO_0000357,,,,,105,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,
1988,,HEK293,B,8,Autocuration,,13267,,BAO_0000219,722.0,,,,105,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
1989,,,B,9,Expert,,1274,Homo sapiens,BAO_0000357,,,,,105,1,Binding affinity against 5-Hydroxytryptamine 1D receptor,9606.0,
1990,,,B,8,Autocuration,,15250,,BAO_0000357,,,,,105,1,,,
1991,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,106,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1992,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,105,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
1993,,HEK293,B,8,Autocuration,,13706,,BAO_0000219,722.0,,,,105,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,
1994,,HEK293,B,8,Autocuration,,13706,,BAO_0000219,722.0,,,,105,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
1995,,,B,8,Autocuration,,13047,,BAO_0000019,,,,,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
1996,,,B,8,Autocuration,,13366,,BAO_0000357,,,,,105,1,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,
1997,,,B,8,Expert,,13366,,BAO_0000357,,,,,105,1,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,
1998,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,
1999,,CHO-K1,B,8,Expert,,12902,,BAO_0000219,485.0,,,,105,1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,
2000,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,105,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,
2001,,,F,8,Autocuration,,13706,,BAO_0000019,,,,,105,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,
2002,,,F,8,Autocuration,,13706,,BAO_0000019,,,,,105,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2003,,,F,8,Autocuration,,14251,,BAO_0000019,,,,,105,1,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2004,,,F,8,Autocuration,,14251,,BAO_0000019,,,,,105,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2005,,,F,8,Autocuration,,14251,,BAO_0000019,,,,,105,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,
2006,,,B,8,Autocuration,,13313,,BAO_0000357,,,,,105,1,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,
2007,,,B,8,Autocuration,,13313,,BAO_0000357,,,,,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,
2008,,,B,8,Autocuration,,13366,,BAO_0000357,,,,,105,1,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,
2009,,,B,8,Expert,,13051,,BAO_0000357,,,,,105,1,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,
2010,,CHO,B,8,Expert,,12903,,BAO_0000219,449.0,,,,105,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,
2011,,,B,9,Autocuration,,12469,Homo sapiens,BAO_0000219,,,,,105,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,9606.0,
2012,,,B,8,Autocuration,,5619,,BAO_0000357,,,,,17106,1,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,
2013,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,105,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,9986.0,
2014,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,105,1,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,
2015,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,105,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2016,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,105,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,
2017,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,105,1,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,
2018,,,B,8,Autocuration,,3269,,BAO_0000357,,,,,105,1,Affinity against 5-hydroxytryptamine 1D receptor alpha,,
2019,,,B,8,Expert,,12409,,BAO_0000357,,,,,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,
2020,,,F,8,Autocuration,,13706,,BAO_0000019,,,,,106,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2021,,HEK293,B,8,Autocuration,,13706,,BAO_0000219,722.0,,,,106,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,
2022,,HEK293,B,8,Autocuration,,13706,,BAO_0000219,722.0,,,,106,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,
2023,,CHO,B,8,Autocuration,,12903,,BAO_0000219,449.0,,,,106,1,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2024,,,B,8,Autocuration,,13047,,BAO_0000019,,,,,106,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,
2025,,,B,9,Expert,,13366,,BAO_0000357,,,,,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2026,,,B,9,Expert,,13366,,BAO_0000357,,,,,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2027,,,B,9,Expert,,13366,,BAO_0000357,,,,,106,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,
2028,,,B,8,Autocuration,,13366,,BAO_0000357,,,,,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,
2029,,,B,8,Autocuration,,13366,,BAO_0000357,,,,,106,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,
2030,,CHO,B,8,Autocuration,,12469,,BAO_0000219,449.0,,,,106,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,
2031,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,106,1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,
2032,,CHO-K1,B,8,Autocuration,,13706,,BAO_0000219,485.0,,,,106,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,
2033,,,F,8,Autocuration,,13706,,BAO_0000019,,,,,106,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,
2034,,CHO-K1,B,8,Expert,,12902,,BAO_0000219,485.0,,,,106,1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,
2035,,,B,8,Expert,,13051,,BAO_0000357,,,,,105,1,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,
2036,,CHO,B,8,Expert,,12903,,BAO_0000219,449.0,,,,106,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,
2037,,CHO-K1,F,8,Autocuration,,1558,,BAO_0000219,485.0,,,,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,
2038,,CHO-K1,F,8,Autocuration,,1558,,BAO_0000219,485.0,,,,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,
2039,,CHO-K1,F,8,Autocuration,,1558,,BAO_0000219,485.0,,,,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,
2040,,CHO-K1,F,8,Autocuration,,1558,,BAO_0000219,485.0,,,,105,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,
2041,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,105,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,
2042,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,106,1,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,9986.0,
2043,,,B,8,Autocuration,,13313,,BAO_0000357,,,,,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,
2044,,,B,8,Autocuration,,13313,,BAO_0000357,,,,,105,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,
2045,,,B,8,Expert,,12409,,BAO_0000357,,,,,105,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,
2046,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,10618,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,
2047,,,B,9,Expert,,1348,Homo sapiens,BAO_0000357,,,,,10618,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,9606.0,
2048,,,B,8,Autocuration,,1348,,BAO_0000357,,,,,10618,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,
2049,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,10618,1,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,9606.0,
2050,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,10618,1,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,
2051,,,B,8,Autocuration,,10444,,BAO_0000019,,,,,10618,1,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,
2052,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,10618,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,
2053,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,10618,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,
2054,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,10618,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,
2055,,CHO,B,9,Expert,,12936,Homo sapiens,BAO_0000219,449.0,,,,10618,1,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,9606.0,
2056,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,10618,1,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,
2057,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,10618,1,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2058,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,10618,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,
2059,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,10618,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,
2060,,,B,8,Autocuration,,13181,,BAO_0000357,,,,,10618,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,
2061,,CHO,B,8,Autocuration,,4199,,BAO_0000219,449.0,,,,10618,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,
2062,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,10618,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,
2063,,CHO,B,8,Autocuration,,15146,,BAO_0000219,449.0,,,,10618,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,
2064,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,10618,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,
2065,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,10618,1,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,
2066,,CHO,B,8,Autocuration,,13267,,BAO_0000219,449.0,,,,10618,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,
2067,,CHO,B,8,Autocuration,,14818,,BAO_0000219,449.0,,,,10618,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,
2068,,CHO,B,8,Autocuration,,4829,,BAO_0000219,449.0,,,,10618,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,
2069,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10618,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,
2070,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10618,1,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,
2071,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,10618,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,
2072,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10618,1,Binding affinity towards 5-hydroxytryptamine 1E receptor,,
2073,,,F,8,Autocuration,,17085,,BAO_0000019,,,,,279,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,
2074,,,F,8,Expert,,17085,,BAO_0000019,,,,,279,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,
2075,,,F,8,Autocuration,,16209,,BAO_0000019,,,,,279,1,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,
2076,,,F,8,Autocuration,,16209,,BAO_0000019,,,,,279,1,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,
2077,,,F,8,Expert,,17085,,BAO_0000019,,,,,279,1,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,
2078,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,279,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,
2079,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,279,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,
2080,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,279,1,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,
2081,,CHO,B,8,Autocuration,,16190,,BAO_0000219,449.0,,,,279,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,
2082,,,B,8,Autocuration,,16190,,BAO_0000357,,,,,279,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,
2083,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,
2084,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,
2085,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,279,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,
2086,,,B,8,Autocuration,,6866,,BAO_0000357,,,,,279,1,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,
2087,,,B,8,Expert,,17085,,BAO_0000019,,,,,279,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,
2088,,,B,8,Autocuration,,16312,,BAO_0000357,,,,,279,1,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,
2089,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,279,1,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,
2090,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,279,1,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,
2091,,CHO,B,8,Autocuration,,4199,,BAO_0000219,449.0,,,,279,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,
2092,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,279,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,
2093,,CHO,B,8,Autocuration,,15146,,BAO_0000219,449.0,,,,279,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,
2094,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,279,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,
2095,,CHO,B,8,Autocuration,,14818,,BAO_0000219,449.0,,,,279,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,
2096,,CHO,B,8,Autocuration,,4829,,BAO_0000219,449.0,,,,279,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2097,,CHO,B,8,Autocuration,,4829,,BAO_0000219,449.0,,,,279,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,
2098,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,279,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,
2099,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,279,1,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,
2100,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,279,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,
2101,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,
2102,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2103,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2104,,,B,8,Autocuration,,14093,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2105,,,F,4,Autocuration,In vivo,11200,,BAO_0000218,,,,,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,
2106,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2107,,,B,8,Intermediate,,12352,,BAO_0000019,,,,,17005,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,
2108,,,B,0,Autocuration,,13657,Bos taurus,BAO_0000019,,,,,22226,1,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",9913.0,
2109,,,B,0,Autocuration,,14331,Bos taurus,BAO_0000019,,,,,22226,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,9913.0,
2110,,,B,0,Autocuration,,14331,Bos taurus,BAO_0000019,,,,,22226,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,9913.0,
2111,,,B,0,Autocuration,,14331,,BAO_0000019,,,,,22226,1,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,
2112,,,B,4,Autocuration,,12685,Cavia porcellus,BAO_0000019,,,,,104784,1,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,10141.0,
2113,,,B,4,Autocuration,,14389,Cavia porcellus,BAO_0000019,,,,,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,10141.0,
2114,,,B,4,Autocuration,,14386,Cavia porcellus,BAO_0000019,,,,,104784,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,10141.0,
2115,,,B,4,Autocuration,,5732,,BAO_0000224,,,,,104784,1,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,
2116,,,B,4,Autocuration,,16293,,BAO_0000224,,,,,104784,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2117,,,B,4,Autocuration,,2078,,BAO_0000224,,,,,104784,1,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,
2118,,,B,8,Autocuration,,5486,,BAO_0000357,,,,,10209,1,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,
2119,,,B,4,Autocuration,In vivo,11820,,BAO_0000218,,,,,104826,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,
2120,,,B,4,Autocuration,,10297,,BAO_0000019,,,,,104826,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,
2121,,,B,4,Autocuration,,13704,,BAO_0000224,,,,,104826,1,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,
2122,,,B,5,Autocuration,,10297,Mus musculus,BAO_0000019,,,,,104826,1,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,10090.0,
2123,,,B,4,Autocuration,In vivo,11820,,BAO_0000218,,,,,104826,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,
2124,,,B,5,Autocuration,,10297,Mus musculus,BAO_0000019,,,,,104826,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,10090.0,
2125,,,B,4,Autocuration,,11555,,BAO_0000224,,,,,104826,1,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,
2126,,,B,4,Autocuration,,11555,,BAO_0000224,,,,,104826,1,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,
2127,,,B,4,Autocuration,,11555,,BAO_0000224,,,,,104826,1,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,
2128,,,B,5,Autocuration,,10297,Mus musculus,BAO_0000019,,,,,104826,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,10090.0,
2129,,,B,4,Autocuration,,16688,Sus scrofa,BAO_0000224,,,,,104784,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,9823.0,
2130,,,B,4,Autocuration,,16688,Sus scrofa,BAO_0000224,,,,,104784,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,9823.0,
2131,,,B,0,Autocuration,,5333,,BAO_0000221,,,,,22226,1,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2132,,,B,0,Autocuration,,4437,,BAO_0000221,,,,,22226,1,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,
2133,,,B,8,Autocuration,,5033,Sus scrofa,BAO_0000357,,,,,17005,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,9823.0,
2134,,,B,4,Autocuration,,15267,,BAO_0000019,,,,,104686,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2135,,,B,4,Autocuration,,15267,,BAO_0000019,,,,,104686,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,
2136,,,B,4,Autocuration,,11820,,BAO_0000019,,,,,104826,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,
2137,,,B,4,Autocuration,,9069,,BAO_0000224,,,,,104686,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2138,,,B,5,Autocuration,,9162,Rattus norvegicus,BAO_0000019,,,,,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,10116.0,
2139,,,B,4,Autocuration,,9162,,BAO_0000019,,,,,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,
2140,,,B,4,Autocuration,,9162,,BAO_0000019,,,,,104686,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,
2141,,,F,4,Autocuration,,10428,,BAO_0000019,,,,,104686,1,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,
2142,,,B,4,Autocuration,,9628,,BAO_0000019,,,,,104686,1,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,
2143,,,B,4,Autocuration,,12704,,BAO_0000224,,,,,104686,1,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,
2144,,,B,5,Autocuration,,15453,Rattus norvegicus,BAO_0000224,,,,,104686,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,10116.0,
2145,,,B,4,Autocuration,,188,,BAO_0000224,,,,,104686,1,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,
2146,,,B,4,Autocuration,,10349,,BAO_0000224,,,,,104686,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,
2147,,,B,4,Autocuration,,10349,,BAO_0000224,,,,,104686,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,
2148,,,B,4,Autocuration,,8868,,BAO_0000224,,,,,104686,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,
2149,,,B,4,Autocuration,,10025,,BAO_0000224,,,,,104686,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,
2150,,,B,4,Autocuration,,10025,,BAO_0000224,,,,,104686,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,
2151,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,
2152,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,
2153,,,B,4,Autocuration,,11702,,BAO_0000224,,,,,104686,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,
2154,,,F,4,Autocuration,,11702,,BAO_0000019,,,,,104686,1,Compound was tested for the inhibition of quipazine induced head twitches in rats,,
2155,,,F,4,Autocuration,,11702,,BAO_0000019,,,,,104686,1,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,
2156,,,B,4,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,104686,1,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,,
2157,,,B,4,Autocuration,,10085,,BAO_0000221,,Hippocampus,,,104686,1,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,,
2158,,,B,5,Autocuration,,9630,Rattus norvegicus,BAO_0000221,,Brain,,,104686,1,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,10116.0,
2159,,,B,4,Autocuration,,11070,,BAO_0000019,,,,,104686,1,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,
2160,Membranes,,B,4,Autocuration,,9841,,BAO_0000249,,,,,104686,1,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2161,Membranes,,B,4,Autocuration,,9841,,BAO_0000249,,,,,104686,1,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,
2162,,,B,4,Autocuration,,13291,,BAO_0000019,,,,,104686,1,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,
2163,,,F,4,Autocuration,,10590,,BAO_0000019,,,,,104686,1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,
2164,,,B,5,Autocuration,,9064,Rattus norvegicus,BAO_0000221,,Brain,,,104686,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,10116.0,
2165,Membranes,,B,5,Autocuration,,12268,Rattus norvegicus,BAO_0000249,,,,,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,10116.0,
2166,,,B,4,Autocuration,,13508,,BAO_0000221,,Brain,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,,
2167,,,F,4,Autocuration,,11279,,BAO_0000019,,,,,104686,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2168,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,
2169,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2170,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2171,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,
2172,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2173,,,B,4,Autocuration,,9231,,BAO_0000220,,Brain,,,104686,1,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,,
2174,,,B,4,Autocuration,,9737,,BAO_0000019,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2175,,,B,4,Autocuration,,9737,,BAO_0000249,,Brain,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,,
2176,,,B,4,Autocuration,,9737,,BAO_0000019,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,
2177,,,B,4,Autocuration,,9737,,BAO_0000019,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,
2178,,,B,5,Autocuration,,11828,Rattus norvegicus,BAO_0000019,,,,,104686,1,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,10116.0,
2179,,,B,4,Autocuration,,12253,,BAO_0000019,,,,,104686,1,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,
2180,,,B,4,Autocuration,,12253,,BAO_0000019,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,
2181,,,F,4,Autocuration,,11279,,BAO_0000019,,,,,104686,1,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,
2182,,,B,4,Autocuration,,11866,,BAO_0000019,,,,,104686,1,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,
2183,,,B,5,Autocuration,,14424,Rattus norvegicus,BAO_0000224,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,10116.0,
2184,,,B,5,Autocuration,,15180,Rattus norvegicus,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,10116.0,
2185,,,B,5,Autocuration,,15180,Rattus norvegicus,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,10116.0,
2186,,,B,5,Autocuration,,9786,Rattus norvegicus,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,10116.0,
2187,,,B,4,Autocuration,,12132,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,
2188,,,B,4,Autocuration,,5486,,BAO_0000249,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,
2189,,,B,4,Autocuration,,15316,,BAO_0000019,,,,,104686,1,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,
2190,,,B,4,Autocuration,,16429,,BAO_0000019,,,,,104686,1,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,
2191,,,B,4,Autocuration,,14617,,BAO_0000224,,,,,104686,1,pKi value for 5-hydroxytryptamine 2 receptor binding site,,
2192,,,B,4,Autocuration,,11351,,BAO_0000221,,Brain,,,104686,1,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,,
2193,,,F,4,Autocuration,,11279,,BAO_0000019,,,,,104686,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,
2194,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2195,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2196,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2197,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2198,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,
2199,,,B,4,Autocuration,,9523,,BAO_0000019,,,,,105075,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,
2200,,,B,4,Autocuration,,9523,,BAO_0000224,,,,,105075,1,Hill coefficient of compound was determined,,
2201,,,B,0,Autocuration,,4771,,BAO_0000019,,,,,22226,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,
2202,,,B,5,Autocuration,,5033,Rattus norvegicus,BAO_0000019,,,,,104686,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,10116.0,
2203,,,B,8,Expert,,10845,,BAO_0000019,,,,,12687,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,
2204,,,B,8,Expert,,10845,,BAO_0000019,,,,,12687,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,
2205,,,B,8,Autocuration,,16288,,BAO_0000357,,,,,12687,1,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,
2206,,,B,8,Autocuration,,16288,,BAO_0000019,,,,,12687,1,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,
2207,,,B,8,Autocuration,,16190,,BAO_0000019,,,,,12687,1,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,
2208,,,B,5,Autocuration,,12463,Rattus norvegicus,BAO_0000224,,,,,104686,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,10116.0,
2209,,,B,4,Autocuration,,9699,,BAO_0000224,,,,,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,
2210,,,B,4,Autocuration,,9699,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,
2211,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2212,,,B,4,Autocuration,,1205,,BAO_0000224,,,,,104784,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,
2213,,,B,0,Autocuration,,11376,,BAO_0000219,,,,,22226,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,
2214,,,B,4,Autocuration,,11376,,BAO_0000219,,,,,104784,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,
2215,,,B,4,Autocuration,,4639,,BAO_0000224,,,,,104784,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,
2216,,,B,4,Autocuration,,2222,,BAO_0000224,,,,,104784,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,
2217,,,B,4,Autocuration,,1558,,BAO_0000224,,,,,104784,1,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,
2218,,,B,4,Autocuration,,1089,,BAO_0000224,,,,,104784,1,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,
2219,Brain membranes,,B,4,Autocuration,,386,,BAO_0000249,,,,,104784,1,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,
2220,,,B,4,Autocuration,,2474,,BAO_0000224,,,,,104784,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,
2221,,,B,4,Autocuration,,17066,,BAO_0000224,,,,,104784,1,Binding affinity towards 5-HT2 receptor,,
2222,,,B,4,Autocuration,,959,,BAO_0000224,,,,,104784,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2223,,,B,4,Autocuration,,6398,,BAO_0000224,,,,,104784,1,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,
2224,,,B,4,Autocuration,,11889,,BAO_0000224,,,,,104686,1,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,
2225,,,B,4,Autocuration,,4221,,BAO_0000224,,,,,104784,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2226,,,B,4,Autocuration,,11026,,BAO_0000224,,,,,104784,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,
2227,,,B,4,Autocuration,,11866,,BAO_0000224,,,,,104784,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,
2228,,,B,4,Autocuration,,4221,,BAO_0000224,,,,,104784,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2229,,,B,0,Autocuration,,13950,,BAO_0000019,,,,,22226,1,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,
2230,,,B,4,Autocuration,,1263,,BAO_0000224,,,,,104784,1,5-hydroxytryptamine 2 receptor binding affinity,,
2231,,,B,8,Autocuration,,13291,,BAO_0000357,,,,,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,
2232,,,B,8,Autocuration,,10812,,BAO_0000357,,,,,17005,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,
2233,,,B,4,Autocuration,,13020,,BAO_0000224,,,,,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2234,,,B,4,Autocuration,,13021,,BAO_0000224,,,,,104784,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,
2235,,,B,4,Autocuration,,13020,,BAO_0000224,,,,,104784,1,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,
2236,,,B,8,Autocuration,,14532,,BAO_0000357,,,,,17005,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,
2237,,,B,8,Autocuration,,13944,,BAO_0000357,,,,,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2238,,,B,8,Autocuration,,14331,,BAO_0000357,,,,,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,
2239,,,B,8,Autocuration,,14118,,BAO_0000357,,,,,17005,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2240,,,B,8,Autocuration,,13033,,BAO_0000357,,,,,17005,1,Binding affinity against serotonergic 5-HT2 receptor,,
2241,,,B,8,Autocuration,,10321,,BAO_0000357,,,,,17005,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,
2242,,,B,8,Autocuration,,12918,,BAO_0000357,,,,,17005,1,Compound was evaluated for the binding affinity at 5- HT2 receptor,,
2243,,,B,8,Autocuration,,15120,,BAO_0000357,,,,,17005,1,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,
2244,,,B,8,Autocuration,,2613,,BAO_0000218,,,,,17005,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,
2245,,,B,5,Autocuration,,13378,Homo sapiens,BAO_0000224,,,,,104784,1,Inhibitory activity against cloned human 5-HT2 receptor,9606.0,
2246,,CHO,B,5,Autocuration,,2331,Homo sapiens,BAO_0000219,449.0,,,,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",9606.0,
2247,,CHO,B,5,Autocuration,,2331,Homo sapiens,BAO_0000219,449.0,,,,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",9606.0,
2248,,CHO,B,5,Autocuration,,2331,Homo sapiens,BAO_0000219,449.0,,,,104784,1,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",9606.0,
2249,,CHO,B,5,Autocuration,,2331,Homo sapiens,BAO_0000219,449.0,,,,104784,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",9606.0,
2250,,,B,4,Autocuration,,4170,,BAO_0000224,,,,,104784,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2251,,,B,4,Autocuration,,15453,,BAO_0000224,,,,,104784,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,
2252,,,B,8,Autocuration,,1479,,BAO_0000357,,,,,17005,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2253,,,B,4,Autocuration,,11139,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,
2254,,,B,8,Expert,,13969,,BAO_0000357,,,,,17005,1,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,
2255,,,B,8,Expert,,13392,,BAO_0000357,,,,,17005,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2256,,,B,8,Expert,,14430,,BAO_0000019,,,,,17005,1,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,
2257,,,B,8,Autocuration,,13181,Cavia porcellus,BAO_0000357,,,,,107,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,10141.0,
2258,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,51,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2259,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,107,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2260,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,51,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2261,,,B,8,Autocuration,,13463,,BAO_0000357,,,,,107,1,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,
2262,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,107,1,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2263,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,107,1,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,
2264,,,F,8,Autocuration,,4176,,BAO_0000219,,,,,107,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2265,,,F,8,Autocuration,,4176,,BAO_0000219,,,,,107,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,
2266,,,F,8,Autocuration,,4176,,BAO_0000219,,,,,107,1,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,
2267,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,107,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,
2268,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,107,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,
2269,,,B,8,Autocuration,,15331,,BAO_0000357,,,,,107,1,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,
2270,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,107,1,Inhibition of human 5-hydroxytryptamine 2A receptor,9606.0,
2271,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,107,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2272,,,B,8,Expert,,13631,,BAO_0000219,,,,,107,1,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,
2273,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,107,1,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,
2274,,CHO,B,8,Autocuration,,4011,,BAO_0000219,449.0,,,,107,1,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,
2275,,CHO,B,8,Expert,,4012,,BAO_0000219,449.0,,,,107,1,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,
2276,,L929,B,8,Expert,,6366,,BAO_0000219,307.0,,,,107,1,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,
2277,,CHO,B,8,Expert,,15949,,BAO_0000219,449.0,,,,107,1,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2278,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,107,1,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,
2279,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,107,1,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2280,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,107,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,
2281,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,107,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,
2282,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,107,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,
2283,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,107,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,
2284,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,107,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2285,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,107,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,
2286,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,107,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2287,,,B,8,Autocuration,,14755,,BAO_0000357,,,,,107,1,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,
2288,,,B,8,Autocuration,,16441,,BAO_0000357,,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,
2289,,,B,8,Autocuration,,14744,,BAO_0000357,,,,,107,1,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,
2290,,CHO,B,8,Expert,,16659,,BAO_0000219,449.0,,,,107,1,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2291,,,B,8,Autocuration,,3307,,BAO_0000357,,,,,107,1,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,
2292,,,B,9,Expert,,6857,Homo sapiens,BAO_0000019,,,,,107,1,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,9606.0,
2293,,,B,8,Expert,,5635,,BAO_0000357,,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,
2294,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,107,1,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,9606.0,
2295,,,B,8,Autocuration,,15527,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2296,,CHO,B,8,Expert,,6588,,BAO_0000219,449.0,,,,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,
2297,,,B,8,Expert,,13631,,BAO_0000219,,,,,107,1,Binding affinity towards human 5-HT2A receptor in BEK cells,,
2298,,,B,8,Autocuration,,17723,,BAO_0000357,,,,,107,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,
2299,,,B,8,Autocuration,,14770,,BAO_0000357,,,,,107,1,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,
2300,,,B,9,Expert,,16293,Homo sapiens,BAO_0000357,,,,,107,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,9606.0,
2301,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2302,,,B,8,Autocuration,,12469,,BAO_0000219,,,,,107,1,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,
2303,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,107,1,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,
2304,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,107,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,
2305,,,B,8,Expert,,16441,,BAO_0000019,,,,,107,1,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,
2306,,,B,8,Autocuration,,8,,BAO_0000357,,,,,107,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,
2307,,HEK293,B,8,Autocuration,,4176,,BAO_0000219,722.0,,,,107,1,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,
2308,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,107,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,
2309,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,107,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,
2310,,,B,9,Expert,,17200,Homo sapiens,BAO_0000357,,,,,107,1,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,9606.0,
2311,,CHO,B,9,Expert,,4013,Homo sapiens,BAO_0000219,449.0,,,,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,9606.0,
2312,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,107,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,
2313,,,B,9,Expert,,5088,Homo sapiens,BAO_0000357,,,,,107,1,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,9606.0,
2314,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,107,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,
2315,,,B,9,Expert,,5088,Homo sapiens,BAO_0000357,,,,,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,9606.0,
2316,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,107,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,
2317,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,107,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2318,,,B,4,Autocuration,,9786,,BAO_0000019,,,,,104686,1,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,
2319,,,B,5,Autocuration,,9205,Rattus norvegicus,BAO_0000019,,,,,104686,1,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,10116.0,
2320,,,B,4,Autocuration,,11257,,BAO_0000224,,,,,104686,1,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,
2321,,,B,4,Autocuration,,9362,,BAO_0000019,,,,,104686,1,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2322,,,B,4,Autocuration,,9362,,BAO_0000019,,,,,104686,1,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,
2323,,,B,4,Autocuration,,10590,,BAO_0000224,,,,,104686,1,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,
2324,,,B,4,Autocuration,,10468,,BAO_0000019,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2325,,,B,4,Autocuration,,13050,,BAO_0000019,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,
2326,,,B,4,Autocuration,,11624,,BAO_0000019,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,
2327,,,B,4,Autocuration,,10468,,BAO_0000019,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,
2328,,,B,4,Autocuration,,10330,,BAO_0000224,,,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,
2329,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104686,1,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,
2330,,,B,4,Autocuration,,11642,,BAO_0000224,,,,,104686,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2331,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104686,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,
2332,,,B,4,Autocuration,In vitro,13427,,BAO_0000219,,,,,104686,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,
2333,,,B,5,Autocuration,,12280,Rattus norvegicus,BAO_0000224,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,10116.0,
2334,,,B,5,Autocuration,,4101,Rattus norvegicus,BAO_0000224,,,,,104686,1,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,10116.0,
2335,,,B,4,Autocuration,,10062,,BAO_0000224,,,,,104686,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,
2336,,,B,4,Autocuration,,11147,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,
2337,,CHO-K1,B,5,Autocuration,,2395,Rattus norvegicus,BAO_0000219,485.0,,,,104686,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,
2338,,CHO-K1,B,5,Autocuration,,2395,Rattus norvegicus,BAO_0000219,485.0,,,,104686,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,10116.0,
2339,,,B,5,Autocuration,,9098,Rattus norvegicus,BAO_0000019,,,,,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,10116.0,
2340,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,
2341,,,B,5,Autocuration,,9098,Rattus norvegicus,BAO_0000019,,,,,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,10116.0,
2342,,,B,4,Autocuration,,9443,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,
2343,,,B,4,Autocuration,,9443,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,
2344,,,B,4,Autocuration,,9699,,BAO_0000019,,,,,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,
2345,,,B,4,Autocuration,,9699,,BAO_0000019,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,
2346,,,B,4,Autocuration,,9098,,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,
2347,,,B,5,Autocuration,,3070,Rattus norvegicus,BAO_0000224,,,,,104686,1,Affinity for 5-hydroxytryptamine 2 receptor,10116.0,
2348,,,B,4,Autocuration,,9547,,BAO_0000224,,,,,104686,1,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,
2349,,,B,4,Autocuration,,10444,,BAO_0000019,,,,,104686,1,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,
2350,,,B,4,Autocuration,,14617,,BAO_0000019,,,,,104686,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,
2351,,,B,4,Autocuration,,14617,,BAO_0000019,,,,,104686,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,
2352,,,B,4,Autocuration,,11130,,BAO_0000224,,,,,104686,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,
2353,,,B,4,Autocuration,In vivo,11130,,BAO_0000218,,,,,104686,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,
2354,,,B,4,Autocuration,,14542,,BAO_0000221,,Brain,,,104686,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,,
2355,,,B,4,Autocuration,,2797,,BAO_0000224,,,,,104686,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,
2356,,,B,4,Autocuration,,11332,,BAO_0000019,,,,,104686,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2357,,,B,4,Autocuration,,11332,,BAO_0000019,,,,,104686,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,
2358,,,B,4,Autocuration,,10752,,BAO_0000019,,Frontal cortex,,,104686,1,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,,
2359,,,B,4,Autocuration,,1185,,BAO_0000224,,,,,104686,1,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2360,,,B,4,Autocuration,,1185,,BAO_0000224,,,,,104686,1,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,
2361,,,B,5,Autocuration,,11624,Rattus norvegicus,BAO_0000224,,,,,104686,1,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,10116.0,
2362,,,B,4,Autocuration,,1344,,BAO_0000019,,,,,104686,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,
2363,,,B,5,Autocuration,,15453,Rattus norvegicus,BAO_0000019,,Striatum,,,104686,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,10116.0,
2364,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,
2365,,,B,4,Autocuration,,11662,,BAO_0000019,,,,,104686,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,
2366,,,B,4,Autocuration,,10796,,BAO_0000224,,,,,104686,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,
2367,,,B,4,Autocuration,,9069,,BAO_0000224,,,,,104686,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,
2368,,,B,5,Autocuration,,8814,Rattus norvegicus,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,10116.0,
2369,,,B,5,Autocuration,,8908,Rattus norvegicus,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,10116.0,
2370,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2371,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,
2372,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,
2373,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,
2374,,,B,4,Autocuration,,9098,,BAO_0000249,,,,,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,
2375,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,
2376,,,B,4,Autocuration,,9098,,BAO_0000019,,,,,104686,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,
2377,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,
2378,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,
2379,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,
2380,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,
2381,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,
2382,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,
2383,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,
2384,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,
2385,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,
2386,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,
2387,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,
2388,,,B,4,Autocuration,,9161,,BAO_0000019,,,,,104686,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,
2389,,,B,4,Autocuration,,12094,,BAO_0000019,,,,,104686,1,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,
2390,,,B,4,Autocuration,,12018,,BAO_0000249,,,,,104686,1,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,
2391,,,B,4,Autocuration,,10394,,BAO_0000249,,,,,104686,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,
2392,,,B,4,Autocuration,,15260,,BAO_0000224,,,,,104686,1,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,
2393,,,B,5,Autocuration,,11624,Rattus norvegicus,BAO_0000224,,,,,104686,1,Inhibitory constant against 5-hydroxytryptamine 2 receptor,10116.0,
2394,,,B,4,Autocuration,,13654,,BAO_0000224,,,,,104686,1,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,
2395,,,B,4,Autocuration,,9541,,BAO_0000019,,,,,104686,1,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,
2396,,,B,4,Autocuration,,11933,,BAO_0000224,,,,,104686,1,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,
2397,,,B,4,Autocuration,,15538,,BAO_0000019,,,,,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,
2398,,,B,4,Autocuration,,15538,,BAO_0000019,,,,,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,
2399,,,B,4,Autocuration,,15538,,BAO_0000019,,,,,104686,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,
2400,,,B,5,Autocuration,,8841,,BAO_0000019,,,,,104686,1,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,
2401,,,B,4,Autocuration,,1455,,BAO_0000224,,,,,104686,1,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,
2402,,,B,4,Autocuration,,1455,,BAO_0000224,,,,,104686,1,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,
2403,,,B,4,Autocuration,,11752,,BAO_0000019,,,,,104686,1,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,
2404,,,B,4,Autocuration,,11642,,BAO_0000221,,Brain,,,104686,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,,
2405,,,B,4,Autocuration,,12092,,BAO_0000224,,,,,104686,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,
2406,,,B,4,Autocuration,,3967,,BAO_0000224,,,,,104686,1,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,
2407,,,B,5,Autocuration,,12771,Rattus norvegicus,BAO_0000224,,,,,104686,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,10116.0,
2408,,,B,4,Autocuration,,11642,,BAO_0000019,,,,,104686,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,
2409,,,B,4,Autocuration,,11628,,BAO_0000224,,,,,104686,1,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,
2410,,,B,4,Autocuration,,13654,,BAO_0000224,,,,,104686,1,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,
2411,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2412,,,F,4,Autocuration,,11200,,BAO_0000019,,,,,104686,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,
2413,,,F,4,Autocuration,In vivo,11200,,BAO_0000218,,,,,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,
2414,,,F,4,Autocuration,In vivo,11200,,BAO_0000218,,,,,104686,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,
2415,,,F,4,Autocuration,In vivo,11200,,BAO_0000218,,,,,104686,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,
2416,,,F,4,Autocuration,In vivo,11200,,BAO_0000218,,,,,104686,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,
2417,,,B,8,Expert,,15436,,BAO_0000221,,Brain,,,12687,1,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,,
2418,,,B,9,Expert,,15436,Rattus norvegicus,BAO_0000019,,,,,12687,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,
2419,,,B,8,Autocuration,,14025,,BAO_0000019,,,,,12687,1,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,
2420,,,B,8,Autocuration,,4342,,BAO_0000357,,,,,12687,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,
2421,,,B,9,Expert,,13735,Rattus norvegicus,BAO_0000019,,,,,12687,1,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,10116.0,
2422,,,B,9,Expert,,5816,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,10116.0,
2423,,,B,8,Expert,,14287,,BAO_0000019,,,,,12687,1,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,
2424,,,B,8,Autocuration,,15738,,BAO_0000357,,,,,12687,1,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,
2425,,,B,9,Expert,,15738,Rattus norvegicus,BAO_0000357,,,,,12687,1,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,10116.0,
2426,,,B,8,Autocuration,,15026,,BAO_0000019,,,,,12687,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,
2427,,,B,8,Expert,,16647,,BAO_0000019,,,,,12687,1,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2428,,,B,8,Autocuration,,16647,,BAO_0000019,,,,,12687,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,
2429,,,B,9,Expert,,13345,Rattus norvegicus,BAO_0000019,,,,,12687,1,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,10116.0,
2430,Membranes,,B,8,Autocuration,,1543,,BAO_0000249,,,,,12687,1,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,
2431,,,B,8,Autocuration,,12444,,BAO_0000019,,,,,12687,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,
2432,,,B,8,Expert,,16404,,BAO_0000019,,,,,12687,1,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,
2433,,CHO,B,8,Autocuration,,16404,,BAO_0000219,449.0,,,,12687,1,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,
2434,,,B,8,Expert,,15577,,BAO_0000357,,,,,12687,1,Kinetic inhibition constant evaluated by measuring serotonergic activity,,
2435,,,B,8,Autocuration,,15577,,BAO_0000357,,,,,12687,1,Serotonergic activity of the compound.,,
2436,,,B,8,Autocuration,,2495,,BAO_0000249,,,,,12687,1,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,
2437,,,B,9,Expert,,15042,Rattus norvegicus,BAO_0000019,,,,,12687,1,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,10116.0,
2438,,,B,8,Expert,,15026,,BAO_0000249,,,,,12687,1,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,
2439,,,F,9,Expert,,12919,Rattus norvegicus,BAO_0000019,,,,,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,
2440,,,F,9,Expert,,12919,Rattus norvegicus,BAO_0000019,,,,,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,
2441,,,F,9,Expert,,12919,Rattus norvegicus,BAO_0000019,,,,,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,
2442,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,12687,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2443,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,12687,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,
2444,,,B,8,Expert,,4820,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2445,,,B,8,Autocuration,,6736,,BAO_0000357,,,,,107,1,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,
2446,,,B,8,Autocuration,,5163,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,
2447,,,B,8,Autocuration,,5163,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,
2448,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,107,1,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,
2449,,,B,9,Expert,,14294,Homo sapiens,BAO_0000357,,,,,107,1,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,9606.0,
2450,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,107,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,
2451,,,B,8,Expert,,17066,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2452,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,107,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,
2453,,,B,8,Expert,,6736,,BAO_0000357,,,,,107,1,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,
2454,,,B,8,Expert,,5163,,BAO_0000357,,,,,107,1,Affinity for 5-hydroxytryptamine 2A receptor,,
2455,,NIH3T3,B,8,Expert,,16911,,BAO_0000219,723.0,,,,107,1,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,
2456,,,B,8,Expert,,6841,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,
2457,,,B,8,Expert,,6119,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,
2458,,,B,8,Autocuration,,3962,,BAO_0000357,,,,,107,1,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,
2459,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,107,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,
2460,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,107,1,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,
2461,,,F,8,Autocuration,,3962,,BAO_0000019,,,,,107,1,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,
2462,,,B,8,Expert,,1633,,BAO_0000357,,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,
2463,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,107,1,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,
2464,,,B,8,Expert,,6576,,BAO_0000357,,,,,107,1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,
2465,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,107,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,
2466,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,107,1,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,
2467,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,107,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,
2468,,CHO,B,8,Expert,,3032,Mus musculus,BAO_0000219,449.0,,,,107,1,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,10090.0,
2469,,,B,8,Autocuration,,16655,,BAO_0000357,,,,,107,1,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2470,,,B,8,Autocuration,,13964,,BAO_0000357,,,,,107,1,Binding affinity at 5-hydroxytryptamine 2A receptor,,
2471,,,B,8,Expert,,16989,,BAO_0000357,,,,,107,1,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,
2472,,,B,8,Autocuration,,16117,,BAO_0000357,,,,,107,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,
2473,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,107,1,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,
2474,,,B,8,Autocuration,,3269,,BAO_0000357,,,,,107,1,Affinity against 5-hydroxytryptamine 2A receptor,,
2475,,,B,9,Expert,,1274,Homo sapiens,BAO_0000357,,,,,107,1,Binding affinity against 5-Hydroxytryptamine 2A receptor,9606.0,
2476,,,B,8,Autocuration,,1317,,BAO_0000357,,,,,107,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2477,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,107,1,Tested against 5-hydroxytryptamine 2A receptor,,
2478,,,B,4,Autocuration,,12652,,BAO_0000224,,,,,105075,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2479,,,B,4,Autocuration,,12652,,BAO_0000224,,,,,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,
2480,,,B,4,Autocuration,,12652,,BAO_0000224,,,,,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,
2481,,,B,4,Autocuration,,12652,,BAO_0000224,,,,,105075,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,
2482,,,B,8,Autocuration,,16647,,BAO_0000357,,,,,107,1,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,
2483,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,9606.0,
2484,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,227,1,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,
2485,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,227,1,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,
2486,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,227,1,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,9606.0,
2487,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,227,1,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,
2488,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,227,1,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,
2489,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,
2490,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,
2491,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,227,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,
2492,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,227,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2493,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,
2494,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,
2495,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,
2496,,,B,8,Autocuration,,12369,,BAO_0000357,,,,,107,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,
2497,,,B,8,Expert,,12369,,BAO_0000357,,,,,107,1,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,
2498,,,B,8,Expert,,12369,,BAO_0000357,,,,,107,1,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,
2499,,,B,8,Autocuration,,14447,,BAO_0000019,,,,,107,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,
2500,,,B,8,Autocuration,,14447,,BAO_0000019,,,,,107,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,
2501,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2502,,CHO,F,8,Autocuration,,6857,,BAO_0000219,449.0,,,,107,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,
2503,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,107,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,
2504,,,B,4,Autocuration,,5635,,BAO_0000224,,,,,104817,1,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,
2505,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,107,1,Binding activity radioligand.,,
2506,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,107,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2507,,L929,B,8,Autocuration,,5105,,BAO_0000219,307.0,,,,107,1,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2508,,L929,B,8,Expert,,5104,,BAO_0000219,307.0,,,,107,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,
2509,,L929,B,8,Expert,,5105,,BAO_0000219,307.0,,,,107,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,
2510,,L929,B,8,Autocuration,,5105,,BAO_0000219,307.0,,,,107,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,
2511,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,107,1,Binding affinity against 5-HT2A receptor,,
2512,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2513,,HEK293,B,8,Autocuration,,13267,,BAO_0000219,722.0,,,,107,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,
2514,,HEK293,B,8,Autocuration,,13267,,BAO_0000219,722.0,,,,107,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2515,,HEK293,B,9,Expert,,14157,Homo sapiens,BAO_0000219,722.0,,,,107,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,9606.0,
2516,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,
2517,,,B,8,Expert,,14068,,BAO_0000357,,,,,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,
2518,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,
2519,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,
2520,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,9606.0,
2521,,,B,8,Expert,,6166,,BAO_0000357,,,,,107,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,
2522,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2523,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,
2524,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,107,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,
2525,,HEK293,B,9,Expert,,15779,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,9606.0,
2526,,HEK293,B,8,Expert,,14391,,BAO_0000219,722.0,,,,107,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,
2527,,HEK293,B,8,Expert,,15851,,BAO_0000219,722.0,,,,107,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,
2528,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,107,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,9606.0,
2529,,HEK293,B,8,Expert,,3832,,BAO_0000219,722.0,,,,107,1,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,
2530,,HEK293,B,8,Expert,,3833,,BAO_0000219,722.0,,,,107,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,
2531,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,107,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,9606.0,
2532,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2533,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2534,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,107,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2535,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,107,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,
2536,,CHO-K1,B,8,Autocuration,,1883,,BAO_0000219,485.0,,,,107,1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,
2537,,CHO-K1,B,8,Expert,,1883,,BAO_0000219,485.0,,,,107,1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,
2538,,,B,9,Expert,,14875,Homo sapiens,BAO_0000357,,,,,107,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,9606.0,
2539,,HEK293,B,8,Autocuration,,15146,,BAO_0000219,722.0,,,,107,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,
2540,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,107,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2541,,CHO,B,9,Expert,,16404,Homo sapiens,BAO_0000219,449.0,,,,107,1,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,9606.0,
2542,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,107,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,
2543,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,107,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,
2544,,NIH3T3,F,8,Autocuration,,12652,,BAO_0000219,723.0,,,,10620,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,
2545,,NIH3T3,B,8,Expert,,4682,,BAO_0000219,723.0,,,,107,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,
2546,,,F,8,Autocuration,,12652,,BAO_0000019,,,,,10620,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,
2547,,,B,8,Autocuration,,4921,,BAO_0000357,,,,,10621,1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,
2548,,,B,8,Autocuration,,4921,,BAO_0000357,,,,,10621,1,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,
2549,,,B,8,Autocuration,,16312,Oryctolagus cuniculus,BAO_0000357,,,,,107,1,Binding affinity against rabbit aorta 5-HT2A receptor,9986.0,
2550,,,B,8,Expert,,14998,Oryctolagus cuniculus,BAO_0000357,,,,,107,1,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,9986.0,
2551,,,B,8,Expert,,14025,Oryctolagus cuniculus,BAO_0000357,,,,,107,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,9986.0,
2552,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,107,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,9986.0,
2553,,,B,8,Expert,,13047,Oryctolagus cuniculus,BAO_0000357,,,,,107,1,The compound was tested for binding affinity against 5-HT2A receptor,9986.0,
2554,,CHO-K1,B,8,Autocuration,,1883,,BAO_0000219,485.0,,,,10576,1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,
2555,,,B,8,Autocuration,,13463,,BAO_0000019,,,,,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,
2556,,,B,8,Autocuration,,13463,,BAO_0000019,,,,,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2557,,,B,8,Autocuration,,13463,,BAO_0000019,,Stomach,,,12687,1,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,,
2558,,,B,9,Expert,,13463,Rattus norvegicus,BAO_0000019,,Stomach,,,12687,1,Binding affinity for 5-HT 2A in rat stomach fundus,10116.0,
2559,,,B,8,Autocuration,,13463,,BAO_0000019,,,,,12687,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,
2560,,NIH3T3,B,8,Expert,,16326,,BAO_0000219,723.0,,,,12687,1,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,
2561,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,12687,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,
2562,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,12687,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,
2563,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,12687,1,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2564,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,12687,1,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,
2565,,,F,9,Expert,,17200,Rattus norvegicus,BAO_0000019,,,,,12687,1,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,10116.0,
2566,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2567,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2568,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12687,1,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,
2569,,,F,8,Autocuration,,17200,,BAO_0000219,,,,,12687,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2570,,,F,8,Autocuration,,15363,,BAO_0000019,,,,,12687,1,Efficacy at 5-hydroxytryptamine 2A receptor,,
2571,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,
2572,,,B,9,Expert,,17200,Rattus norvegicus,BAO_0000357,,,,,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),10116.0,
2573,,,B,9,Expert,,17200,Rattus norvegicus,BAO_0000357,,,,,12687,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),10116.0,
2574,,,F,9,Expert,,17200,Rattus norvegicus,BAO_0000219,,,,,12687,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,10116.0,
2575,,,F,8,Autocuration,,17200,,BAO_0000219,,,,,12687,1,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,
2576,,,B,8,Autocuration,,17211,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,
2577,,,B,8,Expert,,17331,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,
2578,,,B,8,Expert,,13565,,BAO_0000249,,,,,12687,1,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,
2579,,,B,8,Expert,,13730,,BAO_0000357,,,,,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,
2580,,,B,8,Expert,,12416,,BAO_0000019,,,,,12687,1,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,
2581,,,B,8,Autocuration,,15295,,BAO_0000357,,,,,12687,1,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,
2582,,,B,8,Autocuration,,1742,,BAO_0000019,,,,,12687,1,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,
2583,,,B,8,Autocuration,,15295,,BAO_0000357,,,,,12687,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,
2584,,,B,8,Expert,,14970,,BAO_0000019,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,
2585,,,B,8,Expert,,16693,,BAO_0000019,,,,,12687,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,
2586,,,B,9,Expert,,14776,Rattus norvegicus,BAO_0000019,,,,,12687,1,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,10116.0,
2587,,,B,8,Autocuration,,14286,,BAO_0000249,,,,,12687,1,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2588,,,B,9,Expert,,17200,Rattus norvegicus,BAO_0000019,,,,,12687,1,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,10116.0,
2589,,,B,8,Expert,,15306,,BAO_0000357,,,,,12687,1,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,
2590,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,12687,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,10116.0,
2591,,,B,9,Expert,,14229,Rattus norvegicus,BAO_0000019,,,,,12687,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,10116.0,
2592,,,B,8,Expert,,12884,,BAO_0000357,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,
2593,,,B,8,Expert,,13149,,BAO_0000357,,,,,12687,1,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,
2594,,,B,9,Expert,,15295,Rattus norvegicus,BAO_0000019,,,,,12687,1,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,10116.0,
2595,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,12687,1,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,
2596,,,B,8,Autocuration,,15185,,BAO_0000019,,,,,12687,1,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,
2597,,,B,8,Autocuration,,15185,,BAO_0000019,,,,,12687,1,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,
2598,,,B,8,Expert,,17529,,BAO_0000019,,,,,12687,1,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,
2599,,,B,8,Autocuration,,14826,,BAO_0000019,,,,,12687,1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2600,,,B,8,Expert,,17211,,BAO_0000019,,,,,12687,1,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,
2601,,,B,8,Autocuration,,14826,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,
2602,,,B,8,Autocuration,,14093,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,
2603,,,B,8,Autocuration,,14093,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,
2604,,NIH3T3,B,8,Expert,,13246,,BAO_0000219,723.0,,,,12687,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,
2605,,,B,8,Expert,,13246,,BAO_0000357,,,,,12687,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,
2606,,,B,9,Expert,,15436,Rattus norvegicus,BAO_0000019,,,,,12687,1,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,
2607,,,B,9,Expert,,15436,Rattus norvegicus,BAO_0000019,,,,,12687,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,10116.0,
2608,,,B,8,Autocuration,,14442,,BAO_0000221,,Brain,,,12687,1,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,,
2609,,,B,8,Expert,,12457,,BAO_0000357,,,,,12687,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,
2610,,NIH3T3,B,8,Expert,,12457,,BAO_0000219,723.0,,,,12687,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,
2611,,,F,8,Autocuration,,14755,,BAO_0000221,,,,,12687,1,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,
2612,,,B,8,Autocuration,,4707,,BAO_0000357,,,,,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,
2613,,,B,8,Expert,,13297,,BAO_0000357,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,
2614,,,B,8,Expert,,17331,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,
2615,,,B,8,Autocuration,,4664,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,
2616,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2617,,NIH3T3,B,9,Expert,,4664,Rattus norvegicus,BAO_0000219,723.0,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,10116.0,
2618,,,B,8,Expert,,16133,,BAO_0000357,,,,,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2619,,,B,8,Expert,,16133,,BAO_0000357,,,,,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2620,,,B,9,Expert,,14060,Rattus norvegicus,BAO_0000019,,,,,12687,1,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,10116.0,
2621,,,B,8,Expert,,16326,,BAO_0000357,,,,,12687,1,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2622,,CHO,B,8,Expert,,16659,,BAO_0000219,449.0,,,,12687,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,
2623,,,B,8,Autocuration,,14776,,BAO_0000019,,,,,12687,1,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,
2624,,,B,8,Autocuration,,13481,,BAO_0000357,,,,,12687,1,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,
2625,,,B,8,Autocuration,,17386,,BAO_0000357,,,,,12687,1,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,
2626,,,B,9,Expert,,6611,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity for 5-hydroxytryptamine 2A receptor,10116.0,
2627,,,B,8,Autocuration,,14423,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,
2628,,,B,8,Autocuration,,15412,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,
2629,,,B,8,Autocuration,,15412,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,
2630,,,B,8,Autocuration,,6238,,BAO_0000019,,,,,12687,1,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,
2631,,,B,8,Expert,,6648,,BAO_0000357,,,,,12687,1,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,
2632,,,B,8,Expert,,5667,,BAO_0000357,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,
2633,,,B,9,Expert,,6611,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,10116.0,
2634,,,B,8,Autocuration,,13481,,BAO_0000357,,,,,12687,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2635,,,B,8,Autocuration,,13481,,BAO_0000357,,,,,12687,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,
2636,,NIH3T3,B,8,Expert,,15558,,BAO_0000219,723.0,,,,12687,1,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,
2637,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,
2638,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,
2639,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,
2640,,,B,9,Expert,,6013,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,10116.0,
2641,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,
2642,,,B,8,Expert,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,
2643,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,
2644,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,12687,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,
2645,,,B,8,Autocuration,,16293,,BAO_0000357,,,,,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2646,,NIH3T3,B,8,Expert,,17175,,BAO_0000219,723.0,,,,12687,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,
2647,,,B,9,Expert,,13278,Rattus norvegicus,BAO_0000357,,,,,12687,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,10116.0,
2648,,,B,8,Autocuration,,3682,,BAO_0000019,,Caudate-putamen,,,12687,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,,
2649,,,B,8,Autocuration,,2014,,BAO_0000357,,,,,12687,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,
2650,,,B,8,Autocuration,,2014,,BAO_0000357,,,,,12687,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,
2651,,,B,8,Autocuration,,4932,,BAO_0000357,,,,,12687,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,
2652,,,B,8,Autocuration,,4932,,BAO_0000019,,,,,12687,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,
2653,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,12687,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,
2654,,,B,9,Expert,,5432,Rattus norvegicus,BAO_0000221,,Hippocampus,,,12687,1,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,10116.0,
2655,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,12687,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,
2656,,,B,8,Autocuration,,13672,,BAO_0000357,,,,,12687,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,
2657,,,B,8,Autocuration,,13672,,BAO_0000357,,,,,12687,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,
2658,,NIH3T3,B,8,Expert,,14749,,BAO_0000219,723.0,,,,12687,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,
2659,,,B,8,Autocuration,,13462,,BAO_0000019,,,,,12687,1,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,
2660,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,12687,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,
2661,,,B,8,Expert,,16647,,BAO_0000019,,,,,12687,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,
2662,,,B,8,Autocuration,,13345,,BAO_0000221,,Brain,,,12687,1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,,
2663,,,B,8,Autocuration,,16740,,BAO_0000249,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2664,,,B,8,Autocuration,,16740,,BAO_0000249,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2665,,,B,9,Expert,,15535,Rattus norvegicus,BAO_0000019,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,10116.0,
2666,,,B,8,Expert,,16740,,BAO_0000249,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2667,,,B,8,Autocuration,,16740,,BAO_0000249,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2668,,,B,8,Autocuration,,16740,,BAO_0000249,,,,,12687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,
2669,,,B,9,Expert,,4795,Rattus norvegicus,BAO_0000019,,,,,12687,1,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,10116.0,
2670,,,B,8,Expert,,8,,BAO_0000019,,,,,12687,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,
2671,,,B,8,Autocuration,,8,,BAO_0000019,,,,,12687,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,
2672,,,B,9,Expert,,17200,Rattus norvegicus,BAO_0000019,,,,,12687,1,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,10116.0,
2673,,,B,9,Expert,,2148,Rattus norvegicus,BAO_0000019,,,,,12687,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,10116.0,
2674,,,B,5,Expert,,13345,Rattus norvegicus,BAO_0000224,,,,,105102,1,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",10116.0,
2675,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,12687,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,
2676,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,12687,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,
2677,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12687,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,
2678,,,B,9,Expert,,17133,Rattus norvegicus,BAO_0000357,,,,,12687,1,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,10116.0,
2679,,,B,8,Autocuration,,16532,,BAO_0000357,,,,,12687,1,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,
2680,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,12687,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,
2681,,,B,9,Expert,,2309,Rattus norvegicus,BAO_0000019,,,,,12687,1,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,10116.0,
2682,,,B,8,Expert,,12953,,BAO_0000019,,,,,12687,1,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,
2683,,,B,8,Autocuration,,12953,,BAO_0000019,,,,,12687,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,
2684,,,B,8,Autocuration,,12953,,BAO_0000019,,,,,12687,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,
2685,,CHO,B,8,Autocuration,,16659,,BAO_0000219,449.0,,,,12687,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,
2686,,,B,8,Autocuration,,16740,,BAO_0000019,,,,,12687,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2687,,,B,8,Autocuration,,16740,,BAO_0000019,,,,,12687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,
2688,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12687,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,
2689,,,B,8,Autocuration,,17211,,BAO_0000019,,,,,12687,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,
2690,,,B,8,Autocuration,,17331,,BAO_0000019,,,,,12687,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,
2691,,,B,8,Autocuration,,16633,,BAO_0000218,,,,,12687,1,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,
2692,,,B,8,Autocuration,,16633,,BAO_0000218,,,,,12687,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,
2693,,,B,8,Autocuration,,16633,,BAO_0000218,,,,,12687,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,
2694,,,B,8,Expert,,15026,,BAO_0000357,,,,,12687,1,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,
2695,,,B,8,Expert,,15026,,BAO_0000357,,,,,12687,1,Ratio of pKi of 5-HT2A to that of D2 receptor,,
2696,,,B,4,Expert,,16404,,BAO_0000224,,,,,105093,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2697,,,B,4,Expert,,16404,,BAO_0000224,,,,,105093,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,
2698,,,B,4,Expert,,16404,,BAO_0000224,,,,,105075,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,
2699,,,B,8,Autocuration,,16404,,BAO_0000357,,,,,12687,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,
2700,,,B,8,Expert,,16326,,BAO_0000357,,,,,12687,1,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,
2701,,,F,8,Autocuration,,15847,,BAO_0000019,,,,,12687,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,
2702,,,F,8,Autocuration,,15847,,BAO_0000019,,,,,12687,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,
2703,,,F,8,Autocuration,,15329,,BAO_0000019,,,,,12687,1,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,
2704,,,F,8,Expert,,16404,,BAO_0000019,,Thoracic aorta,,,12687,1,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,,
2705,,,F,8,Expert,,16404,,BAO_0000019,,Thoracic aorta,,,12687,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,,
2706,,,F,8,Autocuration,,16404,,BAO_0000019,,Thoracic aorta,,,12687,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,,
2707,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,12687,1,Binding activity radioligand.,,
2708,,,B,8,Expert,,12861,,BAO_0000019,,,,,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2709,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2710,,,B,8,Expert,,12490,,BAO_0000019,,,,,12687,1,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,
2711,,N1E-115,B,8,Autocuration,,12827,,BAO_0000219,339.0,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,
2712,,N1E-115,B,8,Autocuration,,12827,,BAO_0000219,339.0,,,,12687,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,
2713,,,B,8,Autocuration,,12918,,BAO_0000019,,,,,12687,1,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,
2714,,,F,9,Expert,,12919,Rattus norvegicus,BAO_0000019,,,,,12687,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,10116.0,
2715,,,B,8,Autocuration,,17723,,BAO_0000357,,,,,108,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,
2716,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2717,,,B,8,Autocuration,,16293,,BAO_0000357,,,,,108,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,
2718,,,B,8,Expert,,3857,,BAO_0000019,,,,,108,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2719,,,B,8,Expert,,3857,,BAO_0000019,,,,,108,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,
2720,,,B,8,Expert,,3857,,BAO_0000019,,,,,108,1,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,
2721,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,108,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2722,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,108,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,
2723,,,B,8,Expert,,16441,,BAO_0000019,,,,,108,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,
2724,,,B,8,Expert,,16441,,BAO_0000019,,,,,108,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,
2725,,HEK293,B,8,Autocuration,,4176,,BAO_0000219,722.0,,,,108,1,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,
2726,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,108,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,
2727,,,B,9,Expert,,17200,Homo sapiens,BAO_0000357,,,,,108,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,9606.0,
2728,,,B,8,Expert,,5088,,BAO_0000357,,,,,108,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,
2729,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,
2730,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2731,,,B,8,Autocuration,,5088,,BAO_0000357,,,,,108,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2732,,CHO,B,8,Autocuration,,16659,,BAO_0000219,449.0,,,,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2733,,CHO,B,8,Autocuration,,16659,,BAO_0000219,449.0,,,,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,
2734,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,108,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,
2735,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,108,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,
2736,,,B,8,Expert,,3857,,BAO_0000019,,,,,108,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2737,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,108,1,Binding activity radioligand.,,
2738,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,108,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,
2739,,CHO,B,8,Expert,,5104,,BAO_0000219,449.0,,,,108,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,
2740,,CHO,B,8,Expert,,5105,,BAO_0000219,449.0,,,,108,1,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,
2741,,CHO,B,8,Autocuration,,5105,,BAO_0000219,449.0,,,,108,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,
2742,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,108,1,Binding affinity against 5-HT2C receptor,,
2743,,HEK293,B,8,Autocuration,,13267,,BAO_0000219,722.0,,,,108,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,
2744,,HEK293,B,9,Expert,,14157,Homo sapiens,BAO_0000219,722.0,,,,108,1,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,9606.0,
2745,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9606.0,
2746,,,B,8,Expert,,14068,,BAO_0000357,,,,,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,
2747,,HEK293,B,9,Expert,,12936,Homo sapiens,BAO_0000219,722.0,,,,108,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,9606.0,
2748,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,108,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,9606.0,
2749,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,108,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,9606.0,
2750,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,108,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,
2751,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,
2752,,HEK293,B,8,Autocuration,,17296,,BAO_0000219,722.0,,,,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,
2753,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,108,1,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2754,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
2755,,HEK293,B,8,Expert,,14391,,BAO_0000219,722.0,,,,108,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,
2756,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,
2757,,HEK293,B,8,Expert,,15851,,BAO_0000219,722.0,,,,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,
2758,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,108,1,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,9606.0,
2759,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,108,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,
2760,,HEK293,B,8,Expert,,3832,,BAO_0000219,722.0,,,,108,1,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,
2761,,HEK293,B,8,Expert,,3833,,BAO_0000219,722.0,,,,108,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,
2762,,NIH3T3,B,8,Autocuration,,17451,,BAO_0000219,723.0,,,,108,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,
2763,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,108,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,
2764,,CHO-K1,B,8,Expert,,1883,,BAO_0000219,485.0,,,,108,1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,
2765,,,B,9,Expert,,4321,Homo sapiens,BAO_0000357,,,,,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor,9606.0,
2766,,,B,8,Autocuration,,14875,,BAO_0000357,,,,,108,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,
2767,,HEK293,B,8,Autocuration,,15146,,BAO_0000219,722.0,,,,108,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,
2768,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,108,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,
2769,,HeLa,B,8,Autocuration,,16404,,BAO_0000219,308.0,,,,108,1,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,
2770,,,F,8,Autocuration,,13267,,BAO_0000019,,,,,108,1,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,
2771,,,F,8,Autocuration,,13267,,BAO_0000221,,Hippocampus,,,108,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,,
2772,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,108,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,
2773,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,108,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,
2774,,,B,8,Autocuration,,13463,,BAO_0000357,,,,,11864,1,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,
2775,,,B,8,Autocuration,,13463,,BAO_0000019,,Stomach,,,11864,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus,,
2776,,,B,8,Autocuration,,13463,,BAO_0000019,,Stomach,,,11864,1,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,,
2777,,A9,F,8,Autocuration,,12652,,BAO_0000219,625.0,,,,11864,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,
2778,,NIH3T3,B,8,Autocuration,,4682,,BAO_0000219,723.0,,,,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2779,,NIH3T3,B,8,Autocuration,,4682,,BAO_0000219,723.0,,,,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,
2780,,NIH3T3,B,8,Autocuration,,4682,,BAO_0000219,723.0,,,,11864,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,
2781,,,F,8,Autocuration,,12652,,BAO_0000019,,,,,11864,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,
2782,,,B,8,Autocuration,,13463,Mus musculus,BAO_0000019,,Stomach,,,12689,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,10090.0,
2783,,,B,9,Expert,,13463,Rattus norvegicus,BAO_0000019,,Stomach,,,12689,1,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,10116.0,
2784,,,B,8,Expert,,13969,,BAO_0000357,,,,,108,1,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,
2785,,,B,8,Expert,,13392,Sus scrofa,BAO_0000357,,,,,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor,9823.0,
2786,,,B,8,Expert,,13392,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2787,,,B,8,Expert,,14430,,BAO_0000019,,,,,108,1,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,
2788,,,B,8,Autocuration,,1742,,BAO_0000019,,,,,108,1,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,
2789,,,B,8,Autocuration,,14286,,BAO_0000249,,,,,108,1,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,
2790,,,B,8,Autocuration,,5619,,BAO_0000357,,,,,108,1,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,
2791,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,108,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2792,,,B,8,Autocuration,,12861,,BAO_0000357,,,,,108,1,Binding activity radioligand.,,
2793,,,B,8,Expert,,12861,,BAO_0000019,,,,,108,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2794,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,108,1,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,
2795,,,B,8,Autocuration,,12827,,BAO_0000249,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,
2796,,,B,8,Autocuration,,12827,,BAO_0000249,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,
2797,,,F,8,Expert,,12919,Sus scrofa,BAO_0000019,,,,,108,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,9823.0,
2798,,,F,8,Expert,,12919,Sus scrofa,BAO_0000019,,,,,108,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,9823.0,
2799,,,B,8,Autocuration,,16429,Sus scrofa,BAO_0000357,,,,,108,1,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,9823.0,
2800,,,B,8,Autocuration,,773,Sus scrofa,BAO_0000019,,,,,108,1,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,9823.0,
2801,,,B,8,Autocuration,,5033,Sus scrofa,BAO_0000357,,,,,108,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,9823.0,
2802,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,12687,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,
2803,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,12689,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,
2804,,,B,8,Expert,,14970,,BAO_0000357,,,,,12689,1,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,
2805,,,B,8,Autocuration,,14970,,BAO_0000357,,,,,12689,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,
2806,,,B,8,Autocuration,,14970,,BAO_0000357,,,,,12689,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,
2807,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,12689,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,10116.0,
2808,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,12689,1,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,10116.0,
2809,Brain membranes,,B,9,Expert,,14229,Rattus norvegicus,BAO_0000249,,,,,12689,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,10116.0,
2810,,,B,8,Autocuration,,16532,,BAO_0000357,,,,,12689,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,
2811,,,B,8,Autocuration,,14826,,BAO_0000019,,,,,12689,1,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,
2812,,,B,8,Autocuration,,17211,,BAO_0000019,,,,,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,
2813,,,B,8,Expert,In vitro,17211,,BAO_0000219,,,,,12689,1,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,
2814,,NIH3T3,B,8,Expert,,13246,,BAO_0000219,723.0,,,,12689,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,
2815,,,B,8,Expert,,13246,,BAO_0000357,,,,,12689,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,
2816,,,B,8,Expert,,12457,,BAO_0000357,,,,,12689,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,
2817,,NIH3T3,B,8,Expert,,12457,,BAO_0000219,723.0,,,,12689,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,
2818,,,B,8,Autocuration,,4707,,BAO_0000357,,,,,12689,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,
2819,,,B,8,Expert,,13297,,BAO_0000357,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,
2820,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2821,,,B,8,Expert,,16133,,BAO_0000357,,,,,12689,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2822,,,B,8,Expert,,16326,,BAO_0000357,,,,,12689,1,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,
2823,,,B,8,Autocuration,,14423,,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,
2824,,,B,8,Autocuration,,15412,,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,
2825,,,B,8,Autocuration,,15412,,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,
2826,,A9,B,8,Expert,,15558,,BAO_0000219,625.0,,,,12689,1,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,
2827,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,12689,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2828,,,B,8,Expert,,6013,,BAO_0000357,,,,,12689,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,
2829,,,B,8,Expert,In vitro,17175,,BAO_0000219,,,,,12689,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,
2830,,,B,8,Autocuration,,12469,,BAO_0000219,,,,,12689,1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,
2831,,,B,8,Autocuration,,3682,,BAO_0000019,,Caudate-putamen,,,12689,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,,
2832,,,B,8,Autocuration,,4932,,BAO_0000357,,,,,12689,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,
2833,,,B,8,Autocuration,,4932,,BAO_0000019,,,,,12689,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,
2834,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,12689,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,
2835,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,12689,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,
2836,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,12689,1,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,
2837,,,B,8,Expert,,14749,,BAO_0000219,,,,,12689,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,
2838,,,B,8,Autocuration,,15740,,BAO_0000357,,,,,12689,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,
2839,,,B,9,Expert,,17133,Rattus norvegicus,BAO_0000357,,,,,12689,1,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,10116.0,
2840,,,B,8,Autocuration,,16532,,BAO_0000357,,,,,12689,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,
2841,,,B,8,Autocuration,,12369,,BAO_0000357,,,,,12689,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,
2842,,,B,8,Expert,,12369,,BAO_0000219,,,,,12689,1,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,
2843,,,B,9,Expert,,2309,Rattus norvegicus,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,10116.0,
2844,,,B,8,Autocuration,,12953,,BAO_0000357,,,,,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,
2845,,,B,8,Autocuration,,12953,,BAO_0000019,,,,,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,
2846,,,B,8,Autocuration,,12953,,BAO_0000357,,,,,12689,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,
2847,,,B,8,Expert,,12953,,BAO_0000357,,,,,12689,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,
2848,,,B,8,Autocuration,,17133,,BAO_0000357,,,,,12689,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,
2849,,,B,8,Autocuration,,17211,,BAO_0000019,,,,,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,
2850,,,B,8,Autocuration,,17211,,BAO_0000019,,,,,12689,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,
2851,,,B,8,Autocuration,,14025,,BAO_0000019,,,,,12689,1,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,
2852,,,B,8,Autocuration,,14998,,BAO_0000019,,,,,12689,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,
2853,,,B,8,Autocuration,,4342,,BAO_0000357,,,,,12689,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,
2854,,,B,9,Expert,,13735,Rattus norvegicus,BAO_0000019,,,,,12689,1,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,10116.0,
2855,,,B,8,Autocuration,,13181,,BAO_0000357,,,,,12689,1,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,
2856,,CHO-K1,B,8,Autocuration,,1883,,BAO_0000219,485.0,,,,12689,1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,
2857,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,12689,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2858,,,B,8,Autocuration,,15194,,BAO_0000357,,,,,12689,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,
2859,,,F,8,Autocuration,,14579,,BAO_0000019,,,,,12689,1,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,
2860,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,108,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,
2861,,,B,8,Expert,,4820,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,
2862,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,227,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,
2863,,,B,8,Autocuration,,14755,,BAO_0000357,,,,,227,1,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,
2864,,,B,8,Autocuration,,14744,,BAO_0000357,,,,,227,1,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,
2865,,,B,9,Expert,,6857,Homo sapiens,BAO_0000019,,,,,227,1,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,9606.0,
2866,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,227,1,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,
2867,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,227,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2868,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,227,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,
2869,,,B,8,Autocuration,,15363,,BAO_0000357,,,,,227,1,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,
2870,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,227,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,
2871,,,B,9,Expert,,17200,Homo sapiens,BAO_0000357,,,,,227,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,9606.0,
2872,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9606.0,
2873,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,9606.0,
2874,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,227,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,
2875,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,227,1,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,9606.0,
2876,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,227,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2877,,HEK293,B,8,Expert,,15851,,BAO_0000219,722.0,,,,227,1,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,
2878,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,227,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,
2879,,HEK293,B,9,Expert,,14157,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,9606.0,
2880,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,227,1,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,9606.0,
2881,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,227,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,
2882,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,227,1,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,
2883,,HEK293,B,8,Expert,,14391,,BAO_0000219,722.0,,,,227,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,
2884,,HEK293,B,8,Expert,,3832,,BAO_0000219,722.0,,,,227,1,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,
2885,,HEK293,B,8,Expert,,3833,,BAO_0000219,722.0,,,,227,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,
2886,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,9606.0,
2887,,HEK293,B,9,Expert,,15851,Homo sapiens,BAO_0000219,722.0,,,,227,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,9606.0,
2888,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,227,1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,
2889,,CHO-K1,B,8,Expert,,1883,,BAO_0000219,485.0,,,,227,1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,
2890,,,B,8,Expert,,4321,,BAO_0000357,,,,,227,1,Binding affinity against 5-hydroxytryptamine 2B receptor,,
2891,,HEK293,B,8,Autocuration,,15146,,BAO_0000219,722.0,,,,227,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,
2892,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,227,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,
2893,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,227,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,
2894,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,227,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2895,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,227,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,
2896,,,B,8,Autocuration,,14025,Oryctolagus cuniculus,BAO_0000019,,,,,227,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,9986.0,
2897,,,B,8,Expert,,13463,,BAO_0000019,,Stomach,,,12688,1,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,,
2898,,,B,8,Expert,,7259,,BAO_0000357,,Stomach,,,12688,1,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,,
2899,,,B,8,Autocuration,,7259,,BAO_0000357,,Stomach,,,12688,1,Affinity against serotonergic receptor in the isolated rat stomach fundus,,
2900,,,F,9,Expert,,7185,Rattus norvegicus,BAO_0000019,,Stomach,,,12688,1,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,10116.0,
2901,,,F,9,Expert,,7185,Rattus norvegicus,BAO_0000019,,,,,12688,1,Antagonistic against 5-hydroxytryptamine 2B receptor,10116.0,
2902,,,F,8,Autocuration,,13267,,BAO_0000019,,Stomach,,,12688,1,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,,
2903,,,B,9,Expert,,13735,Rattus norvegicus,BAO_0000357,,Stomach,,,12688,1,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,10116.0,
2904,,,F,8,Autocuration,,15738,,BAO_0000019,,,,,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,
2905,,,F,8,Autocuration,,15738,,BAO_0000019,,,,,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,
2906,,,F,8,Autocuration,,15738,,BAO_0000019,,,,,12688,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,
2907,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,Stomach,,,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,
2908,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,Stomach,,,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,
2909,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,Stomach,,,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,
2910,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,Stomach,,,12688,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,10116.0,
2911,,,F,8,Autocuration,,16404,,BAO_0000019,,Stomach,,,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2912,,,F,8,Expert,,16404,,BAO_0000019,,Stomach,,,12688,1,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,,
2913,,,F,8,Autocuration,,16404,,BAO_0000019,,Stomach,,,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,,
2914,,,F,8,Autocuration,,16404,,BAO_0000019,,Stomach,,,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,,
2915,,,F,9,Expert,,16404,Rattus norvegicus,BAO_0000019,,Stomach,,,12688,1,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,10116.0,
2916,,,F,8,Autocuration,,16404,,BAO_0000019,,Thoracic aorta,,,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,,
2917,,,B,8,Autocuration,,7483,,BAO_0000357,,,,,12688,1,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2918,,,B,8,Expert,,7483,,BAO_0000357,,,,,12688,1,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,
2919,,,B,8,Autocuration,,7483,,BAO_0000357,,,,,12688,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,
2920,,,B,8,Autocuration,,7483,,BAO_0000357,,,,,12688,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,
2922,,,F,9,Autocuration,,16404,Rattus norvegicus,BAO_0000019,,Stomach,,,12688,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,10116.0,
2923,,,B,8,Autocuration,,6347,,BAO_0000357,,,,,227,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,
2924,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,227,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,
2925,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,227,1,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,
2926,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,227,1,Evaluated for the binding affinity to 5-HT 2B receptor,,
2927,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,227,1,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,
2928,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,227,1,Binding affinities against 5-hydroxytryptamine 2B receptor,,
2929,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,227,1,Binding affinities towards 5-hydroxytryptamine 2B receptor,,
2930,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,227,1,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,
2931,,,B,8,Expert,,15026,,BAO_0000357,,,,,108,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,
2932,,,B,8,Autocuration,,15738,Bos taurus,BAO_0000357,,,,,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,9913.0,
2933,,,B,8,Autocuration,,15738,Bos taurus,BAO_0000357,,,,,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,9913.0,
2934,,,B,8,Autocuration,,15738,Bos taurus,BAO_0000357,,,,,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,9913.0,
2935,,,B,8,Autocuration,,15738,Bos taurus,BAO_0000357,,,,,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,9913.0,
2936,,,B,8,Expert,,16404,Bos taurus,BAO_0000357,,,,,108,1,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,9913.0,
2937,,,B,8,Expert,,15026,Bos taurus,BAO_0000357,,,,,108,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,9913.0,
2938,,,B,8,Autocuration,,15738,Bos taurus,BAO_0000357,,,,,108,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,9913.0,
2939,,,B,8,Autocuration,,16312,Cavia porcellus,BAO_0000019,,,,,108,1,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,10141.0,
2940,,,B,9,Intermediate,,5486,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,10141.0,
2941,,,B,8,Autocuration,,5254,,BAO_0000357,,,,,51,1,Binding affinity against 5-HT1A receptor,,
2942,,CHO,F,8,Expert,,3857,,BAO_0000219,449.0,,,,108,1,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,
2943,,CHO,F,9,Expert,,6857,Homo sapiens,BAO_0000219,449.0,,,,108,1,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,9606.0,
2944,,,F,8,Autocuration,,4176,,BAO_0000219,,,,,108,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,
2945,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,108,1,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,
2946,,CHO,B,8,Autocuration,,6347,,BAO_0000219,449.0,,,,108,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,
2947,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,108,1,Inhibition of human 5-hydroxytryptamine 2C receptor,9606.0,
2948,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,108,1,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,
2949,,,B,8,Autocuration,,3857,,BAO_0000019,,,,,108,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,
2950,,,B,8,Autocuration,,5635,,BAO_0000357,,,,,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,
2951,,,B,8,Autocuration,,5635,,BAO_0000357,,,,,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2952,,,B,8,Autocuration,,5635,,BAO_0000357,,,,,108,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,
2953,,CHO,B,8,Expert,,4012,,BAO_0000219,449.0,,,,108,1,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,
2954,,CHO,B,8,Expert,,6366,,BAO_0000219,449.0,,,,108,1,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,
2955,,CHO,B,8,Expert,,15949,,BAO_0000219,449.0,,,,108,1,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2956,,CHO,B,8,Autocuration,,17211,,BAO_0000219,449.0,,,,108,1,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,
2957,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,108,1,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,9606.0,
2958,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,108,1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,
2959,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,108,1,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,
2960,,CHO,B,8,Expert,,6347,Rattus norvegicus,BAO_0000219,449.0,,,,108,1,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,10116.0,
2961,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,108,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,
2962,,,F,8,Autocuration,,14093,,BAO_0000019,,,,,108,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,
2963,,,F,8,Autocuration,,13481,,BAO_0000019,,,,,108,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
2964,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,
2965,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,
2966,,,B,8,Autocuration,,14442,,BAO_0000357,,,,,108,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,
2967,,,B,8,Autocuration,,14755,,BAO_0000357,,,,,108,1,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,
2968,,,B,8,Autocuration,,14744,,BAO_0000357,,,,,108,1,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,
2969,,CHO,B,8,Expert,,16659,,BAO_0000219,449.0,,,,108,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,
2970,,,B,9,Expert,,6857,Homo sapiens,BAO_0000019,,,,,108,1,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,9606.0,
2971,,,B,8,Expert,,5635,,BAO_0000357,,,,,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,
2972,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,108,1,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,9606.0,
2973,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,108,1,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,
2974,Membranes,,B,7,Autocuration,,5778,Rattus norvegicus,BAO_0000249,,,,,104698,1,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,10116.0,
2975,,,B,6,Autocuration,,5094,,BAO_0000223,,,,,104698,1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,
2976,,,B,7,Autocuration,,809,Rattus norvegicus,BAO_0000019,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,10116.0,
2977,,,B,6,Autocuration,,1578,,BAO_0000019,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,
2978,,,B,6,Autocuration,,809,,BAO_0000019,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,
2979,,,B,6,Autocuration,,12469,,BAO_0000219,,,,,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,
2980,,,B,6,Autocuration,,14290,,BAO_0000019,,,,,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,
2981,,,B,6,Autocuration,,14290,,BAO_0000019,,,,,104698,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,
2982,,,B,6,Autocuration,,10609,,BAO_0000223,,,,,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,
2983,,,B,6,Autocuration,,10609,,BAO_0000223,,,,,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,
2984,,,B,6,Autocuration,,10609,,BAO_0000223,,,,,104698,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,
2985,,,B,6,Autocuration,,15253,,BAO_0000249,,,,,104698,1,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2986,,,B,6,Autocuration,,15253,,BAO_0000249,,,,,104698,1,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,
2987,Membranes,,B,6,Autocuration,,11683,,BAO_0000249,,,,,104698,1,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,
2988,,,B,6,Autocuration,,12092,,BAO_0000223,,,,,104698,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,
2989,,,B,6,Autocuration,,1946,,BAO_0000019,,,,,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
2990,,,B,6,Autocuration,,11623,,BAO_0000223,,,,,104698,1,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,
2991,,,B,6,Autocuration,,11623,,BAO_0000223,,,,,104698,1,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,
2992,,,B,6,Autocuration,,14788,,BAO_0000019,,,,,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,
2993,,,B,7,Autocuration,,5432,Rattus norvegicus,BAO_0000019,,,,,104698,1,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,10116.0,
2994,,,B,6,Autocuration,,14826,,BAO_0000249,,,,,104698,1,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
2995,,,B,6,Autocuration,,2222,,BAO_0000223,,,,,104698,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
2996,,,B,6,Autocuration,,11963,,BAO_0000019,,,,,104698,1,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,
2997,,,B,6,Autocuration,,14145,,BAO_0000019,,,,,104698,1,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,
2998,,,B,6,Autocuration,,17819,,BAO_0000019,,,,,104698,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,
2999,,,B,6,Autocuration,,10394,,BAO_0000249,,,,,104698,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3000,,,B,6,Autocuration,,10394,,BAO_0000249,,,,,104698,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,
3001,,,B,6,Autocuration,,15034,,BAO_0000019,,,,,104698,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3002,,,B,6,Autocuration,,691,,BAO_0000019,,,,,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,
3003,Membranes,,B,6,Autocuration,,12092,,BAO_0000249,,,,,104698,1,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,
3004,,,B,7,Autocuration,,11752,Rattus norvegicus,BAO_0000223,,,,,104698,1,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,10116.0,
3005,,,B,6,Autocuration,,11752,,BAO_0000221,,Brain,,,104698,1,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,,
3006,,,B,6,Autocuration,,301,,BAO_0000019,,,,,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,
3007,,,B,6,Autocuration,,16532,,BAO_0000223,,,,,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,
3008,,,B,6,Autocuration,,16532,,BAO_0000223,,,,,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3009,,,B,6,Autocuration,,12092,,BAO_0000223,,,,,104698,1,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,
3010,,,B,6,Autocuration,,11684,,BAO_0000223,,,,,104698,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,
3011,,,B,6,Autocuration,,11684,,BAO_0000223,,,,,104698,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,
3012,,,B,6,Autocuration,,12953,,BAO_0000019,,,,,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,
3013,,,B,6,Autocuration,,12953,,BAO_0000019,,,,,104698,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,
3014,,,B,6,Autocuration,,12953,,BAO_0000223,,,,,104698,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,
3015,,,B,6,Autocuration,,12861,,BAO_0000019,,,,,104698,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,
3016,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3017,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,
3018,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,
3019,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,
3020,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3021,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,
3022,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,
3023,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,
3024,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,
3025,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3026,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,
3027,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,
3028,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,
3029,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,
3030,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,
3031,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,
3032,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,
3033,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,
3034,,,F,6,Autocuration,,10609,,BAO_0000019,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,
3035,,,B,6,Autocuration,,12861,,BAO_0000019,,,,,104698,1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,
3036,,,B,7,Autocuration,,12861,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,10116.0,
3037,,,B,6,Autocuration,,12861,,BAO_0000223,,,,,104698,1,Binding activity radioligand.,,
3038,Brain membranes,,B,6,Autocuration,,10728,,BAO_0000249,,,,,104698,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,
3039,Brain membranes,,B,6,Autocuration,,10728,,BAO_0000249,,,,,104698,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,
3040,,,B,8,Autocuration,,5163,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,
3041,,,B,8,Autocuration,,5163,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,
3042,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,108,1,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,
3043,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,108,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,
3044,,,B,8,Autocuration,,5635,,BAO_0000357,,,,,108,1,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,
3045,,,B,8,Expert,,5163,,BAO_0000357,,,,,108,1,Affinity for 5-hydroxytryptamine 2C receptor,,
3046,,,B,8,Autocuration,,6841,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,
3047,,,B,8,Expert,,6119,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,
3048,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,108,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,
3049,,,B,8,Autocuration,,1633,,BAO_0000357,,,,,108,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,
3050,,,B,8,Expert,,1633,,BAO_0000357,,,,,108,1,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,
3051,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,
3052,,,B,8,Expert,,6576,,BAO_0000357,,,,,108,1,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,
3053,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,108,1,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,
3054,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,108,1,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,
3055,,,B,8,Autocuration,,12146,,BAO_0000357,,,,,108,1,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,
3056,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,108,1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,
3057,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,108,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,
3058,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,108,1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,
3059,,,B,8,Autocuration,,3269,,BAO_0000357,,,,,108,1,Affinity against 5-hydroxytryptamine 2C receptor,,
3060,,,B,9,Expert,,1274,Homo sapiens,BAO_0000357,,,,,108,1,Binding affinity against 5-hydroxytryptamine 2C receptor,9606.0,
3061,,,B,8,Autocuration,,1317,,BAO_0000357,,,,,108,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,
3062,,,B,8,Autocuration,,5834,Bos taurus,BAO_0000357,,,,,144,1,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,9913.0,
3063,,,B,8,Autocuration,,11147,Bos taurus,BAO_0000357,,,,,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,9913.0,
3064,,,F,4,Expert,,14145,Cavia porcellus,BAO_0000019,,,,,104714,1,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,10141.0,
3065,,,B,4,Autocuration,,10561,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10141.0,
3066,,,F,4,Autocuration,,15847,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,10141.0,
3067,,,F,4,Autocuration,,15847,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,10141.0,
3068,,,B,4,Autocuration,,10561,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,10141.0,
3069,,,B,4,Autocuration,,11454,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,10141.0,
3070,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,10141.0,
3071,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,10141.0,
3072,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,10141.0,
3073,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,10141.0,
3074,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,10141.0,
3075,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,10141.0,
3076,,,F,4,Autocuration,,15253,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",10141.0,
3077,,,F,4,Autocuration,,15253,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",10141.0,
3078,,,F,4,Autocuration,,11963,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,10141.0,
3079,,,B,4,Autocuration,,1946,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,10141.0,
3080,,,B,4,Autocuration,,1946,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,10141.0,
3081,,,B,4,Autocuration,,12045,Cavia porcellus,BAO_0000223,,,,,104714,1,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,10141.0,
3082,,,B,4,Autocuration,,1559,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,
3083,,,F,4,Autocuration,,273,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),10141.0,
3084,,,F,4,Autocuration,,273,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),10141.0,
3085,,,F,4,Autocuration,,188,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,10141.0,
3086,,,F,4,Autocuration,,12919,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,10141.0,
3087,,,F,4,Autocuration,,12918,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,10141.0,
3088,,,B,4,Autocuration,,1559,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,
3089,,,F,4,Autocuration,,273,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),10141.0,
3090,,,B,4,Autocuration,,1559,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,10141.0,
3091,,,B,4,Autocuration,,1559,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,10141.0,
3092,,,B,4,Autocuration,,1559,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,10141.0,
3093,,,B,4,Autocuration,,14424,Cavia porcellus,BAO_0000221,,Ileum,,,104714,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,10141.0,
3094,,,B,0,Autocuration,,13181,Cavia porcellus,BAO_0000019,,,,,22226,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,10141.0,
3095,,,B,8,Autocuration,,5486,,BAO_0000357,,,,,51,1,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,
3096,,,B,5,Expert,,6491,Homo sapiens,BAO_0000223,,,,,104714,1,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,9606.0,
3097,,,B,4,Autocuration,,6013,,BAO_0000223,,,,,104714,1,Binding affinity towards 5-HT3 receptor,,
3098,,,B,4,Autocuration,,12861,,BAO_0000223,,,,,104714,1,Binding activity radioligand.,,
3099,,,B,4,Autocuration,,12861,,BAO_0000019,,,,,104714,1,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,
3100,,,B,4,Autocuration,,5104,,BAO_0000223,,,,,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3101,,,B,4,Autocuration,,5105,,BAO_0000223,,,,,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,
3102,,,B,4,Autocuration,,5104,,BAO_0000223,,,,,104714,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,
3103,,,B,0,Autocuration,,3935,,BAO_0000019,,,,,22226,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,
3104,,NG108-15,B,4,Expert,,13657,,BAO_0000219,433.0,,,,105030,1,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,
3105,,,B,4,Autocuration,In vivo,10369,,BAO_0000218,,,,,105030,1,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,
3106,,,B,4,Autocuration,,10369,,BAO_0000019,,,,,105030,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3107,,,B,4,Autocuration,,12918,,BAO_0000224,,,,,105030,1,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,
3108,,,B,4,Autocuration,,12918,,BAO_0000224,,,,,105030,1,Compound was evaluated for the binding affinity at 5- HT3 receptor,,
3109,,,B,4,Autocuration,,10369,,BAO_0000019,,,,,105030,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,
3110,,,B,4,Autocuration,,773,,BAO_0000019,,,,,105030,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3111,,,F,4,Autocuration,,12918,,BAO_0000218,,,,,105030,1,5-hydroxytryptamine 3 receptor agonism in mouse,,
3112,,,B,4,Autocuration,,10561,,BAO_0000219,,,,,105030,1,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,
3113,,,B,4,Autocuration,,12827,,BAO_0000019,,,,,105030,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3114,,,B,4,Autocuration,,12827,,BAO_0000019,,,,,105030,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,
3115,,,B,4,Autocuration,,12918,,BAO_0000224,,,,,105030,1,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,
3116,,,B,4,Autocuration,,273,,BAO_0000219,,,,,105030,1,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3117,,,B,4,Autocuration,,273,,BAO_0000219,,,,,105030,1,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,
3118,,,B,4,Autocuration,,10561,,BAO_0000224,,,,,105030,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,
3119,,,B,4,Autocuration,In vitro,5033,,BAO_0000219,,,,,105030,1,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,
3120,,N1E-115,B,4,Autocuration,,16429,,BAO_0000219,339.0,,,,105030,1,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,
3121,,,B,8,Autocuration,,10322,,BAO_0000019,,,,,11765,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3122,,,B,8,Autocuration,,14331,,BAO_0000219,,,,,11765,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,
3123,,,B,9,Autocuration,,13462,Mus musculus,BAO_0000357,,,,,10630,1,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10090.0,
3124,,,B,8,Autocuration,,12861,,BAO_0000019,,,,,17106,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,
3125,,,B,8,Autocuration,,15086,Sus scrofa,BAO_0000357,,,,,144,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,9823.0,
3126,,,B,8,Autocuration,,12861,Sus scrofa,BAO_0000357,,,,,144,1,Binding activity radioligand.,9823.0,
3127,,,B,4,Autocuration,,10561,Oryctolagus cuniculus,BAO_0000223,,,,,104714,1,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,9986.0,
3128,,,B,4,Autocuration,,10561,Oryctolagus cuniculus,BAO_0000223,,,,,104714,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,9986.0,
3129,,,B,4,Autocuration,,10561,Oryctolagus cuniculus,BAO_0000223,,,,,104714,1,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,9986.0,
3130,,,B,4,Autocuration,,10561,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,9986.0,
3131,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,
3132,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,
3133,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000221,,Ileum,,,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),9986.0,
3134,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,
3135,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,
3136,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),9986.0,
3137,,,F,4,Autocuration,,273,Oryctolagus cuniculus,BAO_0000019,,,,,104714,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),9986.0,
3138,,CHO,B,4,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000219,449.0,,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,9986.0,
3139,,,B,7,Autocuration,,1650,Rattus norvegicus,BAO_0000019,,,,,104698,1,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,10116.0,
3140,,,B,8,Autocuration,,16288,,BAO_0000019,,,,,12020,1,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,
3141,,,B,8,Autocuration,,16288,,BAO_0000357,,,,,12020,1,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,
3142,,,B,7,Autocuration,,10254,Rattus norvegicus,BAO_0000019,,,,,104698,1,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,10116.0,
3143,,,B,6,Autocuration,,14532,,BAO_0000019,,,,,104698,1,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,
3144,,,F,6,Autocuration,In vivo,13392,,BAO_0000218,,Heart,,,104698,1,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3145,,,F,6,Autocuration,,13392,,BAO_0000019,,Heart,,,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3146,,,F,6,Autocuration,,13392,,BAO_0000019,,Heart,,,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",,
3147,,,F,6,Autocuration,,13392,,BAO_0000019,,Heart,,,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",,
3148,,,F,6,Autocuration,,13392,,BAO_0000019,,Heart,,,104698,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",,
3149,,,F,6,Autocuration,,13392,,BAO_0000019,,,,,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,
3150,,,F,6,Autocuration,,13392,,BAO_0000019,,,,,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3151,,,F,6,Autocuration,,13392,,BAO_0000019,,,,,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,
3152,,,F,6,Autocuration,,13392,,BAO_0000019,,,,,104698,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,
3153,,,F,7,Autocuration,In vivo,1089,Rattus norvegicus,BAO_0000218,,,,,104698,1,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),10116.0,
3154,,,F,6,Autocuration,In vivo,1089,,BAO_0000218,,,,,104698,1,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,
3155,,,F,7,Autocuration,In vivo,11454,Rattus norvegicus,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,10116.0,
3156,,,F,7,Autocuration,,11454,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,10116.0,
3157,,,F,7,Autocuration,In vivo,12205,Rattus norvegicus,BAO_0000218,,,,,104698,1,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,10116.0,
3158,,,F,7,Autocuration,,1089,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),10116.0,
3159,,,B,6,Autocuration,,5094,,BAO_0000019,,,,,104698,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3160,,,B,7,Autocuration,,2622,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,10116.0,
3161,,,B,6,Autocuration,,245,,BAO_0000223,,,,,104698,1,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,
3162,,,B,6,Autocuration,,14788,,BAO_0000019,,,,,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,
3163,,,B,6,Autocuration,,14788,,BAO_0000019,,,,,104698,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,
3164,,,B,6,Autocuration,,3020,,BAO_0000249,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,
3165,,,B,6,Autocuration,,1742,,BAO_0000019,,,,,104698,1,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,
3166,,,B,6,Autocuration,,17394,,BAO_0000249,,Brain,,,104698,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,,
3167,,,B,6,Autocuration,,17394,,BAO_0000221,,Brain,,,104698,1,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,,
3168,,,B,6,Autocuration,,17394,,BAO_0000249,,,,,104698,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3169,,,B,6,Autocuration,,14286,,BAO_0000249,,,,,104698,1,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,
3170,,,B,6,Autocuration,,14178,,BAO_0000019,,,,,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,
3171,,,B,7,Autocuration,,14178,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,10116.0,
3172,,,B,7,Autocuration,,14178,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,10116.0,
3173,,,B,7,Autocuration,,14178,Rattus norvegicus,BAO_0000223,,,,,104698,1,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,10116.0,
3174,,,B,6,Autocuration,,15034,,BAO_0000019,,,,,104698,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,
3175,Membranes,,B,6,Autocuration,,1089,,BAO_0000249,,,,,104698,1,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,
3176,,,B,7,Autocuration,,1089,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,10116.0,
3177,,,B,6,Autocuration,,16532,,BAO_0000223,,,,,104698,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,
3178,,,B,7,Autocuration,,12801,Rattus norvegicus,BAO_0000223,,,,,104698,1,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,10116.0,
3179,,NG108-15,B,6,Autocuration,,15194,,BAO_0000219,433.0,,,,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,
3180,,NG108-15,B,6,Autocuration,,15194,,BAO_0000219,433.0,,,,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,
3181,,,B,6,Autocuration,,15194,,BAO_0000019,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,
3182,,,B,6,Autocuration,,15194,,BAO_0000019,,,,,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,
3183,,,B,6,Autocuration,,15194,,BAO_0000019,,,,,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,
3184,,,B,6,Autocuration,,15194,,BAO_0000019,,,,,104698,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,
3185,,,F,6,Autocuration,,10610,,BAO_0000019,,,,,104698,1,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,
3186,,,F,7,Autocuration,,10355,Rattus norvegicus,BAO_0000019,,,,,104698,1,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,10116.0,
3187,,,F,6,Autocuration,,691,,BAO_0000019,,,,,104698,1,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,
3188,,,F,6,Autocuration,,10611,,BAO_0000218,,,,,104698,1,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,
3189,,,F,6,Autocuration,In vivo,12801,,BAO_0000218,,,,,104698,1,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,
3190,,,F,6,Autocuration,,10609,,BAO_0000218,,,,,104698,1,Inhibition of 5-HT evoked reflex bradycardia in rat.,,
3191,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3192,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,
3193,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,
3194,,,F,7,Autocuration,In vivo,11454,Rattus norvegicus,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,10116.0,
3195,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3196,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,
3197,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,
3198,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,
3199,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,
3200,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3201,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,
3202,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,
3203,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,
3204,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3205,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,
3206,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,
3207,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,
3208,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,
3209,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,
3210,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,
3211,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,
3212,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,
3213,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,
3214,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,
3215,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,
3216,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,
3217,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,
3218,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,
3219,,,F,6,Autocuration,In vivo,11454,,BAO_0000218,,,,,104698,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,
3220,,,F,6,Autocuration,,670,,BAO_0000218,,,,,104698,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,
3221,,,F,6,Autocuration,,670,,BAO_0000218,,,,,104698,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,
3222,,,F,6,Autocuration,In vivo,10321,,BAO_0000218,,,,,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,
3223,,,F,6,Autocuration,In vivo,10321,,BAO_0000218,,,,,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,
3224,,,F,6,Autocuration,In vivo,10321,,BAO_0000218,,,,,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,
3225,,,F,6,Autocuration,In vivo,10321,,BAO_0000218,,,,,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,
3226,,,F,6,Autocuration,In vivo,10321,,BAO_0000218,,,,,104698,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,
3227,,,F,6,Autocuration,In vivo,10322,,BAO_0000218,,,,,104698,1,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,
3228,,,F,6,Autocuration,,15412,,BAO_0000019,,,,,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3229,,,F,6,Autocuration,,15412,,BAO_0000019,,,,,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,
3230,,,B,7,Autocuration,,15412,Rattus norvegicus,BAO_0000223,,,,,104698,1,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,10116.0,
3231,,,F,6,Autocuration,,15412,,BAO_0000019,,,,,104698,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,
3232,,,B,7,Intermediate,,15412,,BAO_0000221,,Hippocampus,,,104698,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,,
3233,,,B,7,Autocuration,,15412,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,10116.0,
3234,,,B,7,Autocuration,,17394,Rattus norvegicus,BAO_0000019,,,,,104698,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,10116.0,
3235,,,B,6,Autocuration,,12457,,BAO_0000223,,,,,104698,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,
3236,,,B,6,Autocuration,,12457,,BAO_0000019,,,,,104698,1,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,
3237,,,B,6,Autocuration,,12205,,BAO_0000019,,,,,104698,1,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,
3238,,,B,6,Autocuration,,14532,,BAO_0000019,,,,,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,
3239,,,B,6,Autocuration,,1122,,BAO_0000019,,,,,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,
3240,,,B,6,Autocuration,,5094,,BAO_0000019,,,,,104698,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,
3241,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,10141.0,
3242,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,10141.0,
3243,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",10141.0,
3244,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",10141.0,
3245,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",10141.0,
3246,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",10141.0,
3247,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",10141.0,
3248,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,10141.0,
3249,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,10141.0,
3250,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,10141.0,
3251,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,10141.0,
3252,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,10141.0,
3253,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",10141.0,
3254,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",10141.0,
3255,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",10141.0,
3256,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,10141.0,
3257,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",10141.0,
3258,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",10141.0,
3259,,,B,9,Intermediate,,15034,Cavia porcellus,BAO_0000357,,,,,20033,1,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,10141.0,
3260,,,B,9,Intermediate,,5094,Cavia porcellus,BAO_0000249,,Striatum,,,20033,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,
3261,,,B,9,Intermediate,,5094,Cavia porcellus,BAO_0000249,,Striatum,,,20033,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,
3262,,,B,9,Intermediate,,5399,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,10141.0,
3263,,,B,9,Intermediate,,17394,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,10141.0,
3264,,,B,9,Intermediate,,17394,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,10141.0,
3265,,,B,9,Intermediate,,17394,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,10141.0,
3266,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,10141.0,
3267,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,10141.0,
3268,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,10141.0,
3269,,,B,9,Intermediate,,16946,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,10141.0,
3270,,,B,9,Intermediate,,16946,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,10141.0,
3271,,,F,9,Intermediate,,15034,Cavia porcellus,BAO_0000019,,,,,20033,1,Agonistic activity against 5-hydroxytryptamine 4 receptor,10141.0,
3272,,,F,9,Intermediate,,15034,Cavia porcellus,BAO_0000019,,,,,20033,1,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,10141.0,
3273,,,F,9,Intermediate,,12918,Cavia porcellus,BAO_0000019,,,,,20033,1,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,10141.0,
3274,,,B,9,Intermediate,,16946,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,10141.0,
3275,,,B,9,Intermediate,,17394,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,10141.0,
3276,,,B,9,Intermediate,,15034,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,10141.0,
3277,,,B,9,Intermediate,,5094,Cavia porcellus,BAO_0000249,,Striatum,,,20033,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,
3278,,,B,9,Intermediate,,5094,Cavia porcellus,BAO_0000249,,Striatum,,,20033,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,10141.0,
3279,,,B,9,Intermediate,,17358,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,10141.0,
3280,,,B,9,Expert,,12953,Cavia porcellus,BAO_0000357,,,,,20033,1,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,10141.0,
3281,,,B,9,Intermediate,,12953,Cavia porcellus,BAO_0000357,,,,,20033,1,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,10141.0,
3282,,,B,9,Intermediate,,12953,Cavia porcellus,BAO_0000357,,,,,20033,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,10141.0,
3283,,,B,9,Intermediate,,12953,Cavia porcellus,BAO_0000357,,,,,20033,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,10141.0,
3284,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,
3285,,,F,9,Intermediate,,12918,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,10141.0,
3286,,,F,9,Intermediate,,12919,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,10141.0,
3287,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,10141.0,
3288,,,F,9,Intermediate,,273,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,10141.0,
3289,,,B,9,Intermediate,,13181,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,10141.0,
3290,,,B,8,Autocuration,,13181,Cavia porcellus,BAO_0000357,,,,,168,1,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,10141.0,
3291,,,F,9,Intermediate,,15034,Cavia porcellus,BAO_0000019,,,,,20033,1,Antagonistic activity against 5-hydroxytryptamine 4 receptor,10141.0,
3292,,,B,9,Intermediate,,5033,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,10141.0,
3293,,,B,9,Intermediate,,1980,Cavia porcellus,BAO_0000019,,,,,20033,1,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,10141.0,
3294,,HEK293,B,8,Autocuration,,13181,Cavia porcellus,BAO_0000219,722.0,,,,168,1,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,10141.0,
3295,,,B,9,Intermediate,,14287,Cavia porcellus,BAO_0000019,,,,,20033,1,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,10141.0,
3296,,,B,9,Intermediate,,1317,Cavia porcellus,BAO_0000357,,,,,20033,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,10141.0,
3297,,,B,9,Intermediate,,15316,Cavia porcellus,BAO_0000357,,,,,20033,1,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,10141.0,
3298,,,B,9,Intermediate,,16429,Cavia porcellus,BAO_0000357,,Striatum,,,20033,1,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,10141.0,
3299,,,B,9,Intermediate,,14818,Cavia porcellus,BAO_0000221,,Hippocampus,,,20033,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,10141.0,
3300,,,B,9,Intermediate,,15194,Cavia porcellus,BAO_0000357,,,,,20033,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,10141.0,
3301,,,B,9,Intermediate,,15194,Cavia porcellus,BAO_0000357,,,,,20033,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,10141.0,
3302,,,F,9,Intermediate,,13961,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,10141.0,
3303,,,B,8,Autocuration,,5486,,BAO_0000357,,,,,108,1,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,
3304,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,168,1,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,
3305,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,168,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,
3306,,HeLa,B,8,Autocuration,,4199,,BAO_0000219,308.0,,,,168,1,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,
3307,,,B,8,Autocuration,,15146,,BAO_0000357,,,,,168,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,
3308,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,168,1,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,
3309,,HeLa,B,8,Autocuration,,4829,,BAO_0000219,308.0,,,,168,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,
3310,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,10622,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,
3311,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,10622,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,
3312,,,B,8,Autocuration,,16946,,BAO_0000219,,,,,10622,1,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,
3313,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,10622,1,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,
3314,,,F,8,Autocuration,,268,,BAO_0000019,,Cardiac atrium,,,11249,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,,
3315,,,F,8,Autocuration,,268,,BAO_0000019,,Cardiac atrium,,,11249,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,,
3316,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,11249,1,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,
3317,,,B,8,Autocuration,,14875,,BAO_0000221,,Hippocampus,,,11249,1,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,,
3318,,,B,8,Autocuration,,13267,Sus scrofa,BAO_0000221,,Hippocampus,,,168,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,9823.0,
3319,,,B,8,Autocuration,,13047,Oryctolagus cuniculus,BAO_0000019,,,,,168,1,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,9986.0,
3320,,,B,9,Expert,,1650,Rattus norvegicus,BAO_0000357,,,,,10623,1,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10116.0,
3321,,,F,8,Autocuration,,567,,BAO_0000019,,,,,10623,1,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3322,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,10623,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,
3323,,,B,8,Autocuration,,188,,BAO_0000357,,,,,10623,1,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,
3324,,,F,8,Autocuration,,670,,BAO_0000019,,,,,10623,1,lntrinsic activity relative to 5-HT receptor,,
3325,,,F,8,Autocuration,,204,,BAO_0000019,,,,,10623,1,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,
3326,,,F,8,Expert,,1946,,BAO_0000019,,,,,10623,1,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,
3327,,,F,8,Autocuration,,6398,,BAO_0000019,,,,,10623,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,
3328,,,F,8,Autocuration,,6398,,BAO_0000019,,,,,10623,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,
3329,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,10623,1,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,
3330,,,F,8,Autocuration,,6398,,BAO_0000019,,,,,10623,1,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,
3331,,,B,8,Expert,,11752,,BAO_0000357,,,,,10623,1,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,
3332,,,F,8,Autocuration,,809,,BAO_0000019,,,,,10623,1,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,
3333,,,B,9,Expert,,14178,Rattus norvegicus,BAO_0000357,,,,,10623,1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10116.0,
3334,,,B,8,Autocuration,,567,,BAO_0000357,,,,,10623,1,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,
3335,,,B,8,Autocuration,,1946,,BAO_0000357,,,,,10623,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,
3336,,,B,8,Autocuration,,1946,,BAO_0000357,,,,,10623,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,
3337,,,B,9,Expert,,13961,Rattus norvegicus,BAO_0000019,,,,,10623,1,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10116.0,
3338,,,B,8,Autocuration,,6238,,BAO_0000249,,Striatum,,,10623,1,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,,
3339,,,B,8,Autocuration,,14290,,BAO_0000249,,,,,10623,1,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,
3340,,,B,8,Expert,,14290,,BAO_0000249,,,,,10623,1,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,
3341,,,B,9,Expert,,809,Rattus norvegicus,BAO_0000019,,Striatum,,,10623,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10116.0,
3342,,,B,8,Autocuration,,1578,,BAO_0000019,,Striatum,,,10623,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,,
3343,,,B,8,Expert,,16709,,BAO_0000249,,Striatum,,,10623,1,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,,
3344,,,B,8,Expert,,1946,,BAO_0000019,,Striatum,,,10623,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,,
3345,,,B,8,Expert,,15253,,BAO_0000249,,Striatum,,,10623,1,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,,
3346,,,B,8,Expert,,4535,,BAO_0000249,,Striatum,,,10623,1,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3347,,,B,8,Expert,,13961,,BAO_0000249,,,,,10623,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,
3348,,,F,8,Autocuration,,17358,,BAO_0000221,,Brain,,,10623,1,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,,
3349,,,F,8,Autocuration,,15847,,BAO_0000019,,,,,10623,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,
3350,,,F,8,Autocuration,,15847,,BAO_0000019,,,,,10623,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,
3351,,,F,8,Autocuration,,670,,BAO_0000019,,,,,10623,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,
3352,,,F,8,Autocuration,,670,,BAO_0000019,,,,,10623,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,
3353,,,F,8,Autocuration,,1317,,BAO_0000019,,,,,10623,1,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,
3354,,,B,9,Expert,,12936,Rattus norvegicus,BAO_0000357,,,,,10623,1,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10116.0,
3355,,,B,8,Expert,,4535,,BAO_0000249,,Striatum,,,10623,1,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,,
3356,,,F,9,Expert,,14424,Rattus norvegicus,BAO_0000019,,,,,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10116.0,
3357,,,F,8,Expert,,14424,,BAO_0000019,,,,,10623,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,
3358,,,F,8,Expert,,14424,,BAO_0000019,,,,,10623,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3359,,,F,9,Expert,,14424,Rattus norvegicus,BAO_0000019,,,,,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10116.0,
3360,,,F,8,Autocuration,,14424,,BAO_0000019,,,,,10623,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,
3361,,,F,8,Expert,,14424,,BAO_0000019,,,,,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,
3362,,,F,8,Expert,,14424,,BAO_0000218,,,,,10623,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,
3363,,,F,8,Autocuration,,14424,,BAO_0000019,,,,,10623,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,
3364,,,F,8,Autocuration,,1980,Rattus norvegicus,BAO_0000019,,,,,168,1,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,10116.0,
3365,,,F,8,Autocuration,,4639,,BAO_0000019,,,,,168,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,
3366,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,
3367,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,
3368,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,
3369,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,168,1,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,
3370,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3371,,,B,8,Autocuration,,16117,,BAO_0000357,,,,,168,1,In vitro binding affinity towards 5-HT4 receptor was determined,,
3372,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3373,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,168,1,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,
3374,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,
3375,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,
3376,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,
3377,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,168,1,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,
3378,,,B,8,Expert,,1274,,BAO_0000357,,,,,168,1,Binding affinity against 5-Hydroxytryptamine 4 receptor,,
3379,Brain membranes,,B,6,Autocuration,,10728,,BAO_0000249,,,,,104698,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,
3380,Brain membranes,,B,6,Autocuration,,11695,,BAO_0000249,,,,,104698,1,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,
3381,Brain membranes,,B,6,Autocuration,,11695,,BAO_0000249,,,,,104698,1,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,
3382,,,B,6,Autocuration,,12490,,BAO_0000019,,,,,104698,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,
3383,,,B,7,Autocuration,,11828,Rattus norvegicus,BAO_0000019,,,,,104698,1,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,10116.0,
3384,,,B,6,Autocuration,,12253,,BAO_0000221,,Hippocampus,,,104698,1,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,,
3385,,,B,6,Autocuration,,10561,,BAO_0000019,,,,,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,
3386,,,B,6,Autocuration,,10561,,BAO_0000019,,,,,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,
3387,,,F,6,Autocuration,,14432,,BAO_0000019,,,,,104698,1,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,
3388,,,B,7,Autocuration,,12936,Rattus norvegicus,BAO_0000223,,,,,104698,1,Binding affinity against rat 5-hydroxytryptamine 3 receptor,10116.0,
3389,,,B,7,Autocuration,,1274,Rattus norvegicus,BAO_0000223,,,,,104698,1,Binding affinity against 5-Hydroxytryptamine 3 receptor,10116.0,
3390,,,B,6,Autocuration,,1980,,BAO_0000019,,,,,104698,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,
3391,,,B,6,Autocuration,,670,,BAO_0000249,,,,,104698,1,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,
3392,,,B,7,Autocuration,,968,Rattus norvegicus,BAO_0000019,,,,,104698,1,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,10116.0,
3393,,,B,6,Autocuration,,14287,,BAO_0000019,,,,,104698,1,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,
3394,,,B,6,Autocuration,,567,,BAO_0000019,,,,,104698,1,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,
3395,,,B,6,Autocuration,,13267,,BAO_0000019,,,,,104698,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,
3396,,,B,6,Autocuration,,14826,,BAO_0000249,,,,,104698,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,
3397,,,B,6,Autocuration,,15194,,BAO_0000223,,,,,104698,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,
3398,,,B,6,Autocuration,,15194,,BAO_0000223,,,,,104698,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,
3399,,,B,7,Autocuration,,10394,Rattus norvegicus,BAO_0000223,,,,,104698,1,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,10116.0,
3400,,,B,9,Expert,,13657,,BAO_0000249,,,,,10576,1,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,
3401,,,F,8,Autocuration,,1879,,BAO_0000221,,Brain,,,12020,1,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,,
3402,,,F,8,Autocuration,,1879,,BAO_0000019,,,,,12020,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,
3403,,,F,8,Autocuration,,1879,,BAO_0000019,,,,,12020,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,
3404,,,F,8,Autocuration,In vivo,204,,BAO_0000218,,,,,12020,1,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,
3405,,,B,8,Autocuration,,1879,,BAO_0000019,,,,,12020,1,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3406,,,B,8,Autocuration,,1879,,BAO_0000357,,,,,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3407,,,B,8,Autocuration,,1879,,BAO_0000019,,,,,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,
3408,,,B,8,Autocuration,,1879,,BAO_0000019,,,,,12020,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,
3409,,,B,6,Autocuration,,10641,,BAO_0000019,,,,,104698,1,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,
3410,,,B,8,Autocuration,,773,,BAO_0000019,,,,,12020,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,
3411,,,B,6,Autocuration,,11952,,BAO_0000249,,,,,104698,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,
3412,,,F,9,Autocuration,,14145,Rattus norvegicus,BAO_0000019,,,,,12020,1,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,10116.0,
3413,,,B,8,Expert,,17066,,BAO_0000357,,,,,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3414,,,B,4,Autocuration,,6398,,BAO_0000223,,,,,104714,1,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,
3415,,,B,0,Autocuration,,10321,,BAO_0000019,,,,,22226,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3416,,,F,4,Autocuration,,511,,BAO_0000019,,,,,104714,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,
3417,,,B,4,Autocuration,,4639,,BAO_0000223,,,,,104714,1,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,
3418,,,B,4,Autocuration,,4639,,BAO_0000223,,,,,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3419,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,10141.0,
3420,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,10141.0,
3421,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,10141.0,
3422,,,B,4,Autocuration,,1558,,BAO_0000223,,,,,104714,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3423,,,F,4,Autocuration,,268,,BAO_0000019,,,,,104714,1,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,
3424,,,B,4,Autocuration,,2474,,BAO_0000223,,,,,104714,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,
3425,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,
3426,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,
3427,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,
3428,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,
3429,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,
3430,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,
3431,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,
3432,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,
3433,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,
3434,,,F,4,Autocuration,,5067,,BAO_0000019,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,
3435,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,
3436,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3437,,,B,4,Autocuration,,14331,,BAO_0000219,,,,,104714,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,
3438,,,B,4,Autocuration,,5067,,BAO_0000223,,,,,104714,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,
3439,,NG108-15,B,4,Autocuration,,6179,,BAO_0000219,433.0,,,,104714,1,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,
3440,,,B,4,Autocuration,,4265,,BAO_0000019,,,,,104714,1,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,
3441,,NG108-15,B,4,Autocuration,,4265,,BAO_0000219,433.0,,,,104714,1,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,
3442,,,B,4,Autocuration,,17358,,BAO_0000223,,,,,104714,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3443,,,B,4,Autocuration,,17358,,BAO_0000223,,,,,104714,1,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,
3444,,,B,4,Autocuration,In vitro,13628,,BAO_0000219,,,,,104714,1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,
3445,,,B,4,Autocuration,,4612,,BAO_0000223,,,,,104714,1,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3446,,,F,4,Autocuration,,17358,,BAO_0000019,,,,,104714,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,
3447,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,10141.0,
3448,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,10141.0,
3449,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,10141.0,
3450,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,10141.0,
3451,,,B,4,Autocuration,,511,,BAO_0000223,,,,,104714,1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,
3452,,,B,4,Autocuration,,1479,,BAO_0000223,,,,,104714,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3453,,,B,4,Autocuration,,1317,,BAO_0000223,,,,,104714,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,
3454,,,B,4,Autocuration,,12146,,BAO_0000223,,,,,104714,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,
3455,,,B,4,Autocuration,,12146,,BAO_0000223,,,,,104714,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,
3456,,,B,4,Autocuration,,13969,,BAO_0000223,,,,,104714,1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,
3457,,,B,8,Expert,,13392,,BAO_0000357,,,,,108,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,
3458,,,B,6,Autocuration,,13392,,BAO_0000223,,,,,104698,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,
3459,,,B,8,Autocuration,,14159,,BAO_0000357,,,,,144,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,
3460,,,B,8,Autocuration,,1558,,BAO_0000357,,,,,144,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,
3461,,,B,8,Autocuration,,16655,,BAO_0000357,,,,,144,1,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,
3462,,,B,4,Autocuration,,13020,,BAO_0000223,,,,,104714,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3463,,,B,4,Autocuration,,13021,,BAO_0000223,,,,,104714,1,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,
3464,,,B,4,Autocuration,,13020,,BAO_0000223,,,,,104714,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,
3465,,,B,8,Autocuration,,10321,,BAO_0000019,,,,,144,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,
3466,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,144,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3467,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,144,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,
3468,,,B,8,Autocuration,,17358,,BAO_0000357,,,,,144,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,
3469,,,B,8,Autocuration,,2222,,BAO_0000357,,,,,144,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,
3470,,,B,8,Autocuration,,10322,,BAO_0000019,,,,,144,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,
3471,,,B,8,Autocuration,,16117,,BAO_0000357,,,,,144,1,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,
3472,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,144,1,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,
3473,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,144,1,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,
3474,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,144,1,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,
3475,,,B,8,Autocuration,,1980,,BAO_0000019,,,,,144,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,
3476,,,B,8,Autocuration,,1980,,BAO_0000019,,,,,144,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,
3477,,,B,4,Autocuration,,12409,,BAO_0000223,,,,,104714,1,Binding affinity against the 5-hydroxytryptamine 3 receptor,,
3478,,,B,8,Autocuration,,4365,,BAO_0000357,,,,,144,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3479,,,F,8,Autocuration,,4365,,BAO_0000019,,,,,144,1,Percent efficacy against 5-hydroxytryptamine 3A receptor,,
3480,,,B,8,Autocuration,,4365,,BAO_0000357,,,,,144,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,
3481,,Oocytes,F,9,Expert,,6769,Rattus norvegicus,BAO_0000219,,,,,12020,1,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,10116.0,
3482,,Oocytes,F,9,Expert,,6769,Rattus norvegicus,BAO_0000219,,,,,12020,1,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,10116.0,
3483,,Oocytes,F,9,Expert,,6769,Rattus norvegicus,BAO_0000219,,,,,12020,1,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,10116.0,
3484,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,10141.0,
3485,,,F,9,Intermediate,,809,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,10141.0,
3486,,,F,9,Intermediate,,14290,Cavia porcellus,BAO_0000019,,,,,20033,1,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,10141.0,
3487,,,B,9,Intermediate,,17358,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,10141.0,
3488,,,B,9,Intermediate,,17358,Cavia porcellus,BAO_0000357,,,,,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,10141.0,
3489,,,B,9,Intermediate,,17358,Cavia porcellus,BAO_0000221,,Ileum,,,20033,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,10141.0,
3490,,,B,8,Autocuration,,17386,,BAO_0000221,,Ileum,,,10209,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3491,,,B,8,Autocuration,,3269,,BAO_0000357,,,,,10209,1,Affinity against 5-hydroxytryptamine 7 receptor,,
3492,,,B,4,Autocuration,,7721,Cavia porcellus,BAO_0000224,,,,,104841,1,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,10141.0,
3493,,,B,4,Autocuration,,7721,Cavia porcellus,BAO_0000224,,,,,104841,1,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,10141.0,
3494,,,B,4,Autocuration,,9117,Cavia porcellus,BAO_0000221,,Ileum,,,104841,1,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,10141.0,
3495,,,B,4,Autocuration,,7721,Cavia porcellus,BAO_0000224,,,,,104841,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",10141.0,
3496,,,B,4,Autocuration,,7721,Cavia porcellus,BAO_0000224,,,,,104841,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",10141.0,
3497,,,F,4,Autocuration,,15796,Cavia porcellus,BAO_0000019,,,,,104841,1,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,10141.0,
3498,,,F,4,Autocuration,,15796,Cavia porcellus,BAO_0000019,,,,,104841,1,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,10141.0,
3499,,,B,9,Expert,,15650,Homo sapiens,BAO_0000219,,Cardiac atrium,,,168,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,9606.0,
3500,,,B,9,Expert,,15650,Homo sapiens,BAO_0000219,,Cardiac atrium,,,168,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,9606.0,
3501,,,F,5,Autocuration,,6866,Homo sapiens,BAO_0000019,,,,,104841,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",9606.0,
3502,,,F,9,Expert,,15650,Homo sapiens,BAO_0000219,,Cardiac atrium,,,168,1,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",9606.0,
3503,,,B,0,Autocuration,,10063,Mus musculus,BAO_0000019,,,,,22226,1,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,10090.0,
3504,,,B,0,Autocuration,,12665,Mus musculus,BAO_0000019,,,,,22226,1,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,10090.0,
3505,,,B,4,Autocuration,,7504,,BAO_0000019,,,,,104705,1,5-hydroxytryptamine receptor binding affinity was determined in rats,,
3506,,,B,4,Autocuration,,7504,,BAO_0000224,,,,,104705,1,Binding affinity at rat 5-hydroxytryptamine receptor.,,
3507,,,B,4,Autocuration,,7038,,BAO_0000019,,,,,104705,1,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,
3508,,,B,4,Autocuration,,7626,,BAO_0000224,,,,,104705,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,
3509,,,B,4,Autocuration,,7626,,BAO_0000224,,,,,104705,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,
3510,,,F,4,Autocuration,,7185,,BAO_0000019,,Stomach,,,104705,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,,
3511,,,F,4,Autocuration,,7185,,BAO_0000019,,Stomach,,,104705,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,,
3512,,,F,4,Autocuration,,7185,,BAO_0000019,,,,,104705,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,
3513,,,B,4,Autocuration,,6960,,BAO_0000224,,,,,104705,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,
3514,,,B,4,Autocuration,,6960,,BAO_0000224,,,,,104705,1,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,
3515,,,B,8,Autocuration,,12416,,BAO_0000221,,Hippocampus,,,10576,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,,
3516,,,B,8,Expert,,15753,,BAO_0000357,,,,,12198,1,Binding affinity for rat 5-hydroxytryptamine transporter.,,
3517,,,B,4,Autocuration,,8062,,BAO_0000019,,,,,104705,1,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,
3518,,,B,5,Autocuration,,9036,Rattus norvegicus,BAO_0000019,,,,,104705,1,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,10116.0,
3519,,,B,5,Autocuration,,15067,Rattus norvegicus,BAO_0000224,,,,,104705,1,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,10116.0,
3520,,,F,9,Expert,,15753,Rattus norvegicus,BAO_0000019,,Brain,,,12198,1,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,10116.0,
3521,,,F,9,Expert,,15753,Rattus norvegicus,BAO_0000221,,Cerebellum,,,12198,1,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,10116.0,
3522,,,B,5,Autocuration,,15295,Rattus norvegicus,BAO_0000019,,,,,104705,1,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,10116.0,
3523,,,B,5,Autocuration,,6347,Rattus norvegicus,BAO_0000224,,,,,104705,1,Percent binding affinity against 5-hydroxytryptamine receptor,10116.0,
3524,,,B,0,Autocuration,,6763,,BAO_0000019,,,,,22226,1,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,
3525,,,B,5,Autocuration,,12092,Rattus norvegicus,BAO_0000224,,,,,104705,1,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,10116.0,
3526,,,B,5,Autocuration,,1579,Rattus norvegicus,BAO_0000224,,,,,104705,1,Affinity against 5-hydroxytryptamine receptor was determined,10116.0,
3527,,,B,5,Autocuration,,1579,Rattus norvegicus,BAO_0000019,,Stomach,,,104705,1,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,10116.0,
3528,,,B,9,Expert,In vitro,5963,Homo sapiens,BAO_0000219,,,,,121,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9606.0,
3529,,,B,9,Expert,In vitro,5963,Homo sapiens,BAO_0000219,,,,,121,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,9606.0,
3530,,,B,8,Autocuration,,5030,,BAO_0000357,,,,,18065,1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,
3531,,,B,8,Expert,,15796,,BAO_0000357,,,,,121,1,Inhibition of 5-hydroxytryptamine reuptake,,
3532,,,F,8,Autocuration,,15413,,BAO_0000019,,,,,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,
3533,,,F,8,Autocuration,,15413,,BAO_0000019,,,,,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,
3534,,,F,8,Autocuration,,15413,,BAO_0000019,,,,,18065,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,
3535,,,F,8,Autocuration,,12409,,BAO_0000019,,,,,18065,1,Tested for 5-hydroxytryptamine receptor uptake,,
3536,,CHO,B,9,Expert,,16909,Homo sapiens,BAO_0000219,449.0,,,,51,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,9606.0,
3537,,,F,9,Expert,,16909,Homo sapiens,BAO_0000019,,,,,51,1,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,9606.0,
3538,,,B,8,Autocuration,,15629,Homo sapiens,BAO_0000249,,,,,10576,1,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,9606.0,
3539,,,B,8,Autocuration,,15629,,BAO_0000357,,,,,10576,1,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,
3540,,,B,8,Expert,,15629,,BAO_0000249,,,,,10576,1,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,
3541,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,,
3542,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,,
3543,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,,
3544,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3545,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,,
3546,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,,
3547,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,,
3548,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,,
3549,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,,
3550,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,,
3551,,,F,8,Autocuration,,10034,,BAO_0000019,,Striatum,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,,
3552,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,,
3553,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3554,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,,
3555,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,,
3556,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,,
3557,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,,
3558,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,,
3559,,,B,8,Expert,,1274,,BAO_0000357,,,,,168,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,
3560,,,F,8,Autocuration,,17358,,BAO_0000019,,,,,168,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,
3561,,,B,8,Autocuration,,14532,,BAO_0000357,,,,,168,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,
3562,,,B,8,Expert,,16989,,BAO_0000357,,,,,168,1,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,
3563,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,168,1,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,
3564,,,B,8,Autocuration,,15779,,BAO_0000357,,,,,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor,,
3565,,,B,8,Autocuration,,15779,,BAO_0000357,,,,,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3566,,,B,8,Autocuration,,15779,,BAO_0000357,,,,,168,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,
3567,,COS-7,B,8,Autocuration,,15650,,BAO_0000219,643.0,,,,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,
3568,,COS-7,B,8,Autocuration,,15650,,BAO_0000219,643.0,,,,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,
3569,,COS-7,B,8,Autocuration,,15650,,BAO_0000219,643.0,,,,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,
3570,,COS-7,B,8,Autocuration,,15650,,BAO_0000219,643.0,,,,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,
3571,,C6,B,8,Autocuration,,17046,,BAO_0000219,673.0,,,,168,1,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3572,,C6,B,8,Expert,,17046,,BAO_0000219,673.0,,,,168,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,
3573,,C6,B,8,Expert,,15650,,BAO_0000219,673.0,,,,168,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,
3574,,C6,B,8,Expert,,17046,,BAO_0000219,673.0,,,,168,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,
3575,,,B,8,Expert,,17066,,BAO_0000357,,,,,10624,1,Binding affinity towards 5-hydroxytryptamine 5 receptor,,
3576,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,105,1,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,
3577,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,10624,1,Binding affinity against 5-hydroxytryptamine 5A receptor,9606.0,
3578,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,10624,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,
3579,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,10624,1,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,9606.0,
3580,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor,9606.0,
3581,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,9606.0,
3582,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,10624,1,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,9606.0,
3583,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,10624,1,Binding affinity towards 5-HT5A receptor,,
3584,,,B,8,Expert,,17175,,BAO_0000357,,,,,10624,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3585,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,10624,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,
3586,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,10624,1,Binding affinity towards cloned human 5-HT5A receptor was determined,,
3587,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3588,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3589,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,10624,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,
3590,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10090.0,
3591,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10090.0,
3592,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10090.0,
3593,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10090.0,
3594,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10625,1,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10090.0,
3595,,,B,8,Expert,,17175,,BAO_0000357,,,,,10625,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,
3596,,HEK293,B,8,Autocuration,,16190,,BAO_0000219,722.0,,,,10576,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3597,,HEK293,B,8,Autocuration,,16190,,BAO_0000219,722.0,,,,10626,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,
3598,,,B,8,Expert,,4820,,BAO_0000357,,,,,10624,1,Binding affinity towards 5-HT5a receptor,,
3599,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor,9606.0,
3600,,,B,8,Expert,,17066,,BAO_0000357,,,,,10624,1,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,
3601,,,B,8,Expert,,17175,,BAO_0000357,,,,,10624,1,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,
3602,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10624,1,Binding affinities against 5-hydroxytryptamine 5A receptor,,
3603,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10624,1,Binding affinities towards 5-hydroxytryptamine 5A receptor,,
3604,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,10624,1,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,
3605,,,F,4,Autocuration,,4639,Cavia porcellus,BAO_0000019,,,,,104714,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,10141.0,
3606,,,B,4,Autocuration,,5486,,BAO_0000223,,,,,104714,1,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,
3607,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,10627,1,Inhibition of human 5-hydroxytryptamine 6 receptor,9606.0,
3608,,,B,9,Expert,,17273,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,9606.0,
3609,,,B,8,Autocuration,,17687,,BAO_0000357,,,,,10627,1,Inhibition against human 5-hydroxytryptamine 6 receptor,,
3610,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,10627,1,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,9606.0,
3611,,HeLa,B,8,Expert,,16190,,BAO_0000219,308.0,,,,10627,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,
3612,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,9606.0,
3613,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,9606.0,
3614,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,9606.0,
3615,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,9606.0,
3616,,,B,9,Expert,,3555,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity against 5-hydroxytryptamine 6 receptor,9606.0,
3617,,,B,8,Expert,,5808,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3618,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3619,,HEK293,B,8,Expert,,15818,,BAO_0000219,722.0,,,,10627,1,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,
3620,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,
3621,,HEK293,B,8,Expert,,3935,,BAO_0000219,722.0,,,,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,
3622,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,10627,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3623,,HEK293,B,9,Expert,,3805,Homo sapiens,BAO_0000219,722.0,,,,10627,1,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,9606.0,
3624,,,B,8,Expert,,16441,,BAO_0000019,,,,,10627,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,
3625,,,B,8,Expert,,16441,,BAO_0000019,,,,,10627,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3626,,COS-7,B,8,Expert,,6786,,BAO_0000219,643.0,,,,10627,1,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,
3627,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,10627,1,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,9606.0,
3628,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,10627,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,
3629,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,10627,1,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,
3630,,HEK293,B,8,Autocuration,,17451,,BAO_0000219,722.0,,,,10627,1,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,
3631,,,F,8,Autocuration,,3935,,BAO_0000019,,,,,10627,1,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,
3632,,,B,8,Autocuration,,5033,,BAO_0000357,,,,,10627,1,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,
3633,,,B,8,Expert,,4540,,BAO_0000357,,,,,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3634,,HeLa,B,9,Expert,,4540,Homo sapiens,BAO_0000219,308.0,,,,10627,1,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,9606.0,
3635,,HeLa,B,9,Expert,,4540,Homo sapiens,BAO_0000219,308.0,,,,10627,1,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,9606.0,
3636,,HeLa,B,8,Autocuration,,17296,,BAO_0000219,308.0,,,,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,
3637,,HeLa,B,8,Autocuration,,17296,,BAO_0000219,308.0,,,,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3638,,HeLa,B,8,Autocuration,,17296,,BAO_0000219,308.0,,,,10627,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,
3639,,CHO,B,8,Autocuration,,15779,,BAO_0000219,449.0,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,
3640,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,
3641,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,
3642,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,
3643,,HeLa,B,8,Autocuration,,15779,,BAO_0000219,308.0,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,
3644,,,B,8,Autocuration,,6166,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3645,,HeLa,B,8,Autocuration,,17451,,BAO_0000219,308.0,,,,10627,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,
3646,,,B,8,Autocuration,,15316,,BAO_0000357,,,,,10627,1,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,
3647,,,B,8,Expert,,4199,,BAO_0000357,,,,,10627,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,
3648,,HeLa,B,8,Expert,,15146,,BAO_0000219,308.0,,,,10627,1,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,
3649,,,B,8,Autocuration,,5213,,BAO_0000357,,,,,10627,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,
3650,,,B,8,Autocuration,,16429,,BAO_0000219,,,,,10627,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,
3651,,HeLa,B,8,Autocuration,,14818,,BAO_0000219,308.0,,,,10627,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,
3652,,HeLa,B,8,Autocuration,,4829,,BAO_0000219,308.0,,,,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,
3653,,HeLa,B,8,Autocuration,,4829,,BAO_0000219,308.0,,,,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,
3654,,HeLa,B,8,Autocuration,,4829,,BAO_0000219,308.0,,,,10627,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,
3655,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,10628,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,
3656,,,B,8,Autocuration,,14423,,BAO_0000019,,,,,10628,1,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,
3657,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,10628,1,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,
3658,,,B,8,Autocuration,,4342,,BAO_0000357,,,,,10628,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,
3659,,HeLa,B,9,Autocuration,,16190,Homo sapiens,BAO_0000219,308.0,,,,10627,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,9606.0,
3660,,,B,8,Expert,,4820,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3661,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,10627,1,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,
3662,,,F,9,Expert,,17066,Homo sapiens,BAO_0000019,,,,,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,9606.0,
3663,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,10627,1,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,
3664,,,B,8,Expert,,17066,,BAO_0000357,,,,,10627,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,
3665,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,10627,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,
3666,,,B,8,Autocuration,,5014,,BAO_0000357,,,,,10627,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,
3667,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10627,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,
3668,,,F,8,Expert,,17066,,BAO_0000019,,,,,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,
3669,,,F,8,Expert,,17066,,BAO_0000019,,,,,10627,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,
3670,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10627,1,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,
3671,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,10627,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,
3672,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,10627,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,
3673,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,10627,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,
3674,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10627,1,Binding affinities against 5-hydroxytryptamine 6 receptor,,
3675,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10627,1,Binding affinities towards 5-hydroxytryptamine 6 receptor,,
3676,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10627,1,Binding affinity towards 5-hydroxytryptamine 6 receptor,9606.0,
3677,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,10627,1,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,
3678,,,B,8,Autocuration,,3269,,BAO_0000357,,,,,10627,1,Affinity against 5-hydroxytryptamine 6 receptor,,
3679,,,B,8,Autocuration,,5486,,BAO_0000357,,,,,10627,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,
3680,,,B,9,Expert,,16146,Homo sapiens,BAO_0000357,,,,,10209,1,Inhibition of human 5-hydroxytryptamine 7 receptor,9606.0,
3681,,HEK293,B,8,Autocuration,,5014,,BAO_0000219,722.0,,,,10209,1,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,
3682,,,B,8,Autocuration,,15463,,BAO_0000357,,,,,10209,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,
3683,,,B,8,Autocuration,,3805,,BAO_0000357,,,,,10209,1,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,
3684,,HEK293,B,8,Expert,,5014,,BAO_0000219,722.0,,,,10209,1,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,
3685,,,B,9,Expert,,6491,Homo sapiens,BAO_0000357,,,,,10209,1,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,9606.0,
3686,,CHO,B,8,Autocuration,,16190,,BAO_0000219,449.0,,,,10209,1,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,
3687,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9606.0,
3688,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10209,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,9606.0,
3689,,,B,9,Expert,,3555,Homo sapiens,BAO_0000357,,,,,10209,1,Binding affinity against 5-hydroxytryptamine 7 receptor,9606.0,
3690,,CHO,B,8,Expert,,6588,,BAO_0000219,449.0,,,,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,
3691,,,B,8,Autocuration,,15463,,BAO_0000357,,,,,10209,1,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,
3692,,,B,8,Autocuration,,6013,,BAO_0000357,,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3693,,,B,8,Autocuration,,16209,,BAO_0000357,,,,,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3694,,,B,8,Autocuration,,3935,,BAO_0000357,,,,,10209,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,
3695,,,B,8,Autocuration,,15818,,BAO_0000357,,,,,10209,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,
3696,,HEK293,B,8,Expert,,5014,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,
3697,,,B,8,Expert,,16441,,BAO_0000019,,,,,10209,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,
3698,,,B,8,Expert,,16441,,BAO_0000019,,,,,10209,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,
3699,,,B,9,Expert,,4234,Homo sapiens,BAO_0000357,,,,,10209,1,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,9606.0,
3700,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,10209,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,
3701,,,B,8,Autocuration,,17200,,BAO_0000357,,,,,10209,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,
3702,,CHO,B,8,Autocuration,,17451,,BAO_0000219,449.0,,,,10209,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,
3703,,,B,8,Autocuration,,17085,,BAO_0000019,,,,,10209,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,
3704,,,B,8,Autocuration,,5104,,BAO_0000357,,,,,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,
3705,,,B,8,Autocuration,,5104,,BAO_0000357,,,,,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,
3706,,COS-7,B,9,Expert,,5033,Homo sapiens,BAO_0000219,643.0,,,,10209,1,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,9606.0,
3707,,COS-7,B,8,Autocuration,,5486,,BAO_0000219,643.0,,,,10209,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,
3708,,HEK293,B,9,Expert,,4540,Homo sapiens,BAO_0000219,722.0,,,,10209,1,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,9606.0,
3709,,,B,8,Expert,,6166,,BAO_0000357,,,,,10209,1,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,
3710,,HEK293,B,8,Expert,,17342,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,
3711,,,B,8,Expert,,17342,,BAO_0000357,,,,,10209,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,
3712,,,B,8,Autocuration,,17296,,BAO_0000357,,,,,10209,1,Binding affinity against 5-hydroxytryptamine 7 human receptors,,
3713,,,B,8,Expert,,16429,,BAO_0000219,,,,,10209,1,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,
3714,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10209,1,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,
3715,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3716,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3717,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,
3718,,HEK293,B,8,Autocuration,,15779,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,
3719,,CHO,B,8,Autocuration,,17451,,BAO_0000219,449.0,,,,10209,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,
3720,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,10209,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,
3721,,HEK293,B,9,Expert,,4199,,BAO_0000219,722.0,,,,10209,1,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,
3722,,HEK293,B,8,Autocuration,,4199,,BAO_0000219,722.0,,,,10209,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,
3723,,HEK293,B,9,Intermediate,,3680,,BAO_0000219,722.0,,,,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,
3724,,,B,9,Intermediate,,3680,,BAO_0000357,,,,,10209,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,
3725,,COS-7,B,8,Autocuration,,15316,,BAO_0000219,643.0,,,,10209,1,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,
3726,,HEK293,B,8,Autocuration,,15146,,BAO_0000219,722.0,,,,10209,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,
3727,,HEK293,B,8,Expert,,5213,,BAO_0000219,722.0,,,,10209,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,
3728,,HEK293,B,8,Autocuration,,5213,,BAO_0000219,722.0,,,,10209,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,
3729,,HEK293,B,9,Expert,,14818,Homo sapiens,BAO_0000219,722.0,,,,10209,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,9606.0,
3730,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,10209,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,
3731,,HEK293,B,8,Autocuration,,14818,,BAO_0000219,722.0,,,,10209,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,
3732,,HEK293,B,8,Autocuration,,4829,,BAO_0000219,722.0,,,,10209,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,
3733,,,B,9,Autocuration,,17200,Homo sapiens,BAO_0000357,,,,,10209,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,9606.0,
3734,,,B,9,Expert,,17066,Mus musculus,BAO_0000357,,,,,10022,1,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10090.0,
3735,,,B,8,Autocuration,,14025,Oryctolagus cuniculus,BAO_0000019,,,,,10209,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,9986.0,
3736,,CHO,B,8,Autocuration,,15250,,BAO_0000219,449.0,,,,11923,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,
3737,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,
3738,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,
3739,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,
3740,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,
3741,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,
3742,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,
3743,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,
3744,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,
3745,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,
3746,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,
3747,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,
3748,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,
3749,,,B,8,Expert,,17066,,BAO_0000357,,,,,11923,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,
3750,,,B,9,Expert,,17066,Rattus norvegicus,BAO_0000357,,,,,11923,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10116.0,
3751,,,B,8,Expert,,17386,,BAO_0000357,,,,,11923,1,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,
3752,,,B,8,Autocuration,,14423,,BAO_0000019,,,,,11923,1,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,
3753,,,B,9,Expert,,15874,Rattus norvegicus,BAO_0000357,,,,,11923,1,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,10116.0,
3754,,,B,9,Expert,,15874,Rattus norvegicus,BAO_0000357,,,,,11923,1,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,10116.0,
3755,,CHO,B,9,Expert,,16372,Rattus norvegicus,BAO_0000219,449.0,,,,11923,1,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,10116.0,
3756,,,B,8,Autocuration,,4622,,BAO_0000357,,,,,11923,1,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,
3757,,,B,8,Autocuration,,15086,,BAO_0000357,,,,,11923,1,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,
3758,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,
3759,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,
3760,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,
3761,,CHO,B,8,Autocuration,,16372,,BAO_0000219,449.0,,,,11923,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,
3762,,,F,8,Autocuration,,17386,,BAO_0000221,,Ileum,,,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3763,,,F,8,Autocuration,,17386,,BAO_0000221,,Ileum,,,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,,
3764,,,F,8,Autocuration,,17386,,BAO_0000221,,Ileum,,,11923,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,,
3765,Membranes,,B,9,Expert,,5831,Rattus norvegicus,BAO_0000249,,,,,11923,1,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,10116.0,
3766,,,B,8,Autocuration,,4342,,BAO_0000357,,,,,11923,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,
3767,,,B,8,Expert,,17319,,BAO_0000357,,,,,11923,1,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,
3768,,,B,8,Expert,,17342,,BAO_0000019,,Hypothalamus,,,11923,1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,,
3769,,,B,8,Autocuration,,17342,,BAO_0000357,,,,,11923,1,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,
3770,,,B,8,Expert,,3680,,BAO_0000249,,Hypothalamus,,,11923,1,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,,
3771,,,B,8,Expert,,3680,,BAO_0000357,,,,,11923,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3772,,HEK293,F,9,Expert,,17319,Rattus norvegicus,BAO_0000219,722.0,,,,11923,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,10116.0,
3773,,HEK293,F,9,Expert,,17319,Rattus norvegicus,BAO_0000219,722.0,,,,11923,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,10116.0,
3774,,HEK293,F,9,Autocuration,,17319,Rattus norvegicus,BAO_0000219,722.0,,,,11923,1,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,10116.0,
3775,,,B,8,Expert,,4820,,BAO_0000357,,,,,10209,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,
3776,,,B,8,Autocuration,,4639,,BAO_0000357,,,,,10209,1,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,
3777,,,B,8,Autocuration,,6011,,BAO_0000357,,,,,10209,1,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,
3778,,,B,9,Expert,,17066,Homo sapiens,BAO_0000357,,,,,10209,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,9606.0,
3779,,,B,8,Expert,,17066,,BAO_0000357,,,,,10209,1,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,
3780,,,B,8,Autocuration,,17515,,BAO_0000357,,,,,10209,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,
3781,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10209,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3782,,,F,8,Expert,,17066,,BAO_0000019,,,,,10209,1,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,
3783,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10209,1,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,
3784,,,B,8,Autocuration,,4373,,BAO_0000357,,,,,10209,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,
3785,,,B,8,Autocuration,,4687,,BAO_0000357,,,,,10209,1,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,
3786,,,B,8,Expert,,17342,,BAO_0000357,,,,,10209,1,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,
3787,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,10209,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,
3788,,,B,8,Autocuration,,16946,,BAO_0000357,,,,,10209,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,
3789,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10209,1,Binding affinities against 5-hydroxytryptamine 7 receptor,,
3790,,,B,8,Autocuration,,16633,,BAO_0000357,,,,,10209,1,Binding affinities towards 5-hydroxytryptamine 7 receptor,,
3791,,,B,8,Expert,,17066,,BAO_0000357,,,,,10209,1,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,
3792,,,B,8,Autocuration,,16700,,BAO_0000357,,,,,10209,1,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,
3793,,,B,8,Autocuration,,17386,,BAO_0000221,,Ileum,,,10209,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,,
3794,,,F,8,Autocuration,,14080,,BAO_0000019,,,,,55,1,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,
3795,,,F,9,Expert,,14080,Homo sapiens,BAO_0000019,,,,,55,1,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,9606.0,
3796,,,B,8,Autocuration,,409,,BAO_0000357,,,,,55,1,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,
3797,,,B,8,Autocuration,,409,,BAO_0000357,,,,,55,1,In vitro inhibition of human recombinant lipoxygenase enzyme,,
3798,,,B,8,Autocuration,,409,,BAO_0000357,,,,,55,1,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,
3799,,,B,8,Expert,,11090,,BAO_0000357,,Blood,,,55,1,Inhibition of 5-lipoxygenase in human whole blood.,,
3800,,,B,8,Expert,,11090,,BAO_0000357,,Blood,,,55,1,Inhibition of 5-lipoxygenase in human whole blood.,,
3801,,,B,8,Autocuration,,948,,BAO_0000357,,,,,55,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,
3802,,,B,8,Autocuration,,948,,BAO_0000357,,,,,55,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,
3803,,,F,8,Expert,,13622,,BAO_0000219,,,,,55,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,
3804,,,F,8,Autocuration,,13622,,BAO_0000019,,Blood,,,55,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,,
3805,,,B,8,Autocuration,,9637,,BAO_0000357,,,,,55,1,In vitro inhibition of 5-lipoxygenase from human polymorphs,,
3806,,,B,8,Autocuration,,11320,,BAO_0000357,,,,,55,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,
3807,,,B,8,Expert,,11320,,BAO_0000357,,,,,55,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,
3808,,,B,8,Autocuration,,6838,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,
3809,,,B,9,Expert,,17667,Homo sapiens,BAO_0000357,,Blood,,,55,1,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),9606.0,
3810,,,B,8,Autocuration,,12703,,BAO_0000357,,,,,55,1,In vitro potency against human 5-Lipoxygenase,,
3811,,,F,9,Expert,,14312,Homo sapiens,BAO_0000019,,,,,55,1,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,9606.0,
3812,,,F,8,Autocuration,,14312,,BAO_0000019,,Blood,,,55,1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,,
3813,,,F,8,Autocuration,,5364,,BAO_0000019,,,,,55,1,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3814,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,
3815,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,
3816,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,
3817,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,
3818,,,B,8,Autocuration,,12365,,BAO_0000219,,,,,55,1,Inhibition of human 5-lipoxygenase in human cells,,
3819,,,B,8,Expert,,10603,,BAO_0000357,,,,,55,1,Inhibition of human neutrophil 5-lipoxygenase,,
3820,,,B,8,Autocuration,,10501,,BAO_0000019,,,,,55,1,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,
3821,,,B,8,Expert,,12281,,BAO_0000357,,Blood,,,55,1,Inhibition of 5-lipoxygenase from human whole blood,,
3822,,,B,8,Autocuration,,2567,,BAO_0000357,,,,,55,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3823,,,B,8,Autocuration,,2567,,BAO_0000219,,,,,55,1,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,
3824,,,B,8,Expert,,10193,,BAO_0000357,,,,,55,1,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,
3825,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3826,,,B,8,Expert,,13623,,BAO_0000357,,,,,55,1,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,
3827,,,B,8,Autocuration,,12780,,BAO_0000357,,,,,55,1,Tested against 5-lipoxygenase,,
3828,,,B,8,Autocuration,,12780,,BAO_0000357,,,,,55,1,Tested for activity against 5-Lipoxygenase (5-LO),,
3829,,,B,8,Autocuration,,12780,,BAO_0000357,,,,,55,1,Tested for activity against 5-lipoxygenase,,
3830,,,B,8,Autocuration,,11966,,BAO_0000357,,,,,55,1,Tested for inhibition of 5-HPETE production by human 5-LO,,
3831,,,F,8,Autocuration,,5364,,BAO_0000019,,,,,55,1,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,
3832,,,B,8,Expert,,13165,,BAO_0000357,,,,,55,1,Inhibition of Human 5-lipoxygenase,,
3833,,,B,8,Autocuration,,5364,,BAO_0000019,,,,,55,1,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,
3834,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,55,1,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,
3835,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,55,1,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,
3836,,,B,8,Autocuration,,14863,,BAO_0000019,,,,,55,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,
3837,,,B,8,Autocuration,,14863,,BAO_0000019,,,,,55,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,
3838,,,B,8,Autocuration,,11087,,BAO_0000357,,Blood,,,55,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),,
3839,,,B,8,Autocuration,,455,,BAO_0000357,,,,,55,1,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,
3840,,,B,8,Autocuration,,13183,,BAO_0000357,,,,,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
3841,,,B,8,Expert,,10319,,BAO_0000019,,,,,55,1,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,
3842,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3843,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,
3844,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,
3845,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,
3846,,,B,8,Autocuration,,951,,BAO_0000219,,,,,55,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,
3847,,,B,8,Expert,,9859,,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,
3848,,,B,8,Expert,,9859,,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,
3849,,,B,8,Autocuration,,9859,,BAO_0000357,,,,,55,1,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,
3850,,,B,8,Autocuration,,2567,,BAO_0000357,,,,,55,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,
3851,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,
3852,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,
3853,,,B,8,Autocuration,,949,,BAO_0000019,,,,,55,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,
3854,,,B,8,Autocuration,,949,,BAO_0000019,,,,,55,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,
3855,,,B,8,Expert,,10603,,BAO_0000357,,,,,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,
3856,,,B,8,Expert,,10603,,BAO_0000357,,,,,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3857,,,F,8,Autocuration,,10603,,BAO_0000019,,,,,55,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,
3858,,,B,8,Expert,,10603,,BAO_0000357,,,,,55,1,Inhibition of lipoxygenase at the concentration of 0.1 uM,,
3859,,,B,8,Expert,,10603,,BAO_0000357,,,,,55,1,Inhibition of lipoxygenase at the concentration of 1 uM,,
3860,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,55,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,
3861,,,B,9,Expert,,14580,Homo sapiens,BAO_0000357,,,,,55,1,Inhibition of 5-Lipoxygenase (5-LOX),9606.0,
3862,,,B,8,Expert,,11090,,BAO_0000357,,,,,17087,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3863,,,B,8,Expert,,11090,,BAO_0000357,,,,,17087,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,
3864,,,B,8,Autocuration,,6339,,BAO_0000357,,,,,17087,1,Inhibitory activity against lipoxygenase-2 in mice,,
3865,,,B,8,Expert,,6339,,BAO_0000357,,,,,17087,1,Inhibitory activity against murine lipoxygenase-2.,,
3866,,,B,9,Expert,,12281,Mus musculus,BAO_0000357,,,,,17087,1,Inhibition of 5-lipoxygenase from mouse macrophage,10090.0,
3867,,,B,8,Autocuration,,11311,,BAO_0000357,,,,,17087,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,
3868,,,B,8,Autocuration,,11089,Sus scrofa,BAO_0000019,,,,,55,1,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,9823.0,
3869,,,B,8,Autocuration,,10091,Sus scrofa,BAO_0000019,,,,,55,1,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,9823.0,
3870,,,B,8,Autocuration,,14352,Oryctolagus cuniculus,BAO_0000019,,,,,55,1,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,9986.0,
3871,,,B,9,Expert,,13329,Rattus norvegicus,BAO_0000019,,,,,12166,1,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,10116.0,
3872,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,
3873,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3874,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,
3875,,,B,8,Expert,,13329,,BAO_0000019,,,,,12166,1,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,
3876,,,B,8,Expert,,13329,,BAO_0000019,,,,,12166,1,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,
3877,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,
3878,,,B,8,Autocuration,,11311,,BAO_0000019,,,,,12166,1,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,
3879,,,B,8,Autocuration,,11311,,BAO_0000019,,,,,12166,1,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,
3880,,RBL-1,B,8,Autocuration,,105,,BAO_0000219,702.0,,,,12166,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3881,,RBL-1,B,8,Autocuration,,105,,BAO_0000219,702.0,,,,12166,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,
3882,,,B,8,Autocuration,,9138,,BAO_0000357,,,,,12166,1,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,
3883,,,B,8,Autocuration,,9138,,BAO_0000357,,,,,12166,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,
3884,,,B,8,Autocuration,,9138,,BAO_0000357,,,,,12166,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,
3885,,,B,8,Autocuration,,14427,,BAO_0000357,,,,,12166,1,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3886,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,
3887,,,B,8,Autocuration,,13329,,BAO_0000019,,,,,12166,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,
3888,,RBL-2H3,B,9,Expert,,14427,Rattus norvegicus,BAO_0000219,663.0,,,,12166,1,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,10116.0,
3889,,,B,8,Autocuration,,14427,,BAO_0000357,,,,,12166,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,
3890,,,B,8,Autocuration,,14427,,BAO_0000357,,,,,12166,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,
3891,,RBL-1,B,8,Expert,,10293,,BAO_0000219,702.0,,,,12166,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,
3892,,RBL-1,B,9,Expert,,338,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,10116.0,
3893,,,B,8,Autocuration,,303,,BAO_0000357,,,,,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,
3894,,RBL-1,B,8,Autocuration,,303,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,
3895,,RBL-1,B,8,Expert,,9247,,BAO_0000219,702.0,,,,12166,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,
3896,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
3897,,RBL-1,B,8,Autocuration,,137,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,
3898,,,B,8,Expert,,11481,,BAO_0000357,,,,,12166,1,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,
3899,,,B,8,Expert,,11481,,BAO_0000357,,,,,12166,1,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,
3900,,,B,8,Expert,,9029,,BAO_0000357,,,,,12166,1,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,
3901,,,B,8,Autocuration,,1701,,BAO_0000019,,,,,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,
3902,,,B,8,Autocuration,,1701,,BAO_0000019,,,,,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,
3903,,,B,8,Autocuration,,1701,,BAO_0000019,,,,,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,
3904,,,B,8,Autocuration,,1701,,BAO_0000019,,,,,12166,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,
3905,,RBL-1,F,8,Expert,,13358,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,
3906,,RBL-1,B,8,Expert,,1175,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,
3907,,RBL-1,B,8,Expert,,8797,,BAO_0000219,702.0,,,,12166,1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,
3908,,,B,8,Autocuration,,8797,,BAO_0000019,,,,,12166,1,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,
3909,,,B,9,Expert,,577,Rattus norvegicus,BAO_0000357,,,,,12166,1,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,10116.0,
3910,,RBL-1,B,8,Expert,,9295,,BAO_0000219,702.0,,,,12166,1,In vitro inhibitory activity against RBL-1 5-LO,,
3911,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,
3912,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,
3913,,,B,8,Autocuration,,9295,,BAO_0000218,,,,,12166,1,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,
3914,,,B,8,Autocuration,,9295,,BAO_0000357,,,,,12166,1,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,
3915,,,B,8,Autocuration,,216,,BAO_0000218,,,,,12166,1,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,
3916,,RBL-1,B,8,Autocuration,,11090,,BAO_0000219,702.0,,,,12166,1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,
3917,,,B,8,Autocuration,,11090,,BAO_0000019,,Blood,,,12166,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,,
3918,,,B,8,Expert,,10091,,BAO_0000357,,,,,12166,1,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,
3919,,,F,8,Autocuration,,10274,,BAO_0000019,,,,,12166,1,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,
3920,,,F,8,Autocuration,,13622,,BAO_0000219,,,,,12166,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,
3921,,RBL-1,B,8,Expert,,12118,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,
3922,,,B,8,Expert,,12576,,BAO_0000357,,,,,12166,1,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,
3923,,RBL-1,B,8,Expert,,9546,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,
3924,,RBL-1,B,8,Autocuration,,9521,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,
3925,,RBL-1,B,8,Expert,,10626,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,
3926,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase,,
3927,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,
3928,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,
3929,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,
3930,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,
3931,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,
3932,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,
3933,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,
3934,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,
3935,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,
3936,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,
3937,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,
3938,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,
3939,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,
3940,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,
3941,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,
3942,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,
3943,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,
3944,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,
3945,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,
3946,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,
3947,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,
3948,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,
3949,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,
3950,,,B,8,Expert,,9401,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,
3951,,,B,8,Autocuration,,10325,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,
3952,,RBL-2H3,F,8,Expert,,1556,,BAO_0000219,663.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,
3953,,RBL-2H3,F,8,Expert,,1556,,BAO_0000219,663.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,
3954,,RBL-1,B,9,Expert,,961,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,10116.0,
3955,,,B,8,Autocuration,,6838,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,
3956,,,B,8,Expert,,10325,,BAO_0000019,,,,,12166,1,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,
3957,,RBL-1,B,9,Expert,,9209,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,10116.0,
3958,,RBL-1,B,8,Expert,,11520,,BAO_0000219,702.0,,,,12166,1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,
3959,,,B,8,Autocuration,,137,,BAO_0000357,,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined,,
3960,,RBL-1,B,8,Autocuration,,4717,,BAO_0000219,702.0,,,,12166,1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,
3961,,RBL-1,B,8,Expert,,10636,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,
3962,,,F,9,Expert,,14312,Rattus norvegicus,BAO_0000019,,,,,12166,1,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,10116.0,
3963,,RBL-1,B,8,Autocuration,,1203,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,
3964,,,B,8,Autocuration,,1203,,BAO_0000019,,,,,12166,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,
3965,,RBL-1,B,8,Expert,,13622,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,
3966,,,B,8,Autocuration,,9793,,BAO_0000357,,,,,12166,1,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,
3967,,RBL-1,B,9,Expert,,1143,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,10116.0,
3968,,RBL-1,B,9,Expert,,11854,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,10116.0,
3969,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
3970,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
3971,,RBL-1,B,9,Expert,,10501,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,10116.0,
3972,,RBL-1,B,8,Expert,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
3973,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,,
3974,,,F,8,Autocuration,,10034,,BAO_0000019,,Limbic system,,,10825,1,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,,
3975,,,F,8,Autocuration,,10034,,BAO_0000019,,,,,10825,1,Approximate dose levels for a half maximal reduction of 5-HTP levels,,
3976,,,B,8,Autocuration,,10046,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3977,,,B,8,Autocuration,,10046,,BAO_0000221,,Hippocampus,,,10576,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,,
3978,,,B,8,Autocuration,,10046,,BAO_0000019,,,,,10577,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,
3979,,,F,8,Autocuration,,12079,Canis lupus familiaris,BAO_0000019,,Blood,,,55,1,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,9615.0,
3980,,,F,8,Autocuration,,12079,,BAO_0000019,,Blood,,,55,1,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,,
3981,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
3982,,,B,8,Expert,,12338,,BAO_0000219,,,,,17140,1,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,
3983,,,B,8,Expert,,12143,,BAO_0000219,,,,,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,
3984,,,B,8,Autocuration,,12143,,BAO_0000219,,,,,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,
3985,,,B,8,Expert,,12143,,BAO_0000219,,,,,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3986,,,B,8,Autocuration,,12143,,BAO_0000219,,,,,17140,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,
3987,,,B,8,Expert,,12365,,BAO_0000357,,,,,17140,1,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,
3988,,,B,8,Expert,,13500,,BAO_0000357,,,,,17140,1,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,
3989,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3990,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3991,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3992,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3993,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3994,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3995,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3996,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3997,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3998,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
3999,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4000,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4001,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4002,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4003,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4004,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4005,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4006,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4007,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4008,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4009,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4010,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4011,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4012,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4013,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4014,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4015,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4016,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4017,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4018,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4019,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4020,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4021,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4022,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4023,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",9615.0,
4024,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4025,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",9615.0,
4026,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4027,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4028,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4029,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4030,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4031,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",9615.0,
4032,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4033,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4034,,,F,8,Autocuration,In vivo,12832,Canis lupus familiaris,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",9615.0,
4035,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,9615.0,
4036,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,9615.0,
4037,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,9615.0,
4038,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,9615.0,
4039,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,9615.0,
4040,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,9615.0,
4041,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,9615.0,
4042,,,B,8,Autocuration,,3595,Canis lupus familiaris,BAO_0000218,,,,,55,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,9615.0,
4043,,,B,8,Autocuration,,9203,Cavia porcellus,BAO_0000357,,,,,55,1,Ability to inhibit 5-lipoxygenase in guinea pig,10141.0,
4044,,,B,8,Expert,,82,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),10141.0,
4045,,,B,8,Autocuration,,11090,Cavia porcellus,BAO_0000357,,,,,55,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,10141.0,
4046,,,B,8,Autocuration,,12832,Cavia porcellus,BAO_0000218,,Blood,,,55,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",10141.0,
4047,,,B,8,Autocuration,,1065,Cavia porcellus,BAO_0000357,,,,,55,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,10141.0,
4048,,,B,8,Autocuration,,1065,Cavia porcellus,BAO_0000357,,,,,55,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,10141.0,
4049,,,B,8,Expert,,12832,Cavia porcellus,BAO_0000019,,,,,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,
4050,,,B,8,Expert,,12832,Cavia porcellus,BAO_0000019,,,,,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,
4051,,,B,8,Autocuration,,12832,Cavia porcellus,BAO_0000019,,,,,55,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,10141.0,
4052,,,B,8,Autocuration,,10504,Cavia porcellus,BAO_0000019,,,,,55,1,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10141.0,
4053,,,B,8,Autocuration,,7788,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase,10141.0,
4054,,,B,8,Autocuration,,10001,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,10141.0,
4055,,,B,8,Autocuration,,10193,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,10141.0,
4056,,,B,8,Autocuration,,13243,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,10141.0,
4057,,,B,8,Autocuration,,13243,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity uM,10141.0,
4058,,,B,8,Autocuration,,969,Cavia porcellus,BAO_0000219,,,,,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,10141.0,
4059,,,B,8,Autocuration,,10001,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase at 10 uM,10141.0,
4060,,,B,8,Autocuration,,7788,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,10141.0,
4061,,,B,8,Autocuration,,10001,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,10141.0,
4062,,,B,8,Autocuration,,10193,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,10141.0,
4063,,,B,8,Autocuration,,13243,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity uM,10141.0,
4064,,,B,8,Autocuration,,13243,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,10141.0,
4065,,,B,8,Expert,,13243,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity uM,10141.0,
4066,,,F,8,Autocuration,,13243,Cavia porcellus,BAO_0000019,,,,,55,1,Inhibitory activity uM,10141.0,
4067,,,B,8,Autocuration,,10504,Cavia porcellus,BAO_0000019,,,,,55,1,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,10141.0,
4068,,,B,8,Autocuration,,7788,Cavia porcellus,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,10141.0,
4069,,,F,8,Expert,,10546,Cavia porcellus,BAO_0000221,,Ileum,,,55,1,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,10141.0,
4070,,,B,8,Autocuration,,13183,,BAO_0000357,,,,,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4071,,,B,8,Autocuration,,13183,,BAO_0000357,,,,,55,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,
4072,,,B,8,Autocuration,,2578,,BAO_0000357,,,,,55,1,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,
4073,,,B,8,Expert,,12780,,BAO_0000357,,,,,55,1,In vitro inhibition of human 5-Lipoxygenase.,,
4074,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,10116.0,
4075,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,10116.0,
4076,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,10116.0,
4077,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,10116.0,
4078,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,10116.0,
4079,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,
4080,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,
4081,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,10116.0,
4082,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,10116.0,
4083,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,10116.0,
4084,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,10116.0,
4085,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,10116.0,
4086,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,10116.0,
4087,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,
4088,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,10116.0,
4089,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,
4090,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,
4091,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,
4092,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,10116.0,
4093,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,10116.0,
4094,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,10116.0,
4095,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,10116.0,
4096,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,10116.0,
4097,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,10116.0,
4098,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,10116.0,
4099,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,10116.0,
4100,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,10116.0,
4101,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,
4102,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,10116.0,
4103,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,10116.0,
4104,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,10116.0,
4105,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,10116.0,
4106,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,10116.0,
4107,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,10116.0,
4108,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,10116.0,
4109,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,10116.0,
4110,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,10116.0,
4111,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,10116.0,
4112,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,10116.0,
4113,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,10116.0,
4114,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,
4115,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,10116.0,
4116,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,10116.0,
4117,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,10116.0,
4118,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,10116.0,
4119,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,10116.0,
4120,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,10116.0,
4121,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,,,,22226,1,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,10116.0,
4122,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,
4123,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,
4124,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",10116.0,
4125,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",10116.0,
4126,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",10116.0,
4127,,RPMI-8226,F,1,Intermediate,,10797,Homo sapiens,BAO_0000219,741.0,,,,80433,1,In vitro inhibition of 7226/S myeloma cancer cell line,9606.0,
4128,,BEL-7404 tumor cell line,F,1,Intermediate,,6881,Homo sapiens,BAO_0000219,993.0,,,,80698,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),9606.0,
4129,,786-0,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,9606.0,
4130,,786-0,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,9606.0,
4131,,V79,F,1,Expert,,12981,Cricetulus griseus,BAO_0000219,505.0,,,,81264,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,10029.0,
4132,,V79,F,1,Expert,,12981,Cricetulus griseus,BAO_0000219,505.0,,,,81264,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,10029.0,
4133,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,10116.0,
4134,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,10116.0,
4135,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,10116.0,
4136,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,10116.0,
4137,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,10116.0,
4138,,7800C1 cell line,F,1,Intermediate,,7653,Rattus norvegicus,BAO_0000219,1119.0,,,,80635,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,10116.0,
4139,,786-0,F,1,Intermediate,,17229,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro antitumor activity against renal 786-0 tumor cell lines,9606.0,
4140,,786-0,F,1,Intermediate,,12858,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Cytotoxic activity against 786-0 Renal cancer cell line,9606.0,
4141,,786-0,F,1,Intermediate,,16325,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,9606.0,
4142,,786-0,F,1,Intermediate,,16325,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,9606.0,
4143,,786-0,F,1,Intermediate,,5858,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro antitumor activity against human renal 786-0 cell line,9606.0,
4144,,786-0,F,1,Intermediate,,16325,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Inhibition of Renal cancer in 786-0 cancer cell lines,9606.0,
4145,,786-0,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,9606.0,
4146,,786-0,F,1,Intermediate,,3786,Homo sapiens,BAO_0000219,391.0,,,,80640,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,9606.0,
4147,,786-0,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,391.0,,,,80640,1,inhibition of the growth of renal cancer(786-0) cell line,9606.0,
4148,,786-0,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),9606.0,
4149,,786-0,F,1,Intermediate,,15354,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,9606.0,
4150,,786-0,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,391.0,,,,80640,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,9606.0,
4151,,786-0,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,391.0,,,,80640,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,9606.0,
4152,,786-0,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,391.0,,,,80640,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,9606.0,
4153,,786-0,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,9606.0,
4154,,786-0,F,1,Intermediate,,12016,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,9606.0,
4155,,786-0,F,1,Intermediate,,2597,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was tested for growth inhibitory activity against 786-0 cell line,9606.0,
4156,,RBL-1,B,8,Autocuration,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,
4157,,RBL-1,B,8,Autocuration,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,
4158,,,B,8,Autocuration,,14799,,BAO_0000019,,,,,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,
4159,,RBL-1,B,8,Expert,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,
4160,,RBL-1,B,8,Expert,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,
4161,,,B,8,Autocuration,,12767,,BAO_0000357,,,,,12166,1,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,
4162,,,B,8,Autocuration,,10997,,BAO_0000219,,,,,12166,1,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,
4163,,RBL-1,B,8,Autocuration,,11388,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,
4164,,,B,8,Autocuration,,167,,BAO_0000357,,,,,12166,1,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,
4165,,,B,8,Autocuration,,167,,BAO_0000357,,,,,12166,1,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,
4166,,,B,8,Expert,,13744,,BAO_0000357,,,,,12166,1,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,
4167,,,B,8,Autocuration,,1630,,BAO_0000357,,,,,12166,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,
4168,,,B,8,Autocuration,,1630,,BAO_0000357,,,,,12166,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,
4169,,,B,9,Expert,,969,Rattus norvegicus,BAO_0000019,,,,,12166,1,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",10116.0,
4170,,RBL-1,B,8,Autocuration,,13621,,BAO_0000219,702.0,,,,12166,1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,
4171,,,B,8,Autocuration,,10089,,BAO_0000357,,,,,12166,1,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,
4172,,,B,8,Expert,,10193,,BAO_0000357,,,,,12166,1,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,
4173,,,B,8,Autocuration,,11966,,BAO_0000357,,,,,12166,1,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,
4174,,,B,8,Autocuration,,12251,,BAO_0000019,,,,,12166,1,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4175,,RBL-1,B,8,Autocuration,,211,,BAO_0000219,702.0,,,,12166,1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,
4176,,,F,8,Expert,,12251,,BAO_0000019,,,,,12166,1,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,
4177,,RBL-1,B,8,Autocuration,,12495,,BAO_0000219,702.0,,,,12166,1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,
4178,,,B,8,Autocuration,,414,,BAO_0000357,,,,,12166,1,Tested for its inhibitory activity against 5-lipoxygenase,,
4179,,,B,8,Autocuration,,414,,BAO_0000357,,,,,12166,1,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,
4180,,,B,8,Expert,,10325,,BAO_0000019,,,,,12166,1,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,
4181,,,B,8,Expert,,11966,,BAO_0000019,,,,,12166,1,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4182,,RBL-1,B,8,Expert,,165,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4183,,RBL-1,B,8,Autocuration,,165,,BAO_0000219,702.0,,,,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,
4184,,RBL-1,B,8,Autocuration,,165,,BAO_0000219,702.0,,,,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4185,,RBL-1,B,8,Expert,,165,,BAO_0000219,702.0,,,,12166,1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,
4186,,,B,8,Autocuration,,11311,,BAO_0000218,,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,
4187,,RBL-1,B,8,Autocuration,,11311,,BAO_0000219,702.0,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,
4188,,RBL-1,B,8,Autocuration,,11311,,BAO_0000219,702.0,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,
4189,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,
4190,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,
4191,,,B,8,Autocuration,In vivo,11311,,BAO_0000218,,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,
4192,,RBL-2H3,F,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,
4193,,RBL-2H3,F,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,
4194,,,B,8,Autocuration,,11311,,BAO_0000019,,,,,12166,1,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,
4195,,,B,8,Autocuration,,11732,,BAO_0000019,,,,,12166,1,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,
4196,,,B,8,Expert,,11732,,BAO_0000019,,,,,12166,1,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,
4197,,,B,8,Expert,,11087,,BAO_0000019,,,,,12166,1,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,
4198,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,
4199,,RBL-1,B,8,Autocuration,,11087,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,
4200,,,B,9,Expert,,11087,Rattus norvegicus,BAO_0000357,,,,,12166,1,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,10116.0,
4201,,RBL-1,B,8,Autocuration,,496,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,
4202,,RBL-1,F,8,Expert,,13986,,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,
4203,,,B,8,Autocuration,,11520,,BAO_0000357,,,,,12166,1,Compound was evaluated for the inhibition of 5-lipoxygenase,,
4204,,RBL-1,B,8,Autocuration,,10293,,BAO_0000219,702.0,,,,12166,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,
4205,,RBL-1,B,8,Autocuration,,303,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,
4206,,RBL-1,B,8,Autocuration,,303,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,
4207,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,
4208,,RBL-1,B,9,Expert,,9247,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,10116.0,
4209,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,
4210,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,
4211,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,
4212,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,
4213,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,
4214,,RBL-1,B,8,Autocuration,,9247,,BAO_0000219,702.0,,,,12166,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,
4215,,,B,9,Expert,,11481,Rattus norvegicus,BAO_0000357,,,,,12166,1,Inhibitory activity against 5-lipoxygenase at 10 uM,10116.0,
4216,,,B,8,Autocuration,,105,,BAO_0000357,,,,,12166,1,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,
4217,,,B,8,Expert,,9029,,BAO_0000357,,,,,12166,1,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,
4218,,RBL-1,B,8,Expert,,1175,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,
4219,,RBL-1,B,8,Autocuration,,12118,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,
4220,,RBL-1,B,8,Autocuration,,12118,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,
4221,,RBL-1,B,8,Autocuration,,12118,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,
4222,,RBL-1,B,8,Autocuration,,9225,,BAO_0000219,702.0,,,,12166,1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,
4223,,,B,8,Autocuration,,9401,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,
4224,,,B,8,Autocuration,,137,,BAO_0000357,,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4225,,,B,8,Autocuration,,137,,BAO_0000357,,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,
4226,,RBL-1,B,8,Autocuration,,4717,,BAO_0000219,702.0,,,,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4227,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4228,,RBL-1,B,8,Autocuration,,10501,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,
4229,,RBL-1,B,8,Autocuration,,10501,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,
4230,,RBL-1,B,8,Autocuration,,10501,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,
4231,,RBL-1,B,8,Autocuration,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4232,,RBL-1,B,9,Expert,,14799,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,10116.0,
4233,,,B,8,Autocuration,,14799,,BAO_0000019,,,,,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,
4234,,RBL-1,B,8,Autocuration,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,
4235,,RBL-1,B,8,Expert,,3595,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,
4236,,RBL-1,B,8,Autocuration,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4237,,RBL-1,B,8,Autocuration,,12526,,BAO_0000219,702.0,,,,12166,1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,
4238,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4239,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4240,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,
4241,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,
4242,,,B,8,Expert,,9138,,BAO_0000357,,,,,12166,1,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,
4243,,,B,8,Autocuration,,9138,,BAO_0000357,,,,,12166,1,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,
4244,,,B,8,Autocuration,,11966,,BAO_0000019,,,,,12166,1,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,
4245,,RBL-1,B,8,Autocuration,,165,,BAO_0000219,702.0,,,,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,
4246,,RBL-1,B,8,Autocuration,,165,,BAO_0000219,702.0,,,,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,
4247,,RBL-2H3,B,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,
4248,,RBL-2H3,B,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4249,,RBL-2H3,F,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,
4250,,,F,8,Autocuration,,11311,,BAO_0000019,,,,,12166,1,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,
4251,,,B,8,Autocuration,,11311,,BAO_0000357,,,,,12166,1,The compound was tested for inhibition of isolated 5-lipoxygenase,,
4252,,RBL-2H3,F,8,Autocuration,,11311,,BAO_0000219,663.0,,,,12166,1,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,
4253,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,
4254,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,
4255,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,
4256,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4257,,,B,8,Autocuration,,11087,,BAO_0000019,,,,,12166,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,
4258,,RBL-1,B,8,Autocuration,,496,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,
4259,,RBL-1,B,8,Autocuration,,496,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,
4260,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,
4261,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,
4262,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,
4263,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,
4264,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,
4265,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,
4266,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,
4267,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,
4268,,RBL-1,F,8,Autocuration,,13986,,BAO_0000219,702.0,,,,12166,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,
4269,,,F,9,Expert,,13986,Rattus norvegicus,BAO_0000019,,,,,12166,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,10116.0,
4270,,,B,8,Autocuration,,10193,,BAO_0000357,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,
4271,,,B,8,Autocuration,,9295,,BAO_0000357,,,,,12166,1,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,
4272,,RBL-1,B,8,Autocuration,,4717,,BAO_0000219,702.0,,,,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,
4273,,RBL-1,B,8,Autocuration,,4717,,BAO_0000219,702.0,,,,12166,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,
4274,,RBL-1,B,8,Autocuration,,11854,,BAO_0000219,702.0,,,,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,
4275,,RBL-1,B,8,Autocuration,,11854,,BAO_0000219,702.0,,,,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,
4276,,RBL-1,B,8,Autocuration,,11854,,BAO_0000219,702.0,,,,12166,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,
4277,,,B,8,Autocuration,,10193,,BAO_0000019,,,,,12166,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,
4278,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,
4279,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,
4280,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,
4281,,RBL-1,B,8,Autocuration,,9295,,BAO_0000219,702.0,,,,12166,1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,
4282,,RBL-1,B,8,Autocuration,,165,,BAO_0000219,702.0,,,,12166,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,
4283,,,B,8,Autocuration,,11311,,BAO_0000219,,,,,12166,1,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,
4284,,RBL-1,B,8,Expert,,10489,Homo sapiens,BAO_0000219,702.0,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),9606.0,
4285,,RBL-1,B,9,Expert,,10489,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),10116.0,
4286,,RBL-1,B,9,Expert,,10489,Rattus norvegicus,BAO_0000219,702.0,,,,12166,1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),10116.0,
4287,,,B,9,Autocuration,,14799,Rattus norvegicus,BAO_0000019,,,,,12166,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,10116.0,
4288,,,B,8,Autocuration,,9295,Glycine max,BAO_0000357,,,,,12054,1,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),3847.0,
4289,,,B,0,Autocuration,,16811,,BAO_0000019,,,,,22226,1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,
4290,,,B,8,Expert,,168,,BAO_0000357,,,,,55,1,In vitro inhibition of 5-Lipoxygenase; Inactive.,,
4291,,,B,8,Autocuration,,6309,,BAO_0000357,,,,,55,1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,
4292,,,B,8,Autocuration,,6309,,BAO_0000357,,,,,55,1,Inhibitory concentration against 5-lipoxygenase; No inhibition,,
4293,,RBL-1,B,8,Autocuration,,3092,,BAO_0000219,702.0,,,,55,1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,
4294,,,B,8,Expert,,168,,BAO_0000357,,,,,55,1,Inhibitory activity against 5-lipoxygenase.,,
4295,,,B,8,Autocuration,,168,,BAO_0000357,,,,,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,
4296,,,B,8,Autocuration,,168,,BAO_0000357,,,,,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,
4297,,,B,8,Autocuration,,168,,BAO_0000357,,,,,55,1,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,
4298,,,F,8,Expert,,12338,,BAO_0000019,,,,,55,1,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,
4299,,,B,8,Autocuration,,4501,,BAO_0000357,,,,,55,1,Tested for the inhibitory activity against 5-lipoxygenase,,
4300,,,B,8,Autocuration,,1132,,BAO_0000357,,,,,55,1,Compound was tested for its inhibitory activity against 5-lipoxygenase,,
4301,,,B,8,Autocuration,,2117,,BAO_0000357,,,,,55,1,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,
4302,,,B,8,Autocuration,,168,,BAO_0000357,,,,,55,1,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,
4303,,,B,8,Autocuration,,168,,BAO_0000357,,,,,55,1,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,
4304,,RBL-1,B,8,Autocuration,,13575,,BAO_0000219,702.0,,,,12166,1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,
4305,,,B,8,Autocuration,,11089,,BAO_0000357,,,,,12166,1,,,
4306,,,B,8,Autocuration,,216,,BAO_0000357,,,,,10102,1,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,
4307,,,B,8,Autocuration,,13165,,BAO_0000019,,,,,10102,1,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,
4308,,,B,8,Autocuration,,3278,,BAO_0000357,,,,,10102,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,
4309,,,B,8,Expert,,3278,,BAO_0000357,,,,,10102,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,
4310,,,B,8,Autocuration,,11966,,BAO_0000357,,,,,10102,1,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,
4311,,,B,8,Autocuration,,175,,BAO_0000357,,,,,10102,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,
4312,,,B,8,Autocuration,,175,,BAO_0000357,,,,,10102,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,
4313,,,B,8,Autocuration,,13449,,BAO_0000357,,,,,10102,1,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,
4314,,,B,8,Autocuration,,12014,,BAO_0000019,,,,,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,
4315,,,B,8,Autocuration,,12014,,BAO_0000019,,,,,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,
4316,,,B,8,Autocuration,,12014,,BAO_0000019,,,,,11238,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,
4317,,,B,2,Intermediate,,99,,BAO_0000220,,,,,100284,1,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,
4318,,,F,0,Autocuration,,4349,Homo sapiens,BAO_0000019,,,,,22226,1,The dark toxicity against 543 human galactophore carcinoma cells,9606.0,
4319,,Panel (56 tumour cell lines),F,1,Expert,,4071,Homo sapiens,BAO_0000219,390.0,,,,80623,1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,9606.0,
4320,,5637,F,1,Expert,,17589,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,9606.0,
4321,,5637,F,1,Intermediate,,15002,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,9606.0,
4322,,5637,F,1,Intermediate,,13958,Homo sapiens,BAO_0000219,345.0,,,,80008,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",9606.0,
4323,,5637,F,1,Expert,,17589,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Growth inhibition against human 5637 cell lines,9606.0,
4324,,5637,F,1,Expert,,16748,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Antitumor activity against human bladder carcinoma 5637 cells.,9606.0,
4325,,5637,F,1,Intermediate,,16747,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Antitumor activity against human bladder carcinoma 5637 cells,9606.0,
4326,,5637,F,1,Intermediate,,16747,Homo sapiens,BAO_0000219,345.0,,,,80008,1,Antitumor activity against human bladder carcinoma 5637 cells,9606.0,
4327,,,B,9,Expert,,15285,Bos taurus,BAO_0000357,,,,,10443,1,In vitro inhibition of bovine trypsin(Trp).,9913.0,
4328,,CV-1,B,8,Expert,,3726,Cercopithecidae,BAO_0000219,407.0,,,,240,1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,9527.0,
4329,,,B,8,Autocuration,,5033,,BAO_0000357,,,,,10577,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,
4330,,,F,6,Autocuration,,11756,,BAO_0000019,,,,,104698,1,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,
4331,,,F,0,Autocuration,In vivo,11953,,BAO_0000218,,,,,22226,1,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,
4332,,,B,9,Intermediate,,5033,Cavia porcellus,BAO_0000357,,,,,20033,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,10141.0,
4333,Microsomes,,A,8,Expert,,11347,Rattus norvegicus,BAO_0000251,,,,,17045,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,10116.0,
4334,Microsomes,,A,8,Expert,,11347,Rattus norvegicus,BAO_0000251,,,,,17045,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,10116.0,
4335,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4336,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,
4337,,,B,8,Expert,,17588,Trypanosoma brucei,BAO_0000019,,,,,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,5691.0,
4338,,,B,8,Autocuration,,17588,Trypanosoma brucei,BAO_0000019,,,,,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,5691.0,
4339,,,B,8,Expert,,17588,Ovis aries,BAO_0000019,,,,,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,9940.0,
4340,,,B,8,Autocuration,,17588,Ovis aries,BAO_0000019,,,,,11938,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,9940.0,
4341,,,B,8,Autocuration,,16485,,BAO_0000357,,,,,11938,1,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,
4342,,,F,0,Intermediate,,4337,Homo sapiens,BAO_0000019,,,,,22226,1,Average inhibitory concentration against 60 human cell lines was reported,9606.0,
4343,,,F,0,Expert,,4112,Homo sapiens,BAO_0000019,,,,,22226,1,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,9606.0,
4344,,Panel NCI-60 (60 carcinoma cell lines),F,1,Intermediate,,16160,Homo sapiens,BAO_0000219,542.0,,,,80315,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,9606.0,
4345,,Panel NCI-60 (60 carcinoma cell lines),F,1,Intermediate,,16160,Homo sapiens,BAO_0000219,542.0,,,,80315,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,9606.0,
4346,,Panel NCI-60 (60 carcinoma cell lines),F,1,Expert,,17376,,BAO_0000219,542.0,,,,80315,1,In vitro mean growth inhibitory activity against 60-cell panel,,
4347,,Panel NCI-60 (60 carcinoma cell lines),F,1,Expert,,17376,,BAO_0000219,542.0,,,,80315,1,In vitro mean growth lethal concentration against 60-cell panel,,
4348,,Panel NCI-60 (60 carcinoma cell lines),F,1,Expert,,17376,,BAO_0000219,542.0,,,,80315,1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,
4349,,Panel NCI-60 (60 carcinoma cell lines),F,1,Expert,,17376,,BAO_0000219,542.0,,,,80315,1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,
4350,,,F,4,Autocuration,,3241,,BAO_0000019,,,,,104775,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4351,,,F,4,Autocuration,,3241,,BAO_0000019,,,,,104775,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,
4352,,,B,8,Expert,,3725,,BAO_0000357,,,,,275,1,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,
4353,,,F,1,Expert,,10805,Plasmodium falciparum,BAO_0000218,,,,,50425,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,5833.0,
4354,,,F,1,Expert,,10805,Plasmodium falciparum,BAO_0000218,,,,,50425,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,5833.0,
4355,,,F,1,Expert,,10805,Plasmodium falciparum,BAO_0000218,,,,,50425,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,5833.0,
4356,,,F,1,Expert,,10805,Plasmodium falciparum,BAO_0000218,,,,,50425,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,5833.0,
4357,,,F,1,Intermediate,,10805,Plasmodium falciparum,BAO_0000218,,,,,50425,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,5833.0,
4358,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10090.0,
4359,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10090.0,
4360,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,10090.0,
4361,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10090.0,
4362,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10090.0,
4363,,6C3HED,F,1,Intermediate,,10144,Mus musculus,BAO_0000218,850.0,,,,80628,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,10090.0,
4364,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,10090.0,
4365,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,10090.0,
4366,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),10090.0,
4367,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,10090.0,
4368,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,10090.0,
4369,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,10090.0,
4370,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,10090.0,
4371,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",10090.0,
4372,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),10090.0,
4373,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),10090.0,
4374,,,F,0,Autocuration,In vivo,10685,Mus musculus,BAO_0000218,,,,,22224,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,10090.0,
4375,,,F,0,Autocuration,,10144,Mus musculus,BAO_0000218,,,,,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,10090.0,
4376,,,F,0,Autocuration,,10144,Mus musculus,BAO_0000218,,,,,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,10090.0,
4377,,,F,0,Autocuration,,10144,Mus musculus,BAO_0000218,,,,,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,10090.0,
4378,,,F,0,Autocuration,,10144,Mus musculus,BAO_0000218,,,,,22224,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,10090.0,
4379,,,F,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,10090.0,
4380,,,F,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,10090.0,
4381,,,F,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,10090.0,
4382,,,F,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,10090.0,
4383,,,A,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,10090.0,
4384,,,A,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,10090.0,
4385,,,A,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,10090.0,
4386,,,A,0,Autocuration,,10685,Mus musculus,BAO_0000218,,,,,22224,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,10090.0,
4387,,6C3HED,F,1,Intermediate,,8831,Mus musculus,BAO_0000218,850.0,,,,80628,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",10090.0,
4388,,,F,0,Autocuration,In vivo,11704,,BAO_0000218,,,,,22224,1,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,
4389,,,A,1,Intermediate,,11704,Mus musculus,BAO_0000218,,,,,50594,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,10090.0,
4390,,6C3HED,F,1,Intermediate,In vivo,10685,Mus musculus,BAO_0000218,850.0,,,,80628,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,10090.0,
4391,,6C3HED,F,1,Intermediate,In vivo,10685,Mus musculus,BAO_0000218,850.0,,,,80628,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,10090.0,
4392,,6C3HED,F,1,Expert,,11368,Mus musculus,BAO_0000218,850.0,,,,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),10090.0,
4393,,6C3HED,F,1,Intermediate,,11368,Mus musculus,BAO_0000218,850.0,,,,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),10090.0,
4394,,6C3HED,F,1,Expert,,11368,Mus musculus,BAO_0000218,850.0,,,,80628,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),10090.0,
4395,,,B,0,Autocuration,,17763,Staphylococcus aureus,BAO_0000019,,,,,22226,1,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1280.0,
4396,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,10116.0,
4397,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,10116.0,
4398,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,10116.0,
4399,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,10116.0,
4400,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,10116.0,
4401,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,10116.0,
4402,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,10116.0,
4403,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,10116.0,
4404,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,10116.0,
4405,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,10116.0,
4406,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,10116.0,
4407,Microsomes,,B,0,Autocuration,,7411,Rattus norvegicus,BAO_0000251,,Liver,,,22226,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,10116.0,
4408,,,A,0,Autocuration,In vivo,347,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,The apparent total plasma clearance in monkey,9527.0,
4409,,,A,0,Autocuration,In vivo,3341,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for Hepatic clearance in monkey,9527.0,
4410,,,A,0,Autocuration,In vivo,17853,Cercopithecidae,BAO_0000218,,,,,22224,1,Lower clearance in monkey (i.v.) at 0.5 mpk,9527.0,
4411,,,A,0,Autocuration,In vivo,4514,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in rhesus monkey,9527.0,
4412,,,A,0,Autocuration,In vivo,6062,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,9527.0,
4413,,,A,0,Autocuration,In vivo,6821,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance of compound was determined in monkey,9527.0,
4414,,,A,0,Autocuration,In vivo,6057,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was calculated in rhesus monkey,9527.0,
4415,,,A,0,Autocuration,In vivo,5145,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in rhesus monkey,9527.0,
4416,,,A,0,Autocuration,In vivo,6641,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,
4417,,,A,0,Autocuration,In vivo,5472,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was evaluated in rhesus,9527.0,
4418,,,A,0,Autocuration,In vivo,4257,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,9527.0,
4419,,,A,0,Autocuration,In vivo,5546,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,
4420,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,
4421,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,
4422,,,A,0,Autocuration,In vivo,17509,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax 24 hr after 2 mg/kg oral administration in monkeys,9527.0,
4423,,,A,0,Autocuration,In vivo,6535,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax in monkey after administration of 1 mg/kg iv,9527.0,
4424,,,A,0,Autocuration,In vivo,5668,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,9527.0,
4425,,,A,0,Autocuration,In vivo,5922,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax in cynomolgus monkey by iv administration,9527.0,
4426,,,A,0,Autocuration,In vivo,5922,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax in cynomolgus monkey by po administration,9527.0,
4427,,,A,0,Autocuration,In vivo,6078,Cercopithecidae,BAO_0000218,,,,,22224,1,Cmax value evaluated in monkey,9527.0,
4428,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,
4429,,,A,0,Autocuration,In vivo,3249,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,9527.0,
4430,,,A,0,Autocuration,In vivo,3249,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,9527.0,
4431,,,A,0,Autocuration,In vivo,5553,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Maximal plasma concentration in squirrel monkeys,9527.0,
4432,,,A,0,Autocuration,In vivo,1916,Cercopithecidae,BAO_0000218,,,,,22224,1,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,
4433,,,A,0,Autocuration,In vivo,6227,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,9527.0,
4434,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,
4435,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,9527.0,
4436,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,9527.0,
4437,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,9527.0,
4438,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,9527.0,
4439,,,A,0,Autocuration,In vivo,6221,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,9527.0,
4440,,,A,0,Autocuration,,167,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,9527.0,
4441,,,A,0,Autocuration,,167,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,9527.0,
4442,,,A,0,Autocuration,In vivo,4257,monkey,BAO_0000218,,,,,22224,1,Absolute bioavailability was evaluated in monkey,9443.0,
4443,,,A,0,Autocuration,In vivo,6221,monkey,BAO_0000218,,,,,22224,1,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,9443.0,
4444,,,A,0,Autocuration,In vivo,17667,monkey,BAO_0000218,,,,,22224,1,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,9443.0,
4445,,,A,0,Autocuration,In vivo,17267,Macaca mulatta,BAO_0000218,,,,,22224,1,Bioavailability of compound was determined in rhesus monkey,9544.0,
4446,,,A,0,Autocuration,In vivo,4256,marmosets,BAO_0000218,,,,,22224,1,Bioavailability determined after oral administration in marmoset,38020.0,
4447,,,A,0,Autocuration,In vivo,4256,Macaca fascicularis,BAO_0000218,,,,,22224,1,Oral bioavailability in cynomolgus monkey,9541.0,
4448,,,A,0,Autocuration,In vivo,17853,monkey,BAO_0000218,,,,,22224,1,Bioavailability in monkey (p.o.) at 2.0 mpk,9443.0,
4449,,,A,0,Autocuration,In vivo,16365,monkey,BAO_0000218,,,,,22224,1,Bioavailability was evaluated after oral administration in monkey,9443.0,
4450,,,A,0,Autocuration,In vivo,1916,Macaca fascicularis,BAO_0000218,,,,,22224,1,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9541.0,
4451,,,A,0,Autocuration,In vivo,5334,Macaca mulatta,BAO_0000218,,,,,22224,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9544.0,
4452,,,A,0,Autocuration,In vivo,5334,Macaca mulatta,BAO_0000218,,,,,22224,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9544.0,
4453,,,A,0,Autocuration,In vivo,17592,monkey,BAO_0000218,,,,,22224,1,Bioavailability of the compound was determined in monkey,9443.0,
4454,,,A,0,Autocuration,In vivo,1399,Saimiri sciureus,BAO_0000218,,,,,22224,1,Bioavailability in squirrel monkey (dose 5 mg/kg),9521.0,
4455,,,A,0,Autocuration,In vivo,4809,monkey,BAO_0000218,,,,,22224,1,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),9443.0,
4456,,,A,0,Autocuration,In vivo,3341,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4457,,,A,0,Autocuration,In vivo,64,Saimiri sciureus,BAO_0000218,,,,,22224,1,Compound was tested for bioavailability in squirrel monkey,9521.0,
4458,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in Rhesus monkey,9544.0,
4459,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),9544.0,
4460,,,A,0,Autocuration,In vivo,5237,Macaca fascicularis,BAO_0000218,,,,,22224,1,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,9541.0,
4461,,,A,0,Autocuration,In vivo,5237,Macaca fascicularis,BAO_0000218,,,,,22224,1,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,9541.0,
4462,,,A,0,Autocuration,In vivo,5302,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey (dose 5 mg/kg),9443.0,
4463,,,A,0,Autocuration,In vivo,17667,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability of compound at 5 mg/kg in monkey,9443.0,
4464,,,A,1,Intermediate,In vivo,6161,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,9615.0,
4465,,,A,1,Intermediate,In vivo,6161,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,9615.0,
4466,,,A,1,Intermediate,,3854,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half life determined,9615.0,
4467,,,A,1,Intermediate,,993,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half life in dog,9615.0,
4468,,,A,1,Intermediate,,4514,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half-life in Beagle dogs,9615.0,
4469,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,
4470,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),9615.0,
4471,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,
4472,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,
4473,,,A,1,Intermediate,,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for the half life period in dog,9615.0,
4474,,,A,1,Intermediate,In vivo,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for the half life period in dog at dosage of 10 mpk,9615.0,
4475,,,A,1,Intermediate,,3880,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for half life in dog,9615.0,
4476,,,A,1,Intermediate,,3639,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",9615.0,
4477,,,A,1,Intermediate,,3880,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The half life was determined,9615.0,
4478,,,A,1,Intermediate,,3918,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,The plasma half-life in dogs,9615.0,
4479,,,A,1,Intermediate,,16452,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,9615.0,
4480,,,A,1,Intermediate,,17796,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog,9615.0,
4481,,,A,1,Intermediate,In vivo,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,9615.0,
4482,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,
4483,,,A,1,Intermediate,In vivo,16456,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,
4484,,,A,1,Expert,In vivo,6113,Mustela putorius furo,BAO_0000218,,,,,50506,1,Cmax in ferrets after 30 mg/kg oral dose,9669.0,
4485,,,F,1,Expert,In vivo,6113,Mustela putorius furo,BAO_0000218,,,,,50506,1,Emesis in ferrets at 30 mg/kg oral dose,9669.0,
4486,,,A,0,Autocuration,In vivo,17796,Macaca fascicularis,BAO_0000218,,,,,22224,1,Bioavailability in cynomolgus monkey,9541.0,
4487,,,A,1,Intermediate,In vivo,17796,Macaca fascicularis,BAO_0000218,,,,,100710,1,Volume of distribution in cynomolgus,9541.0,
4488,,,A,0,Autocuration,,5308,Cavia porcellus,BAO_0000218,,Plasma,,,22224,1,AUC tested in guinea pig when 3 mg/kg dose was given perorally,10141.0,
4489,,,A,0,Autocuration,,4877,Cavia porcellus,BAO_0000218,,,,,22224,1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,10141.0,
4490,,,A,0,Autocuration,,4876,Cavia porcellus,BAO_0000218,,,,,22224,1,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",10141.0,
4491,,,A,0,Autocuration,In vivo,4878,Cavia porcellus,BAO_0000218,,Plasma,,,22224,1,AUC in guinea pig after 3mg/kg oral dose,10141.0,
4492,,,A,0,Autocuration,In vivo,5308,Cavia porcellus,BAO_0000218,,,,,22224,1,Bioavailability in guinea pig was tested,10141.0,
4493,,,A,0,Autocuration,In vivo,4877,Cavia porcellus,BAO_0000218,,,,,22224,1,Tested for oral bioavailability in guinea pig at 5 mg/kg,10141.0,
4494,,,A,0,Autocuration,In vivo,4876,Cavia porcellus,BAO_0000218,,,,,22224,1,Tested for the oral bioavailability of the compound,10141.0,
4495,,,A,0,Autocuration,In vivo,4876,Cavia porcellus,BAO_0000218,,,,,22224,1,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,10141.0,
4496,,,A,0,Autocuration,In vivo,5308,Cavia porcellus,BAO_0000218,,,,,22224,1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,10141.0,
4497,,,A,0,Autocuration,In vivo,4877,Cavia porcellus,BAO_0000218,,Lung,,,22224,1,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,10141.0,
4498,,,A,0,Autocuration,In vivo,4878,Cavia porcellus,BAO_0000218,,,,,22224,1,Cmax in guinea pig after 3mg/kg oral dose,10141.0,
4499,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Blood,,,22224,1,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4500,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Brain,,,22224,1,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4501,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,,,,22224,1,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4502,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Intestine,,,22224,1,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4503,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Kidney,,,22224,1,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4504,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Liver,,,22224,1,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4505,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,,,,22224,1,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4506,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,Spleen,,,22224,1,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,10141.0,
4507,,,A,0,Autocuration,In vivo,14465,Cavia porcellus,BAO_0000218,,,,,22224,1,Elimination T1/2 in Guinea pig (PO dose),10141.0,
4508,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,,,,22224,1,Partition coefficient was measured as -log (counts per min ),10141.0,
4509,,,A,0,Autocuration,In vivo,611,Cavia porcellus,BAO_0000218,,,,,22224,1,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,10141.0,
4510,,,A,0,Autocuration,In vivo,611,Cavia porcellus,BAO_0000218,,,,,22224,1,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,10141.0,
4511,,,A,0,Autocuration,In vivo,14465,Cavia porcellus,BAO_0000218,,,,,22224,1,Elimination T1/2 in Guinea pig (PO dose),10141.0,
4512,,,A,0,Autocuration,In vivo,4876,Cavia porcellus,BAO_0000218,,,,,22224,1,"Tested for the half life period of the compound, intravenously",10141.0,
4513,,,A,0,Autocuration,,5689,Cavia porcellus,BAO_0000019,,,,,22224,1,Half-life was measured,10141.0,
4514,,,A,0,Autocuration,,7515,Cavia porcellus,BAO_0000019,,,,,22224,1,The time required for onset of inotropy after addition of a single dose of delta F75,10141.0,
4515,,,A,0,Autocuration,In vivo,17667,Cavia porcellus,BAO_0000218,,,,,22224,1,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,10141.0,
4516,,,A,0,Autocuration,In vivo,17667,Cavia porcellus,BAO_0000218,,,,,22224,1,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,10141.0,
4517,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,10029.0,
4518,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
4519,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
4520,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
4521,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
4522,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,10090.0,
4523,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
4524,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
4525,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,10090.0,
4526,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,10090.0,
4527,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,10090.0,
4528,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,10090.0,
4529,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,10090.0,
4530,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,10090.0,
4531,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,10090.0,
4532,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,10090.0,
4533,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,10090.0,
4534,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,10090.0,
4535,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,10090.0,
4536,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,10090.0,
4537,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,10090.0,
4538,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,10090.0,
4539,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,10090.0,
4540,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,10090.0,
4541,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,10090.0,
4542,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,10090.0,
4543,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,10090.0,
4544,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,10090.0,
4545,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,10090.0,
4546,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,10090.0,
4547,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,10090.0,
4548,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,10090.0,
4549,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,10090.0,
4550,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,10090.0,
4551,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,10090.0,
4552,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,10090.0,
4553,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,10090.0,
4554,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,10090.0,
4555,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,10090.0,
4556,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,10090.0,
4557,,,A,1,Intermediate,In vivo,3655,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,10090.0,
4558,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,10090.0,
4559,,,F,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,10090.0,
4560,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
4561,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,10090.0,
4562,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,10090.0,
4563,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,10090.0,
4564,,A2780,F,1,Intermediate,,3830,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,9606.0,
4565,,A2780,F,1,Intermediate,,3829,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,9606.0,
4566,,A2780,F,1,Intermediate,,2040,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,9606.0,
4567,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,9606.0,
4568,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,9606.0,
4569,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,9606.0,
4570,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,9606.0,
4571,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,9606.0,
4572,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,9606.0,
4573,,A2780,F,1,Intermediate,,2859,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated for cytotoxicity against A2780 cell line,9606.0,
4574,,A2780,F,1,Intermediate,,5618,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro inhibitory activity against human tumor cell line A2780,9606.0,
4575,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,9606.0,
4576,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,9606.0,
4577,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,9606.0,
4578,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,9606.0,
4579,,A2780,F,1,Intermediate,,2113,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,9606.0,
4580,,A2780,F,1,Intermediate,,2113,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,9606.0,
4581,,A2780,F,1,Intermediate,,16745,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,9606.0,
4582,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000218,478.0,,,,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,
4583,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,9606.0,
4584,,A2780,F,1,Intermediate,,15684,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,9606.0,
4585,,A2780,F,1,Intermediate,,2040,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,9606.0,
4586,,A2780,F,1,Intermediate,,2040,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Relative resistance factor in A2780 cisplatin-resistant line,9606.0,
4587,,A2780,F,1,Intermediate,,16165,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,9606.0,
4588,,A2780,F,1,Intermediate,,16165,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,9606.0,
4589,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000218,478.0,,,,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,
4590,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000218,478.0,,,,81034,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,9606.0,
4591,,A2780,F,1,Intermediate,,3992,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,9606.0,
4592,,A2780,F,1,Intermediate,,10553,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,9606.0,
4593,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,9606.0,
4594,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,9606.0,
4595,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,9606.0,
4596,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,9606.0,
4597,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,9606.0,
4598,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,9606.0,
4599,,A2780,F,1,Intermediate,,15569,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,9606.0,
4600,,A2780,F,1,Intermediate,,17420,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Antiproliferative effect of compound on A2780/DX cell line,9606.0,
4601,,A2780,F,1,Intermediate,,17420,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,9606.0,
4602,,A2780,F,1,Intermediate,,15099,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),9606.0,
4603,,A2780,F,1,Intermediate,,15099,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),9606.0,
4604,,A2780,F,1,Intermediate,,17672,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,9606.0,
4605,,A2780,F,1,Intermediate,,17672,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,9606.0,
4606,,A2780,F,1,Intermediate,,17270,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780ADR cell line,9606.0,
4607,,A2780,F,1,Intermediate,,17270,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780CIS cell line,9606.0,
4608,,A2780,F,1,Intermediate,,5574,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,9606.0,
4609,,A2780,F,1,Intermediate,,2113,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,9606.0,
4610,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,
4611,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,
4612,,,A,0,Autocuration,In vivo,17839,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability of compound in rhesus macaques,9544.0,
4613,,,A,0,Autocuration,In vivo,6821,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4614,,,A,0,Autocuration,In vivo,6078,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability evaluated in monkey,9443.0,
4615,,,A,0,Autocuration,In vivo,6535,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey (dose 1 mg/kg p.o.),9443.0,
4616,,,A,0,Autocuration,In vivo,4449,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in Rhesus monkey,9544.0,
4617,,,A,0,Autocuration,In vivo,6057,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability was calculated in rhesus monkey,9544.0,
4618,,,A,0,Autocuration,In vivo,5922,Macaca fascicularis,BAO_0000218,,,,,22224,1,Oral bioavailability in cynomolgus monkey,9541.0,
4619,,,A,0,Autocuration,In vivo,5940,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4620,,,A,0,Autocuration,In vivo,6265,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4621,,,A,0,Autocuration,In vivo,6265,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey (dose 1 mg/kg),9443.0,
4622,,,A,0,Autocuration,In vivo,6265,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey (dose 5 mg/kg),9443.0,
4623,,,A,0,Autocuration,In vivo,5940,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4624,,,A,0,Autocuration,In vivo,5940,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey,9443.0,
4625,,,A,0,Autocuration,In vivo,4514,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in rhesus monkey,9544.0,
4626,,,A,0,Autocuration,In vivo,5546,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,9544.0,
4627,,,A,0,Autocuration,In vivo,5553,Saimiri sciureus,BAO_0000218,,,,,22224,1,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,9521.0,
4628,,,A,0,Autocuration,In vivo,6641,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9443.0,
4629,,,A,0,Autocuration,In vivo,5472,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in Rhesus monkey,9544.0,
4630,,,A,0,Autocuration,In vivo,5668,Macaca mulatta,BAO_0000218,,,,,22224,1,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),9544.0,
4631,,,A,0,Autocuration,In vivo,5711,monkey,BAO_0000218,,,,,22224,1,Oral bioavailability in monkey at 10 mg/kg of the compound,9443.0,
4632,,,A,0,Autocuration,In vivo,5145,Macaca mulatta,BAO_0000218,,,,,22224,1,Bioavailability in Rhesus monkey,9544.0,
4633,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4634,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4635,,,A,0,Autocuration,In vivo,3249,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,9527.0,
4636,,,A,0,Autocuration,In vivo,3249,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,9527.0,
4637,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Mean residence time was determined after intravenous administration in cynomolgus monkeys,9527.0,
4638,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,
4639,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,
4640,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,
4641,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,
4642,Microsomes,,A,0,Autocuration,,14294,Cercopithecidae,BAO_0000251,,,,,22224,1,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),9527.0,
4643,Microsomes,,A,0,Autocuration,,14294,Cercopithecidae,BAO_0000251,,,,,22224,1,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),9527.0,
4644,Microsomes,,A,0,Autocuration,,14294,Cercopithecidae,BAO_0000251,,,,,22224,1,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),9527.0,
4645,Microsomes,,A,0,Autocuration,,14294,Cercopithecidae,BAO_0000251,,,,,22224,1,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),9527.0,
4646,,,A,0,Autocuration,In vivo,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4647,,,A,0,Autocuration,In vivo,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4648,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,9527.0,
4649,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4650,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4651,,,A,0,Autocuration,,6821,Cercopithecidae,BAO_0000019,,,,,22224,1,Elimination Half-life of compound was determined in monkey,9527.0,
4652,,,A,0,Autocuration,,17267,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life of compound was determined in rhesus monkey,9527.0,
4653,,,A,0,Autocuration,,5819,Cercopithecidae,BAO_0000366,,Plasma,,,22224,1,Half life in monkey plasma,9527.0,
4654,,,A,0,Autocuration,,5819,Cercopithecidae,BAO_0000366,,Plasma,,,22224,1,Half life in monkey plasma; Not detected,9527.0,
4655,,,A,0,Autocuration,In vivo,1916,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,
4656,,,A,0,Autocuration,In vivo,17509,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life 24 hr after 2 mg/kg iv administration in monkeys,9527.0,
4657,,,A,0,Autocuration,,1399,Cercopithecidae,BAO_0000019,,,,,22224,1,Terminal half life of the compound.,9527.0,
4658,,,A,0,Autocuration,In vivo,1916,Cercopithecidae,BAO_0000218,,,,,22224,1,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,
4659,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),9527.0,
4660,,,A,0,Autocuration,,5546,Cercopithecidae,BAO_0000218,,,,,22224,1,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,
4661,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,Urine,,,22224,1,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4662,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,Urine,,,22224,1,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4663,,,A,0,Autocuration,In vivo,4257,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,9527.0,
4664,,,A,0,Autocuration,In vivo,6221,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,9527.0,
4665,,,A,0,Autocuration,In vivo,5472,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution was evaluated in rhesus,9527.0,
4666,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,10029.0,
4667,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,10029.0,
4668,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Bioavailability in hamster was determined,10029.0,
4669,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,10029.0,
4670,,,A,0,Autocuration,In vivo,4727,Cricetulus griseus,BAO_0000218,,,,,22224,1,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,10029.0,
4671,,,A,0,Autocuration,,4727,Cricetulus griseus,BAO_0000221,,Blood,,,22224,1,Half life of compound was determined in hamster blood,10029.0,
4672,,,A,0,Autocuration,,1452,Sus scrofa,BAO_0000019,,,,,22224,1,Michaelis-Menten constant of the compound.,9823.0,
4673,,,A,0,Autocuration,,1452,Sus scrofa,BAO_0000019,,,,,22224,1,Vmax value was measured at 0 uM concentration of silyl ether.,9823.0,
4674,,,A,0,Autocuration,,1452,Sus scrofa,BAO_0000019,,,,,22224,1,Vmax value was measured at 10 uM concentration of silyl ether.,9823.0,
4675,,,A,0,Autocuration,,1452,Sus scrofa,BAO_0000019,,,,,22224,1,Vmax value was measured at 5 uM concentration of silyl ether.,9823.0,
4676,,,B,9,Expert,,11706,Homo sapiens,BAO_0000357,,,,,235,1,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,9606.0,
4677,,,A,0,Autocuration,,1916,Homo sapiens,BAO_0000218,,,,,22224,1,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,
4678,,,A,0,Autocuration,,17791,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),9606.0,
4679,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,,,,22224,1,Active metabolite of ifosfamide determined in humans; A-Active,9606.0,
4680,,,A,0,Autocuration,,6567,Homo sapiens,BAO_0000019,,,,,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,9606.0,
4681,,,A,0,Autocuration,,6567,Homo sapiens,BAO_0000019,,,,,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,9606.0,
4682,,,A,0,Autocuration,,6567,Homo sapiens,BAO_0000019,,,,,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,9606.0,
4683,,,A,0,Autocuration,,6567,Homo sapiens,BAO_0000019,,,,,22224,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,9606.0,
4684,,,A,0,Autocuration,,17791,Homo sapiens,BAO_0000218,,,,,22224,1,Compound was evaluated for oral bioavailability in human,9606.0,
4685,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Metabolite of ifosfamide determined in urine; NF-Not found,9606.0,
4686,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),9606.0,
4687,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,9606.0,
4688,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,9606.0,
4689,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,9606.0,
4690,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,9606.0,
4691,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),9606.0,
4692,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent of compound in healthy individuals (Group D),9606.0,
4693,Microsomes,,A,0,Autocuration,,4397,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,9606.0,
4694,,,A,0,Autocuration,,17409,Homo sapiens,BAO_0000019,,,,,22224,1,Binding towards human plasma protein at 10 uM,9606.0,
4695,,,A,0,Autocuration,,17409,Homo sapiens,BAO_0000019,,,,,22224,1,Binding towards human plasma protein at 100 uM,9606.0,
4696,,,A,0,Autocuration,,17176,Homo sapiens,BAO_0000019,,,,,22224,1,Human plasma protein binding activity was determined,9606.0,
4697,,,A,0,Autocuration,,15444,Homo sapiens,BAO_0000019,,,,,22224,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),9606.0,
4698,,,A,0,Autocuration,,17267,Homo sapiens,BAO_0000019,,,,,22224,1,Percent binding of compound towards human plasma protein was determined,9606.0,
4699,Microsomes,,A,0,Autocuration,In vitro,5944,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Plasma clearance in human liver microsomes,9606.0,
4700,Microsomes,,A,0,Autocuration,In vitro,5668,Homo sapiens,BAO_0000251,,Liver,,,22224,1,In vitro intrinsic clearance in human liver microsome,9606.0,
4701,Microsomes,,A,0,Autocuration,In vitro,5669,Homo sapiens,BAO_0000251,,Liver,,,22224,1,In vitro intrinsic clearance in human liver microsome,9606.0,
4702,Microsomes,,A,0,Autocuration,In vitro,5041,Homo sapiens,BAO_0000251,,,,,22224,1,In vitro microsome metabolism clearance in human was determined,9606.0,
4703,Microsomes,,A,0,Autocuration,In vitro,5041,Homo sapiens,BAO_0000251,,,,,22224,1,In vitro microsome metabolism clearance in human was determined; High,9606.0,
4704,Microsomes,,A,0,Autocuration,In vitro,5041,Homo sapiens,BAO_0000251,,,,,22224,1,In vitro microsome metabolism clearance in human was determined; ND denotes no data,9606.0,
4705,Microsomes,,A,0,Autocuration,In vitro,5676,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Pharmacokinetic property (clearance) in human liver microsome,9606.0,
4706,Microsomes,,A,0,Autocuration,In vitro,5944,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Plasma clearance in human liver microsomes,9606.0,
4707,Microsomes,,A,0,Autocuration,In vitro,17538,Homo sapiens,BAO_0000251,,Liver,,,22224,1,In vitro clearance in human liver microsomes,9606.0,
4708,Microsomes,,A,0,Autocuration,In vitro,6331,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Intrinsic clearance in human liver microsomes was determined,9606.0,
4709,Microsomes,,A,0,Autocuration,In vitro,5948,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Intrinsic clearance in human liver microsomes was determined,9606.0,
4710,,,A,0,Autocuration,In vivo,5965,Homo sapiens,BAO_0000218,,,,,22224,1,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,9606.0,
4711,,,A,0,Autocuration,In vivo,1916,Homo sapiens,BAO_0000218,,,,,22224,1,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,
4712,,,A,0,Autocuration,,5965,Homo sapiens,BAO_0000218,,,,,22224,1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,9606.0,
4713,,,A,0,Autocuration,,1299,Homo sapiens,BAO_0000019,,,,,22224,1,Stability in human plasma 2 hr after incubation expressed as percent concentration,9606.0,
4714,,,A,0,Autocuration,,1299,Homo sapiens,BAO_0000019,,,,,22224,1,Stability in human plasma 4 hr after incubation expressed as percent concentration,9606.0,
4715,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4716,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4717,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4718,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4719,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,10090.0,
4720,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,10090.0,
4721,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,10090.0,
4722,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,10090.0,
4723,,,A,1,Intermediate,,14294,Mus musculus,BAO_0000218,,,,,50594,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),10090.0,
4724,,,A,1,Intermediate,,14294,Mus musculus,BAO_0000218,,,,,50594,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),10090.0,
4725,,,A,1,Intermediate,,14294,Mus musculus,BAO_0000218,,,,,50594,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),10090.0,
4726,,,A,1,Intermediate,,6251,Mus musculus,BAO_0000218,,Liver,,,50594,1,In vitro metabolic potential in mouse liver microsomes,10090.0,
4727,,,A,1,Intermediate,,17582,Mus musculus,BAO_0000218,,,,,50594,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,10090.0,
4728,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,Adrenal gland,,,50594,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),10090.0,
4729,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,Brain,,,50594,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,10090.0,
4730,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,Brain,,,50594,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,10090.0,
4731,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,,,,50594,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),10090.0,
4732,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),10090.0,
4733,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,,,,50594,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),10090.0,
4734,,,A,1,Intermediate,,5288,Mus musculus,BAO_0000218,,,,,50594,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,10090.0,
4735,,,A,1,Intermediate,,2717,Mus musculus,BAO_0000218,,Serum,,,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,10090.0,
4736,,,A,1,Intermediate,,2717,Mus musculus,BAO_0000218,,Serum,,,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,10090.0,
4737,,,A,1,Intermediate,,2717,Mus musculus,BAO_0000218,,Serum,,,50594,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,10090.0,
4738,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,10090.0,
4739,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,10090.0,
4740,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,10090.0,
4741,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intraperitoneal administration in mice at 18 uM/kg,10090.0,
4742,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intraperitoneal administration in mice at 23 uM/kg,10090.0,
4743,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intraperitoneal administration in mice at 25 uM/kg,10090.0,
4744,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intraperitoneal administration in mice at 26 uM/kg,10090.0,
4745,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intravenous administration in mice at 23 uM/kg,10090.0,
4746,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Half life after intravenous administration in mice at 24 uM/kg,10090.0,
4747,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,10090.0,
4748,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,10090.0,
4749,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,10090.0,
4750,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),10090.0,
4751,,,A,1,Intermediate,In vivo,4890,Mus musculus,BAO_0000218,,,,,50594,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",10090.0,
4752,,,A,1,Intermediate,In vivo,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,10090.0,
4753,,,A,1,Intermediate,In vivo,17837,Mus musculus,BAO_0000218,,Blood,,,50594,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,
4754,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
4755,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Half life at a dose of 10 mg/kg peroral administration in mice.,10090.0,
4756,,,A,1,Intermediate,,6619,Mus musculus,BAO_0000218,,,,,50594,1,Half life in ob/ob mice,10090.0,
4757,,,A,1,Intermediate,In vivo,4066,Mus musculus,BAO_0000218,,,,,50594,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,10090.0,
4758,,,A,1,Intermediate,,4239,Mus musculus,BAO_0000218,,,,,50594,1,Half-life was measured in mouse,10090.0,
4759,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,10090.0,
4760,,,A,1,Intermediate,,8999,Mus musculus,BAO_0000218,,,,,50594,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,10090.0,
4761,,,A,1,Intermediate,,8999,Mus musculus,BAO_0000218,,,,,50594,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,10090.0,
4762,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Brain,,,50594,1,T2 in brain of mice at the oral dose of 50 mg/kg,10090.0,
4763,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Kidney,,,50594,1,T2 in kidney of mice at the oral dose of 50 mg/kg,10090.0,
4764,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Liver,,,50594,1,T2 in liver of mice at the oral dose of 50 mg/kg,10090.0,
4765,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Lung,,,50594,1,T2 in lungs of mice at the oral dose of 50 mg/kg,10090.0,
4766,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Spleen,,,50594,1,T2 in spleen of mice at the oral dose of 50 mg/kg,10090.0,
4767,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,10090.0,
4768,,,A,1,Intermediate,In vivo,4890,Mus musculus,BAO_0000218,,,,,50594,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",10090.0,
4769,,,A,1,Intermediate,In vivo,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,10090.0,
4770,,,A,1,Intermediate,In vivo,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,10090.0,
4771,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,10090.0,
4772,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,
4773,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",9606.0,
4774,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,
4775,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,
4776,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,
4777,,A2780,F,1,Intermediate,,16913,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",9606.0,
4778,,A2780,F,1,Intermediate,,17270,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780TAX cell line,9606.0,
4779,,A2780cisR,F,1,Intermediate,,5618,Homo sapiens,BAO_0000219,481.0,,,,80017,1,In vitro inhibitory activity against human tumor cell line A2780cis,9606.0,
4780,,A2780,F,1,Expert,,17777,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,9606.0,
4781,,A2780cisR,F,1,Intermediate,,16112,Homo sapiens,BAO_0000219,481.0,,,,80017,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,9606.0,
4782,,A2780cisR,F,1,Intermediate,,15748,Homo sapiens,BAO_0000219,481.0,,,,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),9606.0,
4783,,A2780,F,1,Intermediate,,6633,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,9606.0,
4784,,A2780,F,1,Intermediate,,16930,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,9606.0,
4785,,A2780,F,1,Intermediate,,17496,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,9606.0,
4786,,A2780,F,1,Expert,,12989,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro antitumor activity against A2780cisR cell line.,9606.0,
4787,,A2780,F,1,Intermediate,,4840,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),9606.0,
4788,,A2780,F,1,Expert,,12989,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,9606.0,
4789,,A2780cisR,F,1,Intermediate,,16745,Homo sapiens,BAO_0000219,481.0,,,,80017,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,9606.0,
4790,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,9606.0,
4791,,,B,9,Expert,,16547,Rattus norvegicus,BAO_0000019,,,,,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,10116.0,
4792,,,F,8,Expert,,16547,,BAO_0000019,,,,,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,
4793,,,F,9,Expert,,16547,Rattus norvegicus,BAO_0000019,,,,,11736,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),10116.0,
4794,,HEK293,F,9,Expert,,15856,Homo sapiens,BAO_0000219,722.0,,,,278,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,9606.0,
4795,,HEK293,F,9,Expert,,15856,Homo sapiens,BAO_0000219,722.0,,,,278,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,9606.0,
4796,,,B,9,Expert,,16547,Mus musculus,BAO_0000019,,,,,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,10090.0,
4797,,,F,8,Expert,,16547,,BAO_0000019,,,,,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,
4798,,,F,9,Expert,,16547,Mus musculus,BAO_0000019,,,,,11831,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),10090.0,
4799,,,B,8,Expert,,17402,,BAO_0000357,,,,,280,1,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,
4800,,T-cells,F,0,Autocuration,,11746,Homo sapiens,BAO_0000219,574.0,,,,22226,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),9606.0,
4801,,T-cells,F,0,Autocuration,,11746,Homo sapiens,BAO_0000219,574.0,,,,22226,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,9606.0,
4802,,A-375,F,1,Intermediate,,5455,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,9606.0,
4803,,A-375,F,1,Intermediate,,2068,Homo sapiens,BAO_0000219,455.0,,,,80018,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,9606.0,
4804,,A-375,F,1,Intermediate,,2683,Homo sapiens,BAO_0000219,455.0,,,,80018,1,In vitro antitumor activity against A375cell line extracted form melanoma,9606.0,
4805,,A-375,F,1,Expert,,15313,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Inhibition of cell growth in (A375) melan cell line,9606.0,
4806,,A-375,F,1,Intermediate,,13739,Homo sapiens,BAO_0000219,455.0,,,,80018,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,9606.0,
4807,,A-375,F,1,Intermediate,,13739,Homo sapiens,BAO_0000219,455.0,,,,80018,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,9606.0,
4808,,A-375,F,1,Intermediate,,14750,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,9606.0,
4809,,A-427,F,1,Intermediate,,14777,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Antiproliferative activity measured against A427 human lung carcinoma,9606.0,
4810,,A-427,F,1,Intermediate,,14777,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Antiproliferative activity measured against A427 human lung carcinoma,9606.0,
4811,,A-427,F,1,Intermediate,,17672,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,9606.0,
4812,,A-427,F,1,Intermediate,,14368,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Inhibition of large cell lung carcinoma (A427),9606.0,
4813,,A-427,F,1,Intermediate,,14368,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,9606.0,
4814,,A-427,F,1,Intermediate,,13866,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,9606.0,
4815,,A-427,F,1,Intermediate,,2545,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Inhibitory concentration in human lung carcinoma A427 cell line,9606.0,
4816,,A-427,F,1,Intermediate,,2545,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,9606.0,
4817,,,A,0,Autocuration,In vivo,6062,Cercopithecidae,BAO_0000218,,,,,22224,1,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,9527.0,
4818,,,A,0,Autocuration,In vivo,4578,Cercopithecidae,BAO_0000218,,,,,22224,1,Tested for volume of distribution upon iv administration to african green monkey,9527.0,
4819,,,A,0,Autocuration,In vivo,17592,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution in monkey,9527.0,
4820,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,,,,22224,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,
4821,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,,,,22224,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,9544.0,
4822,,,A,0,Autocuration,In vivo,5922,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic property(Vdss) in cynomolgus monkey,9527.0,
4823,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The distribution volume after intravenous administration in cynomolgus monkeys,9527.0,
4824,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,
4825,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,
4826,,,A,0,Autocuration,In vivo,6057,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume displacement was calculated in rhesus monkey,9527.0,
4827,,,A,0,Autocuration,In vivo,5145,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution in steady state was determined in rhesus monkey,9527.0,
4828,,,A,0,Autocuration,In vivo,6821,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution of compound was determined in monkey,9527.0,
4829,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,
4830,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,
4831,,,A,0,Autocuration,In vivo,6641,Cercopithecidae,BAO_0000218,,,,,22224,1,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,
4832,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,
4833,,,A,0,Autocuration,In vivo,6535,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume distribution in monkey after administration of 1 mg/kg iv,9527.0,
4834,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,
4835,,,A,0,Autocuration,In vivo,6062,Cercopithecidae,BAO_0000218,,,,,22224,1,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,9527.0,
4836,,,A,0,Autocuration,In vivo,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
4837,,,A,0,Autocuration,In vivo,4578,Cercopithecidae,BAO_0000218,,,,,22224,1,Oral systemic bioavailability upon iv administration to african green monkey,9527.0,
4838,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,
4839,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Baboon plasma free fraction. ,9527.0,
4840,,,A,0,Autocuration,,6057,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under the curve was calculated in rhesus monkey after iv administration,9527.0,
4841,,,A,0,Autocuration,,6057,Cercopithecidae,BAO_0000019,,,,,22224,1,Area under the curve was calculated in rhesus monkey after peroral administration,9527.0,
4842,,,A,0,Autocuration,,17853,Cercopithecidae,BAO_0000019,,,,,22224,1,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,9527.0,
4843,,,A,0,Autocuration,In vivo,5302,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period in monkey after 5 mg/kg dose,9527.0,
4844,,,A,0,Autocuration,In vivo,4257,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose,9527.0,
4845,,,A,0,Autocuration,In vivo,4257,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,9527.0,
4846,,,A,0,Autocuration,In vivo,13501,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,9527.0,
4847,,,A,0,Autocuration,In vivo,5394,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,9527.0,
4848,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,
4849,,,A,0,Autocuration,,3341,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound was evaluated for terminal half life in monkey,9527.0,
4850,,,A,0,Autocuration,In vivo,3045,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,9527.0,
4851,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,Plasma,,,22224,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,
4852,,,A,0,Autocuration,,4847,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life of compound was determined in squirrel monkey,9527.0,
4853,,,A,0,Autocuration,In vivo,4256,Macaca fascicularis,BAO_0000218,,,,,22224,1,Half life after iv administration in cynomolgus monkey,9541.0,
4854,,,A,0,Autocuration,In vivo,6535,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Half life in monkey plasma after administration of 1 mg/kg iv,9527.0,
4855,,,A,0,Autocuration,,6057,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life was calculated in rhesus monkey,9527.0,
4856,,,A,0,Autocuration,,17592,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life in monkey,9527.0,
4857,,,A,0,Autocuration,In vivo,6641,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),9527.0,
4858,,,A,0,Autocuration,,5472,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life was evaluated in rhesus,9527.0,
4859,,,A,0,Autocuration,In vivo,6221,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period after oral administration (2.5 mg/kg) in monkey was determined,9527.0,
4860,,,A,0,Autocuration,In vivo,5668,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period was determine after peroral administration at 10 mpk in Rhesus,9527.0,
4861,,,A,0,Autocuration,In vivo,4809,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),9527.0,
4862,,,A,0,Autocuration,In vivo,5546,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,9527.0,
4863,,,A,0,Autocuration,In vivo,5553,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,9527.0,
4864,,,A,0,Autocuration,,6078,Cercopithecidae,BAO_0000019,,,,,22224,1,Half-life was calculated in monkey,9527.0,
4865,,,A,0,Autocuration,,5147,Cercopithecidae,BAO_0000019,,,,,22224,1,Half-life in Squirrel monkey,9527.0,
4866,,,A,0,Autocuration,,5145,Cercopithecidae,BAO_0000019,,,,,22224,1,Half-life in rhesus monkey,9527.0,
4867,,,A,0,Autocuration,In vivo,6062,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life was measured in monkey after an iv dose of 1 mg/kg,9527.0,
4868,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life period after intravenous administration in cynomolgus monkeys,9527.0,
4869,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life period after oral administration in cynomolgus monkeys,9527.0,
4870,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,9527.0,
4871,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4872,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4873,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4874,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,9606.0,
4875,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,9606.0,
4876,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,9606.0,
4877,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,9606.0,
4878,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,9606.0,
4879,,,A,0,Autocuration,In vivo,1916,Homo sapiens,BAO_0000218,,,,,22224,1,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,9606.0,
4880,,,A,0,Autocuration,In vivo,16643,Homo sapiens,BAO_0000218,,,,,22224,1,Oral bioavailability in human,9606.0,
4881,,,A,0,Autocuration,,17248,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was tested for human plasma protein binding,9606.0,
4882,,,A,0,Autocuration,,17248,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was tested for human plasma protein binding; Not determined,9606.0,
4883,,,A,0,Autocuration,,6241,Homo sapiens,BAO_0000019,,,,,22224,1,Protein binding activity of compound in human plasma; % Free,9606.0,
4884,,,A,0,Autocuration,,17716,Homo sapiens,BAO_0000019,,,,,22224,1,Unbound fraction (plasma),9606.0,
4885,,,A,0,Autocuration,,17605,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life for the hydrolysis of compound in human blood serum,9606.0,
4886,,,A,0,Autocuration,,17625,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life period in human plasma using phosphate buffer (0.08 M),9606.0,
4887,,,A,0,Autocuration,,17625,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life period in human plasma using phosphate buffer (0.1 M),9606.0,
4888,,,A,0,Autocuration,,17747,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life in human plasma was determined,9606.0,
4889,,,A,0,Autocuration,,15613,Homo sapiens,BAO_0000019,,,,,22224,1,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,9606.0,
4890,,,A,0,Autocuration,,354,Homo sapiens,BAO_0000019,,,,,22224,1,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),9606.0,
4891,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000019,,,,,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",9606.0,
4892,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000019,,,,,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",9606.0,
4893,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000019,,,,,22224,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",9606.0,
4894,,,A,0,Autocuration,,17599,Homo sapiens,BAO_0000019,,,,,22224,1,Partition coefficient (logP),9606.0,
4895,,,A,0,Autocuration,,5486,Homo sapiens,BAO_0000019,,,,,22224,1,In vitro metabolic stability in human was measured as pmol/min/mg/protein,9606.0,
4896,Microsomes,,A,0,Autocuration,,5600,Homo sapiens,BAO_0000251,,,,,22224,1,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,9606.0,
4897,,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),9606.0,
4898,,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),9606.0,
4899,,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),9606.0,
4900,Microsomes,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000251,,,,,22224,1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),9606.0,
4901,Microsomes,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000251,,,,,22224,1,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),9606.0,
4902,Microsomes,,A,0,Autocuration,,14294,Homo sapiens,BAO_0000251,,,,,22224,1,Metabolism of compound in human microsomes; Trace,9606.0,
4903,Microsomes,,A,0,Autocuration,,6260,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,9606.0,
4904,Microsomes,,A,0,Autocuration,,6187,Homo sapiens,BAO_0000251,,,,,22224,1,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,9606.0,
4905,Microsomes,,A,0,Autocuration,,6251,Homo sapiens,BAO_0000251,,Liver,,,22224,1,In vitro metabolic potential in human liver microsomes,9606.0,
4906,,,A,0,Autocuration,,3246,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,9606.0,
4907,,,A,0,Autocuration,,17313,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for human plasma protein binding of the compound; Not tested,9606.0,
4908,,,A,0,Autocuration,,6227,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was tested for percent protein binding (PB) in human,9606.0,
4909,,,A,0,Autocuration,,5530,Homo sapiens,BAO_0000019,,Plasma,,,22224,1,Protein binding in human plasma,9606.0,
4910,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Permeability coefficient (B to A) in Caco-2 cell,9606.0,
4911,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,9606.0,
4912,,,A,0,Autocuration,,2774,Homo sapiens,BAO_0000019,,,,,22224,1,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),9606.0,
4913,,,A,0,Autocuration,,16643,Homo sapiens,BAO_0000019,,,,,22224,1,In vitro rate of absorption observed as Caco-2 permeability in humans,9606.0,
4914,,Caco-2,A,0,Autocuration,,17582,Homo sapiens,BAO_0000219,495.0,,,,22224,1,Cellular permeability of compound was determined in Caco-2 cells; High,9606.0,
4915,,Caco-2,A,0,Autocuration,,6838,Homo sapiens,BAO_0000219,495.0,,,,22224,1,Permeability in Caco-2 cells of compound,9606.0,
4916,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Permeability coefficient (A to B) in Caco-2 cell,9606.0,
4917,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Permeability coefficient (B to A) in Caco-2 cell,9606.0,
4918,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Permeability coefficient (Papp) (Caco-2 cell monolayer),9606.0,
4919,,,A,0,Autocuration,,2146,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,9606.0,
4920,,,A,0,Autocuration,,4514,Homo sapiens,BAO_0000019,,,,,22224,1,Compound was tested for protein binding in human plasma,9606.0,
4921,,,A,0,Autocuration,,6108,Homo sapiens,BAO_0000019,,,,,22224,1,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,9606.0,
4922,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,9606.0,
4923,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,10090.0,
4924,,,A,1,Intermediate,In vivo,3277,Mus musculus,BAO_0000218,,,,,50594,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,
4925,,,A,1,Intermediate,In vivo,3802,Mus musculus,BAO_0000218,,,,,50594,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,10090.0,
4926,,,A,1,Intermediate,In vivo,2862,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,10090.0,
4927,,,A,1,Intermediate,In vivo,6348,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,
4928,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,10090.0,
4929,,,A,1,Intermediate,In vivo,5781,Mus musculus,BAO_0000218,,,,,50594,1,Tmax after oral administration at 30 mg/kg in ICR mouse,10090.0,
4930,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax after peroral administration in mice at 2.4 uM/kg,10090.0,
4931,,,A,1,Intermediate,In vivo,4066,Mus musculus,BAO_0000218,,,,,50594,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,10090.0,
4932,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Brain,,,50594,1,Tmax in brain of mice at the oral dose of 50 mg/kg,10090.0,
4933,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,10090.0,
4934,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Liver,,,50594,1,Tmax in liver of mice at the oral dose of 50 mg/kg,10090.0,
4935,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Lung,,,50594,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,10090.0,
4936,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax in mice at 18 uM/kg i.p. administration,10090.0,
4937,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax in mice at 23 uM/kg i.v. administration,10090.0,
4938,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax in mice at 25 uM/kg i.p. administration,10090.0,
4939,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Tmax in mice at 26 uM/kg i.p. administration,10090.0,
4940,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,10090.0,
4941,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
4942,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,10090.0,
4943,,,A,1,Intermediate,,5951,Mus musculus,BAO_0000218,,,,,50594,1,Tmax value in IRC mice,10090.0,
4944,,,A,1,Intermediate,In vivo,5506,Mus musculus,BAO_0000218,,,,,50594,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,
4945,,,A,1,Intermediate,In vivo,5506,Mus musculus,BAO_0000218,,,,,50594,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,
4946,,,A,1,Intermediate,,429,Mus musculus,BAO_0000218,,Urine,,,50594,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),10090.0,
4947,,,A,1,Intermediate,,429,Mus musculus,BAO_0000218,,Urine,,,50594,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),10090.0,
4948,,,A,1,Intermediate,,4066,Mus musculus,BAO_0000218,,Urine,,,50594,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),10090.0,
4949,,,A,1,Intermediate,,17734,Mus musculus,BAO_0000218,,,,,50594,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,
4950,,,A,1,Intermediate,,17734,Mus musculus,BAO_0000218,,,,,50594,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,
4951,,,A,1,Intermediate,In vivo,6062,Mus musculus,BAO_0000218,,,,,50594,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,10090.0,
4952,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,10090.0,
4953,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,10090.0,
4954,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,
4955,,,A,1,Intermediate,In vivo,5980,Mus musculus,BAO_0000218,,,,,50594,1,Vd in mice,10090.0,
4956,,,A,1,Intermediate,In vivo,17592,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution in mouse,10090.0,
4957,,,A,1,Intermediate,In vivo,6348,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,
4958,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,10090.0,
4959,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,10090.0,
4960,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,10090.0,
4961,,,A,1,Intermediate,In vivo,4239,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (vdss) was measured in mouse,10090.0,
4962,,,A,1,Intermediate,In vivo,2862,Mus musculus,BAO_0000218,,,,,50594,1,Value distribution upon iv administration in mouse,10090.0,
4963,,,A,1,Intermediate,In vivo,17734,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,10090.0,
4964,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution was evaluated in mice after intravenous administration,10090.0,
4965,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution was evaluated in mice after oral administration,10090.0,
4966,,,A,1,Intermediate,In vivo,17837,Mus musculus,BAO_0000218,,,,,50594,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,
4967,,,A,1,Intermediate,In vivo,5727,Mus musculus,BAO_0000218,,,,,50594,1,Steady state volume of distribution was determined in mice,10090.0,
4968,,,A,1,Intermediate,In vivo,17852,Mus musculus,BAO_0000218,,,,,50594,1,Volume distribution (steady state) of compound was determined in mouse,10090.0,
4969,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,10090.0,
4970,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
4971,,,A,1,Intermediate,In vivo,6062,Mus musculus,BAO_0000218,,,,,50594,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,10090.0,
4972,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of compound (oxidized form) in in kidney tissue,10090.0,
4973,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,
4974,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,
4975,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
4976,,A-427,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,9606.0,
4977,,A-431,F,1,Expert,,16597,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,9606.0,
4978,,A-431,F,1,Expert,,16062,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,9606.0,
4979,,A-431,F,1,Expert,,16062,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,9606.0,
4980,,A-431,F,1,Expert,,16958,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,9606.0,
4981,,A-431,F,1,Expert,,6700,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of A431 human carcinoma cell proliferation,9606.0,
4982,,A-431,F,1,Expert,,17226,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,9606.0,
4983,,A-431,F,1,Intermediate,,6828,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,9606.0,
4984,,A-431,F,1,Intermediate,,12314,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro cytotoxicity against epidermoid carcinoma cell line,9606.0,
4985,,A-431,F,9,Expert,,13412,Homo sapiens,BAO_0000218,500.0,,,,9,1,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9606.0,
4986,,A-431,F,1,Intermediate,,13299,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,9606.0,
4987,,A-431,F,1,Intermediate,,17420,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,9606.0,
4988,,A-431,F,1,Intermediate,,13678,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,9606.0,
4989,,A-431,F,8,Expert,,14171,,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,
4990,,A-431,F,1,Expert,,6333,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Tested for antiproliferative activity against human A431 cells,9606.0,
4991,,A-431,F,9,Expert,,2356,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9606.0,
4992,,A-431,F,1,Expert,,15578,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,9606.0,
4993,,A-431,F,1,Expert,,5126,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of A431 cell proliferation,9606.0,
4994,,A-431,F,1,Expert,,6844,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,9606.0,
4995,,A-431,F,1,Expert,,6844,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),9606.0,
4996,,A-431,F,1,Intermediate,,4925,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,9606.0,
4997,,A-431,F,1,Intermediate,,4925,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,9606.0,
4998,,A-431,F,1,Intermediate,,13978,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,9606.0,
4999,,A-431,F,1,Intermediate,,16786,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,9606.0,
5000,,A-431,F,8,Expert,,13412,,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,
5001,,A-431,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,500.0,,,,80852,1,In vivo antiproliferative activity against A431 cell line,9606.0,
5002,,A-431,F,9,Expert,,12751,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9606.0,
5003,,A-431,F,1,Expert,,12380,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,9606.0,
5004,,A-431,F,9,Expert,,4959,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9606.0,
5005,,A-431,F,1,Intermediate,,6333,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),9606.0,
5006,,A-431,F,1,Intermediate,,6333,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),9606.0,
5007,,A-431,F,1,Intermediate,,6333,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),9606.0,
5008,,,F,9,Expert,,5296,Homo sapiens,BAO_0000019,,,,,9,1,Inhibition of EGFR overexpressing A431 cell proliferation,9606.0,
5009,,A-431,F,1,Expert,,12624,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibition of A431 cell proliferation,9606.0,
5010,,A-431,F,9,Expert,,14926,Homo sapiens,BAO_0000219,500.0,,,,9,1,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9606.0,
5011,,A-431,F,9,Expert,,14926,Homo sapiens,BAO_0000219,500.0,,,,9,1,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9606.0,
5012,,A-431,F,8,Expert,,14926,,BAO_0000219,500.0,,,,9,1,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,
5013,,A-431,F,1,Intermediate,,15144,Homo sapiens,BAO_0000219,500.0,,,,80852,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,9606.0,
5014,,A-431,F,1,Intermediate,,15144,Homo sapiens,BAO_0000219,500.0,,,,80852,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,9606.0,
5015,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,9606.0,
5016,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,9606.0,
5017,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,9606.0,
5018,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,9606.0,
5019,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,9606.0,
5020,,,A,0,Autocuration,,5922,Cercopithecidae,BAO_0000019,,,,,22224,1,Half-life period in cynomolgus monkey,9527.0,
5021,,,A,0,Autocuration,In vitro,1116,Cercopithecidae,BAO_0000366,,Plasma,,,22224,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",9527.0,
5022,,,A,0,Autocuration,In vivo,17853,Cercopithecidae,BAO_0000218,,,,,22224,1,Longer half-life in monkey (i.v.) at 0.5 mpk,9527.0,
5023,,,A,0,Autocuration,,993,Cercopithecidae,BAO_0000366,,Plasma,,,22224,1,Plasma half life in monkey,9527.0,
5024,,,A,0,Autocuration,,4514,Cercopithecidae,BAO_0000366,,Plasma,,,22224,1,Plasma half-life in rhesus monkey,9527.0,
5025,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),9527.0,
5026,,,A,0,Autocuration,In vivo,5334,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),9527.0,
5027,,,A,0,Autocuration,In vivo,4578,Cercopithecidae,BAO_0000218,,,,,22224,1,Tested for half life upon iv administration to african green monkey,9527.0,
5028,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,
5029,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,9527.0,
5030,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,9527.0,
5031,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The time for peak concentration value after oral administration in cynomolgus monkeys,9527.0,
5032,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,9527.0,
5033,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,9527.0,
5034,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,9527.0,
5035,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,9527.0,
5036,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,9527.0,
5037,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,9527.0,
5038,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,9527.0,
5039,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,9527.0,
5040,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,9527.0,
5041,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,9527.0,
5042,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,9527.0,
5043,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,9527.0,
5044,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,9527.0,
5045,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,9527.0,
5046,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,9527.0,
5047,,,A,0,Autocuration,,11271,Cercopithecidae,BAO_0000019,,,,,22224,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,9527.0,
5048,,,A,1,Intermediate,In vivo,5809,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),10116.0,
5049,,,A,1,Intermediate,In vivo,17720,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,10116.0,
5050,,,A,1,Intermediate,,3546,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,AUC value in rat after IV administration at a dose of 10 mg/kg,10116.0,
5051,,,A,1,Intermediate,,3546,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,AUC value in rat after oral administration at a dose of 10 mg/kg,10116.0,
5052,,,A,1,Intermediate,In vivo,3546,Rattus norvegicus,BAO_0000218,,,,,50597,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,10116.0,
5053,,,A,1,Intermediate,In vivo,3546,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,10116.0,
5054,,,A,1,Intermediate,In vivo,3546,Rattus norvegicus,BAO_0000218,,,,,50597,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,10116.0,
5055,,,A,1,Intermediate,,3546,Rattus norvegicus,BAO_0000218,,,,,50597,1,Vc value in rat after IV administration at a dose of 10 mg/kg,10116.0,
5056,,,A,1,Intermediate,In vivo,3546,Rattus norvegicus,BAO_0000218,,,,,50597,1,Half life period in rat after IV administration at a dose of 10 mg/kg,10116.0,
5057,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,9557.0,
5058,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),9557.0,
5059,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),9557.0,
5060,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,9557.0,
5061,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,9557.0,
5062,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,9557.0,
5063,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,9557.0,
5064,,,A,0,Autocuration,,10625,Papio hamadryas,BAO_0000019,,,,,22224,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,9557.0,
5065,,,A,0,Autocuration,,3510,beagle,BAO_0000019,,,,,22224,1,Area under curve after 1 mpk peroral administration to beagles,9615.0,
5066,,,A,0,Autocuration,,3510,beagle,BAO_0000019,,,,,22224,1,Area under curve after 2 mpk peroral administration to beagles,9615.0,
5067,,,A,0,Autocuration,In vivo,3510,beagle,BAO_0000218,,,,,22224,1,Cmax value after 1 mpk peroral administration to beagles,9615.0,
5068,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,9606.0,
5069,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,9606.0,
5070,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,9606.0,
5071,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,9606.0,
5072,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,9606.0,
5073,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,9606.0,
5074,,,A,0,Autocuration,,7766,Homo sapiens,BAO_0000019,,Urine,,,22224,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,9606.0,
5075,Microsomes,,A,0,Autocuration,,16643,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Metabolic stability observed at 30 min after administration in human liver microsomes,9606.0,
5076,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,9606.0,
5077,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,9606.0,
5078,,,A,0,Autocuration,,6852,Homo sapiens,BAO_0000019,,,,,22224,1,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,9606.0,
5079,Microsomes,,A,0,Autocuration,,6567,Homo sapiens,BAO_0000251,,Liver,,,22224,1,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",9606.0,
5080,,,A,0,Autocuration,,6570,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolic stability (% remaining at 30 mins) in human S9.,9606.0,
5081,,,A,0,Autocuration,,6570,Homo sapiens,BAO_0000019,,,,,22224,1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,9606.0,
5082,Microsomes,,A,0,Autocuration,,5237,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes,9606.0,
5083,Microsomes,,A,0,Autocuration,,5237,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,9606.0,
5084,Microsomes,,A,0,Autocuration,,5237,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,9606.0,
5085,,,A,0,Autocuration,,5202,Homo sapiens,BAO_0000218,,,,,22224,1,First pass metabolism and metabolic bioavailability using human hepatic microsomes,9606.0,
5086,,,A,0,Autocuration,,5481,Homo sapiens,BAO_0000019,,,,,22224,1,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,9606.0,
5087,,,A,0,Autocuration,,5481,Homo sapiens,BAO_0000019,,,,,22224,1,Percent remaining in human plasma after incubation for 60 min at 37 C.,9606.0,
5088,,,A,0,Autocuration,,3956,Homo sapiens,BAO_0000019,,,,,22224,1,The percent remaining in human plasma after 30 min was determined,9606.0,
5089,,,A,0,Autocuration,,5074,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Conversion rate of the prodrug in human plasma,9606.0,
5090,,,A,0,Autocuration,,5074,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Conversion rate of the prodrug in human plasma; ND means no data,9606.0,
5091,,,A,0,Autocuration,,4727,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Half life of compound was determined in human blood,9606.0,
5092,,,A,0,Autocuration,,5965,Homo sapiens,BAO_0000019,,,,,22224,1,Half life of compound was determined in man with once daily dosing,9606.0,
5093,Microsomes,,A,0,Autocuration,In vitro,5732,Homo sapiens,BAO_0000251,,,,,22224,1,Half life in human microsomes,9606.0,
5094,,,A,0,Autocuration,,5819,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life in human plasma,9606.0,
5095,,,A,0,Autocuration,,5819,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life in human plasma; Not detected,9606.0,
5096,,,A,0,Autocuration,In vivo,1916,Homo sapiens,BAO_0000218,,,,,22224,1,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,
5097,Microsomes,,A,0,Autocuration,In vitro,6597,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Half-life for oxidative metabolic stability was determined using rat liver microsomes,9606.0,
5098,,,A,0,Autocuration,,5229,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life in human plasma,9606.0,
5099,,,A,0,Autocuration,,5229,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life of the parent prodrug in plasma,9606.0,
5100,,,A,0,Autocuration,In vitro,2192,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,In vitro half life in human plasma was determined,9606.0,
5101,Microsomes,,A,0,Autocuration,In vitro,3032,Homo sapiens,BAO_0000251,,Liver,,,22224,1,The compound was tested In Vitro for half life in human liver microsomes.,9606.0,
5102,,,A,0,Autocuration,In vivo,1916,Homo sapiens,BAO_0000218,,,,,22224,1,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,9606.0,
5103,,,A,0,Autocuration,In vivo,17716,Homo sapiens,BAO_0000218,,,,,22224,1,Observed volume of distribution,9606.0,
5104,,,A,0,Autocuration,In vivo,15778,Homo sapiens,BAO_0000218,,,,,22224,1,Oral bioavailability in human,9606.0,
5105,,,A,0,Autocuration,,17313,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for human plasma protein binding of the compound,9606.0,
5106,,,A,0,Autocuration,,4231,Homo sapiens,BAO_0000019,,,,,22224,1,"First order rate constant, k was determined in human plasma",9606.0,
5107,,,A,0,Autocuration,,4755,Homo sapiens,BAO_0000019,,,,,22224,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,9606.0,
5108,,,A,0,Autocuration,,4755,Homo sapiens,BAO_0000019,,,,,22224,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,9606.0,
5109,Microsomes,,A,0,Autocuration,,16907,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,9606.0,
5110,,,A,0,Autocuration,,10839,Homo sapiens,BAO_0000019,,,,,22224,1,The compound was tested for the plasma binding in human,9606.0,
5111,,,A,0,Autocuration,,10839,Homo sapiens,BAO_0000019,,,,,22224,1,Plasma protein binding (human),9606.0,
5112,Microsomes,,A,0,Autocuration,In vitro,3199,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Compound was evaluated for half-life in human liver microsomes,9606.0,
5113,,,A,0,Autocuration,In vitro,1345,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Half life measured in vitro for its stability in human blood,9606.0,
5114,,,A,0,Autocuration,,4297,Homo sapiens,BAO_0000019,,Serum,,,22224,1,Half life in human serum,9606.0,
5115,,,A,0,Autocuration,,4297,Homo sapiens,BAO_0000019,,Serum,,,22224,1,Half life in human serum; ND=not determined,9606.0,
5116,,,A,0,Autocuration,,4297,Homo sapiens,BAO_0000019,,,,,22224,1,Half life were determined in CEM-SS cell extract in decomposition step 1,9606.0,
5117,,,A,0,Autocuration,,4297,Homo sapiens,BAO_0000019,,,,,22224,1,Half life were determined in CEM-SS cell extract in decomposition step 2,9606.0,
5118,,,A,0,Autocuration,,4231,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life of the in human plasma,9606.0,
5119,S9,,A,0,Autocuration,In vitro,5633,Homo sapiens,BAO_0000220,,,,,22224,1,Half life period in human hepatic S9 fraction was determined,9606.0,
5120,Microsomes,,A,0,Autocuration,In vitro,5633,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Half life period in human liver microsome was determined,9606.0,
5121,,,A,0,Autocuration,,17791,Homo sapiens,BAO_0000019,,,,,22224,1,Half life period was determined; 6-7,9606.0,
5122,,,A,0,Autocuration,,17791,Homo sapiens,BAO_0000019,,,,,22224,1,Half life period was evaluated in human,9606.0,
5123,,,A,0,Autocuration,,3160,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life time in human plasma,9606.0,
5124,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5125,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5126,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5127,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5128,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,
5129,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5130,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5131,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,
5132,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5133,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,10090.0,
5134,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Spleen,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",10090.0,
5135,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Spleen,,,50594,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5136,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5137,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of compound (oxidized form) in blood tissue,10090.0,
5138,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5139,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,
5140,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5141,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5142,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Blood,,,50594,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,
5143,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of compound (oxidized form) in brain tissue of mice,10090.0,
5144,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5145,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5146,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5147,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,
5148,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Brain,,,50594,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,
5149,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of compound (oxidized form) in heart tissue of mice,10090.0,
5150,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5151,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5152,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5153,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5154,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Heart,,,50594,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,
5155,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5156,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",10090.0,
5157,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5158,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",10090.0,
5159,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Kidney,,,50594,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",10090.0,
5160,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of compound (oxidized form) in liver tissue,10090.0,
5161,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",10090.0,
5162,,,A,1,Intermediate,In vivo,16438,Mus musculus,BAO_0000218,,Liver,,,50594,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",10090.0,
5163,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,9606.0,
5164,,A-431,F,1,Intermediate,,5245,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,9606.0,
5165,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,
5166,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,
5167,,A-431,F,9,Expert,,16093,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9606.0,
5168,,A-431,F,1,Intermediate,,16825,Homo sapiens,BAO_0000219,500.0,,,,80852,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",9606.0,
5169,,A-431,F,1,Intermediate,,4848,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,9606.0,
5170,,A-431,F,9,Expert,,14827,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9606.0,
5171,,A-431,F,9,Expert,,14827,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9606.0,
5172,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,
5173,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5174,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,
5175,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,
5176,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,
5177,,A-431,F,9,Expert,,16289,Homo sapiens,BAO_0000219,500.0,,,,9,1,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9606.0,
5178,,A-431,F,8,Expert,,16289,,BAO_0000219,500.0,,,,9,1,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,
5179,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,
5180,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5181,,A-431,F,1,Expert,,16289,,BAO_0000218,500.0,,,,80852,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,
5182,,A-431,F,1,Expert,,14555,Mus musculus,BAO_0000218,500.0,,,,80852,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,
5183,,A-431,F,1,Expert,,14555,Mus musculus,BAO_0000218,500.0,,,,80852,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,
5184,,A-431,F,1,Expert,,14555,Mus musculus,BAO_0000218,500.0,,,,80852,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,
5185,,A-431,F,1,Expert,,14555,Mus musculus,BAO_0000218,500.0,,,,80852,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",10090.0,
5186,,A-431,F,1,Expert,,1937,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,9606.0,
5187,,A-431,F,1,Intermediate,,13739,Homo sapiens,BAO_0000219,500.0,,,,80852,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,9606.0,
5188,,A-431,F,1,Intermediate,,3558,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,9606.0,
5189,,A-431,F,1,Intermediate,,3558,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Dose giving a 50% decrease in the living cell number (A437 cells),9606.0,
5190,,A549,F,1,Expert,,17686,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory concentration against proliferation of A459 cell line.,9606.0,
5191,,A549,F,1,Intermediate,,5305,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,9606.0,
5192,,A549,F,1,Intermediate,,3614,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,9606.0,
5193,,A498,F,1,Intermediate,,17229,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro antitumor activity against renal A498 tumor cell lines,9606.0,
5194,,A498,F,1,Intermediate,,15935,Homo sapiens,BAO_0000219,624.0,,,,80021,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",9606.0,
5195,,A498,F,1,Intermediate,,15935,Homo sapiens,BAO_0000219,624.0,,,,80021,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",9606.0,
5196,,A498,F,1,Intermediate,,15560,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,9606.0,
5197,,A498,F,1,Intermediate,,13891,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,9606.0,
5198,,A498,F,1,Intermediate,,13891,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,9606.0,
5199,,A498,F,1,Intermediate,,13788,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity on kidney carcinoma (A-498) cell line,9606.0,
5200,,A498,F,1,Intermediate,,15403,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was evaluated against Human cell line renal A498,9606.0,
5201,,A498,F,1,Intermediate,,1009,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was tested for inhibition of A498 human renal cancer cell line,9606.0,
5202,,A498,F,1,Intermediate,,1043,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Growth inhibitory activity against A498 human cancer cell line,9606.0,
5203,,A498,F,1,Intermediate,,5858,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro antitumor activity against human renal A498 cell line,9606.0,
5204,,A498,F,1,Intermediate,,5958,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxic activity against renal (A498) cell line,9606.0,
5205,,A498,F,1,Intermediate,,5506,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,9606.0,
5206,,A498,F,1,Intermediate,,12781,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Tested for cytostatic activity against renal A498 cell line,9606.0,
5207,,A498,F,1,Intermediate,,14399,Homo sapiens,BAO_0000219,624.0,,,,80021,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,9606.0,
5208,,A498,F,1,Expert,,5958,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,9606.0,
5209,,,A,0,Autocuration,In vivo,3510,beagle,BAO_0000218,,,,,22224,1,Cmax value after 2 mpk peroral administration to beagles,9615.0,
5210,,,A,0,Autocuration,In vivo,3510,Canis lupus familiaris,BAO_0000218,,,,,22224,1,Bioavailability,9615.0,beagle
5211,,,A,0,Autocuration,In vivo,3510,Canis lupus familiaris,BAO_0000218,,,,,22224,1,Bioavailability after 1 mpk peroral administration to beagles,9615.0,beagle
5212,,,A,0,Autocuration,In vivo,3510,Canis lupus familiaris,BAO_0000218,,,,,22224,1,Bioavailability after 2 mpk peroral administration to beagles,9615.0,beagle
5213,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,9913.0,
5214,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,9913.0,
5215,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,9913.0,
5216,,,A,0,Autocuration,,9372,Bos taurus,BAO_0000019,,,,,22224,1,Solubility against bovine alpha-chymotrypsin,9913.0,
5217,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,9913.0,
5218,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,9913.0,
5219,,,A,0,Autocuration,,1469,Bos taurus,BAO_0000221,,Spleen,,,22224,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,9913.0,
5220,,,A,0,Autocuration,,4297,Bos taurus,BAO_0000019,,,,,22224,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum,9913.0,
5221,,,A,0,Autocuration,,4297,Bos taurus,BAO_0000019,,,,,22224,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,9913.0,
5222,,,A,0,Autocuration,,17585,Bos taurus,BAO_0000019,,,,,22224,1,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,9913.0,
5223,,,A,0,Autocuration,,1336,Bos taurus,BAO_0000221,,Spleen,,,22224,1,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,9913.0,
5224,,,A,0,Autocuration,,3085,Bos taurus,BAO_0000019,,,,,22224,1,Half life in presence of 2 mg/mL BSA at pH 8.8,9913.0,
5225,,,A,0,Autocuration,,2857,Bos taurus,BAO_0000019,,,,,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,9913.0,
5226,,,A,0,Autocuration,,2857,Bos taurus,BAO_0000019,,,,,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,9913.0,
5227,,,A,0,Autocuration,,2857,Bos taurus,BAO_0000019,,,,,22224,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,9913.0,
5228,,,A,0,Autocuration,,1540,Bos taurus,BAO_0000019,,,,,22224,1,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),9913.0,
5229,,,A,1,Intermediate,,6316,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,9615.0,
5230,,,A,1,Intermediate,,17594,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC after administration at 100 mg/kg/day in dogs,9615.0,
5231,,,A,1,Intermediate,,4953,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,9615.0,
5232,,,A,1,Intermediate,,16907,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC value after 15 mg/kg iv dose in Dogs,9615.0,
5233,,,A,1,Intermediate,,16907,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC value after 30 mg/kg po dose in Dogs,9615.0,
5234,,,A,1,Intermediate,,2959,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC value after administration of 4 mg/Kg oral dose in dog,9615.0,
5235,,,A,1,Intermediate,,17594,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,9615.0,
5236,,,A,1,Intermediate,,5356,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,9615.0,
5237,,,A,1,Intermediate,,16807,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,9615.0,
5238,,,A,1,Intermediate,,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,9615.0,
5239,,,A,1,Intermediate,,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,
5240,,,A,1,Intermediate,,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,9615.0,
5241,,,A,1,Intermediate,,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dogs after oral administration of 10 mg/kg,9615.0,
5242,,,A,1,Intermediate,,5802,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,
5243,,,A,1,Expert,,3598,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
5244,,,A,1,Expert,,3598,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
5245,,,A,1,Intermediate,,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,
5246,,,A,1,Intermediate,,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,9615.0,
5247,,,A,1,Intermediate,,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,
5248,,,A,1,Intermediate,,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,9615.0,
5249,,,A,1,Intermediate,,4186,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,9615.0,
5250,,,A,1,Intermediate,,5007,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,
5251,,,A,1,Intermediate,,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determine after peroral administration at 10 mpk in dog,9615.0,
5252,,,A,1,Intermediate,,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determine after peroral administration at 5 mpk in dog,9615.0,
5253,,,A,1,Intermediate,,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined,9615.0,
5254,,,A,1,Intermediate,,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dogs,9615.0,
5255,,,A,1,Intermediate,,3771,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,9615.0,
5256,,,A,1,Intermediate,,3771,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),9615.0,
5257,,,A,1,Intermediate,,3771,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,9615.0,
5258,,,A,1,Intermediate,,1916,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,
5259,,,A,1,Intermediate,,5302,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve value in dog at a dose of 5 mg/kg,9615.0,
5260,,,A,1,Intermediate,,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,9615.0,
5261,,,A,1,Intermediate,,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined after 0.3 mg/kg po administration in dog,9615.0,
5262,,,A,1,Intermediate,,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,
5263,,,A,1,Intermediate,,4368,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,9615.0,
5264,,,A,0,Autocuration,,5318,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,9606.0,
5265,,,A,0,Autocuration,,5318,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,9606.0,
5266,,,A,0,Autocuration,,5318,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,9606.0,
5267,,,A,0,Autocuration,,5318,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,9606.0,
5268,,,A,0,Autocuration,,14518,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Time taken to reduce 50% of the concentration of compound in blood plasma,9606.0,
5269,,,A,0,Autocuration,,2209,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",9606.0,
5270,,,A,0,Autocuration,,6787,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life in human plasma,9606.0,
5271,,,A,0,Autocuration,,4898,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life in human plasma was reported,9606.0,
5272,,,A,0,Autocuration,,6072,Homo sapiens,BAO_0000019,,Serum,,,22224,1,Half life in human serum,9606.0,
5273,,,A,0,Autocuration,,16907,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life upon exposure to human plasma,9606.0,
5274,Microsomes,,A,0,Autocuration,In vitro,5656,Homo sapiens,BAO_0000251,,,,,22224,1,t1/2 in human microsomes,9606.0,
5275,,,A,0,Autocuration,,4755,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half life period in 80% human plasma at 37 degree Centigrade,9606.0,
5276,,,A,0,Autocuration,,17503,Homo sapiens,BAO_0000221,,Zone of skin,,,22224,1,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),9606.0,
5277,,,A,0,Autocuration,In vitro,12357,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life measured in in vitro Cathepsin B assay in human plasma,9606.0,
5278,,,A,0,Autocuration,,3076,Homo sapiens,BAO_0000019,,,,,22224,1,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,9606.0,
5279,Microsomes,,A,0,Autocuration,In vitro,6410,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,9606.0,
5280,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",9606.0,
5281,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",9606.0,
5282,,,A,0,Autocuration,,3741,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",9606.0,
5283,,,A,0,Autocuration,,1540,Homo sapiens,BAO_0000019,,,,,22224,1,Half-life in the CEM cell extracts,9606.0,
5284,,,A,0,Autocuration,,2905,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,9606.0,
5285,,,A,0,Autocuration,,2905,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,9606.0,
5286,,,A,0,Autocuration,,5523,Homo sapiens,BAO_0000019,,,,,22224,1,Half-life was determined,9606.0,
5287,,,A,0,Autocuration,,1499,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Half-life (human blood stability),9606.0,
5288,,,A,0,Autocuration,,1499,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Half-life (human blood stability); no data,9606.0,
5289,,,A,0,Autocuration,,17065,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Half-life in human plasma,9606.0,
5290,,,A,0,Autocuration,,6861,Homo sapiens,BAO_0000019,,,,,22224,1,CYP3A4 metabolism half-life (t1/2),9606.0,
5291,,,A,0,Autocuration,,1499,Homo sapiens,BAO_0000221,,Blood,,,22224,1,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),9606.0,
5292,,,A,0,Autocuration,In vitro,530,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,In vitro half life in human plasma,9606.0,
5293,,,A,0,Autocuration,In vitro,1116,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",9606.0,
5294,,,A,0,Autocuration,In vitro,6695,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,In vitro hydrolysis in human plasma,9606.0,
5295,,,A,0,Autocuration,In vitro,6695,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,In vitro hydrolysis in human plasma; no data,9606.0,
5296,Microsomes,,A,0,Autocuration,In vitro,10,Homo sapiens,BAO_0000251,,Liver,,,22224,1,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,9606.0,
5297,,,A,0,Autocuration,,993,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Plasma half life in human,9606.0,
5298,,,A,0,Autocuration,,15429,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,Stability after incubation with human plasma (at 37 degree C),9606.0,
5299,,,A,0,Autocuration,,1675,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,T1/2 was evaluated in human plasma,9606.0,
5300,,,A,0,Autocuration,,2209,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",9606.0,
5301,,,A,0,Autocuration,,2209,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",9606.0,
5302,,,A,0,Autocuration,,5318,Homo sapiens,BAO_0000019,,,,,22224,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,9606.0,
5303,,,A,0,Autocuration,In vitro,2412,Homo sapiens,BAO_0000019,,,,,22224,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,9606.0,
5304,,,A,0,Autocuration,In vitro,2412,Homo sapiens,BAO_0000019,,,,,22224,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,9606.0,
5305,,,A,0,Autocuration,,2906,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,9606.0,
5306,,,A,0,Autocuration,,2906,Homo sapiens,BAO_0000366,,Plasma,,,22224,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,9606.0,
5307,,,A,0,Autocuration,,5495,Homo sapiens,BAO_0000019,,,,,22224,1,Time taken for 50% to be consumed by serum PON1 was determined,9606.0,
5308,,,A,0,Autocuration,,5495,Homo sapiens,BAO_0000019,,,,,22224,1,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,9606.0,
5309,Microsomes,,A,0,Autocuration,,4397,Homo sapiens,BAO_0000251,,Liver,,,22224,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,9606.0,
5310,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5311,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5312,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5313,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5314,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5315,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,
5316,,786-0,F,1,Intermediate,,6058,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound tested for growth inhibition of renal cancer cell line 786-0,9606.0,
5317,,786-0,F,1,Intermediate,,17708,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,9606.0,
5318,,786-0,F,1,Expert,,14017,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,9606.0,
5319,,786-0,F,1,Intermediate,,16818,Homo sapiens,BAO_0000219,391.0,,,,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",9606.0,
5320,,786-0,F,1,Intermediate,,16818,Homo sapiens,BAO_0000219,391.0,,,,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",9606.0,
5321,,786-0,F,1,Intermediate,,16818,Homo sapiens,BAO_0000219,391.0,,,,80640,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",9606.0,
5322,,786-0,F,1,Intermediate,,11970,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,9606.0,
5323,,786-0,F,1,Intermediate,,12400,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,9606.0,
5324,,786-0,F,1,Expert,,12888,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Cytotoxic effect on renal cancer line 786-0,9606.0,
5325,,786-0,F,1,Intermediate,,15300,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,9606.0,
5326,,786-0,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),9606.0,
5327,,786-0,F,1,Intermediate,,15895,Homo sapiens,BAO_0000219,391.0,,,,80640,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",9606.0,
5328,,786-0,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,9606.0,
5329,,786-0,F,1,Intermediate,,14882,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,9606.0,
5330,,786-0,F,1,Intermediate,,14882,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),9606.0,
5331,,786-0,F,1,Intermediate,,15176,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,9606.0,
5332,,786-0,F,1,Intermediate,,12696,Homo sapiens,BAO_0000219,391.0,,,,80640,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,9606.0,
5333,,786-0,F,1,Intermediate,,2496,Homo sapiens,BAO_0000219,391.0,,,,80640,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),9606.0,
5334,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,9606.0,
5335,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),9606.0,
5336,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,9606.0,
5337,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),9606.0,
5338,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),9606.0,
5339,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,9606.0,
5340,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),9606.0,
5341,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),9606.0,
5342,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),9606.0,
5343,,791T cell line,F,1,Intermediate,,11831,Homo sapiens,BAO_0000219,972.0,,,,80641,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,9606.0,
5344,,786-0,F,1,Intermediate,,12782,Homo sapiens,BAO_0000219,391.0,,,,80640,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,9606.0,
5345,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,
5346,,RPMI-8226,F,1,Expert,,15313,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,9606.0,
5347,,RPMI-8226,F,1,Expert,,15313,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,9606.0,
5348,,RPMI-8226,F,1,Intermediate,,11544,Homo sapiens,BAO_0000219,741.0,,,,80433,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,9606.0,
5349,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,
5350,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,
5351,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,
5352,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,
5353,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,
5354,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,
5355,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,
5356,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,
5357,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,
5358,,A498,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),9606.0,
5359,,A498,F,1,Intermediate,,15354,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,9606.0,
5360,,A498,F,1,Intermediate,,17445,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),9606.0,
5361,,A498,F,1,Intermediate,,4337,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro inhibitory concentration against renal cancer cell line A498,9606.0,
5362,,A498,F,1,Intermediate,,15277,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity against A 498 tumor cell line,9606.0,
5363,,A498,F,1,Intermediate,,4812,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro antitumor activity against A498 human cancer cell line,9606.0,
5364,,A498,F,1,Intermediate,,4812,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),9606.0,
5365,,A498,F,1,Intermediate,,4995,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Inhibitory dose required against A498 human tumor cell lines,9606.0,
5366,,A498,F,1,Intermediate,,5847,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Anticancer activity against one renal cancer (A498 cell line),9606.0,
5367,,A498,F,1,Intermediate,,6557,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity against melanoma A498 cell line,9606.0,
5368,,A498,F,1,Intermediate,,2597,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was tested for growth inhibitory activity against A498 cell line,9606.0,
5369,,A498,F,1,Intermediate,,6058,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound tested for growth inhibition of renal cancer cell line A498,9606.0,
5370,,A498,F,1,Intermediate,,17708,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,9606.0,
5371,,A498,F,1,Intermediate,,15176,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,9606.0,
5372,,A498,F,1,Intermediate,,15300,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,9606.0,
5373,,A498,F,1,Intermediate,,11970,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Tested for cytotoxicity against A498 cell lines in renal cancer,9606.0,
5374,,A498,F,1,Intermediate,,12400,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,9606.0,
5375,,A498,F,1,Expert,,12888,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxic effect on renal cancer lines A498,9606.0,
5376,,A498,F,1,Intermediate,,3030,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,9606.0,
5377,,A498,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),9606.0,
5378,,A498,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,9606.0,
5379,,A498,F,1,Intermediate,,16558,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,9606.0,
5380,,A498,F,1,Intermediate,,5194,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,9606.0,
5381,,A498,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,9606.0,
5382,,A549,F,1,Expert,,16880,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,9606.0,
5383,,A549,F,1,Intermediate,,10196,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor activity against A549 human lung carcinoma cell line,9606.0,
5384,,A549,F,1,Intermediate,,10196,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,9606.0,
5385,,A549,F,1,Intermediate,,10196,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,9606.0,
5386,,A549,F,1,Intermediate,,12083,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",9606.0,
5387,,A549,F,1,Expert,,16464,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,9606.0,
5388,,A549,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5389,,A549,F,1,Expert,,16470,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against human lung A549 cell line,9606.0,
5390,,A549,F,1,Intermediate,,16470,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),9606.0,
5391,,A549,F,1,Intermediate,,16470,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against human lung A549 cell line),9606.0,
5392,,A549,F,1,Intermediate,,16470,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,9606.0,
5393,,A549,F,1,Expert,,16582,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,9606.0,
5394,,A549,F,1,Intermediate,,15935,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",9606.0,
5395,,A549,F,1,Intermediate,,15935,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",9606.0,
5396,,A549,F,1,Expert,,16597,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of A549 human lung carcinoma cell proliferation,9606.0,
5397,,A549,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line,9606.0,
5398,,A549,F,1,Intermediate,,16496,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,9606.0,
5399,,A549,F,1,Intermediate,,16152,Homo sapiens,BAO_0000219,646.0,,,,80682,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,9606.0,
5400,,A549,F,1,Intermediate,,16152,Homo sapiens,BAO_0000219,646.0,,,,80682,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,9606.0,
5401,,A549,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5402,,A549,F,1,Intermediate,,2288,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,9606.0,
5403,,A549,F,1,Intermediate,,17350,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,9606.0,
5404,,A549,F,1,Expert,,4090,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of A549 cancer cell proliferation,9606.0,
5405,,A549,F,1,Expert,,4090,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of A549 cancer cell proliferation (Not tested),9606.0,
5406,,A549,F,1,Intermediate,,17350,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,9606.0,
5407,,A549,F,1,Intermediate,,4197,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,9606.0,
5408,,A549,F,1,Intermediate,,17072,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,9606.0,
5409,,A549,F,1,Intermediate,,17072,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,9606.0,
5410,,A549,F,1,Intermediate,,5194,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against Renal cell lines A549 was determined,9606.0,
5411,,,A,1,Intermediate,,4257,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,9615.0,
5412,,,A,1,Intermediate,,6123,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined in dog after oral administration at 1 mg/kg,9615.0,
5413,,,A,1,Intermediate,,1337,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,
5414,,,A,1,Intermediate,,1337,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,
5415,,,A,1,Intermediate,,8833,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),9615.0,
5416,,,A,1,Intermediate,,8833,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),9615.0,
5417,,,A,1,Intermediate,,8833,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),9615.0,
5418,,,A,1,Intermediate,,8833,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),9615.0,
5419,,,A,1,Intermediate,,17657,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Area under plasma concentration time curve in dog upon oral administration,9615.0,
5420,,,A,1,Intermediate,,17650,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,9615.0,
5421,,,A,1,Intermediate,,1977,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,9615.0,
5422,,,A,1,Intermediate,,1977,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,9615.0,
5423,,,A,1,Intermediate,,3132,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve for the compound was obtained when tested in dog,9615.0,
5424,,,A,1,Intermediate,,5473,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve at a dose of 1 mg/kg,9615.0,
5425,,,A,1,Intermediate,,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve at a dose of 1 mg/kg (oral),9615.0,
5426,,,A,1,Intermediate,,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve at i.v. dose of 0.2 mg/kg,9615.0,
5427,,,A,1,Intermediate,,6062,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,9615.0,
5428,,,A,1,Intermediate,,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,9615.0,
5429,,,A,1,Intermediate,,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,9615.0,
5430,,,A,1,Intermediate,,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,9615.0,
5431,,,A,1,Intermediate,,2877,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for area under the curve in dog blood.,9615.0,
5432,,,A,1,Intermediate,,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,9615.0,
5433,,,A,1,Intermediate,,5130,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC in dog after oral dose (1 mg/kg),9615.0,
5434,,,A,1,Intermediate,,6265,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,9615.0,
5435,,,A,1,Intermediate,,4657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",9615.0,
5436,,,A,1,Intermediate,,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,9615.0,
5437,,,A,1,Intermediate,,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter AUC after oral administration to dogs,9615.0,
5438,,,A,1,Intermediate,,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,9615.0,
5439,,,A,1,Intermediate,,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,9615.0,
5440,,,A,1,Intermediate,,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,9615.0,
5441,,,A,1,Intermediate,,6241,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,9615.0,
5442,,,A,1,Intermediate,,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",9615.0,
5443,,,A,1,Intermediate,,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",9615.0,
5444,,,A,1,Intermediate,,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,
5445,,,A,1,Intermediate,,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,
5446,,,A,1,Intermediate,,6641,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),9615.0,
5447,,,A,1,Intermediate,,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),9615.0,
5448,,,A,1,Intermediate,,17791,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for oral bioavailability in dog; 90-100,9615.0,
5449,,,A,1,Intermediate,,17655,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,9615.0,
5450,,,A,1,Intermediate,,17655,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,9615.0,
5451,,,A,1,Intermediate,,6596,Canis lupus familiaris,BAO_0000218,,,,,50588,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,9615.0,
5452,,,A,1,Intermediate,,3880,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5453,,,A,1,Intermediate,,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,9615.0,
5454,,,A,1,Intermediate,,17409,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma protein binding towards dog plasma at 10 uM,9615.0,
5455,,,A,1,Intermediate,,17409,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma protein binding towards dog plasma at 100 uM,9615.0,
5456,,,A,1,Intermediate,In vivo,2959,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 4 mg/kg p.o.),9615.0,
5457,,,A,1,Intermediate,In vivo,13501,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,9615.0,
5458,,,A,1,Intermediate,In vivo,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,
5459,,,A,1,Intermediate,In vivo,15145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dogs,9615.0,
5460,,,A,1,Intermediate,In vivo,4219,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability,9615.0,
5461,,,A,1,Intermediate,In vivo,17538,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
5462,,,A,1,Intermediate,In vivo,17538,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,9615.0,
5463,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),9615.0,
5464,,,A,1,Intermediate,In vivo,17650,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,9615.0,
5465,,,A,1,Intermediate,In vivo,3132,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,9615.0,
5466,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5467,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Liver,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5468,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Liver,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,
5469,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Liver,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5470,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5471,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5472,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Muscle tissue,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5473,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Muscle tissue,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,
5474,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Muscle tissue,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5475,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Spleen,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5476,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,Spleen,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5477,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,10095.0,
5478,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,
5479,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5480,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,10095.0,
5481,,,A,0,Autocuration,,2413,Mus sp.,BAO_0000218,,,,,22224,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,10095.0,
5482,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),9527.0,
5483,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Cerebellum,,,22224,1,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),9527.0,
5484,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Frontal cortex,,,22224,1,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),9527.0,
5485,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),9527.0,
5486,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Striatum,,,22224,1,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),9527.0,
5487,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),9527.0,
5488,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Cerebellum,,,22224,1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),9527.0,
5489,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Frontal cortex,,,22224,1,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),9527.0,
5490,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),9527.0,
5491,,,A,0,Autocuration,,17827,Cercopithecidae,BAO_0000019,,Striatum,,,22224,1,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),9527.0,
5492,,,A,0,Autocuration,,17791,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for oral bioavailability in rats,9527.0,
5493,,,A,0,Autocuration,In vivo,17667,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,9527.0,
5494,,,A,0,Autocuration,,17791,Cercopithecidae,BAO_0000019,,,,,22224,1,Half life period was evaluated in monkey,9527.0,
5495,,,A,0,Autocuration,In vivo,110,Cercopithecidae,BAO_0000218,,,,,22224,1,Half-life in rhesus monkeys by intravenous administration of dose,9527.0,
5496,,,A,1,Intermediate,,5781,Mus musculus,BAO_0000218,,Plasma,,,50594,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,10090.0,
5497,,,A,1,Intermediate,,17734,Mus musculus,BAO_0000218,,Plasma,,,50594,1,AUC after intraperitoneal administration of 100 mg/kg in mice,10090.0,
5498,,,A,1,Intermediate,,17718,Mus musculus,BAO_0000218,,Plasma,,,50594,1,AUC value was determined after oral administration,10090.0,
5499,,,A,1,Intermediate,,4573,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,10090.0,
5500,,,A,1,Intermediate,,3277,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,
5501,,,A,1,Intermediate,,2862,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve by ioral administration in mouse,10090.0,
5502,,,A,1,Intermediate,,2862,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve by iv administration in mouse,10090.0,
5503,,,A,1,Intermediate,,5951,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve at 0-8 hr in IRC mice after peroral administration,10090.0,
5504,,,A,1,Intermediate,,17729,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,10090.0,
5505,,,A,1,Intermediate,,17728,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,10090.0,
5506,,,A,1,Intermediate,,17728,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,10090.0,
5507,,,A,1,Intermediate,,17729,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,10090.0,
5508,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,
5509,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,
5510,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,
5511,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,
5512,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,
5513,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,
5514,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,
5515,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,
5516,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,9606.0,
5517,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,9606.0,
5518,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),9606.0,
5519,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),9606.0,
5520,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),9606.0,
5521,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),9606.0,
5522,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),9606.0,
5523,,RPMI-8226,F,1,Intermediate,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),9606.0,
5524,,RPMI-8226,F,1,Expert,,9424,Homo sapiens,BAO_0000219,741.0,,,,80433,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,9606.0,
5525,,RPMI-8226,F,1,Intermediate,,11544,Homo sapiens,BAO_0000219,741.0,,,,80433,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,9606.0,
5526,,RPMI-8226,F,1,Intermediate,,17378,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Cytotoxicity of compound against 8226/DOX1V cells,9606.0,
5527,,RPMI-8226,F,1,Intermediate,,17378,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Cytotoxicity of compound against 8226/S cells,9606.0,
5528,,RPMI-8226,F,1,Intermediate,,17079,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Inhibitory concentration against 8226 myeloma cancer cell line,9606.0,
5529,,RPMI-8226,F,1,Intermediate,,17079,Homo sapiens,BAO_0000219,741.0,,,,80433,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,9606.0,
5530,,833K,F,1,Intermediate,,13466,Homo sapiens,BAO_0000219,854.0,,,,80647,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,9606.0,
5531,,833K,F,1,Intermediate,,13466,Homo sapiens,BAO_0000219,854.0,,,,80647,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',9606.0,
5532,,833K,F,1,Expert,,2392,Homo sapiens,BAO_0000219,854.0,,,,80647,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,9606.0,
5533,,833K,F,1,Intermediate,,2392,Homo sapiens,BAO_0000219,854.0,,,,80647,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,9606.0,
5534,,,B,0,Autocuration,,6608,,BAO_0000019,,,,,22226,1,Inhibitory activity against caspase-1,,
5535,,,B,8,Autocuration,,10199,Enterococcus faecalis,BAO_0000357,,,,,45,1,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1351.0,
5536,,8701-BC,F,1,Intermediate,,17749,Homo sapiens,BAO_0000219,705.0,,,,80648,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,9606.0,
5537,,8701-BC,F,1,Intermediate,,17749,Homo sapiens,BAO_0000219,705.0,,,,80648,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,9606.0,
5538,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,
5539,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,
5540,,,F,0,Intermediate,,1229,,BAO_0000019,,,,,22226,1,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,
5541,,,B,0,Autocuration,,6390,,BAO_0000019,,,,,22226,1,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,
5542,,,F,0,Autocuration,,16219,Streptococcus pyogenes,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1314.0,
5543,,,F,0,Autocuration,,16219,Streptococcus pyogenes,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1314.0,
5544,,,B,8,Autocuration,,17043,,BAO_0000357,,,,,11922,1,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,
5545,,KB ,F,1,Intermediate,,6929,Homo sapiens,BAO_0000219,324.0,,,,81115,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,9606.0,
5546,,KB ,A,1,Intermediate,,6929,Homo sapiens,BAO_0000219,324.0,,,,81115,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,9606.0,
5547,,,F,0,Autocuration,,7083,Homo sapiens,BAO_0000219,,,,,22226,1,In vitro cytotoxicity of compound was tested against 9KB cells.,9606.0,
5548,,9L,F,1,Intermediate,,12446,Rattus norvegicus,BAO_0000219,392.0,,,,80653,1,Cytotoxic concentration against 9L cells was determined on day 3,10116.0,
5549,,9L,F,1,Expert,,15345,Rattus norvegicus,BAO_0000219,392.0,,,,80653,1,Tested in vitro for anticancer activity against 9L cells,10116.0,
5550,,9L,F,1,Expert,,15345,Rattus norvegicus,BAO_0000219,392.0,,,,80653,1,Tested in vitro for anticancer activity against 9L cells; Not determined,10116.0,
5551,,A549,F,1,Intermediate,,6301,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,9606.0,
5552,,A549,F,1,Intermediate,,4833,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,9606.0,
5553,,A549,F,1,Intermediate,,4833,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,9606.0,
5554,,A549,F,1,Intermediate,,4833,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,9606.0,
5555,,A549,F,1,Expert,,13330,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma A549 cell line,9606.0,
5556,,A549,F,9,Expert,,17517,Homo sapiens,BAO_0000219,646.0,,,,25,1,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,9606.0,
5557,,A549,F,9,Expert,,17517,Homo sapiens,BAO_0000219,646.0,,,,25,1,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",9606.0,
5558,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro growth inhibition of A549, lung carcinoma",9606.0,
5559,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro growth inhibition of A549, lung carcinoma.",9606.0,
5560,,A549,F,1,Expert,,5228,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,
5561,,A549,F,1,Intermediate,,5351,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against human lung cancer A549 cell line was determined,9606.0,
5562,,A549,F,1,Expert,,12198,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,9606.0,
5563,,A549,F,1,Intermediate,,13891,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,9606.0,
5564,,A549,F,1,Expert,,5677,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity in A549 (human carcinoma) cell line.,9606.0,
5565,,A549,F,1,Intermediate,,13788,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity on lung carcinoma (A-549) cell line,9606.0,
5566,,A549,F,1,Expert,,13384,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,9606.0,
5567,,A549,F,1,Intermediate,,6726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effective dose of compound against replication of A549 cell line was evaluated,9606.0,
5568,,A549,F,1,Expert,,3455,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,9606.0,
5569,,A549,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),9606.0,
5570,,A549,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,9606.0,
5571,,A549,F,1,Intermediate,,3936,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was evaluated for antiproliferative activity against A549 cell line,9606.0,
5572,,A549,F,1,Intermediate,,14991,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,9606.0,
5573,,A549,F,1,Intermediate,,5243,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,9606.0,
5574,,A549,F,1,Intermediate,,12858,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,9606.0,
5575,,A549,F,1,Intermediate,,6776,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition against A549 cell line was evaluated,9606.0,
5576,,A549,F,1,Intermediate,,16558,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,9606.0,
5577,,A549,F,1,Expert,,4583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,9606.0,
5578,,A549,F,1,Intermediate,,13514,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,9606.0,
5579,,A549,F,1,Expert,,15166,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,9606.0,
5580,,A549,F,1,Intermediate,,13873,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,9606.0,
5581,,A549,F,1,Expert,,6447,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,9606.0,
5582,,A549,F,1,Intermediate,,2068,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,9606.0,
5583,,A549,F,1,Expert,,1863,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,9606.0,
5584,,A549,F,1,Intermediate,,13873,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,9606.0,
5585,,A549,F,1,Intermediate,,13873,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,9606.0,
5586,,A549,F,1,Expert,,13873,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,9606.0,
5587,,A549,F,1,Intermediate,,579,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),9606.0,
5588,,A549,F,1,Intermediate,,579,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,9606.0,
5589,,A549,F,1,Intermediate,,4584,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,9606.0,
5590,,A549,F,1,Expert,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,9606.0,
5591,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,9606.0,
5592,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,9606.0,
5593,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,9606.0,
5594,,A549,F,1,Intermediate,,14188,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,9606.0,
5595,,A549,F,1,Intermediate,,14188,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,9606.0,
5596,,A549,F,1,Intermediate,,15354,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,9606.0,
5597,,A549,F,1,Expert,,14253,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,9606.0,
5598,,A549,F,1,Intermediate,,13873,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,9606.0,
5599,,,A,1,Intermediate,In vivo,3043,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (conscious),9615.0,
5600,,,A,1,Intermediate,In vivo,3045,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,9615.0,
5601,,,A,1,Intermediate,In vivo,3022,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,9615.0,
5602,,,A,1,Intermediate,In vivo,4453,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5603,,,A,1,Intermediate,In vivo,1696,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5604,,,A,1,Intermediate,In vivo,5045,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5605,,,A,1,Intermediate,In vivo,5356,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (fasted),9615.0,
5606,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,9615.0,
5607,,,A,1,Intermediate,In vivo,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5608,,,A,1,Intermediate,In vivo,1475,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5609,,,A,1,Intermediate,In vivo,3788,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Percent bioavailability in dog,9615.0,
5610,,,A,1,Intermediate,In vivo,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,9615.0,
5611,,,A,1,Intermediate,In vivo,13397,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5612,,,A,1,Intermediate,In vivo,2137,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was evaluated for bioavailability in dogs; 34-44,9615.0,
5613,,,A,1,Intermediate,In vivo,2959,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 4 mg/kg p.o.),9615.0,
5614,,,A,1,Intermediate,In vivo,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
5615,,,A,1,Intermediate,,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,8 hour trough Blood level in dog was measured after administration of compound,9615.0,
5616,,,A,1,Intermediate,In vivo,3639,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,9615.0,
5617,,,A,1,Intermediate,,6316,Canis lupus familiaris,BAO_0000218,,,,,50588,1,C24 after oral administration at 5 mg/kg,9615.0,
5618,,,A,1,Intermediate,,5238,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance after oral and iv dosing in dogs,9615.0,
5619,,,A,1,Intermediate,,17796,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Clearance of the drug was measured in the plasma of dog,9615.0,
5620,,,A,1,Intermediate,,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,9615.0,
5621,,,A,1,Intermediate,In vivo,5654,Canis lupus familiaris,BAO_0000218,,,,,50588,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,
5622,,,A,1,Intermediate,In vivo,6621,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance of compound was determined in dogs,9615.0,
5623,,,A,1,Intermediate,In vivo,6505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,9615.0,
5624,,,A,1,Intermediate,In vivo,5802,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,
5625,,,A,1,Intermediate,In vivo,17267,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog was determined,9615.0,
5626,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,
5627,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,9615.0,
5628,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog after administration of 1 mg/kg iv,9615.0,
5629,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dogs,9615.0,
5630,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,9615.0,
5631,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,9615.0,
5632,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after 15 mg/kg iv dose in Dogs,9615.0,
5633,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after 30 mg/kg po dose in Dogs,9615.0,
5634,,,A,1,Intermediate,In vivo,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma administration to dogs,9615.0,
5635,,,A,1,Intermediate,In vivo,5505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined,9615.0,
5636,,,A,1,Intermediate,In vivo,6215,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,
5637,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,
5638,Microsomes,,A,2,Intermediate,In vitro,5007,Homo sapiens,BAO_0000251,,Liver,,,102164,1,Intrinsic clearance in human liver microsomes,9606.0,
5639,Microsomes,,A,2,Intermediate,In vitro,5007,Homo sapiens,BAO_0000251,,Liver,,,102164,1,Intrinsic clearance in human liver microsomes,9606.0,
5640,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,
5641,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,
5642,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance in dog (dose 1 mg/kg i.v.),9615.0,
5643,,,A,1,Intermediate,In vivo,6221,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,9615.0,
5644,,,A,1,Intermediate,In vivo,5007,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,
5645,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after peroral administration at 10 mpk in dog,9615.0,
5646,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after peroral administration at 5 mpk in dog,9615.0,
5647,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after peroral administration at 5 mg/kg in dog,9615.0,
5648,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was measured in dog,9615.0,
5649,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was measured in dog,9615.0,
5650,,,A,1,Intermediate,In vivo,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,9615.0,
5651,,,A,1,Intermediate,In vivo,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,9615.0,
5652,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,
5653,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,9615.0,
5654,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,9615.0,
5655,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,9615.0,
5656,,,A,1,Intermediate,In vivo,4368,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance by intravenous administration of 1.2 mg/kg in dog,9615.0,
5657,,,A,1,Intermediate,In vivo,4305,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,9615.0,
5658,,,A,1,Intermediate,In vivo,1918,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Clearance value was evaluated in dog plasma,9615.0,
5659,,,A,1,Intermediate,In vivo,6005,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,9615.0,
5660,,,A,1,Intermediate,In vivo,4839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was tested for plasma clearance in dog,9615.0,
5661,,,A,1,Intermediate,In vivo,4239,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (Plasma clearance) was measured in dog,9615.0,
5662,,,A,1,Intermediate,,17729,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,10090.0,
5663,,,A,1,Intermediate,,17728,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,10090.0,
5664,,,A,1,Intermediate,,5302,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve value in mouse at a dose of 10 mg/kg,10090.0,
5665,,,A,1,Intermediate,,5506,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,
5666,,,A,1,Intermediate,,5506,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,
5667,,,F,1,Intermediate,,17764,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,10090.0,
5668,,,F,1,Intermediate,,17764,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,10090.0,
5669,,,F,1,Intermediate,,17764,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,10090.0,
5670,,,F,1,Intermediate,,17764,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,10090.0,
5671,,,A,1,Intermediate,,17764,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,10090.0,
5672,,,A,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for the compound at 24 mg/Kg,10090.0,
5673,,,A,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for the compound at 40 mg/Kg,10090.0,
5674,,,A,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Area under curve was determined for the compound at 5 mg/Kg,10090.0,
5675,,,A,1,Intermediate,,3132,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve for the compound is obtained at dose 25 mg/kg,10090.0,
5676,,,A,1,Intermediate,,3132,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve for the compound was obtained when tested in mouse,10090.0,
5677,,,A,1,Intermediate,,17837,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,10090.0,
5678,,,A,1,Intermediate,,17837,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,10090.0,
5679,,,A,1,Intermediate,,6062,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,10090.0,
5680,,,A,1,Intermediate,,4066,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,10090.0,
5681,,,A,1,Intermediate,,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),10090.0,
5682,,,A,1,Intermediate,,14239,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,10090.0,
5683,,,A,1,Intermediate,,14239,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,10090.0,
5684,,,A,1,Intermediate,,4890,Mus musculus,BAO_0000218,,,,,50594,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",10090.0,
5685,,,A,1,Intermediate,,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),10090.0,
5686,,,A,1,Intermediate,,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),10090.0,
5687,,,A,1,Intermediate,,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,10090.0,
5688,,,A,1,Intermediate,,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,10090.0,
5689,,,A,1,Intermediate,,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,
5690,,,A,1,Intermediate,,6091,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,10090.0,
5691,,,A,1,Intermediate,,6091,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,10090.0,
5692,,,A,1,Intermediate,,6091,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,10090.0,
5693,,,A,1,Intermediate,,6091,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,10090.0,
5694,,,A,1,Intermediate,,6178,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,10090.0,
5695,,,A,1,Intermediate,,6178,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,10090.0,
5696,,,A,1,Intermediate,,6619,Mus musculus,BAO_0000218,,,,,50594,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",10090.0,
5697,,,A,1,Intermediate,,6619,Mus musculus,BAO_0000218,,,,,50594,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",10090.0,
5698,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",10090.0,
5699,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",10090.0,
5700,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",10090.0,
5701,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",10090.0,
5702,,,A,1,Intermediate,,3192,Mus musculus,BAO_0000218,,,,,50594,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,10090.0,
5703,,,A,1,Intermediate,,3192,Mus musculus,BAO_0000218,,,,,50594,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,10090.0,
5704,,,A,1,Intermediate,,2675,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve was evaluated in mice after intravenous administration,10090.0,
5705,,,A,1,Intermediate,,2675,Mus musculus,BAO_0000218,,,,,50594,1,Area under the curve was evaluated in mice after oral administration,10090.0,
5706,,,A,1,Intermediate,,16597,Mus musculus,BAO_0000218,,Plasma,,,50594,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
5707,,,A,1,Intermediate,,16597,Mus musculus,BAO_0000218,,Plasma,,,50594,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,10090.0,
5708,,,A,1,Intermediate,,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),10090.0,
5709,,,A,1,Intermediate,,17734,Mus musculus,BAO_0000218,,,,,50594,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,10090.0,
5710,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,10090.0,
5711,,9L,F,1,Intermediate,,15345,,BAO_0000219,392.0,,,,80653,1,The compound was tested in vitro for anticancer activity against 9L cells,,
5712,,,F,0,Autocuration,,2181,Rattus norvegicus,BAO_0000019,,,,,22226,1,Anti proliferation activity determined; Weak effect,10116.0,
5713,,,F,0,Autocuration,,2181,Rattus norvegicus,BAO_0000219,,,,,22226,1,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,10116.0,
5714,,,F,0,Autocuration,,2181,Rattus norvegicus,BAO_0000219,,,,,22226,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,10116.0,
5715,,,F,0,Autocuration,,2181,Rattus norvegicus,BAO_0000219,,,,,22226,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,10116.0,
5716,,,F,0,Autocuration,,10486,Mus musculus,BAO_0000019,,,,,22226,1,The cytotoxic activity was in vitro tested by 9PS assay method,10090.0,
5717,,,F,0,Autocuration,,10486,Mus musculus,BAO_0000019,,,,,22226,1,The cytotoxic activity was in vitro tested by 9PS assay method.,10090.0,
5718,,,A,0,Autocuration,,15508,,BAO_0000019,,,,,22224,1,Partition coefficient (logD6.5),,
5719,,A2780,F,1,Expert,,5242,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,9606.0,
5720,,A-375,F,1,Intermediate,,16167,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),9606.0,
5721,,A-431,F,1,Expert,,4782,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,9606.0,
5722,,A-431,F,9,Expert,,16093,Homo sapiens,BAO_0000219,500.0,,,,9,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9606.0,
5723,,A498,F,1,Intermediate,,2596,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,9606.0,
5724,,A498,F,1,Intermediate,,2596,Homo sapiens,BAO_0000219,624.0,,,,80021,1,in vitro cytotoxicity against A 498 cancer cell line,9606.0,
5725,,A498,F,1,Intermediate,,3239,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,9606.0,
5726,,A498,F,1,Intermediate,,1847,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxic activity against A 498 renal cancer cell lines.,9606.0,
5727,,A498,F,1,Intermediate,,10553,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,9606.0,
5728,,,F,0,Autocuration,,16219,Staphylococcus aureus,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1280.0,
5729,,,F,0,Autocuration,,16219,Staphylococcus aureus,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1280.0,
5730,,,F,0,Autocuration,,16219,Staphylococcus aureus,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1280.0,
5731,,,F,0,Autocuration,,16219,Staphylococcus aureus,BAO_0000019,,,,,22226,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1280.0,
5732,,A549,F,1,Intermediate,,4782,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration required against A 549 lung cancer cell line,9606.0,
5733,,A549,F,1,Intermediate,,11805,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,9606.0,
5734,,A549,F,1,Intermediate,,11805,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,9606.0,
5735,,A549,F,1,Intermediate,,2007,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against lung cancer A 549 cell lines,9606.0,
5736,,A549,F,1,Intermediate,,4594,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its cytotoxicity against A 549 cell line,9606.0,
5737,,A549,F,1,Expert,,6018,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",9606.0,
5738,,A549,F,1,Intermediate,,6018,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",9606.0,
5739,,A549,F,1,Expert,,3599,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,9606.0,
5740,,A549,F,1,Intermediate,,2551,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,9606.0,
5741,,A549,F,1,Expert,,16132,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibition of A549 (human lung cancer) cell growth.,9606.0,
5742,,A549,F,1,Intermediate,,16132,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,9606.0,
5743,,A549,F,1,Expert,,2551,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,9606.0,
5744,,A549,F,1,Expert,,2551,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),9606.0,
5745,,,F,0,Autocuration,,11913,,BAO_0000218,,,,,22226,1,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,
5746,,,F,4,Autocuration,In vivo,12621,,BAO_0000218,,,,,104694,1,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,
5747,,,F,4,Autocuration,In vivo,12621,,BAO_0000218,,,,,104694,1,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,
5748,,,F,4,Autocuration,In vivo,12621,,BAO_0000218,,,,,104694,1,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,
5749,,,F,4,Autocuration,In vivo,12621,,BAO_0000218,,,,,104694,1,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,
5750,,,F,4,Autocuration,In vivo,12621,,BAO_0000218,,,,,104694,1,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,
5751,,A498,F,1,Expert,,3600,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Inhibition of A-498 human Renal cell proliferation,9606.0,
5752,,,F,0,Autocuration,,1796,Rattus norvegicus,BAO_0000019,,,,,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",10116.0,
5753,,,F,0,Autocuration,,1796,Rattus norvegicus,BAO_0000019,,,,,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",10116.0,
5754,,,F,0,Autocuration,,1796,Rattus norvegicus,BAO_0000019,,,,,22226,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",10116.0,
5755,,A 172,F,1,Expert,,16464,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,9606.0,
5756,,A 172,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5757,,A 172,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5758,,A549,F,1,Expert,,13617,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,9606.0,
5759,,A549,F,1,Intermediate,,4584,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,9606.0,
5760,,A549,F,1,Expert,,13799,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity evaluated against A549 tumor cells,9606.0,
5761,,A549,F,1,Intermediate,,16726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,9606.0,
5762,,A549,F,1,Intermediate,,16109,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,9606.0,
5763,,A549,F,1,Intermediate,,16109,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,9606.0,
5764,,A549,F,1,Intermediate,,15474,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,9606.0,
5765,,A549,F,1,Intermediate,,6851,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity of compound against A549 cell line,9606.0,
5766,,A549,F,1,Expert,,17534,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung cell carcinoma A549 cell line,9606.0,
5767,,A549,F,1,Intermediate,,2621,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,9606.0,
5768,,A549,F,1,Intermediate,,830,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,9606.0,
5769,,A549,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,9606.0,
5770,,A549,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,9606.0,
5771,,A549,F,1,Intermediate,,1590,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,9606.0,
5772,,A549,F,1,Expert,,6146,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,9606.0,
5773,,A549,F,1,Expert,,17427,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,
5774,,A549,F,1,Intermediate,,5280,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,9606.0,
5775,,A549,F,1,Intermediate,,16786,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,9606.0,
5776,,A549,F,1,Intermediate,,5895,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549 (human lung cancer),9606.0,
5777,,A549,F,1,Expert,,14297,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,9606.0,
5778,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,In vivo antiproliferative activity against A549 cell line,9606.0,
5779,,A549,F,1,Intermediate,,14368,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of non-small-cell lung adenocarcinoma (A549),9606.0,
5780,,A549,F,1,Intermediate,,14368,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,9606.0,
5781,,A549,F,1,Intermediate,,14254,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,9606.0,
5782,,A549,F,1,Intermediate,,15897,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),9606.0,
5783,,A549,F,1,Intermediate,,13866,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,9606.0,
5784,,A549,F,1,Intermediate,,13370,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,9606.0,
5785,,A549,F,1,Intermediate,,4862,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 lung cancer cell line,9606.0,
5786,,A549,F,1,Intermediate,,4862,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,9606.0,
5787,,A549,F,1,Intermediate,,4862,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,9606.0,
5788,,A549,F,1,Intermediate,,15970,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration against A549 (lung cancer) cell line,9606.0,
5789,,A549,F,1,Expert,,17713,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,9606.0,
5790,,A549,F,1,Intermediate,,4833,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,9606.0,
5791,,A549,F,1,Expert,,13736,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Activity against A549 cancer cell line.,9606.0,
5792,,A549,F,1,Intermediate,,4312,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was evaluated for cytotoxicity against A549 cell line,9606.0,
5793,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,9606.0,
5794,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,9606.0,
5795,,A549,F,1,Intermediate,,14717,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibitory activity was measured for human A549 tumor cell line.,9606.0,
5796,,A549,F,1,Intermediate,,4634,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 lung cancer cell line,9606.0,
5797,,A549,F,1,Intermediate,,1149,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 cell line; inactive,9606.0,
5798,,A549,F,1,Expert,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,9606.0,
5799,,A549,F,1,Expert,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,9606.0,
5800,,A549,F,1,Intermediate,,5421,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,9606.0,
5801,,A549,F,1,Intermediate,,3320,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),9606.0,
5802,,A549,F,1,Intermediate,,3320,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),9606.0,
5803,,A549,F,1,Intermediate,,3320,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),9606.0,
5804,,A549,F,1,Intermediate,,3320,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),9606.0,
5805,,A549,F,1,Intermediate,,3320,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),9606.0,
5806,,A549,F,1,Intermediate,,5726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,9606.0,
5807,,,A,1,Intermediate,In vivo,17800,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance (in vivo) in mongrel dogs was determined,9615.0,
5808,,,A,1,Intermediate,In vivo,5985,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was measured in dog,9615.0,
5809,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,9615.0,
5810,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,9615.0,
5811,,,A,1,Intermediate,In vivo,4839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Tested for plasma clearance in dog,9615.0,
5812,,,A,1,Intermediate,In vivo,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for clearance in dog plasma.,9615.0,
5813,,,A,1,Intermediate,In vivo,4838,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",9615.0,
5814,,,A,1,Intermediate,In vivo,4137,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,9615.0,
5815,,,A,1,Intermediate,In vivo,5017,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),9615.0,
5816,Microsomes,,A,1,Intermediate,In vitro,17538,Canis lupus familiaris,BAO_0000218,,Liver,,,50588,1,In vitro clearance in dog liver microsomes,9615.0,
5817,,,A,1,Intermediate,In vivo,6161,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,9615.0,
5818,,,A,1,Intermediate,In vivo,6161,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,9615.0,
5819,,,A,1,Intermediate,In vivo,1696,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog,9615.0,
5820,,,A,1,Intermediate,In vivo,6762,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance rate in dog,9615.0,
5821,,,A,1,Intermediate,In vivo,5932,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,9615.0,
5822,,,A,1,Intermediate,In vivo,6305,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance in dogs,9615.0,
5823,,,A,1,Intermediate,In vivo,4942,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dogs,9615.0,
5824,,,A,1,Intermediate,In vivo,4219,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined,9615.0,
5825,,,A,1,Intermediate,In vivo,17853,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Lower clearance in dog (i.v.) at 0.5 mpk,9615.0,
5826,,,A,1,Intermediate,In vivo,4514,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in Beagle dogs,9615.0,
5827,,,A,1,Intermediate,In vivo,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance (Clp) in dog,9615.0,
5828,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,9615.0,
5829,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,9615.0,
5830,,,A,1,Intermediate,In vivo,6062,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,9615.0,
5831,,,A,1,Intermediate,In vivo,6821,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance of compound was determined in dog,9615.0,
5832,,,A,1,Intermediate,In vivo,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,9615.0,
5833,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,
5834,,,A,1,Intermediate,In vivo,5374,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog was determined,9615.0,
5835,,,A,1,Intermediate,In vivo,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was calculated in dog,9615.0,
5836,,,A,1,Intermediate,In vivo,4727,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance at the dose of 2 mg/kg in dog,9615.0,
5837,,,A,1,Intermediate,In vivo,5145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog,9615.0,
5838,,,A,1,Intermediate,In vivo,17657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog,9615.0,
5839,,,A,1,Intermediate,In vivo,17657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog; Unable to calculate,9615.0,
5840,,,A,1,Intermediate,In vivo,5145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in rhesus monkey,9615.0,
5841,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,
5842,,,A,1,Intermediate,In vivo,6641,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
5843,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
5844,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was evaluated in dog,9615.0,
5845,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was evaluated in dog; Not tested,9615.0,
5846,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was evaluated in rhesus,9615.0,
5847,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was evaluated in rhesus; Not tested,9615.0,
5848,,,A,1,Intermediate,In vivo,4257,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,9615.0,
5849,,,A,1,Intermediate,In vivo,6679,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,
5850,,,A,1,Intermediate,In vivo,5546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,
5851,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
5852,,,A,1,Intermediate,In vivo,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Clearance value at a dose of 0.2 mg/kg i.v.,9615.0,
5853,,,A,1,Intermediate,In vivo,6316,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,9615.0,
5854,,,A,1,Intermediate,In vivo,17594,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax after oral dose of compound at 3 mg/kg in dogs,9615.0,
5855,,,A,1,Intermediate,In vivo,17594,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,9615.0,
5856,,,A,1,Intermediate,In vivo,5802,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,
5857,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,9615.0,
5858,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax in dog after administration of 1 mg/kg iv,9615.0,
5859,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,9615.0,
5860,,,A,1,Intermediate,In vivo,6505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,9615.0,
5861,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax was determine after peroral administration at 10 mpk in dog,9615.0,
5862,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax was determine after peroral administration at 5 mpk in dog,9615.0,
5863,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax was determine after peroral administration at 5 mg/kg in dog,9615.0,
5864,,,A,1,Intermediate,In vivo,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax after 0.3 mg/kg po administration in dog,9615.0,
5865,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax after peroral administration in dogs at 2.4 uM/kg,9615.0,
5866,,,A,1,Intermediate,In vivo,6123,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax in dog after oral administration at 1 mg/kg,9615.0,
5867,,,A,1,Intermediate,In vivo,6123,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,9615.0,
5868,,,A,1,Intermediate,In vivo,6757,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,9615.0,
5869,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value after 15 mg/kg iv dose in Dogs,9615.0,
5870,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5871,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5872,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5873,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5874,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5875,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5876,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5877,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5878,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5879,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5880,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5881,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5882,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5883,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5884,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5885,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5886,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5887,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5888,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5889,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5890,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5891,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5892,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5893,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5894,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5895,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5896,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5897,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5898,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,,,,50594,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5899,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5900,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5901,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Intestine,,,50594,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5902,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5903,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5904,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
5905,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
5906,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,10090.0,
5907,,A 172,F,1,Expert,,2036,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Cytotoxicity against A-172 human tumor cell lines,9606.0,
5908,,A 172,F,1,Intermediate,,2357,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,9606.0,
5909,,A204,F,1,Intermediate,,1457,Homo sapiens,BAO_0000219,623.0,,,,80014,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,9606.0,
5910,,A2780,F,1,Intermediate,,4379,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Tested for antiproliferative activity against A-2780 tumoral cell line,9606.0,
5911,,A-375,F,1,Intermediate,,1093,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,9606.0,
5912,,A-375,F,1,Intermediate,,12152,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Tested in vitro against A-375 cell line human melanoma,9606.0,
5913,,A-427,F,1,Expert,,16464,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,9606.0,
5914,,A-427,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5915,,A-427,F,1,Expert,,16582,Homo sapiens,BAO_0000219,797.0,,,,80019,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,9606.0,
5916,,A-427,F,1,Intermediate,,16464,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,9606.0,
5917,,A-427,F,1,Intermediate,,10413,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Antitumor activity on A-427 lung carcinoma cell lines,9606.0,
5918,,A-427,F,1,Intermediate,,6418,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxic activity against human A-427 lung tumor cell line,9606.0,
5919,,A-427,F,1,Expert,,17134,Homo sapiens,BAO_0000219,797.0,,,,80019,1,In vitro antitumor effects against human A-427 cell lines.,9606.0,
5920,,A-427,F,1,Expert,,16132,Homo sapiens,BAO_0000219,797.0,,,,80019,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,9606.0,
5921,,A-427,F,1,Intermediate,,16132,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,9606.0,
5922,,A-427,F,1,Intermediate,,16780,Homo sapiens,BAO_0000219,797.0,,,,80019,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,9606.0,
5923,,A-431,F,1,Expert,,4085,Homo sapiens,BAO_0000219,500.0,,,,80852,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,9606.0,
5924,,A498,F,1,Intermediate,,1276,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,9606.0,
5925,,A498,F,1,Expert,,3498,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,9606.0,
5926,,A498,F,1,Intermediate,,1169,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Cytotoxicity against human kidney carcinoma A-498cell lines,9606.0,
5927,,A498,F,1,Intermediate,,4450,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,9606.0,
5928,,A498,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,9606.0,
5929,,A498,F,1,Intermediate,,4461,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Antitumor cytotoxic activity against A-498 cell line was determined,9606.0,
5930,,A498,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,9606.0,
5931,,A498,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,9606.0,
5932,,A498,F,1,Intermediate,,1457,Homo sapiens,BAO_0000219,624.0,,,,80021,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,9606.0,
5933,,A498,F,1,Intermediate,,3664,Homo sapiens,BAO_0000219,624.0,,,,80021,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,9606.0,
5934,,A498,F,1,Intermediate,,15895,Homo sapiens,BAO_0000219,624.0,,,,80021,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",9606.0,
5935,,A549,F,1,Intermediate,,11843,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,9606.0,
5936,,A549,F,1,Intermediate,,11843,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,9606.0,
5937,,A549,F,1,Intermediate,,17705,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antiproliferative activity against human A-549 NSCL cell line,9606.0,
5938,,A549,F,1,Intermediate,,17705,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,9606.0,
5939,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,9606.0,
5940,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,9606.0,
5941,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,9606.0,
5942,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,9606.0,
5943,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,9606.0,
5944,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,9606.0,
5945,,A549,F,1,Intermediate,,4369,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,9606.0,
5946,,A549,F,1,Expert,,4787,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,9606.0,
5947,,A549,F,1,Intermediate,,4787,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,9606.0,
5948,,A549,F,1,Intermediate,,6513,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against A-549 cell line,9606.0,
5949,,A549,F,1,Intermediate,,6690,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,9606.0,
5950,,A549,F,1,Intermediate,,6690,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,9606.0,
5951,,A549,F,1,Expert,,12263,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",9606.0,
5952,,A549,F,1,Intermediate,,1054,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),9606.0,
5953,,A549,F,1,Intermediate,,1359,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),9606.0,
5954,,A549,F,1,Intermediate,,3547,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,9606.0,
5955,,A549,F,1,Expert,,5771,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity towards A-549 cells,9606.0,
5956,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro percent inhibition of A549, lung carcinoma.",9606.0,
5957,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro percent inhibition of A549, lung carcinoma",9606.0,
5958,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro percent inhibition of A549, lung carcinoma.",9606.0,
5959,,A549,F,1,Intermediate,,14425,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",9606.0,
5960,,A549,F,1,Intermediate,,5280,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,9606.0,
5961,,A549,F,1,Intermediate,,15176,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,9606.0,
5962,,A549,F,1,Intermediate,,15300,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,9606.0,
5963,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,
5964,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,
5965,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,
5966,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,
5967,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000218,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",9606.0,
5968,,A549,F,1,Intermediate,,17824,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",9606.0,
5969,,A549,F,1,Intermediate,,17528,Homo sapiens,BAO_0000218,646.0,,,,80682,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),9606.0,
5970,,A549,F,1,Expert,,6870,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,9606.0,
5971,,A549,F,1,Intermediate,,6870,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,9606.0,
5972,,A549,F,1,Intermediate,,6870,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,9606.0,
5973,,A549,F,1,Intermediate,,6870,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,9606.0,
5974,,A549,F,1,Intermediate,,16726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,9606.0,
5975,,A549,F,1,Intermediate,,6170,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",9606.0,
5976,,A549,F,1,Expert,,6583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,9606.0,
5977,,A549,F,1,Expert,,6583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,9606.0,
5978,,A549,F,1,Expert,,6583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,9606.0,
5979,,A549,F,1,Expert,,6583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,9606.0,
5980,,A549,F,1,Expert,,6583,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,9606.0,
5981,,A549,F,1,Intermediate,,17321,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,9606.0,
5982,,A549,F,1,Expert,,17528,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,9606.0,
5983,,A549,F,1,Expert,,12888,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,9606.0,
5984,,A549,F,1,Intermediate,,4312,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,9606.0,
5985,,A549,F,1,Intermediate,,4312,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,9606.0,
5986,,A549,F,1,Intermediate,,4312,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,9606.0,
5987,,A549,F,1,Intermediate,,17737,Mus musculus,BAO_0000219,646.0,,,,80682,1,In vitro antiproliferative activity against A549 cell line,10090.0,
5988,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Synergism with indomethacin in A549 cells,,
5989,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Synergism with tolmetin in A549 cells,,
5990,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Synergism with sulindac in A549 cells,,
5991,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Antagonism of indomethacin in A549 cells,,
5992,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Antagonism of sulindac in A549 cells,,
5993,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Antagonism of tolmetin in A549 cells,,
5994,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Synergism with indomethacin in A549 cells,,
5995,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Synergism with sulindac in A549 cells,,
5996,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,
5997,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value after 30 mg/kg po dose in Dogs,9615.0,
5998,,,A,1,Intermediate,In vivo,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,
5999,,,A,1,Intermediate,In vivo,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,9615.0,
6000,,,A,1,Intermediate,In vivo,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),9615.0,
6001,,,A,1,Intermediate,In vivo,5944,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,9615.0,
6002,,,A,1,Intermediate,In vivo,2959,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value after administration of 4 mg/Kg oral dose in dog,9615.0,
6003,,,A,1,Intermediate,In vivo,6241,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value in dog,9615.0,
6004,,,A,1,Intermediate,In vivo,6241,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value in dogs after oral administration at 1 mg/kg,9615.0,
6005,,,A,1,Intermediate,In vivo,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,9615.0,
6006,,,A,1,Intermediate,In vivo,1806,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,9615.0,
6007,,,A,1,Intermediate,In vivo,1806,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,9615.0,
6008,,,A,1,Intermediate,In vivo,1021,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Concentration maxima after oral dosing in dogs,9615.0,
6009,,,A,1,Intermediate,In vivo,1021,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Concentration maxima after oral dosing in dogs; not available,9615.0,
6010,,,A,1,Intermediate,In vivo,1021,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Concentration maxima after oral dosing in dogs; not available,9615.0,
6011,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,9615.0,
6012,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,9615.0,
6013,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,9615.0,
6014,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,9615.0,
6015,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,9615.0,
6016,,,A,1,Intermediate,In vivo,5130,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Cmax in dog plasma after oral dose (1 mg/kg),9615.0,
6017,,,A,1,Intermediate,In vivo,3249,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,9615.0,
6018,,,A,1,Intermediate,In vivo,5473,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximal plasma concentration at a dose of 1 mg/kg,9615.0,
6019,,,A,1,Intermediate,In vivo,5474,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),9615.0,
6020,,,A,1,Intermediate,In vivo,4657,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,9615.0,
6021,,,A,1,Intermediate,In vivo,3031,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration of compound in dog was evaluated.,9615.0,
6022,,,A,1,Intermediate,In vivo,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,
6023,,,A,1,Intermediate,In vivo,4186,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,9615.0,
6024,,,A,1,Intermediate,In vivo,5007,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,
6025,,,A,1,Intermediate,In vivo,3132,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum concentration obtained in dog plasma was determined,9615.0,
6026,,,A,1,Intermediate,In vivo,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration was determined,9615.0,
6027,,,A,1,Intermediate,In vivo,4727,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration at the dose of 2 mg/kg in dog,9615.0,
6028,,,A,1,Intermediate,In vivo,1916,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,
6029,,,A,1,Intermediate,In vivo,1918,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum concentration was evaluated in dog plasma,9615.0,
6030,,,A,1,Intermediate,In vivo,3045,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration was evaluated after 75 min after administration in dog,9615.0,
6031,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration determined in dog after oral administration of 17b,9615.0,
6032,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration determined in dog after oral administration of 2b,9615.0,
6033,,,A,1,Intermediate,In vivo,933,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration in dog,9615.0,
6034,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,9615.0,
6035,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,9615.0,
6036,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,9615.0,
6037,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,9615.0,
6038,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
6039,,,A,1,Intermediate,In vivo,16367,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,9615.0,
6040,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,
6041,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,
6042,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,9615.0,
6043,,,A,1,Intermediate,In vivo,17650,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,9615.0,
6044,,,A,1,Intermediate,In vivo,6679,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,9615.0,
6045,,,A,1,Intermediate,In vivo,5356,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,9615.0,
6046,,,A,1,Intermediate,In vivo,5356,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,9615.0,
6047,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,9615.0,
6048,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,9615.0,
6049,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,9615.0,
6050,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,9615.0,
6051,,,A,1,Expert,In vivo,3598,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
6052,,,A,1,Intermediate,In vivo,4368,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,9615.0,
6053,,,A,1,Intermediate,In vivo,6265,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,9615.0,
6054,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,10090.0,
6055,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Urine,,,50594,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,10090.0,
6056,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Urine,,,50594,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,10090.0,
6057,,,A,1,Intermediate,In vivo,7767,Mus musculus,BAO_0000218,,Urine,,,50594,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,10090.0,
6058,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,,,,50594,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,10090.0,
6059,,,A,1,Intermediate,,17811,Mus musculus,BAO_0000218,,,,,50594,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,10090.0,
6060,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),10090.0,
6061,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,Blood,,,50594,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),10090.0,
6062,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),10090.0,
6063,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),10090.0,
6064,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),10090.0,
6065,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,Blood,,,50594,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),10090.0,
6066,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,Blood,,,50594,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),10090.0,
6067,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),10090.0,
6068,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,10090.0,
6069,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,
6070,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,
6071,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",10090.0,
6072,,,A,1,Intermediate,,17257,Mus musculus,BAO_0000218,,,,,50594,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,10090.0,
6073,,,A,1,Intermediate,,17257,Mus musculus,BAO_0000218,,,,,50594,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,10090.0,
6074,,,A,1,Intermediate,,17257,Mus musculus,BAO_0000218,,,,,50594,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,10090.0,
6075,,,A,1,Intermediate,,17257,Mus musculus,BAO_0000218,,,,,50594,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,10090.0,
6076,,,A,1,Intermediate,,17827,Mus musculus,BAO_0000218,,,,,50594,1,Time at maximum activity in mice (Radiolabeled compound),10090.0,
6077,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,10090.0,
6078,,,A,1,Intermediate,,3760,Mus musculus,BAO_0000218,,,,,50594,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,10090.0,
6079,,,A,1,Intermediate,,17409,Mus musculus,BAO_0000218,,,,,50594,1,Binding towards mouse plasma protein at 10 uM,10090.0,
6080,,,A,1,Intermediate,,17409,Mus musculus,BAO_0000218,,,,,50594,1,Binding towards mouse plasma protein at 100 uM,10090.0,
6081,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was evaluated in mice after intravenous administration,10090.0,
6082,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was evaluated in mice after oral administration,10090.0,
6083,,,A,1,Intermediate,In vivo,3132,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,10090.0,
6084,,,A,1,Intermediate,In vivo,3132,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,10090.0,
6085,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,10090.0,
6086,,,A,1,Intermediate,In vivo,2862,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in mouse,10090.0,
6087,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,10090.0,
6088,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6089,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6090,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6091,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6092,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6093,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Brain,,,50594,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6094,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6095,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6096,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6097,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6098,,A549,F,1,Intermediate,,1276,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),9606.0,
6099,,A549,F,1,Expert,,3498,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,9606.0,
6100,,A549,F,1,Intermediate,,1169,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma A-549 cell lines,9606.0,
6101,,A549,F,1,Intermediate,,4450,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,9606.0,
6102,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,9606.0,
6103,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,9606.0,
6104,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,9606.0,
6105,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,9606.0,
6106,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,9606.0,
6107,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,9606.0,
6108,,A549,F,1,Intermediate,,358,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,9606.0,
6109,,A549,F,1,Intermediate,,15167,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A-549 human lung cancer cells,9606.0,
6110,,A549,F,1,Intermediate,,4139,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,9606.0,
6111,,A549,F,1,Intermediate,,833,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,9606.0,
6112,,A549,F,1,Expert,,15718,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,
6113,,A549,F,1,Intermediate,,12373,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,9606.0,
6114,,A549,F,1,Intermediate,,637,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,9606.0,
6115,,A549,F,1,Expert,,14867,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,9606.0,
6116,,A549,F,1,Intermediate,,4461,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor cytotoxic activity against A-549 cell line was determined,9606.0,
6117,,A549,F,1,Intermediate,,5406,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",9606.0,
6118,,A549,F,1,Intermediate,,4457,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,9606.0,
6119,,A549,F,1,Expert,,1386,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,9606.0,
6120,,A549,F,1,Intermediate,,3265,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumoral activity was assayed against A-549 cell line,9606.0,
6121,,A549,F,1,Intermediate,,2359,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,9606.0,
6122,,A549,F,1,Intermediate,,4457,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,9606.0,
6123,,A549,F,1,Expert,,12454,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,9606.0,
6124,,A549,F,1,Intermediate,,1481,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for inhibition of cell growth of A-549 cells,9606.0,
6125,,A549,F,1,Intermediate,,1750,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,9606.0,
6126,,A549,F,1,Intermediate,,5065,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,9606.0,
6127,,A549,F,1,Expert,,808,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,9606.0,
6128,,A549,F,1,Expert,,16364,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,9606.0,
6129,,A549,F,1,Intermediate,,1847,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity against A-549 cell lines.,9606.0,
6130,,A549,F,1,Expert,,1747,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,9606.0,
6131,,A549,F,1,Intermediate,,1003,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human A549 non small cell lung cell lines,9606.0,
6132,,A549,F,1,Expert,,15313,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of cell growth in (A-549) lung cell line,9606.0,
6133,,A549,F,1,Intermediate,,3122,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,9606.0,
6134,,A549,F,1,Intermediate,,16049,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against A-549 tumor cells.,9606.0,
6135,,A549,F,1,Expert,,17134,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor effects against human A-549 cell lines.,9606.0,
6136,,A549,F,1,Intermediate,,6406,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxic activity of compound against A-549 cell line,9606.0,
6137,,A549,F,1,Intermediate,,627,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,9606.0,
6138,,A549,F,1,Intermediate,,12307,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,9606.0,
6139,,A549,F,1,Intermediate,,17861,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,9606.0,
6140,,A549,F,1,Expert,,6682,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,9606.0,
6141,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration of compound against A-549 cell line,9606.0,
6142,,A549,F,1,Intermediate,,2454,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,9606.0,
6143,,A549,F,1,Intermediate,,14709,Homo sapiens,BAO_0000219,646.0,,,,80682,1,cytotoxic activity against leukemia (A-549) cancer cell line,9606.0,
6144,,A549,F,1,Expert,,15718,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,
6145,,A549,F,1,Intermediate,,15718,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,9606.0,
6146,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),9606.0,
6147,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),9606.0,
6148,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),9606.0,
6149,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),9606.0,
6150,,A549,F,1,Intermediate,,6630,,BAO_0000219,646.0,,,,80682,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,
6151,,A549,F,1,Intermediate,,16726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,9606.0,
6152,,A549,F,1,Intermediate,,17846,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against A549 cells; No cytotoxicity,9606.0,
6153,,A549,F,1,Expert,,3415,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma (A549) cell lines,9606.0,
6154,,A549,F,1,Expert,,3415,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,9606.0,
6155,,A549,F,1,Intermediate,,5609,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro anticancer activity against human lung (A549) cell line,9606.0,
6156,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,9606.0,
6157,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,9606.0,
6158,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,9606.0,
6159,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,9606.0,
6160,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,9606.0,
6161,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,9606.0,
6162,,A549,F,1,Expert,,16295,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of A549 human lung tumor cell proliferation,9606.0,
6163,,A549,F,1,Intermediate,,16825,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",9606.0,
6164,,A549,F,1,Expert,,3439,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human tumor cell line A549,9606.0,
6165,,A549,F,1,Intermediate,,10870,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,9606.0,
6166,,A549,F,1,Intermediate,,4845,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,9606.0,
6167,,A549,F,1,Intermediate,,5822,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,9606.0,
6168,,A549,F,1,Intermediate,,5822,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,9606.0,
6169,,A549,F,1,Intermediate,,5822,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,9606.0,
6170,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,9606.0,
6171,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,9606.0,
6172,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,9606.0,
6173,,A549,F,1,Intermediate,,5609,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro anticancer activity against human lung (A549) cell line,9606.0,
6174,,A549,F,1,Intermediate,,4644,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,9606.0,
6175,,A549,F,1,Intermediate,,4644,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,9606.0,
6176,,A549,F,1,Intermediate,,4644,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,9606.0,
6177,,A549,F,1,Intermediate,,4644,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,9606.0,
6178,,A549,F,1,Intermediate,,5822,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,9606.0,
6179,,A549,F,1,Expert,,3415,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percentage inhibition of human lung carcinoma (A549) cell lines,9606.0,
6180,,A549,F,1,Intermediate,,16726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,9606.0,
6181,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",9606.0,
6182,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,9606.0,
6183,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,9606.0,
6184,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",9606.0,
6185,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",9606.0,
6186,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",9606.0,
6187,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",9606.0,
6188,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",9606.0,
6189,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,9606.0,
6190,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,9606.0,
6191,,A549,F,1,Intermediate,,16726,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,9606.0,
6192,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,9606.0,
6193,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,9606.0,
6194,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,9606.0,
6195,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,9606.0,
6196,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,9615.0,
6197,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic activity (Cmax) in dog,9615.0,
6198,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,
6199,,,A,1,Intermediate,In vivo,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,9615.0,
6200,,,A,1,Intermediate,In vivo,6251,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,9615.0,
6201,,,A,1,Intermediate,In vivo,5932,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Cmax in dog plasma after 30mg/kg oral dose,9615.0,
6202,,,A,1,Intermediate,In vivo,4273,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Tested for the peak blood level in dog,9615.0,
6203,,,A,1,Intermediate,In vivo,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",9615.0,
6204,,,A,1,Intermediate,In vivo,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",9615.0,
6205,,,A,1,Intermediate,In vivo,6221,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,9615.0,
6206,,,A,1,Intermediate,,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,9615.0,
6207,,,A,1,Intermediate,,167,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,9615.0,
6208,,,A,1,Intermediate,,6241,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,9615.0,
6209,,,A,1,Intermediate,,344,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,9615.0,
6210,,,A,1,Intermediate,,344,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,9615.0,
6211,,,A,1,Intermediate,,344,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,9615.0,
6212,,,A,1,Intermediate,,2189,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,9615.0,
6213,,,A,1,Intermediate,,2189,Canis lupus familiaris,BAO_0000218,,Urine,,,50588,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,9615.0,
6214,,,A,1,Intermediate,,2189,Canis lupus familiaris,BAO_0000218,,Urine,,,50588,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,9615.0,
6215,,,A,1,Intermediate,,2189,Canis lupus familiaris,BAO_0000218,,Urine,,,50588,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,9615.0,
6216,,,A,1,Intermediate,In vivo,4257,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Absolute bioavailability was evaluated in dog,9615.0,
6217,,,A,1,Intermediate,In vivo,6221,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,9615.0,
6218,,,A,1,Intermediate,In vivo,6215,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,9615.0,
6219,,,A,1,Intermediate,In vivo,17267,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6220,,,A,1,Intermediate,In vivo,6621,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6221,,,A,1,Intermediate,In vivo,3854,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability after intravenous administration in dogs,9615.0,
6222,,,A,1,Intermediate,In vivo,3854,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability after peroral administration in dogs,9615.0,
6223,,,A,1,Intermediate,In vivo,5007,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),9615.0,
6224,,,A,1,Intermediate,In vivo,4333,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,9615.0,
6225,,,A,1,Intermediate,In vivo,4333,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,9615.0,
6226,,,A,1,Intermediate,In vivo,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability,9615.0,
6227,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability,9615.0,
6228,,,A,1,Intermediate,In vivo,4368,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,9615.0,
6229,,,A,1,Intermediate,In vivo,3771,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6230,,,A,1,Intermediate,In vivo,4953,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6231,,,A,1,Intermediate,In vivo,5064,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6232,,,A,1,Intermediate,In vivo,17657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6233,,,A,1,Intermediate,In vivo,17796,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6234,,,A,1,Intermediate,In vivo,17853,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (p.o.) at 2.0 mpk,9615.0,
6235,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),9615.0,
6236,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,
6237,,,A,1,Intermediate,In vivo,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6238,,,A,1,Intermediate,In vivo,16365,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was evaluated after oral administration in dog,9615.0,
6239,,,A,1,Intermediate,In vivo,1916,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,
6240,,,A,1,Intermediate,In vivo,1918,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was evaluated in dog,9615.0,
6241,,,A,1,Intermediate,In vivo,4239,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6242,,,A,1,Intermediate,In vivo,6505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6243,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,
6244,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),9615.0,
6245,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,
6246,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
6247,,,A,1,Intermediate,In vivo,6005,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,9615.0,
6248,,,A,1,Intermediate,In vivo,17804,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability of compound in dog was determined after peroral administration,9615.0,
6249,,,A,1,Intermediate,In vivo,3184,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6250,,,A,1,Intermediate,In vivo,1806,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,9615.0,
6251,,,A,1,Intermediate,In vivo,1806,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,9615.0,
6252,,,A,1,Intermediate,In vivo,1806,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,9615.0,
6253,,,A,1,Intermediate,In vivo,4839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6254,,,A,1,Intermediate,In vivo,5017,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),9615.0,
6255,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6256,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6257,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6258,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6259,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6260,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6261,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6262,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6263,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6264,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6265,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6266,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6267,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6268,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6269,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6270,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6271,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6272,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6273,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,10090.0,
6274,,,A,1,Intermediate,In vivo,846,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,10090.0,
6275,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,10090.0,
6276,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,10090.0,
6277,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,10090.0,
6278,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,10090.0,
6279,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,10090.0,
6280,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Brain,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,10090.0,
6281,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Brain,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,10090.0,
6282,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Brain,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,10090.0,
6283,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Brain,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,10090.0,
6284,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Brain,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,10090.0,
6285,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,10090.0,
6286,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,10090.0,
6287,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,10090.0,
6288,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,10090.0,
6289,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,10090.0,
6290,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Kidney,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,10090.0,
6291,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Kidney,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,10090.0,
6292,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Kidney,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,10090.0,
6293,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,9606.0,
6294,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,9606.0,
6295,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),9606.0,
6296,,A549,F,1,Intermediate,,17130,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),9606.0,
6297,,A549,F,1,Expert,,3263,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,9606.0,
6298,,A549,F,1,Expert,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,9606.0,
6299,,A549,F,1,Expert,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,9606.0,
6300,,A549,F,1,Expert,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,9606.0,
6301,,A549,F,1,Expert,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,9606.0,
6302,,A549,F,1,Expert,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,9606.0,
6303,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,9606.0,
6304,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,9606.0,
6305,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,9606.0,
6306,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,9606.0,
6307,,A549,F,1,Intermediate,,6663,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,9606.0,
6308,,A549,F,1,Intermediate,,3983,Homo sapiens,BAO_0000219,646.0,,,,80682,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,9606.0,
6309,,A549,F,1,Expert,,11141,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,9606.0,
6310,,A549,F,1,Intermediate,,5076,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 tumor cell line.,9606.0,
6311,,A549,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,9606.0,
6312,,A549,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,9606.0,
6313,,A549,F,1,Intermediate,,3311,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,9606.0,
6314,,A549,F,1,Intermediate,,5076,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,9606.0,
6315,,A549,F,1,Intermediate,,4150,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),9606.0,
6316,,A549,F,1,Expert,,2150,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,9606.0,
6317,,A549,F,1,Intermediate,,4644,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,9606.0,
6318,,A549,F,1,Intermediate,,263,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,9606.0,
6319,,A549,F,1,Intermediate,,11333,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic concentration against A-549 tumor cells.,9606.0,
6320,,A549,F,1,Intermediate,,11333,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,9606.0,
6321,,A549,F,1,Intermediate,,15895,Homo sapiens,BAO_0000219,646.0,,,,80682,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",9606.0,
6322,,,F,1,Expert,,16677,Acinetobacter baumannii,BAO_0000218,,,,,50191,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,470.0,
6323,,,F,1,Intermediate,,10624,Acinetobacter calcoaceticus,BAO_0000218,,,,,50192,1,Activity against Acinetobacter calcoaceticus (AC54),471.0,
6324,,,F,1,Expert,,16717,Aspergillus flavus,BAO_0000218,,,,,50274,1,In vitro antifungal activity against Aspergillus flavus CM74,5059.0,
6325,,,F,1,Expert,,16717,Aspergillus flavus,BAO_0000218,,,,,50274,1,In vitro antifungal activity against Aspergillus flavus CM74,5059.0,
6326,,,F,1,Intermediate,,5513,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,746128.0,
6327,,,F,1,Intermediate,,15962,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),746128.0,
6328,,,F,1,Intermediate,,15962,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,Antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,
6329,,,F,1,Intermediate,,15962,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,Antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,
6330,,,F,1,Intermediate,,15962,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),746128.0,
6331,,,F,1,Expert,,16717,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,746128.0,
6332,,,F,1,Expert,,16717,Aspergillus fumigatus,BAO_0000218,,,,,50416,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,746128.0,
6333,,,F,1,Intermediate,,8117,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1655.0,
6334,,,F,1,Intermediate,,8117,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1656.0,
6335,,,F,1,Intermediate,,15472,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),6277.0,
6336,,,F,1,Intermediate,,15472,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),6277.0,
6337,,,F,1,Intermediate,,16443,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,,,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,714.0,
6338,,,F,1,Intermediate,,16443,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,,,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,714.0,
6339,,,F,1,Intermediate,,16443,Aggregatibacter actinomycetemcomitans,BAO_0000218,,,,,50169,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,714.0,
6340,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,9606.0,
6341,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,9606.0,
6342,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,9606.0,
6343,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,9606.0,
6344,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,9606.0,
6345,,A549,F,1,Intermediate,,16381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,GI values against A549 cells (lung cancer),9606.0,
6346,,A549,F,1,Intermediate,,17206,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,9606.0,
6347,,A549,F,1,Intermediate,,16325,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 human adenocarcinoma,9606.0,
6348,,A549,F,1,Intermediate,,10708,Homo sapiens,BAO_0000218,646.0,,,,80682,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,9606.0,
6349,,A549,F,1,Intermediate,,10708,Homo sapiens,BAO_0000218,646.0,,,,80682,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,9606.0,
6350,,A549,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line,9606.0,
6351,,A549,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,9606.0,
6352,,A549,F,1,Intermediate,,17488,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity against human A549 lung cells,9606.0,
6353,,A549,F,1,Intermediate,,17404,Homo sapiens,BAO_0000218,646.0,,,,80682,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,9606.0,
6354,,A549,F,1,Expert,,10958,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibition of A549 (human lung carcinoma) cell line.,9606.0,
6355,,A549,F,1,Expert,,17099,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,9606.0,
6356,,A549,F,1,Intermediate,,17099,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,9606.0,
6357,,A549,F,1,Intermediate,,4096,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,9606.0,
6358,,A549,F,1,Expert,,4096,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,9606.0,
6359,,A549,F,1,Intermediate,,4096,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,9606.0,
6360,,A549,F,1,Intermediate,,2525,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory activity against A549 tumor cell culture,9606.0,
6361,,A549,F,1,Intermediate,,2525,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,9606.0,
6362,,A549,F,1,Intermediate,,5302,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),9606.0,
6363,,A549,F,1,Intermediate,,16325,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,9606.0,
6364,,A549,F,1,Intermediate,,16939,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,9606.0,
6365,,A549,F,1,Intermediate,,17229,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,9606.0,
6366,,A549,F,1,Intermediate,,17380,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,9606.0,
6367,,A549,F,1,Intermediate,,17380,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,9606.0,
6368,,A549,F,1,Intermediate,,1903,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,9606.0,
6369,,A549,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,9606.0,
6370,,A549,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,9606.0,
6371,,A549,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,9606.0,
6372,,A549,F,1,Intermediate,,1522,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,9606.0,
6373,,A549,F,1,Intermediate,,12400,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,9606.0,
6374,,A549,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,646.0,,,,80682,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,9606.0,
6375,,A549,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),9606.0,
6376,,A549,F,1,Intermediate,,14696,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,9606.0,
6377,,A549,F,1,Intermediate,,1888,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,9606.0,
6378,,A549,F,1,Intermediate,,12016,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,9606.0,
6379,,A549,F,1,Intermediate,,6058,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,9606.0,
6380,,A549,F,1,Intermediate,,17708,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,9606.0,
6381,,A549,F,1,Intermediate,,12301,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Antitumor activity against A549/ATCC cell line,9606.0,
6382,,A549,F,1,Intermediate,,11970,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,9606.0,
6383,,A549,F,1,Expert,,11818,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro cytotoxicity against A549/ATCC cell line.,9606.0,
6384,,A549,F,1,Intermediate,,12400,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,9606.0,
6385,,A549,F,1,Intermediate,,3381,Homo sapiens,BAO_0000219,646.0,,,,80682,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,9606.0,
6386,,A549,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,9606.0,
6387,,A549,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,646.0,,,,80682,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,9606.0,
6388,,,F,0,Autocuration,,2964,Homo sapiens,BAO_0000219,,,,,22226,1,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,9606.0,
6389,,,A,0,Intermediate,In vivo,5005,Canis lupus familiaris,BAO_0000218,,,,,22224,1,Compound was tested for oral bioavailability in dogs,9615.0,
6390,,,A,1,Intermediate,In vivo,6229,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,9615.0,
6391,,,A,1,Intermediate,In vivo,6229,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,9615.0,
6392,,,A,1,Intermediate,In vivo,5374,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6393,,,A,1,Intermediate,In vivo,5374,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for the oral bioavailability in dog; No availability,9615.0,
6394,,,A,1,Intermediate,In vivo,6265,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 mg/kg),9615.0,
6395,,,A,1,Intermediate,In vivo,5654,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,9615.0,
6396,,,A,1,Intermediate,In vivo,5654,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,9615.0,
6397,,,A,1,Intermediate,In vivo,16456,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),9615.0,
6398,,,A,1,Intermediate,In vivo,5302,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 mg/kg),9615.0,
6399,,,A,1,Intermediate,In vivo,3624,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),9615.0,
6400,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability of active FTIs in dogs,9615.0,
6401,,,A,1,Intermediate,In vivo,5802,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),9615.0,
6402,,,A,1,Expert,In vivo,3598,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
6403,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6404,,,A,1,Intermediate,In vivo,6762,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6405,,,A,1,Intermediate,In vivo,6821,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6406,,,A,1,Intermediate,In vivo,6821,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability of compound was determined in dog; Not tested,9615.0,
6407,,,A,1,Intermediate,In vivo,5210,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6408,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability (10 mg/kg) was determined in dog,9615.0,
6409,,,A,1,Intermediate,In vivo,761,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability,9615.0,
6410,,,A,1,Intermediate,In vivo,761,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),9615.0,
6411,,,A,1,Intermediate,In vivo,761,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability administered in solution in rats,9615.0,
6412,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability after 30 mg/kg po dose in Dogs,9615.0,
6413,,,A,1,Intermediate,In vivo,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability at a dose of 1 mg/kg in dogs,9615.0,
6414,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),9615.0,
6415,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in Dog; ND = not determined,9615.0,
6416,,,A,1,Intermediate,In vivo,3352,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6417,,,A,1,Intermediate,In vivo,6168,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6418,,,A,1,Intermediate,In vivo,5988,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6419,,,A,1,Intermediate,In vivo,4942,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6420,,,A,1,Intermediate,In vivo,4942,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dogs; No data,9615.0,
6421,,,A,1,Intermediate,In vivo,14541,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability measured in dogs,9615.0,
6422,,,A,1,Intermediate,In vivo,4449,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6423,,,A,1,Intermediate,In vivo,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability was calculated in dog,9615.0,
6424,,,A,1,Intermediate,In vivo,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability after 0.3 mg/kg po administration in dog,9615.0,
6425,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (i.v. dosing),9615.0,
6426,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6427,,,A,1,Intermediate,In vivo,5546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,9615.0,
6428,,,A,1,Intermediate,In vivo,4514,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in Beagle dogs,9615.0,
6429,,,A,1,Intermediate,In vivo,3624,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6430,,,A,1,Intermediate,In vivo,3854,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6431,,,A,1,Intermediate,In vivo,5836,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6432,,,A,1,Intermediate,In vivo,5940,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6433,,,A,1,Intermediate,In vivo,6168,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6434,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6435,,,A,1,Intermediate,In vivo,6251,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6436,,,A,1,Intermediate,In vivo,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6437,,,A,1,Intermediate,In vivo,6647,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6438,,,A,1,Intermediate,In vivo,5940,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6439,,,A,1,Intermediate,In vivo,933,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6440,,,A,1,Intermediate,In vivo,5210,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6441,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),9615.0,
6442,,,A,1,Intermediate,In vivo,6641,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),9615.0,
6443,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),9615.0,
6444,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6445,,,A,1,Intermediate,In vivo,5985,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6446,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6447,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),9615.0,
6448,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),9615.0,
6449,,,A,1,Intermediate,In vivo,6305,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability (F) in dogs,9615.0,
6450,,,A,1,Intermediate,In vivo,5210,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6451,,,A,1,Intermediate,In vivo,5238,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6452,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
6453,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability after peroral administration at 5 mpk in Dog,9615.0,
6454,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 mg/kg),9615.0,
6455,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
6456,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Kidney,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,10090.0,
6457,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Kidney,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,10090.0,
6458,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,10090.0,
6459,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,10090.0,
6460,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,10090.0,
6461,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,10090.0,
6462,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,10090.0,
6463,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,10090.0,
6464,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,10090.0,
6465,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,10090.0,
6466,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,10090.0,
6467,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,10090.0,
6468,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,10090.0,
6469,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,10090.0,
6470,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,10090.0,
6471,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,10090.0,
6472,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,10090.0,
6473,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Spleen,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,10090.0,
6474,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Spleen,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,10090.0,
6475,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Spleen,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,10090.0,
6476,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Spleen,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,10090.0,
6477,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Spleen,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,10090.0,
6478,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,10090.0,
6479,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,10090.0,
6480,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,10090.0,
6481,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,10090.0,
6482,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,10090.0,
6483,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,10090.0,
6484,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,10090.0,
6485,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,10090.0,
6486,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,10090.0,
6487,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,10090.0,
6488,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,10090.0,
6489,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,10090.0,
6490,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,10090.0,
6491,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,10090.0,
6492,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Heart,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,10090.0,
6493,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,10090.0,
6494,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,10090.0,
6495,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,10090.0,
6496,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,10090.0,
6497,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Liver,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,10090.0,
6498,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,10090.0,
6499,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,10090.0,
6500,,,F,1,Intermediate,,12269,aeinetobacter anitrotap,BAO_0000218,,,,,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,
6501,,,F,1,Intermediate,,12269,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,,,,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,
6502,,,F,1,Intermediate,,12269,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,,,,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,
6503,,,F,1,Intermediate,,12269,aeinetobacter anitrotap,BAO_0000218,,,,,50067,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,107673.0,
6504,,,F,1,Intermediate,,10624,Acinetobacter calcoaceticus,BAO_0000218,,,,,50192,1,Activity against Acinetobacter calcoaceticus (AC54),471.0,
6505,,,F,1,Intermediate,,17216,Anolis carolinensis,BAO_0000218,,,,,50714,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,28377.0,
6506,,,F,1,Intermediate,,17216,Anolis carolinensis,BAO_0000218,,,,,50714,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,28377.0,
6507,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,1655.0,
6508,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,1655.0,
6509,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1655.0,
6510,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1655.0,
6511,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Plaque bactericidal index against Actinomyces naeslundii 631,1655.0,
6512,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Plaque bactericidal index against Actinomyces naeslundii N/9,1655.0,
6513,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Plaque bactericidal index against Actinomyces naeslundii B74,1655.0,
6514,,,F,1,Intermediate,,9560,Actinomyces naeslundii,BAO_0000218,,,,,50296,1,Plaque bactericidal index against Actinomyces naeslundii N/3,1655.0,
6515,,,F,1,Intermediate,,114,Artemia salina,BAO_0000218,,,,,50056,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,85549.0,
6516,,,F,1,Intermediate,,114,Artemia salina,BAO_0000218,,,,,50056,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",85549.0,
6517,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,6253.0,
6518,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,6253.0,
6519,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,6253.0,
6520,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,6253.0,
6521,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,6253.0,
6522,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,6253.0,
6523,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,6253.0,
6524,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,6253.0,
6525,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,6253.0,
6526,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,6253.0,
6527,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,6253.0,
6528,,,F,1,Intermediate,,10841,Ascaris suum,BAO_0000218,,,,,50532,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,6253.0,
6529,,,F,1,Intermediate,,8117,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1656.0,
6530,,,F,1,Intermediate,,8117,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1656.0,
6531,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1656.0,
6532,,,F,1,Expert,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,1656.0,
6533,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,1656.0,
6534,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,1656.0,
6535,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Plaque bactericidal index against Actinomyces viscosus 8A06,1656.0,
6536,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Plaque bactericidal index against Actinomyces viscosus M-100,1656.0,
6537,,,F,1,Expert,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1656.0,
6538,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1656.0,
6539,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1656.0,
6540,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Plaque bactericidal index against Actinomyces viscosus 626,1656.0,
6541,,,F,1,Intermediate,,9560,Actinomyces viscosus,BAO_0000218,,,,,50366,1,Plaque bactericidal index against Actinomyces viscosus T14V,1656.0,
6542,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,6277.0,
6543,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,6277.0,
6544,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,6277.0,
6545,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,6277.0,
6546,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,6277.0,
6547,,A673,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,165.0,,,,80023,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,9606.0,
6548,,A704,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,645.0,,,,80661,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,9606.0,
6549,,,F,0,Autocuration,,416,Rattus norvegicus,BAO_0000219,,,,,22226,1,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,10116.0,
6550,,A9,F,1,Intermediate,,14354,Mus musculus,BAO_0000219,625.0,,,,80024,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,10090.0,
6551,,A9,F,1,Intermediate,,14354,Mus musculus,BAO_0000219,625.0,,,,80024,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,10090.0,
6552,,A9,F,1,Intermediate,,5116,Homo sapiens,BAO_0000219,625.0,,,,80024,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,9606.0,
6553,,A9,F,1,Intermediate,,5116,Homo sapiens,BAO_0000219,625.0,,,,80024,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,9606.0,
6554,,Human ovarian carcinoma cell line,F,1,Expert,,15694,Homo sapiens,BAO_0000219,874.0,,,,81037,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,9606.0,
6555,,A9,F,1,Expert,,13038,Mus musculus,BAO_0000219,625.0,,,,80024,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",10090.0,
6556,,A9,F,1,Expert,,13038,Mus musculus,BAO_0000219,625.0,,,,80024,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,10090.0,
6557,,A9,F,1,Expert,,10923,Mus musculus,BAO_0000219,625.0,,,,80024,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,10090.0,
6558,,A9,F,1,Intermediate,,10923,Mus musculus,BAO_0000219,625.0,,,,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,10090.0,
6559,,A9,F,1,Intermediate,,10923,Mus musculus,BAO_0000219,625.0,,,,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,10090.0,
6560,,,F,8,Expert,,10923,,BAO_0000019,,,,,10649,1,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,
6561,,A9,F,1,Intermediate,,10923,Mus musculus,BAO_0000219,625.0,,,,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,10090.0,
6562,,A9,F,1,Intermediate,,10923,Mus musculus,BAO_0000219,625.0,,,,80024,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,10090.0,
6563,,AA6,F,1,Intermediate,,8158,Cricetulus griseus,BAO_0000219,975.0,,,,80663,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,10029.0,
6564,,,F,0,Autocuration,,15494,Homo sapiens,BAO_0000219,,,,,22226,1,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,9606.0,
6565,,,F,0,Autocuration,,15494,Homo sapiens,BAO_0000219,,,,,22226,1,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",9606.0,
6566,,AA5,F,1,Intermediate,,12348,Homo sapiens,BAO_0000219,974.0,,,,80662,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),9606.0,
6567,,AA5,F,1,Intermediate,,12348,Homo sapiens,BAO_0000219,974.0,,,,80662,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),9606.0,
6568,,AA5,F,1,Intermediate,,2726,Homo sapiens,BAO_0000219,974.0,,,,80662,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,9606.0,
6569,,U-937,F,1,Intermediate,,2726,Homo sapiens,BAO_0000219,379.0,,,,80566,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,9606.0,
6570,,UV4,F,1,Intermediate,,10747,Cricetulus griseus,BAO_0000219,274.0,,,,80578,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,10029.0,
6571,,CHO-AA8,F,1,Expert,,11005,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",10029.0,
6572,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Average intracellular compound concentration when the hypoxic SER=1.6,10029.0,
6573,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Average intracellular compound concentration when the hypoxic SER=1.6.,10029.0,
6574,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,10029.0,
6575,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,10029.0,
6576,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,10029.0,
6577,,CHO-AA8,F,1,Intermediate,,13436,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",10029.0,
6578,,CHO-AA8,F,1,Intermediate,,13435,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",10029.0,
6579,,CHO-AA8,F,1,Intermediate,,13302,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,10029.0,
6580,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,10029.0,
6581,,CHO-AA8,A,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,10029.0,
6582,,CHO-AA8,A,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,10029.0,
6583,,CHO-AA8,A,1,Expert,,12878,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,10029.0,
6584,,CHO-AA8,A,1,Intermediate,,12878,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,10029.0,
6585,,CHO-AA8,F,1,Expert,,14367,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,10029.0,
6586,,CHO-AA8,F,1,Intermediate,,14367,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,10029.0,
6587,,CHO-AA8,F,1,Expert,,12398,hampster,BAO_0000219,185.0,,,,80089,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,36483.0,
6588,,CHO-AA8,F,1,Expert,,12878,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Aerobic growth inhibition in Chinese hamster cell line AA8,10029.0,
6589,,CHO-AA8,F,1,Expert,,13820,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,10029.0,
6590,,CHO-AA8,F,1,Expert,,13436,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Inhibition of growth under aerobic conditions in AA8 cells,10029.0,
6591,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
6592,,,A,1,Intermediate,In vivo,5711,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog at 10 mg/kg of the compound,9615.0,
6593,,,A,1,Intermediate,In vivo,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 uM/kg),9615.0,
6594,,,A,1,Intermediate,In vivo,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 uM/kg),9615.0,
6595,,,A,1,Intermediate,In vivo,17800,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (mongrel),9615.0,
6596,,,A,1,Intermediate,In vivo,3994,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
6597,,,F,1,Intermediate,In vivo,3994,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 10 mg/kg),9615.0,
6598,,,A,1,Intermediate,In vivo,5145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6599,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,
6600,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),9615.0,
6601,,,A,1,Intermediate,In vivo,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,9615.0,
6602,,,A,1,Intermediate,In vivo,4273,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6603,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 3-10 mg/kg),9615.0,
6604,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,9615.0,
6605,,,A,1,Intermediate,In vivo,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6606,,,A,1,Intermediate,In vivo,3880,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6607,,,A,1,Intermediate,In vivo,4838,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog,9615.0,
6608,,,A,1,Intermediate,In vivo,15600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,oral bioavailability was measured in dogs,9615.0,
6609,,,A,1,Intermediate,,17248,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for plasma protein binding in dog; Not determined,9615.0,
6610,,,A,1,Intermediate,,17248,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for plasma protein binding of dog,9615.0,
6611,,,A,1,Intermediate,,17248,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for plasma protein binding of dog; Not determined,9615.0,
6612,,,A,1,Intermediate,,17443,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,9615.0,
6613,,,A,1,Intermediate,In vivo,4186,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,9615.0,
6614,,,A,1,Intermediate,,3749,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was determined,9615.0,
6615,,,A,1,Intermediate,In vivo,3249,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,9615.0,
6616,,,A,1,Intermediate,,3022,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was evaluated in dog,9615.0,
6617,,,A,1,Intermediate,,3749,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was determined,9615.0,
6618,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6619,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,Heart,,,50588,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6620,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,Kidney,,,50588,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6621,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,Liver,,,50588,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6622,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,Lung,,,50588,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6623,,,A,1,Intermediate,In vivo,2517,Canis lupus familiaris,BAO_0000218,,Spleen,,,50588,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),9615.0,
6624,,,A,1,Intermediate,,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,LogP in dog,9615.0,
6625,,,A,1,Intermediate,,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Partition coefficient (logP),9615.0,
6626,,,A,1,Intermediate,,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Partition coefficient in dog,9615.0,
6627,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,9615.0,
6628,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),9615.0,
6629,,,A,1,Intermediate,,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,9615.0,
6630,,,A,1,Intermediate,,14294,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),9615.0,
6631,,,A,1,Intermediate,,14294,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),9615.0,
6632,,,A,1,Intermediate,,14294,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Metabolism of compound in dog S9 microsomes; Trace,9615.0,
6633,,,A,1,Intermediate,,6251,Canis lupus familiaris,BAO_0000218,,Liver,,,50588,1,In vitro metabolic potential in dog liver microsomes,9615.0,
6634,,,A,1,Intermediate,In vivo,3748,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,9615.0,
6635,,,A,1,Intermediate,In vivo,2713,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6636,,,A,1,Intermediate,In vivo,6512,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6637,,,A,1,Intermediate,In vivo,6679,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,
6638,,,A,1,Intermediate,In vivo,3749,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for bioavailability in dogs,9615.0,
6639,,,A,1,Intermediate,In vivo,3749,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for oral bioavailability in dogs,9615.0,
6640,,,A,1,Intermediate,In vivo,6742,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog,9615.0,
6641,,,A,1,Intermediate,,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for percent protein binding (PB) in dog,9615.0,
6642,,,A,1,Intermediate,,6874,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,9615.0,
6643,,,A,1,Intermediate,In vivo,2877,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was evaluated for plasma clearance.,9615.0,
6644,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,The compound was tested for plasma clearance in dog,9615.0,
6645,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,9615.0,
6646,,,A,1,Intermediate,,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,9615.0,
6647,,,A,1,Intermediate,,5542,Canis lupus familiaris,BAO_0000218,,Liver,,,50588,1,In vitro relative rate of metabolism was determined in dog liver microsomes,9615.0,
6648,,,A,1,Intermediate,In vivo,17594,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,9615.0,
6649,,,A,1,Intermediate,In vivo,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,9615.0,
6650,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life after intravenous administration in dogs at 1.2 uM/kg,9615.0,
6651,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,10090.0,
6652,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,10090.0,
6653,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,Lung,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,10090.0,
6654,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,10090.0,
6655,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,10090.0,
6656,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,10090.0,
6657,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,10090.0,
6658,,CCRF S-180,A,1,Intermediate,,6599,Mus musculus,BAO_0000218,42.0,,,,50594,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,10090.0,
6659,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Brain,,,50594,1,C2 in brain of mice at the oral dose of 50 mg/kg,10090.0,
6660,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Kidney,,,50594,1,C2 in kidney of mice at the oral dose of 50 mg/kg,10090.0,
6661,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Liver,,,50594,1,C2 in liver of mice at the oral dose of 50 mg/kg,10090.0,
6662,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Lung,,,50594,1,C2 in lungs of mice at the oral dose of 50 mg/kg,10090.0,
6663,,,A,1,Intermediate,,17641,Mus musculus,BAO_0000218,,Spleen,,,50594,1,C2 in spleen of mice at the oral dose of 50 mg/kg,10090.0,
6664,,,A,1,Intermediate,In vivo,17852,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance in mouse,10090.0,
6665,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,10090.0,
6666,,,A,1,Intermediate,In vivo,17837,Mus musculus,BAO_0000218,,,,,50594,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,10090.0,
6667,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Clearance was evaluated in mice after intravenous administration,10090.0,
6668,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,,,,50594,1,Clearance was evaluated in mice after oral administration,10090.0,
6669,,,A,1,Intermediate,In vivo,4239,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,10090.0,
6670,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance of compound was determined at 40 mg/Kg,10090.0,
6671,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance of at 24 mg/Kg,10090.0,
6672,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance at 24 mg/Kg,10090.0,
6673,,,A,1,Intermediate,In vivo,17753,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance at 5 mg/Kg,10090.0,
6674,,,A,1,Intermediate,In vivo,5727,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance in mice,10090.0,
6675,,,A,1,Intermediate,In vivo,2862,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance value upon iv administration in mouse,10090.0,
6676,,,A,1,Intermediate,In vivo,5980,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Total plasma clearance in mice,10090.0,
6677,,,A,1,Intermediate,In vivo,17592,Mus musculus,BAO_0000218,,,,,50594,1,Clearance in mouse,10090.0,
6678,,,A,1,Intermediate,In vivo,17718,Mus musculus,BAO_0000218,,,,,50594,1,Clearance value was determined,10090.0,
6679,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
6680,,,P,0,Intermediate,,17384,,BAO_0000100,,,,,22229,1,Calculated partition coefficient (clogP),,
6681,,,A,1,Intermediate,In vivo,6062,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,10090.0,
6682,,,A,1,Intermediate,In vivo,17734,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,10090.0,
6683,,,A,1,Intermediate,In vivo,6348,Mus musculus,BAO_0000218,,,,,50594,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,
6684,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,10090.0,
6685,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,10090.0,
6686,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,10090.0,
6687,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,10090.0,
6688,,,A,1,Intermediate,In vivo,5781,Mus musculus,BAO_0000218,,,,,50594,1,Cmax after oral administration at 30 mg/kg in ICR mouse,10090.0,
6689,,,A,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax after peroral administration in mice at 2.4 uM/kg,10090.0,
6690,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Brain,,,50594,1,Cmax in brain of mice at the oral dose of 50 mg/kg,10090.0,
6691,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,10090.0,
6692,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Liver,,,50594,1,Cmax in liver of mice at the oral dose of 50 mg/kg,10090.0,
6693,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Lung,,,50594,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,10090.0,
6694,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in mice at 18 uM/kg i.p. administration,10090.0,
6695,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in mice at 23 uM/kg i.v. administration,10090.0,
6696,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in mice at 24 uM/kg i.p. administration,10090.0,
6697,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in mice at 25 uM/kg i.p. administration,10090.0,
6698,,,F,1,Intermediate,In vivo,17764,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in mice at 26 uM/kg i.p. administration,10090.0,
6699,,,A,1,Intermediate,In vivo,17641,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,10090.0,
6700,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,10090.0,
6701,,,A,1,Intermediate,In vivo,16597,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,10090.0,
6702,,,A,1,Intermediate,In vivo,5727,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value was determined,10090.0,
6703,,,A,1,Intermediate,In vivo,5951,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value in IRC mice,10090.0,
6704,,,A,1,Intermediate,In vivo,5506,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,10090.0,
6705,,,A,1,Intermediate,In vivo,5506,Mus musculus,BAO_0000218,,,,,50594,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,10090.0,
6706,,,A,1,Intermediate,In vivo,14239,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,10090.0,
6707,,,A,1,Intermediate,In vivo,4890,Mus musculus,BAO_0000218,,Plasma,,,50594,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",10090.0,
6708,,,A,1,Intermediate,In vivo,429,Mus musculus,BAO_0000218,,,,,50594,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,10090.0,
6709,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,6277.0,
6710,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,6277.0,
6711,,,F,1,Intermediate,,10986,Acanthocheilonema viteae,BAO_0000218,,,,,50535,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,6277.0,
6712,,A-375,F,1,Intermediate,,13227,Homo sapiens,BAO_0000219,455.0,,,,80018,1,Inhibitory activity against human tumor cell line A0375 melanoma.,9606.0,
6713,Brain membranes,,B,9,Expert,,4481,Rattus norvegicus,BAO_0000249,,,,,12512,1,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,10116.0,
6714,,,F,9,Expert,,16931,Homo sapiens,BAO_0000019,,,,,114,1,Forskolin-induced cAMP production at human A1 adenosine receptor,9606.0,
6715,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,
6716,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,
6717,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,
6718,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,
6719,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,
6720,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,
6721,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,
6722,,CHO,F,9,Expert,,3850,Homo sapiens,BAO_0000219,449.0,,,,114,1,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,9606.0,
6723,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,
6724,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,
6725,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,
6726,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,
6727,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,
6728,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,
6729,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6730,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,
6731,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,
6732,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,
6733,,CHO,F,8,Autocuration,,3850,,BAO_0000219,449.0,,,,114,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,
6734,,CHO,F,8,Expert,,3850,,BAO_0000219,449.0,,,,114,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,
6735,,A10,F,1,Intermediate,,12680,Oryctolagus cuniculus,BAO_0000219,164.0,,,,80013,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,9986.0,
6736,,A10,F,0,Autocuration,,1313,Rattus norvegicus,BAO_0000219,164.0,,,,22226,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells,10116.0,
6737,,A10,F,0,Autocuration,,1313,Rattus norvegicus,BAO_0000219,164.0,,,,22226,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,10116.0,
6738,,A10,F,1,Intermediate,,17567,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,10116.0,
6739,,A10,F,1,Intermediate,,17567,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,10116.0,
6740,,A10,F,1,Intermediate,,11819,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,10116.0,
6741,,CHO-AA8,F,1,Intermediate,,13436,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,10029.0,
6742,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,10029.0,
6743,,CHO-AA8,F,1,Intermediate,,12651,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,10029.0,
6744,,CHO-AA8,F,1,Intermediate,,13300,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,10029.0,
6745,,CHO-AA8,F,1,Intermediate,,15296,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,10029.0,
6746,,CHO-AA8,F,1,Intermediate,,15328,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",10029.0,
6747,,CHO-AA8,F,1,Intermediate,,13302,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),10029.0,
6748,,CHO-AA8,F,1,Expert,,14367,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",10029.0,
6749,,CHO-AA8,F,1,Expert,,17002,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,10029.0,
6750,,CHO-AA8,F,1,Intermediate,,13436,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,10029.0,
6751,,CHO-AA8,F,1,Intermediate,,13435,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Inhibitory activity against aerobic growth of AA8 cells.,10029.0,
6752,,CHO-AA8,A,1,Intermediate,,10503,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,
6753,,CHO-AA8,F,1,Expert,,10503,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,
6754,,CHO-AA8,F,1,Intermediate,,10503,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,10029.0,
6755,,CHO-AA8,F,1,Expert,,15090,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,10029.0,
6756,,CHO-AA8,F,1,Expert,,10368,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Cytotoxicity against AA8 cell line,10029.0,
6757,,CHO-AA8,F,1,Intermediate,,12651,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),10029.0,
6758,,CHO-AA8,A,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,
6759,,CHO-AA8,F,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,
6760,,CHO-AA8,A,1,Intermediate,,12687,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),10029.0,
6761,,CHO-AA8,F,1,Intermediate,,1890,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,10029.0,
6762,,CHO-AA8,F,1,Intermediate,,10747,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10029.0,
6763,,CHO-AA8,F,1,Intermediate,,10747,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,10029.0,
6764,,,F,0,Autocuration,,11616,Cricetulus griseus,BAO_0000218,,,,,22224,1,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),10029.0,
6765,,CHO-AA8,F,1,Expert,,11616,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,10029.0,
6766,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,10029.0,
6767,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,10029.0,
6768,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,10029.0,
6769,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,10029.0,
6770,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,10029.0,
6771,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,10029.0,
6772,,CHO-AA8,F,0,Autocuration,,3471,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,10029.0,
6773,,CHO-AA8,F,1,Expert,,11616,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Concentration required to reduce AA8 cell survival by 10%,10029.0,
6774,,CHO-AA8,F,0,Autocuration,,2656,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",10029.0,
6775,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10029.0,
6776,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,10029.0,
6777,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,10029.0,
6778,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,10029.0,
6779,,CHO-AA8,F,0,Autocuration,,16156,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,10029.0,
6780,,CHO-AA8,F,0,Autocuration,,2656,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,10029.0,
6781,,,F,0,Autocuration,,11005,Cricetulus griseus,BAO_0000019,,,,,22224,1,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",10029.0,
6782,,CHO-AA8,F,0,Autocuration,,11942,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,10029.0,
6783,,CHO-AA8,F,0,Autocuration,,2128,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,10029.0,
6784,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period after 15 mg/kg iv dose in Dogs,9615.0,
6785,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period after 30 mg/kg po dose in Dogs,9615.0,
6786,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was measured after oral 2b administration (tested in 6 dogs),9615.0,
6787,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was measured in dog after oral 17b administration,9615.0,
6788,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,9615.0,
6789,,,A,1,Intermediate,In vivo,9579,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,9615.0,
6790,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax value after 15 mg/kg iv dose in Dogs,9615.0,
6791,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax value after 30 mg/kg po dose in Dogs,9615.0,
6792,,,A,1,Intermediate,In vivo,3184,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for its half life when administered intravenously in dog,9615.0,
6793,,,A,1,Intermediate,In vivo,5017,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),9615.0,
6794,,,A,1,Intermediate,,6821,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Elimination Half-life of compound was determined in dog,9615.0,
6795,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life of compound in dog following oral administration,9615.0,
6796,,,A,1,Intermediate,,17267,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life of compound was determined in dog,9615.0,
6797,,,A,1,Intermediate,,4727,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Half life of compound was determined in dog blood,9615.0,
6798,,,A,1,Intermediate,In vivo,5238,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life after oral and iv dosing in dogs,9615.0,
6799,,,A,1,Intermediate,,4942,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dogs in hours,9615.0,
6800,,,A,1,Intermediate,In vivo,6505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life on i.v. administration of 2 mg/kg was measured in dog,9615.0,
6801,,,A,1,Intermediate,In vivo,5130,Canis lupus familiaris,BAO_0000218,,,,,50588,1,t1/2 in dog after oral dose (1 mg/kg),9615.0,
6802,,,A,1,Intermediate,,1475,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was evaluated in dog,9615.0,
6803,,,A,1,Intermediate,In vivo,17804,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,9615.0,
6804,,,A,1,Intermediate,In vivo,17804,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period of compound was determined after peroral administration at 2 mg/kg,9615.0,
6805,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period (10 mg/kg) was determined in dog,9615.0,
6806,,,A,1,Intermediate,In vivo,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period (10 mg/kg) was determined in dog,9615.0,
6807,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,9615.0,
6808,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,9615.0,
6809,,,A,1,Intermediate,,6084,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period in dog,9615.0,
6810,,,A,1,Intermediate,In vivo,6241,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period in dogs after oral administration at 1 mg/kg,9615.0,
6811,,,A,1,Intermediate,In vivo,1916,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,
6812,,,A,1,Intermediate,,6621,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound was determined in dogs,9615.0,
6813,,,A,1,Intermediate,,1696,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half-life in dog plasma,9615.0,
6814,,,A,1,Intermediate,,17800,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in mongrel dogs was determined,9615.0,
6815,,,A,1,Intermediate,In vivo,17657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dog upon oral administration,9615.0,
6816,,,A,1,Intermediate,In vivo,17657,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dog upon oral administration; Unable to calculate,9615.0,
6817,,,A,1,Intermediate,,4239,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was measured in dog,9615.0,
6818,,,A,1,Intermediate,,5985,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was measured in dog,9615.0,
6819,,,A,1,Intermediate,,9932,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,9615.0,
6820,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral half life was determined,9615.0,
6821,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,9615.0,
6822,,,A,1,Intermediate,,1475,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half life was evaluated,9615.0,
6823,,,A,1,Intermediate,,1475,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half life was evaluated in Dog,9615.0,
6824,,,A,1,Intermediate,,1475,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Plasma half life was evaluated in dog,9615.0,
6825,,,A,1,Intermediate,In vivo,6316,Canis lupus familiaris,BAO_0000218,,,,,50588,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,9615.0,
6826,,,A,1,Intermediate,,4883,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for the half life value in dog,9615.0,
6827,,,A,1,Intermediate,In vivo,4727,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum time at the dose of 2 mg/kg in dog,9615.0,
6828,,,A,1,Intermediate,In vivo,1916,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,9615.0,
6829,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,
6830,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,
6831,,,A,1,Intermediate,In vivo,6265,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,9615.0,
6832,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),9615.0,
6833,,,A,1,Intermediate,In vivo,5983,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,9615.0,
6834,,,A,1,Intermediate,,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",9615.0,
6835,,,A,1,Intermediate,In vivo,5313,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",9615.0,
6836,,,A,1,Intermediate,In vivo,17650,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,9615.0,
6837,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,9615.0,
6838,,,A,1,Intermediate,,933,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Time taken for maximum plasma concentration in dog,9615.0,
6839,,,A,1,Intermediate,In vivo,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Time to reach Cmax after oral administration to dogs,9615.0,
6840,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
6841,,,A,1,Intermediate,In vivo,6316,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,9615.0,
6842,,,A,1,Intermediate,In vivo,6215,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax after peroral administration (1 mg/kg) was determined in dog,9615.0,
6843,,,A,1,Expert,In vivo,3598,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
6844,,,A,1,Intermediate,In vivo,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,
6845,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax after peroral administration in dogs at 2.4 uM/kg,9615.0,
6846,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo Cmax in mice at dose of 100 mg/kg,10090.0,
6847,,,A,1,Intermediate,In vivo,5969,Mus musculus,BAO_0000218,,,,,50594,1,In vivo Cmax in mice at dose of 50 mg/kg,10090.0,
6848,,,A,1,Intermediate,In vivo,4573,Mus musculus,BAO_0000218,,,,,50594,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,10090.0,
6849,,,A,1,Intermediate,In vivo,3277,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),10090.0,
6850,,,A,1,Intermediate,In vivo,17734,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,10090.0,
6851,,,A,1,Intermediate,In vivo,3132,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum concentration obtained in mouse plasma was determined,10090.0,
6852,,,A,1,Intermediate,In vivo,3132,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,10090.0,
6853,,,A,1,Intermediate,In vivo,6348,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,
6854,,,A,1,Intermediate,In vivo,17729,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,10090.0,
6855,,,A,1,Intermediate,In vivo,17729,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,10090.0,
6856,,,A,1,Intermediate,In vivo,17729,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,10090.0,
6857,,,A,1,Intermediate,In vivo,17728,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,10090.0,
6858,,,A,1,Intermediate,In vivo,17728,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,10090.0,
6859,,,A,1,Intermediate,In vivo,17728,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,10090.0,
6860,,,A,1,Intermediate,In vivo,4066,Mus musculus,BAO_0000218,,,,,50594,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,10090.0,
6861,,,A,1,Intermediate,In vivo,6178,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,10090.0,
6862,,,A,1,Intermediate,In vivo,6178,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,10090.0,
6863,,,A,1,Intermediate,In vivo,3760,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,10090.0,
6864,,,A,1,Intermediate,In vivo,3760,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,10090.0,
6865,,,A,1,Intermediate,In vivo,3760,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,10090.0,
6866,,,A,1,Intermediate,In vivo,3760,Mus musculus,BAO_0000218,,,,,50594,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,10090.0,
6868,,,A,1,Intermediate,In vivo,5961,Mus musculus,BAO_0000218,,,,,50594,1,Cmax in male mice after 2 mg/kg oral dose,10090.0,
6869,,,A,1,Intermediate,In vivo,6137,Mus musculus,BAO_0000218,,,,,50594,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,10090.0,
6870,,,A,1,Intermediate,In vivo,3802,Mus musculus,BAO_0000218,,,,,50594,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,10090.0,
6871,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,10090.0,
6872,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,10090.0,
6873,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,10090.0,
6874,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,10090.0,
6875,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,10090.0,
6876,,,A,1,Intermediate,,3535,Mus musculus,BAO_0000218,,,,,50594,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,10090.0,
6877,,,A,1,Intermediate,,2862,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum concentration in plasma upon oral administration in mouse,10090.0,
6878,,,A,1,Intermediate,,2675,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration was evaluated in mice after oral administration,10090.0,
6879,,,A,1,Intermediate,In vivo,2675,Mus musculus,BAO_0000218,,Plasma,,,50594,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,10090.0,
6880,,,A,1,Intermediate,,5399,Mus musculus,BAO_0000218,,,,,50594,1,Dose at which the compound induced fecal excretion in mice,10090.0,
6893,,A10,F,1,Expert,,11819,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,10116.0,
6894,,A10,F,1,Expert,,11819,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,10116.0,
6895,,A10,F,1,Expert,,11819,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,10116.0,
6896,,A10,F,1,Expert,,11819,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,10116.0,
6897,,A10,F,1,Intermediate,,16361,Rattus norvegicus,BAO_0000219,164.0,,,,80013,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),10116.0,
6898,,A121,F,1,Intermediate,,2288,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,9606.0,
6899,,A121,F,1,Intermediate,,10404,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Anticancer activity against human ovarian carcinoma A121 cells,9606.0,
6900,,A121,F,1,Intermediate,,14790,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,9606.0,
6901,,A121,F,1,Intermediate,,14790,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,9606.0,
6902,,A121,F,1,Expert,,14253,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Growth inhibition of human ovarian carcinoma (A121) cell line,9606.0,
6903,,A121,F,1,Expert,,13617,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,9606.0,
6904,,A121,F,1,Intermediate,,1003,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Cytotoxicity against human A121 ovarian cells,9606.0,
6905,,A121,F,1,Intermediate,,830,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,9606.0,
6906,,A121,F,1,Intermediate,,12307,Homo sapiens,BAO_0000219,393.0,,,,80655,1,In vitro cytotoxicity against human ovarian carcinoma A21,9606.0,
6907,,A121,F,1,Intermediate,,14254,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,9606.0,
6908,,A121,F,1,Intermediate,,13370,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Inhibitory activity of compound against human A121 ovarian cell line.,9606.0,
6909,,A121,F,1,Intermediate,,14790,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,9606.0,
6910,,A121,F,1,Intermediate,,3614,Homo sapiens,BAO_0000219,393.0,,,,80655,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,9606.0,
6911,,A 172,F,1,Intermediate,,2664,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,9606.0,
6912,,A 172,F,1,Expert,,2037,Homo sapiens,BAO_0000219,622.0,,,,80012,1,In vitro cytotoxicity against A172 human tumor cell lines.,9606.0,
6913,,A 172,F,1,Intermediate,,14539,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,9606.0,
6914,,A 172,F,1,Intermediate,,2836,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,9606.0,
6915,,A 172,F,1,Intermediate,,10708,Homo sapiens,BAO_0000219,622.0,,,,80012,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,9606.0,
6916,,,B,4,Autocuration,,8975,Canis lupus familiaris,BAO_0000224,,,,,104729,1,Association constant against A2 adenosine receptor,9615.0,
6917,,A2,F,1,Intermediate,,7645,fish,BAO_0000219,1085.0,,,,80656,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,
6918,,,B,5,Autocuration,,11377,Rattus norvegicus,BAO_0000224,,,,,104713,1,Ratio of Ki for adenosine A2 and A1 receptor binding,10116.0,
6919,,A204,F,1,Expert,,13528,Homo sapiens,BAO_0000219,623.0,,,,80014,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,9606.0,
6920,,A204,F,1,Expert,,10160,Homo sapiens,BAO_0000219,623.0,,,,80014,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,9606.0,
6921,,A2058,F,1,Intermediate,,15144,Homo sapiens,BAO_0000219,404.0,,,,80015,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,9606.0,
6922,,A253 cell line,F,1,Intermediate,,13160,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition against Human squamous cell line(A 253),9606.0,
6923,,A253 cell line,F,1,Intermediate,,12898,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,9606.0,
6924,,A253 cell line,F,1,Intermediate,,13069,Homo sapiens,BAO_0000219,973.0,,,,80657,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,9606.0,
6925,,A253 cell line,F,1,Intermediate,,15984,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition of A253 cell lines.,9606.0,
6926,,A253 cell line,F,1,Intermediate,,15564,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),9606.0,
6927,,A253 cell line,F,1,Intermediate,,15564,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,9606.0,
6928,,A253 cell line,F,1,Intermediate,,15564,Homo sapiens,BAO_0000219,973.0,,,,80657,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,9606.0,
6929,,A2780,F,1,Intermediate,,4720,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,9606.0,
6930,,A2780,F,1,Intermediate,,16112,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,9606.0,
6931,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,9606.0,
6932,,A2780,F,1,Intermediate,,16378,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),9606.0,
6933,,A2780,F,1,Expert,,16085,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,9606.0,
6934,,A2780,F,1,Intermediate,,16317,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,9606.0,
6935,,A2780,F,1,Intermediate,,15748,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),9606.0,
6936,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,9606.0,
6937,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,9606.0,
6938,,A2780,F,1,Expert,,16597,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,9606.0,
6939,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,9606.0,
6940,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,9606.0,
6941,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,9606.0,
6942,,,F,0,Autocuration,,15296,Cricetulus griseus,BAO_0000019,,,,,22224,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,10029.0,
6943,,CHO-AA8,A,0,Autocuration,,10251,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,10029.0,
6944,,CHO-AA8,F,0,Autocuration,,10251,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic conditions,10029.0,
6945,,CHO-AA8,F,0,Autocuration,,10251,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,10029.0,
6946,,CHO-AA8,F,0,Autocuration,,10251,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),10029.0,
6947,,,F,0,Autocuration,,11858,Cricetulus griseus,BAO_0000019,,,,,22224,1,Growth inhibition against CHO-derived cell line AA8,10029.0,
6948,,CHO-AA8,F,0,Autocuration,,11858,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],10029.0,
6949,,CHO-AA8,F,1,Expert,,11616,hampster,BAO_0000219,185.0,,,,80089,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,36483.0,
6950,,CHO-AA8,F,1,Expert,,11616,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,10029.0,
6951,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,10029.0,
6952,,CHO-AA8,F,0,Autocuration,,11396,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,10029.0,
6953,,CHO-AA8,F,0,Autocuration,,10518,Cricetulus griseus,BAO_0000219,185.0,,,,22224,1,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,10029.0,
6954,,CHO-AA8,F,1,Expert,,11616,Cricetulus griseus,BAO_0000219,185.0,,,,80089,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,10029.0,
6955,,,F,8,Autocuration,,14837,,BAO_0000019,,,,,12675,1,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,
6956,,,F,8,Autocuration,,14837,,BAO_0000019,,,,,12675,1,Number of binding sites (n) of isolated serum protein AAG,,
6957,,,B,3,Intermediate,,16037,,BAO_0000225,,,,,22222,1,Association constant for binding to AATT duplex,,
6958,,ABAE,F,1,Expert,,16597,Homo sapiens,BAO_0000219,416.0,,,,100090,1,Inhibition of ABAE human fibroblast cell proliferation,9606.0,
6959,,AC755,F,1,Intermediate,,8831,Mus musculus,BAO_0000218,1064.0,,,,80668,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",10090.0,
6960,,,F,9,Expert,,13419,Oryctolagus cuniculus,BAO_0000218,,,,,102444,1,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,9986.0,
6961,,,F,9,Expert,In vivo,13419,Oryctolagus cuniculus,BAO_0000218,,,,,102444,1,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,9986.0,
6962,,,B,8,Autocuration,,15778,,BAO_0000357,,,,,69,1,Inhibitory activity against angiotensin-converting enzyme (ACE).,,
6963,,,B,8,Autocuration,,15778,,BAO_0000357,,,,,69,1,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,
6964,,ACH-2 cell line,F,1,Intermediate,,12988,Homo sapiens,BAO_0000219,978.0,,,,80669,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,9606.0,
6965,,ACH-2 cell line,F,1,Intermediate,,12988,Homo sapiens,BAO_0000219,978.0,,,,80669,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),9606.0,
6966,,T cell line,F,0,Autocuration,,12988,Human immunodeficiency virus 1,BAO_0000219,998.0,,,,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,11676.0,
6967,,T cell line,F,0,Autocuration,,12988,Human immunodeficiency virus 1,BAO_0000219,998.0,,,,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),11676.0,
6968,,T cell line,F,0,Autocuration,,12988,Human immunodeficiency virus 1,BAO_0000219,998.0,,,,22224,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),11676.0,
6969,,ACHN,F,1,Intermediate,,11843,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Inhibition of growth of renal cancer ACHN cell line,9606.0,
6970,,ACHN,F,1,Intermediate,,16939,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Inhibition of growth of ACHN renal cancer cell line,9606.0,
6971,,ACHN,F,1,Intermediate,,4782,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Inhibitory concentration required against ACHN renal cancer cell line,9606.0,
6972,,ACHN,F,1,Expert,,6310,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Concentration required to inhibit growth of human renal (ACHN) cell line,9606.0,
6973,,ACHN,F,1,Intermediate,,6310,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,9606.0,
6974,,ACHN,F,1,Intermediate,,12858,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Cytotoxic activity against ACHN Renal cancer cell line,9606.0,
6975,,ACHN,F,1,Intermediate,,17380,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Cytotoxicity evaluation against ACHN renal cancer cells,9606.0,
6976,,ACHN,F,1,Intermediate,,5858,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro antitumor activity against human renal ACHN cell line,9606.0,
6977,,ACHN,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,9606.0,
6978,,ACHN,F,1,Intermediate,,3838,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,9606.0,
6979,,ACHN,F,1,Intermediate,,5406,Homo sapiens,BAO_0000219,626.0,,,,80025,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",9606.0,
6980,,ACHN,F,1,Intermediate,,4071,Homo sapiens,BAO_0000219,626.0,,,,80025,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,9606.0,
6981,,ACHN,F,1,Expert,,4071,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,9606.0,
6982,,ACHN,F,1,Intermediate,,4071,Homo sapiens,BAO_0000219,626.0,,,,80025,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,9606.0,
6983,,ACHN,F,1,Intermediate,,15002,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,9606.0,
6984,,ACHN,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),9606.0,
6985,,ACHN,F,1,Intermediate,,13958,Homo sapiens,BAO_0000219,626.0,,,,80025,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",9606.0,
6986,,ACHN,F,1,Intermediate,,1665,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,9606.0,
6987,,ACHN,F,1,Intermediate,,15354,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,9606.0,
6988,,ACHN,F,1,Intermediate,,15354,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,9606.0,
6989,,ACHN,F,1,Intermediate,,13978,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,9606.0,
6990,,ACHN,F,1,Intermediate,,6798,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,9606.0,
6991,,,A,1,Intermediate,In vivo,2959,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax value after administration of 4 mg/Kg oral dose in dog,9615.0,
6992,,,A,1,Intermediate,,9932,Canis lupus familiaris,BAO_0000218,,,,,50588,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",9615.0,
6993,,,A,1,Intermediate,,5546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,
6994,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution after 15 mg/kg iv dose in Dogs,9615.0,
6995,,,A,1,Intermediate,In vivo,16907,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution after 30 mg/kg po dose in Dogs,9615.0,
6996,,,A,1,Intermediate,In vivo,4257,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,9615.0,
6997,,,A,1,Intermediate,In vivo,4305,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,9615.0,
6998,,,A,1,Intermediate,In vivo,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was evaluated in dog,9615.0,
6999,,,A,1,Intermediate,In vivo,6062,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,9615.0,
7000,,,A,1,Expert,,3598,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,9615.0,
7001,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for volume of distribution in dog,9615.0,
7002,,,A,1,Intermediate,In vivo,12500,Canis lupus familiaris,BAO_0000218,,,,,50588,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,9615.0,
7003,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vd (1 mg/kg) was determined in dog (in vivo),9615.0,
7004,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vd in dog,9615.0,
7005,,,A,1,Intermediate,In vivo,4219,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution was determined,9615.0,
7006,,,A,1,Intermediate,In vivo,1696,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution in dog,9615.0,
7007,,,A,1,Intermediate,In vivo,5542,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution by as 4 fold increase by iv administration in dogs,9615.0,
7008,,,A,1,Intermediate,In vivo,5199,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,9615.0,
7009,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
7010,,,A,1,Intermediate,In vivo,4727,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution at the dose of 2 mg/kg in dog,9615.0,
7011,,,A,1,Intermediate,In vivo,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Steady state volume of distribution was determined,9615.0,
7012,,,A,1,Intermediate,In vivo,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,9615.0,
7013,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,
7014,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,
7015,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,
7016,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),9615.0,
7017,,,A,1,Intermediate,In vivo,4239,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic property (vdss) was measured in dog,9615.0,
7018,,,A,1,Intermediate,In vivo,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,9615.0,
7019,,,A,1,Intermediate,In vivo,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vdss was determined after iv 0.1 mg/kg administration in dog,9615.0,
7020,,,A,1,Intermediate,In vivo,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume displacement was calculated in dog,9615.0,
7021,,,A,1,Intermediate,In vivo,5654,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,
7022,,,A,1,Intermediate,In vivo,5505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution constant was determined,9615.0,
7023,,,A,1,Intermediate,In vivo,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution at a dose of 1 uM/kg in dog was determined,9615.0,
7024,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,
7025,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,
7026,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution (Vdss) was measured in dog,9615.0,
7027,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution (Vdss) was measured in dog,9615.0,
7028,,,A,1,Intermediate,In vivo,6679,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,
7029,,,A,1,Intermediate,In vivo,5145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution in steady state was determined in dog,9615.0,
7030,,,A,1,Intermediate,In vivo,6821,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution of compound was determined in dog,9615.0,
7031,,,A,1,Intermediate,In vivo,4137,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,9615.0,
7032,,,A,1,Intermediate,In vivo,5334,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),9615.0,
7033,,,A,1,Intermediate,In vivo,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution (Vdss) was measured in dog,9615.0,
7034,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,
7035,,,A,1,Intermediate,In vivo,6641,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
7036,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
7037,,,A,1,Intermediate,,11659,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Maximum rate of depolarization of the upstroke of the action potential,9615.0,
7038,,,A,1,Intermediate,In vivo,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Steady state volume distribution in dog,9615.0,
7039,,,A,1,Intermediate,In vivo,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,9615.0,
7040,,,A,1,Intermediate,In vivo,1466,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,9615.0,
7041,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,9615.0,
7042,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution in dog after administration of 1 mg/kg iv,9615.0,
7043,,,A,1,Intermediate,In vivo,17764,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,9615.0,
7044,,,A,1,Intermediate,In vivo,6215,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,
7045,,,A,1,Intermediate,In vivo,6505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vss on i.v. administration of 2 mg/kg was measured in dog,9615.0,
7046,,,A,1,Intermediate,,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vss was determined,9615.0,
7047,,,A,1,Intermediate,,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vss in dog,9615.0,
7048,,,A,1,Intermediate,In vivo,6062,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,9615.0,
7049,,,A,1,Intermediate,In vivo,4942,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume distribution in dogs,9615.0,
7050,,,A,1,Intermediate,In vivo,17796,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Volume of distribution in dog,9615.0,
7051,,,A,1,Intermediate,In vivo,4883,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tested for the oral bioavailability in dog,9615.0,
7060,,,A,1,Intermediate,In vivo,17837,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,10090.0,
7061,,,A,1,Intermediate,In vivo,17729,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,10090.0,
7062,,,A,1,Intermediate,In vivo,17729,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,10090.0,
7063,,,A,1,Intermediate,In vivo,4239,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was measured in mouse,10090.0,
7064,,,A,1,Intermediate,In vivo,17592,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability in mouse,10090.0,
7065,,,A,1,Intermediate,In vivo,6348,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,10090.0,
7066,,,A,1,Intermediate,In vivo,2801,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability in mouse,10090.0,
7067,,,A,1,Intermediate,In vivo,2801,Mus musculus,BAO_0000218,,,,,50594,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,10090.0,
7068,,,A,1,Intermediate,In vivo,17718,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in mouse,10090.0,
7069,,,A,1,Intermediate,In vivo,5727,Mus musculus,BAO_0000218,,,,,50594,1,Oral availability at 50 mg/kg po in male mice,10090.0,
7070,,,A,1,Intermediate,In vivo,5302,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in mouse (dose 10 mg/kg),10090.0,
7071,,,A,1,Expert,In vivo,3598,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,10090.0,
7072,,,A,1,Intermediate,In vivo,5961,Mus musculus,BAO_0000218,,,,,50594,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",10090.0,
7074,,,A,1,Intermediate,In vivo,6091,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in mouse,10090.0,
7075,,,A,1,Intermediate,In vivo,6091,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in vivo in mice;ND=Not determined,10090.0,
7076,,,A,1,Intermediate,In vivo,5711,Mus musculus,BAO_0000218,,,,,50594,1,Oral bioavailability in mouse at 10 mg/kg of the compound,10090.0,
7077,,,A,1,Intermediate,In vivo,17728,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),10090.0,
7078,,,A,1,Intermediate,In vivo,17728,Mus musculus,BAO_0000218,,,,,50594,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),10090.0,
7079,,,A,1,Intermediate,In vivo,3802,Mus musculus,BAO_0000218,,,,,50594,1,Tested for bioavailability of the compound,10090.0,
7080,,,A,1,Intermediate,In vivo,3802,Mus musculus,BAO_0000218,,,,,50594,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,10090.0,
7081,,,A,1,Intermediate,,14029,Mus musculus,BAO_0000218,,Plasma,,,50594,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,10090.0,
7082,,,A,1,Intermediate,,14029,Mus musculus,BAO_0000218,,Plasma,,,50594,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,10090.0,
7083,,,A,1,Intermediate,,14029,Mus musculus,BAO_0000218,,Plasma,,,50594,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,10090.0,
7084,,,A,1,Intermediate,,14029,Mus musculus,BAO_0000218,,Plasma,,,50594,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,10090.0,
7085,,,A,1,Intermediate,,14029,Mus musculus,BAO_0000218,,Plasma,,,50594,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,10090.0,
7086,,,F,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,10090.0,
7087,,,A,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,10090.0,
7088,,,A,1,Intermediate,,17753,Mus musculus,BAO_0000218,,,,,50594,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,10090.0,
7089,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7090,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7091,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7092,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7093,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7094,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7095,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Blood,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7096,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7097,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,
7098,,A2780,F,1,Intermediate,,15608,Homo sapiens,BAO_0000219,478.0,,,,81034,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,9606.0,
7099,,A2780,F,1,Expert,,3290,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,9606.0,
7100,,A2780,F,1,Intermediate,,2859,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated for cytotoxicity against A2780 cell line,9606.0,
7101,,A2780,F,1,Expert,,15688,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of A2780 cell clonogenic assay,9606.0,
7102,,A2780,F,1,Expert,,5642,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic effect on ovarian cancer cell line (A2780),9606.0,
7103,,A2780,F,1,Intermediate,,6633,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,9606.0,
7104,,A2780,F,1,Intermediate,,3906,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",9606.0,
7105,,A2780,F,1,Expert,,6788,Homo sapiens,BAO_0000219,478.0,,,,81034,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,9606.0,
7106,,A2780,F,1,Expert,,17582,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Antiproliferative activity against human A2780 cells,9606.0,
7107,,A2780,F,1,Expert,,17764,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of human A2780 cell proliferation,9606.0,
7108,,A2780,F,1,Expert,,17764,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,9606.0,
7109,,A2780,F,1,Expert,,17764,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of human A2780 cell proliferation (No data),9606.0,
7110,,A2780,F,1,Intermediate,,2815,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,9606.0,
7111,,A2780,F,1,Intermediate,,16930,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,9606.0,
7112,,A2780,F,1,Expert,,17777,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Growth inhibition against A2780 wild-type ovarian cell lines,9606.0,
7113,,A2780,F,1,Intermediate,,17777,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,9606.0,
7114,,,F,5,Autocuration,,16936,Homo sapiens,BAO_0000019,,,,,104766,1,Inhibition of tubulin polymerization in human ovarian cancer cell lines,9606.0,
7115,,A2780,F,1,Intermediate,,13759,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,9606.0,
7116,,A2780,F,1,Intermediate,,13759,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,9606.0,
7117,,A2780,F,1,Intermediate,,13759,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,9606.0,
7118,,A2780,F,1,Intermediate,,13759,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,9606.0,
7119,,A2780,F,1,Intermediate,,15292,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,9606.0,
7120,,A2780,F,1,Intermediate,,15292,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,9606.0,
7121,,A2780,F,1,Expert,,15069,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro inhibition of human ovarian cell line A2780,9606.0,
7122,,A2780,F,1,Expert,,15069,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",9606.0,
7123,,A2780,F,1,Intermediate,,14073,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),9606.0,
7124,,A2780,F,1,Expert,,14553,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit A2780-cell growth by 50%,9606.0,
7125,,A2780,F,1,Expert,,13040,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,9606.0,
7126,,A2780,F,1,Expert,,6891,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,9606.0,
7127,,A2780,F,1,Intermediate,,15569,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,9606.0,
7128,,A2780,F,1,Expert,,14190,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,9606.0,
7129,,A2780,F,1,Expert,,15014,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,9606.0,
7130,,A2780,F,1,Intermediate,,15014,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,9606.0,
7131,,A2780,F,1,Intermediate,,17496,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,9606.0,
7132,,A2780,F,1,Intermediate,,13617,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",9606.0,
7133,,A2780,F,1,Intermediate,,13617,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",9606.0,
7134,,A2780,F,1,Intermediate,,13617,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",9606.0,
7135,,A2780,F,1,Intermediate,,13617,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",9606.0,
7136,,A2780,F,1,Intermediate,,17672,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,9606.0,
7137,,A2780,F,1,Intermediate,,4544,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,9606.0,
7138,,A2780,F,1,Intermediate,,4544,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,9606.0,
7139,,A2780,F,1,Intermediate,,16317,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",9606.0,
7140,,A2780,F,1,Intermediate,,15099,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,9606.0,
7141,,A2780,F,1,Intermediate,,13978,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,9606.0,
7142,,A2780,F,1,Expert,,12989,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro antitumor activity against A2780 cell line.,9606.0,
7143,,A2780,F,1,Intermediate,,5574,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,9606.0,
7144,,A2780,F,1,Expert,,13528,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,9606.0,
7145,,ACHN,F,1,Intermediate,,12782,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,9606.0,
7146,,ACHN,F,1,Intermediate,,14255,Homo sapiens,BAO_0000219,626.0,,,,80025,1,The IC50 value was measured on ACHN cell line in renal tumor type.,9606.0,
7147,,ACHN,F,1,Intermediate,,16364,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,9606.0,
7148,,ACHN,F,1,Expert,,17376,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro lethal concentration against most sensitive ACHN cell line,9606.0,
7149,,ACHN,F,1,Intermediate,,12016,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Tested for cytotoxic activity against renal cancer ACHN cell line,9606.0,
7150,,ACHN,F,1,Intermediate,,6058,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound tested for growth inhibition of renal cancer cell line ACHN,9606.0,
7151,,ACHN,F,1,Intermediate,,17708,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,9606.0,
7152,,ACHN,F,1,Intermediate,,15176,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,9606.0,
7153,,ACHN,F,1,Intermediate,,2806,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro anticancer activity against ACHN renal cancer cell line,9606.0,
7154,,ACHN,F,1,Intermediate,,15300,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,9606.0,
7155,,ACHN,F,1,Intermediate,,16364,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Percent selectivity was evaluated in renal ACHN cell lines,9606.0,
7156,,ACHN,F,1,Intermediate,,13859,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro inhibitory activity against renal ACHN cancer cell line,9606.0,
7157,,ACHN,F,1,Intermediate,,11970,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,9606.0,
7158,,ACHN,F,1,Intermediate,,2450,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,9606.0,
7159,,ACHN,F,1,Intermediate,,12696,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,9606.0,
7160,,ACHN,F,1,Intermediate,,12400,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,9606.0,
7161,,ACHN,F,1,Expert,,12888,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Cytotoxic effect on renal cancer line ACHN,9606.0,
7162,,ACHN,F,1,Intermediate,,3156,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,9606.0,
7163,,ACHN,F,1,Intermediate,,3381,Homo sapiens,BAO_0000219,626.0,,,,80025,1,In vitro inhibition of Renal Cancer ACHN cell lines,9606.0,
7164,,ACHN,F,1,Intermediate,,16747,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Antitumor activity against human renal adenocarcinoma ACHN cells,9606.0,
7165,,ACHN,F,1,Expert,,16748,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,9606.0,
7166,,ACHN,F,1,Intermediate,,12062,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,9606.0,
7167,,ACHN,F,1,Intermediate,,14769,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),9606.0,
7168,,ACHN,F,1,Intermediate,,15895,Homo sapiens,BAO_0000219,626.0,,,,80025,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",9606.0,
7169,,ACHN,F,1,Intermediate,,17376,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,9606.0,
7170,,ACHN,F,1,Intermediate,,14882,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,9606.0,
7171,,ACHN,F,1,Intermediate,,14882,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,9606.0,
7172,,ACHN,F,1,Intermediate,,15661,Homo sapiens,BAO_0000219,626.0,,,,80025,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,9606.0,
7173,,,A,0,Autocuration,,9680,,BAO_0000019,,,,,22224,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,
7174,,,F,8,Autocuration,,14579,,BAO_0000019,,,,,10647,1,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,
7175,,HEL,F,1,Expert,,17290,Cytomegalovirus,BAO_0000218,468.0,,,,50529,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,10358.0,
7176,,,F,1,Intermediate,,17290,Cytomegalovirus,BAO_0000218,,,,,50529,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,10358.0,
7177,,,B,8,Autocuration,,15891,,BAO_0000357,,,,,12159,1,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,
7178,,,B,8,Autocuration,,15890,,BAO_0000357,,,,,12159,1,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,
7179,,ADDP cell line,F,1,Intermediate,,3801,Bos taurus,BAO_0000219,979.0,,,,80670,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,9913.0,
7180,,ADJ/PC6,F,1,Intermediate,,9222,Mus musculus,BAO_0000219,980.0,,,,80671,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,10090.0,
7181,,ADJ/PC6,F,1,Intermediate,,9222,Mus musculus,BAO_0000219,980.0,,,,80671,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,10090.0,
7182,,ADJ/PC6,F,1,Intermediate,,7257,Mus musculus,BAO_0000219,980.0,,,,80671,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",10090.0,
7183,,ADJ/PC6,F,1,Intermediate,,7257,Mus musculus,BAO_0000219,980.0,,,,80671,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,10090.0,
7184,,ADJ/PC6,A,1,Intermediate,,7257,Mus musculus,BAO_0000219,980.0,,,,80671,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,10090.0,
7185,,ADJ/PC6,F,1,Intermediate,,8084,Mus musculus,BAO_0000219,980.0,,,,80671,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,10090.0,
7186,,,F,0,Autocuration,,14943,Mus musculus,BAO_0000019,,,,,22224,1,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,10090.0,
7187,,,F,0,Autocuration,,14943,Mus musculus,BAO_0000019,,,,,22224,1,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,10090.0,
7188,,,F,0,Autocuration,,14943,Mus musculus,BAO_0000019,,,,,22224,1,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,10090.0,
7189,,,A,0,Autocuration,In vivo,10524,Bacillus subtilis,BAO_0000218,,,,,22224,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1423.0,
7190,,,A,1,Intermediate,,3546,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC value in dog after IV administration at a dose of 5 mg/kg,9615.0,
7191,,,A,1,Intermediate,,3546,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,AUC value in dog after oral administration at a dose of 5 mg/kg,9615.0,
7192,,,A,1,Intermediate,In vivo,3546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,9615.0,
7193,,,A,1,Intermediate,In vivo,3546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,9615.0,
7194,,,A,1,Intermediate,In vivo,3546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,9615.0,
7195,,,A,1,Intermediate,In vivo,3184,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for its clearance when administered intravenously in dog,9615.0,
7196,,,A,1,Intermediate,In vivo,16456,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,
7197,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),9615.0,
7198,,,P,0,Intermediate,,4219,,BAO_0000100,,,,,22229,1,Calculated partition coefficient (clogP),,
7199,,,A,1,Intermediate,,3748,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog,9615.0,
7200,,,A,1,Intermediate,,3132,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Time taken for EC90 was determined when tested in dog,9615.0,
7201,,,A,1,Intermediate,,4219,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life (iv) was determined,9615.0,
7202,,,A,1,Intermediate,,16907,Canis lupus familiaris,BAO_0000218,,Liver,,,50588,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,9615.0,
7203,,,A,1,Intermediate,,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve was calculated in dog after iv administration,9615.0,
7204,,,A,1,Intermediate,,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Area under the curve was calculated in dog after peroral administration,9615.0,
7205,,,A,1,Intermediate,,17853,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,9615.0,
7206,,,A,1,Intermediate,,3639,Canis lupus familiaris,BAO_0000218,,,,,50588,1,pKa was evaluated in dog,9615.0,
7207,,,A,1,Intermediate,,14541,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,9615.0,
7208,,,A,1,Intermediate,In vivo,16456,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,
7209,,,A,1,Intermediate,In vivo,16456,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,9615.0,
7210,,,A,1,Intermediate,In vivo,2652,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,9615.0,
7211,,,A,1,Intermediate,,3624,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for the half-life (t 1/2) in hours,9615.0,
7212,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,9615.0,
7213,,,A,1,Intermediate,In vivo,1337,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,9615.0,
7214,,,A,1,Intermediate,In vivo,4709,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life after intravenous administration of 1 mg/kg in dog,9615.0,
7215,,,A,1,Intermediate,,15660,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was measured in dog,9615.0,
7216,,,A,1,Intermediate,In vivo,5302,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period in dog after 5 mg/kg dose,9615.0,
7217,,,A,1,Intermediate,,17791,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was evaluated in dog; 4-4.8,9615.0,
7218,,,A,1,Intermediate,In vivo,6348,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,9615.0,
7219,,,A,1,Intermediate,In vivo,4257,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was determined in dog after a3 mg/kg of iv dose,9615.0,
7220,,,A,1,Intermediate,,3771,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was determined,9615.0,
7221,,,A,1,Intermediate,,6305,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dogs,9615.0,
7222,,,A,1,Intermediate,In vivo,13501,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,9615.0,
7223,,,A,1,Intermediate,In vivo,17594,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,9615.0,
7224,,,A,1,Intermediate,In vivo,3045,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,9615.0,
7225,,,A,1,Intermediate,In vivo,3043,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was evaluated for the half life period after oral administration in conscious dog.,9615.0,
7226,,,A,1,Intermediate,,4839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for half life in dog,9615.0,
7227,,,A,1,Intermediate,,4839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Compound was tested for its half life in dog,9615.0,
7228,,,A,1,Intermediate,In vivo,5802,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,9615.0,
7229,,,A,1,Intermediate,,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life of compound in dog was determined,9615.0,
7230,,,A,1,Intermediate,In vivo,4219,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life (iv) was determined,9615.0,
7231,,,A,1,Intermediate,,13966,Canis lupus familiaris,BAO_0000218,,Blood,,,50588,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),9615.0,
7232,,,A,1,Intermediate,In vivo,3994,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,9615.0,
7233,,,F,1,Intermediate,In vivo,3994,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,9615.0,
7234,,,A,1,Intermediate,,4453,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog,9615.0,
7235,,,A,1,Intermediate,,6535,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in dog plasma,9615.0,
7236,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in dog plasma after administration of 0.25 mg/kg iv,9615.0,
7237,,,A,1,Intermediate,In vivo,6535,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in dog plasma after administration of 1 mg/kg iv,9615.0,
7238,,,A,1,Intermediate,In vivo,3132,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life in dog plasma was determined at dose 10 mg/kg,9615.0,
7239,,,A,1,Intermediate,,5374,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog was determined,9615.0,
7240,,,A,1,Intermediate,In vivo,5007,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),9615.0,
7241,,,A,1,Intermediate,,16907,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half life upon exposure to human plasma,9615.0,
7242,,,A,1,Intermediate,,6057,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was calculated in dog,9615.0,
7243,,,A,1,Intermediate,,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was determined,9615.0,
7244,,,A,1,Intermediate,,5473,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was determined,9615.0,
7245,,,A,1,Intermediate,In vivo,4368,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life by intravenous administration of 1.2 mg/kg in dog,9615.0,
7246,,,A,1,Intermediate,,6448,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog,9615.0,
7247,,,A,1,Intermediate,,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog after intra venous administration of the compound,9615.0,
7248,,,A,1,Intermediate,,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog after intra venous administration of the compound; ND means Not determined,9615.0,
7249,,,A,1,Intermediate,In vivo,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog after po administration of the compound,9615.0,
7250,,,A,1,Intermediate,In vivo,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog after po administration of the compound; ND means Not determined,9615.0,
7251,,,A,1,Intermediate,In vivo,6265,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog at the single oral dose of 1 mg/kg,9615.0,
7252,,,A,1,Intermediate,,5006,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dogs,9615.0,
7253,,,A,1,Intermediate,In vivo,5356,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,9615.0,
7254,,,A,1,Intermediate,,405,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in rat,9615.0,
7255,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),9615.0,
7256,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7257,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7258,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7259,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7260,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Bone,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7261,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7262,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7263,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7264,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7265,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7266,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7267,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Gut,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7268,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7269,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7270,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7271,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7272,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7273,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7274,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Heart,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7275,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7276,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,
7277,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7278,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7279,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7280,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7281,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Kidney,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7282,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7283,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7284,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7285,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7286,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7287,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7288,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Liver,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7289,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7290,,A2780,F,1,Intermediate,,5895,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780 (human ovarian cancer),9606.0,
7291,,A2780,F,1,Intermediate,,6338,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,9606.0,
7292,,A2780,F,1,Intermediate,,15163,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,9606.0,
7293,,A2780,F,1,Intermediate,,15163,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,9606.0,
7294,,A2780,F,1,Expert,,15000,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,9606.0,
7295,,A2780,F,1,Expert,,15000,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,9606.0,
7296,,A2780,F,1,Expert,,14729,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,9606.0,
7297,,A2780,F,1,Intermediate,,17270,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity against A2780 cell line,9606.0,
7298,,A2780,F,1,Intermediate,,5685,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,9606.0,
7299,,A2780,F,1,Intermediate,,3563,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,9606.0,
7300,,A2780,F,1,Intermediate,,17753,Homo sapiens,BAO_0000218,478.0,,,,81034,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,9606.0,
7301,,A2780,F,1,Intermediate,,16317,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",9606.0,
7302,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibition of tubulin polymerization in analogy of ca.,9606.0,
7303,,A2780,F,1,Intermediate,,3801,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,9606.0,
7304,,A2780,F,1,Expert,,6181,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Cytotoxic effect in ovarian cancer cell line (A2780),9606.0,
7305,,A2780,F,1,Intermediate,,5318,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,9606.0,
7306,,A2780,F,1,Intermediate,,4840,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Tested for the cytotoxicity in A2780 ovarian cell line,9606.0,
7307,,A2780,F,1,Intermediate,,15748,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),9606.0,
7308,,A2780,F,1,Intermediate,,15748,Homo sapiens,BAO_0000219,478.0,,,,81034,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,9606.0,
7309,,A2780cisR,F,1,Intermediate,,15748,,BAO_0000219,481.0,,,,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,
7310,,A2780cisR,F,1,Intermediate,,15748,,BAO_0000219,481.0,,,,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,
7311,,A2780cisR,F,1,Intermediate,,15748,,BAO_0000219,481.0,,,,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,
7312,,A2780cisR,F,1,Intermediate,,15748,,BAO_0000219,481.0,,,,80017,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,
7313,,A2780,F,1,Intermediate,,17753,Homo sapiens,BAO_0000218,478.0,,,,81034,1,In vivo log of cells killed after administration of compound in A2780 cell line,9606.0,
7314,,A2780,F,1,Intermediate,In vivo,17753,Homo sapiens,BAO_0000218,478.0,,,,81034,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,9606.0,
7315,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,9606.0,
7316,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,9606.0,
7317,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,9606.0,
7318,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,9606.0,
7319,,A2780,F,1,Intermediate,,17528,Homo sapiens,BAO_0000218,478.0,,,,81034,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),9606.0,
7320,,A2780,F,1,Intermediate,,6633,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,9606.0,
7321,,A2780,F,1,Expert,,15000,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,9606.0,
7322,,A2780,F,1,Expert,,17528,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,9606.0,
7323,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,9606.0,
7324,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,9606.0,
7325,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,9606.0,
7326,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",9606.0,
7327,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),9606.0,
7328,,A2780,F,1,Expert,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",9606.0,
7329,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,
7330,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,
7331,,A2780,F,1,Intermediate,,16936,Homo sapiens,BAO_0000219,478.0,,,,81034,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),9606.0,
7332,,A2780,F,1,Intermediate,,17737,Mus musculus,BAO_0000219,478.0,,,,81034,1,In vitro antiproliferative activity against A2780 cell line,10090.0,
7333,,A2780,F,1,Expert,,17764,Mus musculus,BAO_0000219,478.0,,,,81034,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,10090.0,
7334,,A2780,F,1,Intermediate,,3830,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,9606.0,
7335,,A2780,F,1,Intermediate,,3829,Homo sapiens,BAO_0000219,478.0,,,,81034,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,9606.0,
7336,,,A,1,Intermediate,,3546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Vc value in dog after IV administration at a dose of 5 mg/kg,9615.0,
7337,,,A,1,Intermediate,In vivo,3546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period in dog after IV administration at a dose of 5 mg/kg,9615.0,
7338,,,A,0,Autocuration,,5668,Cercopithecidae,BAO_0000019,,,,,22224,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,9527.0,
7339,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
7340,,,A,0,Autocuration,,3443,Cercopithecidae,BAO_0000218,,Plasma,,,22224,1,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
7341,,,A,0,Autocuration,In vivo,4256,Macaca fascicularis,BAO_0000218,,,,,22224,1,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,9541.0,
7342,,,A,0,Autocuration,In vivo,4256,Macaca fascicularis,BAO_0000218,,,,,22224,1,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,9541.0,
7343,,,A,0,Autocuration,In vivo,4256,Macaca fascicularis,BAO_0000218,,,,,22224,1,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,9541.0,
7344,,,A,0,Autocuration,In vivo,4256,Rattus norvegicus,BAO_0000218,,,,,22224,1,Oral Bioavailability in rat,10116.0,
7345,,,A,0,Autocuration,,1916,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,9527.0,
7346,,,A,0,Autocuration,,5302,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under curve value in monkey at a dose of 5 mg/kg,9527.0,
7347,,,A,0,Autocuration,,4257,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under curve was determined in monkey after a 3 mg/kg of oral dose,9527.0,
7348,,,A,0,Autocuration,,5355,Cercopithecidae,BAO_0000019,,,,,22224,1,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,9527.0,
7349,,,A,0,Autocuration,,5355,Cercopithecidae,BAO_0000019,,,,,22224,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,9527.0,
7350,,,A,0,Autocuration,,5355,Cercopithecidae,BAO_0000019,,,,,22224,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,9527.0,
7351,,,A,0,Autocuration,,6078,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,9527.0,
7352,,,A,0,Autocuration,,6078,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,9527.0,
7353,,,A,0,Autocuration,,6062,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,9527.0,
7354,,,A,0,Autocuration,,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,
7355,,,A,0,Autocuration,,2661,Cercopithecidae,BAO_0000019,,,,,22224,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,
7356,,,A,0,Autocuration,,5394,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,9527.0,
7357,,,A,0,Autocuration,,4397,Cercopithecidae,BAO_0000218,,,,,22224,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,9527.0,
7358,,,A,0,Autocuration,,17509,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,9527.0,
7359,,,A,0,Autocuration,,17509,Cercopithecidae,BAO_0000218,,,,,22224,1,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,9527.0,
7360,,,A,0,Autocuration,In vivo,6641,Cercopithecidae,BAO_0000218,,,,,22224,1,Oral AUCN in monkey (dosed at 0.5 mpk iv ),9527.0,
7361,,,A,0,Autocuration,,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),9527.0,
7362,,,A,0,Autocuration,In vivo,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
7363,,,A,0,Autocuration,In vivo,3443,Cercopithecidae,BAO_0000218,,,,,22224,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,9527.0,
7364,,,A,0,Autocuration,,17409,Cercopithecidae,BAO_0000019,,,,,22224,1,Binding towards monkey plasma protein at 10 uM,9527.0,
7365,,,A,0,Autocuration,,17409,Cercopithecidae,BAO_0000019,,,,,22224,1,Binding towards monkey plasma protein at 100 uM,9527.0,
7366,,,A,0,Autocuration,In vivo,1052,Cercopithecidae,BAO_0000218,,,,,22224,1,Apparent bioavailability in squirrel monkey was determined,9527.0,
7367,,,A,0,Autocuration,In vivo,13501,Cercopithecidae,BAO_0000218,,,,,22224,1,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,9527.0,
7368,,,A,0,Autocuration,In vivo,17509,monkey,BAO_0000218,,,,,22224,1,Bioavailability in monkey (dose 2 mg/kg),9443.0,
7369,,,A,0,Autocuration,In vivo,5394,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,9527.0,
7370,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,9527.0,
7371,,,A,0,Autocuration,In vivo,11219,monkey,BAO_0000218,,,,,22224,1,Bioavailability in monkey (i.d. dosing),9443.0,
7372,,,A,0,Autocuration,In vivo,3045,Cercopithecidae,BAO_0000218,,,,,22224,1,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,9527.0,
7373,,,A,0,Autocuration,,17796,Cercopithecidae,BAO_0000019,,,,,22224,1,Clearance of the drug was measured in cynomolgus,9527.0,
7374,,,A,0,Autocuration,In vivo,1399,Cercopithecidae,BAO_0000218,,,,,22224,1,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,9527.0,
7375,,,A,0,Autocuration,In vivo,2661,Cercopithecidae,BAO_0000218,,,,,22224,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,9527.0,
7376,,,A,0,Autocuration,In vivo,5005,Macaca mulatta,BAO_0000218,,Plasma,,,22224,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,9544.0,
7377,,,A,0,Autocuration,In vivo,17267,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in rhesus monkey was determined,9527.0,
7378,,,A,0,Autocuration,In vivo,6535,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in monkey after administration of 1 mg/kg iv,9527.0,
7379,,,A,0,Autocuration,In vivo,5922,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance in cynomolgus monkey,9527.0,
7380,,,A,0,Autocuration,In vivo,6221,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,9527.0,
7381,,,A,0,Autocuration,In vivo,5668,Cercopithecidae,BAO_0000218,,,,,22224,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,9527.0,
7382,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The total clearance was determined after intravenous administration in cynomolgus monkeys,9527.0,
7383,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,9527.0,
7384,,,A,0,Autocuration,In vivo,5355,Cercopithecidae,BAO_0000218,,,,,22224,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,9527.0,
7385,,,A,0,Autocuration,In vivo,4578,Cercopithecidae,BAO_0000218,,,,,22224,1,Tested for Clearance upon iv administration to african green monkey,9527.0,
7386,,,A,0,Autocuration,In vivo,17592,Cercopithecidae,BAO_0000218,,,,,22224,1,Clearance in monkey,9527.0,
7387,,,A,1,Intermediate,In vivo,6641,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
7388,,,A,1,Intermediate,In vivo,6642,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),9615.0,
7389,,,A,1,Intermediate,In vivo,16367,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was evaluated after intravenous administration to dogs,9615.0,
7390,,,A,1,Intermediate,,5472,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was evaluated in dog,9615.0,
7391,,,A,1,Intermediate,,5474,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life was evaluated in dog,9615.0,
7392,,,A,1,Intermediate,In vivo,5654,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,9615.0,
7393,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),9615.0,
7394,,,A,1,Intermediate,In vivo,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period after intravenous administration in dog,9615.0,
7395,,,A,1,Intermediate,In vivo,6221,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,9615.0,
7396,,,A,1,Intermediate,,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period at a dose of 1 uM/kg in dog was determined,9615.0,
7397,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determine after peroral administration at 10 mpk in dog,9615.0,
7398,,,A,1,Intermediate,In vivo,5668,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determine after peroral administration at 5 mpk in dog,9615.0,
7399,,,A,1,Intermediate,,3854,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determined,9615.0,
7400,,,A,1,Intermediate,,5505,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determined,9615.0,
7401,,,A,1,Intermediate,In vivo,6251,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period by iv administration in dog at a dose of 6 mg/kg,9615.0,
7402,,,A,1,Intermediate,,1918,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was evaluated in dog,9615.0,
7403,,,A,1,Intermediate,In vivo,5546,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,9615.0,
7404,,,A,1,Intermediate,In vivo,4809,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),9615.0,
7405,,,A,1,Intermediate,In vivo,6215,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,9615.0,
7406,,,A,1,Intermediate,In vivo,4527,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,9615.0,
7407,,,A,1,Intermediate,In vivo,17594,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life after oral dose of compound at 3 mg/kg in dogs,9615.0,
7408,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,9615.0,
7409,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,9615.0,
7410,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,9615.0,
7411,,,A,1,Intermediate,In vivo,17839,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,9615.0,
7412,,,A,1,Intermediate,,5210,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half-life of compound in plasma of dog was determined,9615.0,
7413,,,A,1,Intermediate,,5210,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of compound was determined in dogs,9615.0,
7414,,,A,1,Intermediate,In vivo,2959,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life after administration of 4 mg/Kg oral dose in dog,9615.0,
7415,,,A,1,Intermediate,In vivo,4137,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life after intravenous administration of 1 mg/kg/h in dog,9615.0,
7416,,,A,1,Intermediate,,5064,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in Dog,9615.0,
7417,,,A,1,Intermediate,,5147,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in Dog,9615.0,
7418,,,A,1,Intermediate,,5145,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dog,9615.0,
7419,,,A,1,Intermediate,In vivo,6123,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dog after oral administration at 1 mg/kg,9615.0,
7420,,,A,1,Intermediate,In vivo,6123,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,9615.0,
7421,,,A,1,Intermediate,,4333,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dogs,9615.0,
7422,,,A,1,Intermediate,,4333,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in dogs; ND indicates not determined,9615.0,
7423,,,A,1,Intermediate,,12500,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half-life in plasma of dog,9615.0,
7424,,,A,1,Intermediate,,12500,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,Half-life in plasma of dog at dose of 3-10 mgkg,9615.0,
7425,,,A,1,Intermediate,In vivo,6005,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,9615.0,
7426,,,A,1,Intermediate,In vivo,6062,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was measured in dog after an iv dose of 1 mg/kg,9615.0,
7427,,,A,1,Intermediate,In vivo,17650,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,9615.0,
7428,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,9615.0,
7429,,,A,1,Intermediate,In vivo,5530,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,9615.0,
7430,,,A,1,Intermediate,In vivo,5600,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life of the compound after 0.3 mg/kg po administration in dog,9615.0,
7431,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,9615.0,
7432,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,9615.0,
7433,,,A,1,Intermediate,In vivo,6039,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,9615.0,
7434,,,A,1,Intermediate,,6227,Canis lupus familiaris,BAO_0000218,,,,,50588,1,t1/2 in dog,9615.0,
7435,,,A,1,Intermediate,,14541,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period measured in dogs,9615.0,
7436,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,9615.0,
7437,,,A,1,Intermediate,In vivo,4521,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,9615.0,
7438,,,A,1,Intermediate,In vivo,6679,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,9615.0,
7439,,,A,1,Intermediate,In vitro,1116,Canis lupus familiaris,BAO_0000218,,Plasma,,,50588,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",9615.0,
7440,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo half life period was calculated at 1 mg/kg in dog,9615.0,
7441,,,A,1,Intermediate,In vivo,5444,Canis lupus familiaris,BAO_0000218,,,,,50588,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,9615.0,
7442,,,A,1,Intermediate,In vivo,17853,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Longer half-life in dog (i.v.) at 0.5 mpk,9615.0,
7443,,,A,1,Intermediate,In vivo,4353,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Oral bioavailability in dog (dose 5 uM/kg),9615.0,
7444,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,9615.0,
7445,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,9615.0,
7446,,,A,1,Intermediate,In vivo,16452,Canis lupus familiaris,BAO_0000218,,,,,50588,1,Bioavailability in dog (dose 1 mg/kg i.v.),9615.0,
7447,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,
7448,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7449,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7450,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7451,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7452,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Lung,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7453,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7454,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,10090.0,
7455,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7456,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7457,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7458,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7459,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Muscle tissue,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7460,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7461,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7462,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7463,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7464,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7465,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7466,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Zone of skin,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7467,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7468,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7469,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7470,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7471,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7472,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7473,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Spleen,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7474,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,10090.0,
7475,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,10090.0,
7476,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,10090.0,
7477,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,10090.0,
7478,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,10090.0,
7479,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,10090.0,
7480,,,A,1,Intermediate,In vivo,10107,Mus musculus,BAO_0000218,,Stomach,,,50594,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,10090.0,
7481,,,A,1,Intermediate,In vivo,4689,Rattus norvegicus,BAO_0000218,,,,,50597,1,Oral bioavailability in rat,10116.0,
7482,,,A,1,Intermediate,In vivo,4950,Rattus norvegicus,BAO_0000218,,,,,50597,1,Tested for the bioavailability in rat,10116.0,
7483,,,A,1,Intermediate,In vivo,5328,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),10116.0,
7484,,,A,1,Intermediate,In vivo,406,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat,10116.0,
7485,,,A,1,Intermediate,In vivo,12500,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat,10116.0,
7486,,,A,1,Intermediate,In vivo,12500,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat (dose 3-10 mg/kg),10116.0,
7487,,,A,1,Intermediate,In vivo,5247,Rattus norvegicus,BAO_0000218,,,,,50597,1,Bioavailability in rat,10116.0,
7488,,,A,1,Intermediate,In vivo,4186,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,10116.0,
7489,,,A,1,Intermediate,In vivo,4186,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,10116.0,
7490,,,A,1,Intermediate,In vivo,6647,Rattus norvegicus,BAO_0000218,,,,,50597,1,Half life after oral administration was determined in rats at 6 mg/kg,10116.0,
7491,,,A,1,Intermediate,,6484,Rattus norvegicus,BAO_0000218,,,,,50597,1,Half life was determined,10116.0,
7492,,,A,1,Intermediate,In vivo,3249,Rattus norvegicus,BAO_0000218,,,,,50597,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,10116.0,
7493,,,A,1,Intermediate,In vivo,6281,Rattus norvegicus,BAO_0000218,,Plasma,,,50597,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,10116.0,
7494,,,A,1,Intermediate,,3307,Rattus norvegicus,BAO_0000218,,,,,50597,1,Half life in rats,10116.0,
7495,,,A,1,Intermediate,In vivo,12058,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,10116.0,
7496,,,A,1,Intermediate,,8833,Rattus norvegicus,BAO_0000218,,,,,50597,1,Hill coefficient of the compound,10116.0,
7497,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,10116.0,
7498,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,10116.0,
7499,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,10116.0,
7500,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,10116.0,
7501,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,10116.0,
7502,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,10116.0,
7503,,,A,1,Intermediate,,3193,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",10116.0,
7504,,,A,1,Intermediate,,5960,Rattus norvegicus,BAO_0000218,,,,,50597,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,10116.0,
7505,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Brain,,,50597,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,10116.0,
7506,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Brain,,,50597,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,10116.0,
7507,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Brain,,,50597,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,10116.0,
7508,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Brain,,,50597,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,10116.0,
7509,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Brain,,,50597,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,10116.0,
7510,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Thyroid gland,,,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,10116.0,
7511,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Thyroid gland,,,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,10116.0,
7512,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Thyroid gland,,,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,10116.0,
7513,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Thyroid gland,,,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,10116.0,
7514,,,A,1,Intermediate,In vivo,13950,Rattus norvegicus,BAO_0000218,,Thyroid gland,,,50597,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,10116.0,
7515,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,
7516,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,10116.0,
7517,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Blood,,,50597,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,
7518,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Bone,,,50597,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,
7519,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Bone,,,50597,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,10116.0,
7520,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Bone,,,50597,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,
7521,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Heart,,,50597,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,10116.0,
7522,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Heart,,,50597,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,10116.0,
7523,,,A,1,Intermediate,In vivo,9866,Rattus norvegicus,BAO_0000218,,Heart,,,50597,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,10116.0,
